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Summary 
With their unique ability to differentiate into any cell of the three germ layers 
(endoderm, ectoderm and mesoderm) and their capacity for unlimited self-
renewal, pluripotent stem cells (PSC), including human embryonic (hESC) and 
induced pluripotent stem cells (hiPSCs), are thought to hold great potential as 
an unlimited source of functional, transplantable cells for a diverse range of 
scientific and clinical applications. Specifically, in the context of cardiovascular 
and ischemic diseases, it is believed that hESC-derived endothelial cells (hESC-
ECs) may be used to stimulate angio- and vasculogenesis in ischemic tissues, 
therefore restoring blood supply to the affected area.  
Despite the publication of numerous methods for the derivation of hESC-ECs, 
differentiation efficiency is often low, or protocols involve the use of 
cumbersome isolation techniques. Currently, mechanisms governing the 
commitment of pluripotent cells to this specific lineage remain poorly 
understood, although numerous studies have highlighted a role for microRNAs 
(miRNA; miR). miRNAs are short, non-coding RNAs, ~22 nucleotides in length, 
which act post-transcriptionally to control the expression of their specific mRNA 
targets. It was, therefore, hypothesised that specific miRNAs play crucial roles 
during hESC-EC differentiation and commitment. The aim of this study was to 
identify novel miRNAs with roles in early mesodermal and endothelial 
commitment, and their potential mechanisms of action, in two newly developed 
hESC-EC differentiation protocols. Identified miRNAs could then be modulated to 
drive hESCs toward an endothelial lineage, therefore, allowing for increased 
differentiation efficiencies. 
In order to study the role of miRNAs during commitment of pluripotent cells to 
the endothelial lineage, two distinct hESC-EC differentiation systems were 
developed. The first was a direct system, whereby pluripotent cells were taken 
at d0 and differentiated directly to hESC-ECs. By d7 of direct differentiation, 
~40% of cells were CD31+CD144+ hESC-ECs, and this was coupled with a 
significant downregulation of pluripotent-associated genes and surface markers 
at this time point. Furthermore, it was demonstrated that CD31+CD144+ hESC-ECs 
could be isolated and cultured for a further 7 days. Resultant d14 hESC-ECs were 
14 
 
~100% CD31+CD144+ and were functional, demonstrated by their ability to form 
tubules on a Matrigel matrix. 
The second method for hESC-EC generation was indirect, and was developed 
using a pre-existing hematopoietic differentiation system. In vivo, development 
of the hematopoietic and vascular systems are closely linked, with a number of 
publications demonstrating the existence of a bipotent progenitor population 
with the ability to generate both endothelial and hematopoietic lineages, known 
as hemogenic endothelium (HE). In vitro studies using hPSCs have also identified 
and characterised HE populations. Using the cell surface marker profiles defined 
during these studies, a CD31+CD144+CD235a-CD43-CD73- HE population was 
demonstrated to exist on d7 of hematopoietic differentiation. Optimisation was 
then performed, to drive HE cells toward an EC phenotype, and generate a 
second, indirect hESC-EC differentiation protocol. By d10 of indirect hESC-EC 
differentiation, cells formed a confluent monolayer, expressed endothelial 
markers CD144, CD31 and CD73, and were negative for hematopoietic and 
pluripotent-associated markers. 
Profiling miRNAs involved in early stages of mesodermal and endothelial 
specification required identification of a progenitor population, indicating the 
beginning of lineage commitment. Using time course analysis, a CD326lowCD56+ 
mesoderm progenitor (MP) population was identified on d3 during direct hESC-EC 
differentiation, before the appearance of endothelial-associated markers, and 
coinciding with the peak in the expression of mesoderm-associated genes. 
Further characterisation was performed using fluorescence activated cell sorting 
(FACS), to isolate a pure CD326lowCD56+ MP samples, and TLDA card analysis, to 
examine the expression of 48 different genes. The existence of this population 
was also demonstrated in the indirect hESC-EC system, where CD326lowCD56+ MP 
cells were also present on d3 of differentiation, before the expression of 
hematopoietic- or endothelial-associated markers were detected. 
Global analysis of changes in miRNA expression during direct hESC-EC was then 
performed using a miRNA microarray screen, using the previously characterised 
CD326lowCD56+ MP, as well as d0 pluripotent cells, the d3 negative cell fraction 
(NCF) and d7 hESC-ECs. Overall, it was observed that pluripotency-associated 
miRNAs, such as the miR-302 family, were significantly downregulated during 
15 
 
hESC-EC differentiation, with miRNAs associated with endothelial function and 
angiogenesis significantly upregulated as cells moved toward and endothelial 
phenotype. These findings were also validated in samples taken during indirect 
hESC-EC differentiation.  
Direct comparisons between d3 CD326lowCD56+ MP and NCF samples were 
performed to identify novel miRNAs with potential roles in early mesoderm and 
endothelial commitment, and led to the identification of 56 differentially 
expressed miRNAs. Most interestingly, -3p and -5p strands of a number of miRNA 
stem loops, including miR-145 and miR-483, were found to be regulated in a 
similar manner during hESC-EC differentiation. Upon additional analysis, it was 
discovered that both strands of the miR-143 stem loop, transcribed in a cluster 
with miR-145, were also regulated in the same fashion. Therefore, the miR-
143/145 cluster and miR-483 were chosen as miRNA candidates for further 
investigation. 
Modulation of the miR-143/145 cluster and miR-483 was performed during direct 
hESC-EC differentiation. It was hypothesised that overexpression of these 
miRNAs would lead to increased differentiation efficiency, assessed via the 
percentage of CD31+CD144+ hESC-ECs present on d7. Therefore, lentiviral 
vectors, for overexpression of these specific miRNAs, were produced and cells 
infected on d0 of differentiation. Although no significant differences were 
recorded when miRNAs were overexpressed in the system, there are a large 
number of studies which could still be performed in order to fully interrogate 
the roles of miR-143/145 and miR-483 in the differentiation and commitment of 
pluripotent cells to both mesodermal and endothelial lineages. 
In summary, vast changes in global miRNA expression profiles during hESC-EC 
differentiation indicate an important role for these regulatory RNAs. 
Investigation was performed using two newly developed methods for hESC-EC 
generation and miRNAs were screened using microarray technology. Although the 
initial miRNA modulation studies were unsuccessful in increasing the efficiency 
of hESC-EC differentiation, further work must be completed in order to fully 
interrogate the roles of these specific miRNAs.    
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HUVEC Human umbilical vein endothelial cell 
IC Intermittent claudication 
ICC Immunocytochemistry 
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ICM Inner cell mass 
IGF2 Insulin-like growth factor 2 
IMBX 3-isobutyl-1-methylxanthin 
IPO8 Importin 8 
IVEC Immature vascular endothelial cell 
IVF In vitro fertilisation 
Kb Kilobase 
kg Kilogram 
KOSR Knockout serum replacement 
L Litre 
Lenti Lentivirus 
LIF Leukaemia inhibitory factor 
lncRNA long non-coding RNA 
M Molar (moles/L) 
MACS Magnetic activated cell sorting 
MEF Mouse embryonic fibroblast 
MEM Minimal essential medium 
mESC Mouse embryonic stem cell 
MI Myocardial infarction 
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min Minute 
miPSC Mouse induce pluripotent stem cell 
miRNA/miR MicroRNA 
mL  Millilitre 
mM Millimolar 
MOI Multiplicity of infection 
MP Mesoderm progenitors 
mRNA Messenger RNA 
MSC Mesenchymal stem cell 
NCF Negative cell fraction 
ng Nanogram 
nM Nanomolar 
NO Nitric oxide 
nt Nucleotide 
Oct4 Octamer-binding transcription factor 4 
PACT Protein activator of pkt 
PAD Peripheral arterial disease 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
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PE Phycoerythrin 
PerCP-Cy5.5 Peridinin-chlorophyll protein-cyanine 5.5 
pri-miRNA Primary microRNA 
PSC Pluripotent stem cell 
qRT-PCR Quantitative real time-polymerase chain reaction 
RIN RNA integrity number 
RISC RNA induced silencing complex 
RLC RISC loading complex 
RNA Ribonucleic acid 
Rnase Ribonuclease 
rpm Revolutions per minute 
RQ Relative quantification 
rRNA Ribosomal RNA 
RT Room temperature 
RT-PCR Reverse transcription-polymerase chain reaction 
s Second 
SCF Stem cell factor 
SEM Standard error of the mean 
siRNA Small interfering RNA 
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snoRNA Small nucleolar RNA 
Sox2 SRY-box 2 
ss Single stranded 
SSEA3/SSEA4 Stage specific embryonic antigen 3/4 
TF Transcription factor 
TLDA Taqman Low Density Array 
TNF-α Tumour necrosis factor-α 
TPO Thrombopoietin 
Tra1-
60/Tra1-81 Tumour receptor antigen 1-60/1-81 
TRBP TAR RNA binding protein 
UBC Ubiquitin protein C 
UTR Untranslated region 
v/v volume/volume 
VCAM-1 Vascular cell adhesion molecule 1 
VEGF Vascular endothelial growth factor 
VEGFR2 Vascular endothelial growth factor receptor 2 
VSMC Vascular smooth muscle cell 
vWF von Willibrand factor 
23 
 
w/v weight/volume 
ZEB1 Zinc-finger E-box-binding homeodomain 1 
 
 
Chapter 1 Introduction 
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1.1 Cardiovascular disease 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality 
worldwide, with over 160,000 deaths caused by this in the UK alone in 2012 
(BHF, 2014). The term CVD encompasses all diseases of the heart and circulatory 
system, including stroke, myocardial infarction (MI) and a variety of ischemic 
diseases, which in total cost the English National Health Service £6.9 billion in 
2012, and amount to approximately 30% of total deaths in both male and 
females in the UK (Figure 1.1).  
Although the numbers of people living with CVD has fallen in recent years, there 
is still need for the development of novel therapeutic strategies to relieve the 
burden on health services around the world. 
1.2 Ischemic diseases 
A major cause of cardiovascular disease is the development of atherosclerosis, a 
disease characterised by the formation of plaques, causing narrowing, hardening 
and eventual occlusion of arteries. This often leads to ischemia in the affected 
tissues (Figure 1.2).  
Ischemia is defined as a restriction in blood supply within a tissue. A restriction 
in blood supply results in insufficient supply of oxygen, nutrients and removal of 
degradation products, which can subsequently cause inhibition of tissue growth 
and cellular function, ultimately resulting in a death of affected cells and 
tissues. Depending on their location, ischemia induced by the formation of 
atherosclerotic plaques can result in various different disease pathologies, 
including coronary heart disease (CHD, a major cause of myocardial infarction), 
stroke (cerebral vasculature) and peripheral arterial disease. 
1.3 Peripheral arterial disease and critical limb ischemia 
Peripheral arterial disease (PAD) is highly prevalent, thought to affect >25 
million patients across Europe and North America (Raval et al., 2013). In 
2012/13 in the UK alone almost half a million people were on the PAD register, 
equal to approximately 0.7% of the total population (BHF, 2014). Caused as a 
result of atherosclerotic plaque build-up in the systemic and peripheral 
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vasculature, therefore resulting in ischemia in tissues supplied by those vessels, 
symptoms include muscular pain in the leg during physical activity. Currently, 
there is no cure for PAD, and most treatment regimens rely on changes in the 
lifestyle of patients, such as increasing exercise levels, changes in diet and 
stopping smoking (Bendermacher et al., 2005, NHSChoices, 2012). If left 
untreated, however, PAD can lead to a plethora of other cardiovascular 
problems, such as myocardial infarction and stroke, as well as amputation of 
affected limbs. 
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Figure 1.1 – UK deaths by cause and gender. 
Charts showing female and male deaths in the UK in 2012 by cause. In total 28% (females) and 
29% (males) of all deaths in the UK in 2012 were caused by cardiovascular diseases (Source: 
BHF, 2014).  
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The most common clinical manifestation of PAD is intermittent claudication (IC), 
characterised by exertion mediated pain in the lower limbs, caused through an 
inability to meet the demands of exercising skeletal muscle, due to inadequate 
blood flow.  In the most serious cases, however, PAD can result in the 
development of critical limb ischemia (CLI). CLI is thought to affect 
approximately 1% of PAD sufferers, and develops as a consequence of chronic 
ischemia in the peripheral vasculature, and can lead to irreversible tissue 
damage and cell death. A reduced blood supply can result in a failure to meet 
basal metabolic requirements, causing CLI patients can present at clinic with 
severe pain during rest, ischemic ulceration or gangrene, and have a higher risk 
of other cardiovascular events, such as stroke and CHD (Subherwal et al., 2015). 
Large multicentre trials have shown that 25-30% of patients undergo major 
amputations (below or above knee) and up to 20% of patients die within the first 
year after presentation, with the limited amounts of longer-term data suggesting 
that mortality rates continue to rise after this time (Norgren et al., 2007, 
Powell, 2012).  
 
Figure 1.2 – Atherosclerotic plaque formation. 
Diagram showing a normal artery (A) and an artery affected by the formation of an atherosclerotic 
plaque (B). The formation of these plaques causes hardening and narrowing of arteries, resulting in 
restricted blood flow to affected organs, tissues and limbs (NIH, 2014). 
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1.3.1 Current therapies 
Current therapies for the treatment of CLI focus mainly on the prevention of 
major amputation, as well as relieving pain, increasing survival and improving 
the quality of life. Presently, the preferred treatment for patients with limb-
threatening ischemia is revascularisation; the reestablishment of continuous in-
line flow to the affected limb. This can be done in a number of ways, including 
surgical or endovascular revascularisation, or a hybrid, whereby a combination 
of these two therapies are used (Slovut et al., 2008). 
The most common intervention strategy for CLI and symptomatic PAD is 
endovascular revascularisation, via the use of catheter-based therapies, such as 
balloon angioplasty and stenting. Originally, evidence that these strategies were 
leading to long term improvements in patient’s health were lacking, and 1-year 
failure rates were high (Kalbaugh et al., 2006), although it had been claimed 
that some patients reported an improvement in symptoms, function and quality 
of life 1-year post procedure  (Safley et al., 2007). More recently, however, 
innovations in technology and development of specialised therapeutic devices 
has improved clinical outcome, and has, therefore, led to increasing use of 
endovascular revascularisation strategies in the treatment of more advanced CLI 
(Thukkani et al., 2015).   
Surgical revascularisation techniques may also be used to treat CLI, whereby 
bypass grafts are used to restore blood flow to ischemic limbs. This technique is 
particularly used in patients who have more complex lesions, and are therefore 
not suitable for catheter-based revascularisation techniques, and for younger 
patients with a longer life-expectancy, who require more durable 
revascularisation (Slovut et al., 2008). Although  not the preferred therapy, an 
early study showed a limb-based patency  in patients suffering CLI of 87.5% and 
81.8% at 5 and 10 years post-intervention (de Vries et al., 1997). A meta-analysis 
of published studies, including one randomised control trial, comparing both 
endovascular and surgical revascularisation techniques, however, showed no 
significant differences in amputation-free survival and overall survival between 
the two groups (Bradbury et al., 2010, Jones et al., 2014). 
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Due to the varied clinical outcomes of these treatments, coupled with the fact 
that a large number of patients with CLI are considered ineligible for 
revascularisation using either surgical or endovascular-based techniques, the 
development of new treatments is paramount. In recent years, therefore, 
research has focused on the development of novel therapies. Vascular 
regenerative strategies, including gene and cell therapies, are thought to have 
great potential in this area, allowing for the potential generation of new 
vasculature and promotion of angiogenesis in affected limbs. 
1.4 Strategies for vascular regeneration 
Regenerative medicine encompasses all strategies for the repair, replacement or 
regrowth of damaged or destroyed tissues and organs, including the use of 
biomaterials, or human genes, proteins or cells.  
In PAD and CLI, early regenerative medicine strategies focused on the 
administration of angiogenesis-inducing growth factors, such as vascular 
endothelial growth factor (VEGF) or fibroblast growth factor (FGF) (Lederman et 
al., 2002, Henry et al., 2003). Angiogenesis is defined as the migration and 
proliferation of differentiated endothelial cells (ECs) in order to allow sprouting 
of new capillary branches from existing vessels, and stimulate the development 
and growth of new blood vessels in the affected tissue. Although early results 
from these trials were promising, and treatment using these factors was found 
be safe, there were no lasting clinical affects when patients were treated with a 
single dose of VEGF, or when they were administered with a two doses of FGF 
(Lederman et al., 2002, Henry et al., 2003). This may be due to insufficient 
doses – a very large amount of protein may be needed to have a significant 
affect, something which is unrealistic in a clinical setting. 
1.4.1 Gene therapy 
Gene therapy has also been considered for the administration of a number of 
different angiogenic factors. Adenoviral vectors are largely used in gene therapy 
studies, however a number of high profile serious adverse events during clinical 
trials have led to major questions about the safety of these treatments 
(Marshall, 1999, Gansbacher et al., 2003). Another strategy, which has been 
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investigated in the setting of PAD and CLI, is the administration of naked plasmid 
DNA encoding angiogenic factors. These therapies aimed to increase the 
duration of transgene expression, when compared to injection of the proteins 
themselves, and the plasmids induce only a minimal immune response. Despite 
this, expression of the transgene remains low, as plasmids have low transfection 
efficiency and remain episomal (Raval et al., 2013).  
The first case of administration of naked plasmid DNA, encoding for VEGF was 
reported almost 20 years ago (Isner et al., 1996), and although no definitive 
conclusions could be made from the study, results were optimistic. In 1998 a 
trial injecting a similar plasmid construct into 10 limbs of 9 patients suffering 
with CLI, showed an increase in VEGF expression in the injected limbs, possibly 
with an increase in therapeutic angiogenesis (Baumgartner et al., 1998). Since 
then, numerous clinical and pre-clinical studies have been performed, using a 
variety of VEGF family members and viral vectors. A Phase I clinical trial 
confirmed the safety of adenoviral-mediated delivery of VEGF cDNA to patients 
with PAD, although no conclusions could be drawn about efficacy due to the low 
numbers of participants in the trial (Rajagopalan et al., 2002). In 2012, a 10-year 
safety follow up on patients treated with injection of either an adenoviral vector 
containing a VEGF-encoding plasmid, or a plasmid/liposome combination, 
directly into an ischemic lower limb, confirmed the long-term safety of this 
approach, although there was no difference in Fontaine category (the scale used 
to clinically classify PAD) between the VEGF treatment groups and the control 
patients, possibly due to the low numbers of patients surviving to the 10-year 
follow up (Muona et al., 2012). 
Currently, there are 22 known FGF ligands involved in angiogenesis (Murakami et 
al., 2008), and cardiovascular gene therapy trials have been performed using a 
number of these isoforms. The first clinical study of FGF-1 gene therapy showed 
significant improvements in wound healing, pain and transcutaneous oxygen 
pressure, after an intramuscular injection of a naked plasmid, encoding for the 
FGF-1 (NVFGF1) (Comerota et al., 2002). However, a large scale phase III clinical 
trial (TAMARIS) showed that there was no difference in major amputation or 
death between the active and placebo groups, when CLI patients, not suitable 
for revascularisation, were treated with eight intramuscular  injections of either 
NVFGF1 or a placebo (Belch et al., 2011). Trials using a Sendai virus expressing 
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human FGF-2, which had previously been shown to significantly decrease in 
amputation rates in a mouse model through induction of endogenous VEGF 
expression, showed significant improvements of limb function (Masaki et al., 
2002, Yonemitsu et al., 2013). 
A number of gene therapy clinical trials, using other angiogenic factors, such as 
hypoxia-inducible factor-1α (HIF-1α), hepatocyte growth factor (HGF) and 
developmentally regulated endothelial locus (Del-1), have also been performed 
in patients suffering with IC and CLI (Grossman et al., 2007, Powell et al., 2010, 
Creager et al., 2011). Although no significant safety issues were reported in any 
of these trials, results were mixed, with most studies finding no significant 
difference in primary end point between the treatment and placebo groups. 
Overall, strategies using angiogenic growth factors to treat PAD and CLI have 
been largely unsuccessful and, therefore, an increasing knowledge of stem and 
progenitor cells, and their potential clinical applications, has prompted a move 
towards cell-based therapies. 
1.4.2 Cell therapies 
Currently, there are 34 clinical trials involving stem cell therapies in the 
treatment of CLI which have been registered at clinicaltrials.gov (Table 1.1). 
Thus far, cell therapies results have been varied, with the majority of studies 
involving the transplantation or injection of autologous cell populations, broadly 
known as ‘adult stem cells’, including mesenchymal stem cells (MSC), bone 
marrow mononuclear cells (BM-MNC) and endothelial progenitor cells (EPC). 
Autologous cell types have an advantage in that they are derived from the 
patient themselves, reducing the risk of immune rejection.  
MSCs originate in the stromal compartment of the bone marrow, where they 
make up only a small fraction of the total nucleated cells. Other sources of cells 
with mesenchymal potential have also been reported, for example adipose tissue 
and skeletal muscle (Jankowski et al., 2002, De Ugarte et al., 2003). These cells 
are described as multipotent, non-hematopoietic and fibroblast-like, possessing 
the ability to differentiate into a number of cell types, including bone, fat and 
cartilage (Liew et al., 2012). Although their cell surface marker profile has been 
debated (Lv et al., 2014), their broad potential in the field of regenerative 
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medicine is widely accepted, and because of this their safety profile has been 
well documented (Ankrum et al., 2010). In specific conditions, it has been shown 
that MSCs can differentiate directly into ECs, indicating a possible role for these 
cells in the treatment of ischemic diseases (Chen et al., 2009b). Indeed, in 
preclinical models of PAD and CLI, such as the murine model of hind limb 
ischemia, treatment of animals with ECs from MSCs, derived from numerous 
sources, perfusion rates of ischemic limbs were significantly higher in animals 
treated with the cells when compared to control animals (Kang et al., 2010, Lian 
et al., 2010). In clinical trials, however, results have been varied, and many 
trials have shown no significant improvement in secondary outcomes (Perin et 
al., 2011, Kirana et al., 2012) or have failed to publish their results (Table 1.1). 
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Table 1.1 
ClinicalTrials.gov 
Identifier 
Phase Patient 
Number 
Cell Type(s) Autologous/ 
Allogeneic 
Cell Number Primary Outcome 
Measures 
Status Reference 
NCT01257776 I & II 30 Adipose-derived 
MSCs 
Autologous Mid dose - 1x10
6 
* 
weight (kg), Low dose - 
0.5x10
6 
* weight (kg) 
Angiograph to 
assess 
neovasculargenesis; 
Major adverse 
events  
Ongoing ClinicalTrials.
gov 
NCT02287974 I & II 48 
(estimated) 
BM-MNCs; CD133
+
 
EPCs; Bone 
marrow-derived 
MSCs 
Autologous 150-250x10
6 
BM-MNCs; 
2-7x106 EPCs; 0.5x10
6 
Bone marrow-derived 
MSCs 
Serious adverse 
events 
Recruiting ClinicalTrials.
gov 
NCT01484574 II 126 
(estimated) 
Bone marrow-
derived MSCs 
Allogeneic High; Mid; Low Relief of rest pain; 
Healing of 
ulcerations 
Unknown ClinicalTrials.
gov 
NCT02477540 I 10 
(estimated) 
Bone marrow-
derived MSCs 
Autologous 50x10
6
 cells/10mL x 2 
injections 
Ankle Brachial 
Pressure Index; 
Safety 
Not yet 
recruiting 
ClinicalTrials.
gov 
NCT01745744 I & II 33 Adipose-derived 
MSCs 
Autologous High dose - 1x10
6 
* 
weight (kg), Low dose - 
0.5x10
6 
* weight (kg) 
Numbers of adverse 
and serious adverse 
events 
Ongoing ClinicalTrials.
gov 
NCT01867190 I & II 24 
(estimated) 
CD34
+
 and CD45
+
 
bone marrow-
derived stem cells 
Autologous 10x10
6
 CD45
+
 cells/mL; 
5mL/min via intra-
arterial infusion or 6 x 
0.2mL intramuscular 
injections 
Major amputations; 
persisting CLI; Safety 
Recruiting ClinicalTrials.
gov 
NCT00913900 I 10 CD133
+
 cells Autologous Not specified Death or amputation Terminated 
- adequate 
cells for 
minimum 
dose 
ClinicalTrials.
gov 
NCT01824069 I & II 10 Adipose-derived 
MSCs 
Autologous 1x10
6
 * weight (kg) Safety Unknown ClinicalTrials.
gov 
NCT00883870 I & II 20 Bone marrow-
derived MSCs 
Allogeneic Not specified Adverse events; 
symptomatic relief 
Completed ClinicalTrials.
gov 
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Table 1.1 
ClinicalTrials.gov 
Identifier 
Phase Patient 
Number 
Cell Type(s) Autologous/ 
Allogeneic 
Cell Number Primary Outcome 
Measures 
Status Reference 
NCT00371371 I & II 160 BM-MNCs Autologous Not specified Major amputations Completed (Teraa et al., 
2015) 
 
NCT02145897 
I & II 60 
(estimated) 
Stromal vascular 
fraction (SVF); ex 
vivo expanded 
Adipose-derived 
MSCs 
Autologous SVF - not specified; 
MSCs - 2 x 1x106 * 
weight (kg) cells, 1x 
intravenous, 1x 
intramuscular 
Safety Recruiting ClinicalTrials.
gov 
NCT00442143 I 10 BM-MNCs Autologous Not specified Transcutaneous 
oxygen pressure; 1st 
toe blood pressue; 
ankle blood pressue; 
wound healing; pain 
Unknown ClinicalTrials.
gov 
NCT00616980 I & II 28 CD34
+
 cells Autologous High dose - 1x10
6 
* 
weight (kg), Low dose - 
0.1x10
6 
* weight (kg) 
Safety; Rest pain; 
Ulcer healing; 
Functional 
improvement; Limb 
salavage 
Completed (Losordo et 
al., 2012) 
NCT01065337 II 30 Bone marrow stem 
cells; CD90
+
 
enriched bone 
marrow MSCs 
Autologous Not specified Major adverse 
events; Wound 
healing; Ipsilateral 
replase 
Completed (Kirana et al., 
2012) 
NCT01232673 II 96 Bone marrow stem 
cells 
Autologous Not specified Major limb 
amputation 
Completed (Prochazka 
et al., 2010) 
NCT00392509 I & II 20 Bone Marrow 
Derived Aldehyde 
Dehydrogenase-
Bright cells; 
Unfractioned BM-
MNCs 
Autologous Not specified Adverse events; 
Ankle-brachial 
systolic pressure 
index; 
transcutaneous 
oxygen valu; quality 
of life 
Completed (Perin et al., 
2011) 
NCT01480414 I & II 20 BM-MNCs Autologous Not specified Side effect of cell 
injection 
Completed ClinicalTrials.
gov 
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Table 1.1 
ClinicalTrials.gov 
Identifier 
Phase Patient 
Number 
Cell Type(s) Autologous/ 
Allogeneic 
Cell Number Primary Outcome 
Measures 
Status Reference 
NCT00523731 I 6 Non-mobilised 
peripheral blood 
angiogenic cell 
precursors 
Autologous Not specified Safety; Rest pain; 
Pain-free walking 
distance; Ulcer size; 
Gangrene; Perfusion 
improvements 
Completed (Mutirangura 
et al., 2009) 
NCT01584986 II 22 Peripheral blood 
derived angiogenic 
cell precursors 
Autologous Not specified Safety; Rest pain; 
Ulcer healing; 
Functional 
improvement; Limb 
salvage 
Completed (Murphy et 
al., 2011) 
NCT01049919 Not 
specified 
152 Bone marrow 
aspirate 
Autologous Not specified Time to major 
adverse event 
Ongoing ClinicalTrials.
gov 
NCT01483898 III 41 ixmyelocel-T 
(patient specific 
multicellular 
therapy) 
Autologous Not specified Amputation free 
survival 
Unknown ClinicalTrials.
gov 
NCT00922389 I & II 36 
(estimated) 
G-CSF mobilised 
peripheral blood-
derived BM-MNCs 
Autologous Not specified Adverse events; 
Laboratory 
parameters 
Unknown ClinicalTrials.
gov 
NCT01245335 III 210 
(estimated) 
Bone marrow 
aspirate  
Autologous Not specified Amputation free 
survival 
Ongoing ClinicalTrials.
gov 
NCT03454231 II & III 38 BM-MNCs; 
Circulating 
CD14
+
CD34
+
 cells 
Autologous Not specified Safety; Adverse 
events; Changes in 
ischemic leg 
perfusion 
Recruiting ClinicalTrials.
gov 
NCT01386216 I 20 Bone marrow cell 
concentrate 
Autologous Not specified Time to major 
amputation 
Ongoing ClinicalTrials.
gov 
NCT01595776 I & II 8 CD133
+
 EPCs Autologous Not specified Contrast enhance 
ultrasound 
Completed ClinicalTrials.
gov 
NCT01663376 I & II 20 Adipose-derived 
MSCs 
Autologous 3x10
8 
cells at 60 points 
in lower extremities 
Major adverse 
events 
Completed (Lee et al., 
2012) 
NCT00595257 I & II 60 Bone marrow 
aspirate 
concentrate 
Autologous Not specified Amputation free 
survival 
Completed ClinicalTrials.
gov 
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Table 1.1 
Table 1.1 – Current clinical trials using stem cells for the treatment of CLI. 
All data collected from clinicaltrials.gov, references given where trials published. MSC – mesenchymal stem cell, BM-MNC – bone marrow mononuclear cell, EPC – 
endothelial progenitor cell (https://clinicaltrials.gov/, search terms ‘CLI’ and ‘stem cells’, search performed July 2015).  
 
 
ClinicalTrials.gov 
Identifier 
Phase Patient 
Number 
Cell Type(s) Autologous/ 
Allogeneic 
Cell Number Primary Outcome 
Measures 
Status Reference 
NCT01472289 I & II 15 BM-MNCs Autologous Not specified Safety; Limb 
salavage 
Ongoing ClinicalTrials.
gov 
NCT00987363 I & II 60 BM-MNCs Autologous High dose - 1x10
9
; 
Intermediate dose - 
5x10
8
; Low dose 1x10
8
 
Number of adverse 
events; 
Arteriographic 
analysis 
Completed ClinicalTrials.
gov 
NCT01408381 II 38 BM-MNCs Autologous Intermediate dose - 
5x10
8
; Low dose 1x10
8
 
Adverse events Completed ClinicalTrials.
gov 
NCT01558908 I & II 15 Endometrial 
regenerative cells 
(ERC) 
Autologous 25x10
6
; 50x10
6
; 100x10
6
 
ERC 
Safety; Adverse 
events 
Unknown ClinicalTrials.
gov 
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As well as MSCs, studies have shown potential in the use of BM-MNCs for the 
treatment of vascular and ischemic diseases (Table 1.1). The term BM-MNCs is 
broad, and encompasses a number of different bone marrow-derived cell types, 
including hematopoietic cells such as lymphocytes, monocytes and 
hematopoietic stem cells, as well as MSCs. Studies have focused on using this 
entire fraction with the hypothesis that the presence of multiple progenitor cell 
types may work in synergy to promote regeneration in a variety of disease 
settings. Various studies have shown the possible angiogenic capacity of these 
cells in the treatment of CLI in the clinic (Matoba et al., 2008, Madaric et al., 
2013), although this maybe in part due to the presence of MSCs in the BM-MNC 
fraction (Alvarez-Viejo et al., 2013). Indeed, a pilot study, comparing the 
treatment of type 2 diabetic patients suffering with CLI using either bone 
marrow-derived MSCs or BM-MNCs, demonstrated that patients treated with 
MSCs, suggested that MSC transplantation may be more effective than treatment 
with BM-MNCs. Although, results did show substantial improvements in patients, 
in terms of rest pain, pain-free walking time, ankle-brachial index, 
transcutaneous oxygen pressure and formation of new collateral vessels when 
examined using magnetic resonance angiography, for both treatment groups, 
suggesting both MSCs and BM-MNCs may make effective cell therapies (Lu et al., 
2011). The recently published JUVENTAS trial (NCT00371371; Table 1.1), 
however, contradicted these results, showing no reduction in the major 
amputation rates in patients with severe CLI who underwent 3 intra-arterial 
infusions of BM-MNCs (Teraa et al., 2015). A recently published clinical study 
suggested that the efficacy of cell therapies could be improved if they were 
administered alongside gene therapies (Skora et al., 2015). Patients were 
intramuscularly injected with a solution containing BM-MNCs and a plasmid 
encoding VEGF165, directly into the ischemic lower limb. Although the primary 
objective of the study was to demonstrate the safety and feasibility of this 
combination, which was done so successfully, results also showed marginal 
improvements in the conditions of the patients.  
A study, published in 1997, showed that another, distinct, small population of 
bone marrow derived cells can be isolated from peripheral blood, differentiate 
to endothelial cells in vitro and can contribute to vasculogenesis in vivo (Asahara 
et al., 1997, Shi et al., 1998). These cells were termed endothelial progenitor 
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cells (EPC) and, loosely defined, are any cell which retain the ability to form 
endothelial cells. Despite large numbers of both preclinical and clinical studies, 
the exact profile of these cells is still under debate. Asahara et al. described 
these cells as CD34+, and this profile was also used in a further study by Shi et 
al. in 1998 (Shi et al., 1998), where the endothelial potential of these cells was 
once again demonstrated comprehensively in vitro and in vivo. Since then, the 
presence of VEGFR2 (CD309; KDR) and CD133 on the surface of these cells 
(Gehling et al., 2000, Peichev et al., 2000), has also been demonstrated, and 
they have been isolated from a variety of sources, including umbilical cord blood 
and bone marrow (Eggermann et al., 2003). Other research has, however, 
questioned the accepted CD34+CD133+VEGFR2+ profile, and Case et al. failed to 
get these cells to form ECs in culture, and instead demonstrated their ability to 
form haematopoietic precursor cells (Case et al., 2007). Preclinical studies 
showed increase blood flow recovery in an in vivo model of hind limb ischemia, 
compared to the control group, when animals were administered with human 
EPCs, which had been expanded ex vivo (Kalka et al., 2000), and recent clinical 
studies have also shown positive results, both in the safety and efficacy of these 
cells.  
The efficacy of these cellular-based therapies does not always translate in 
clinical trials, and many studies fail to progress past phase I or II, as shown in 
Table 1.1. Cell survival may be low, and the estimated percentage incorporation 
of cells has been widely variable, for examples, some studies have shown EPCs 
located on the periphery of newly formed arteries, and not actually 
incorporated. This has led to speculation that MSC-, BMNC- and EPC-mediated 
vasculogenesis occurs almost entirely through paracrine mechanisms, via the 
secretion of angiogenic factors, such as VEGF (Kinnaird et al., 2004, Liang et al., 
2014). 
Although meta-analyses have shown that overall cell therapies have a beneficial 
effect in the reduction of amputations (Liu et al., 2012, Liu et al., 2015), clinical 
trials have shown varying degrees of success in terms of symptomatic relief and 
revascularisation. Although research and trials are continuing with ever 
increasing levels of specificity, research has also started to look at the use of 
pluripotent stem cell (PSC)-derived cells, in particular those derived from human 
embryonic (hESC) and induced pluripotent (hiPSC) stem cells, as a source of 
40 
 
 
functional, transplantable cells for the treatment of PAD and CLI, as well as a 
wide range of other ischemic diseases, including CHD and stroke. As of yet, no 
clinical trials have been registered for the use of these cells in CLI or PAD 
treatment (Table 1.1). 
1.5 Pluripotent Stem Cells 
Due to their unique ability to differentiate into any cell of the three germ layers 
(endoderm, ectoderm and mesoderm) and their capacity for unlimited self-
renewal, hPSCs hold great potential for a number of diverse scientific and 
clinical applications, including pharmacology, toxicology and for the 
development of cellular-based therapies and regenerative medicine. Currently, 
there are 2 different types of pluripotent stem cells which have been described – 
embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). 
1.5.1 Human embryonic stem cells 
The first of the two pluripotent stem cell types to be identified and isolated, 
human ESCs (hESC) are important tools in the fields of developmental biology 
and regenerative medicine. Prior to the derivation of ESCs, embryonal carcinoma 
cells (ECC), isolated from teratocarinomas formed after the implantation of 
early stage mouse embryos, were originally used as an in vitro model of the 
developing embryo (Martin, 1980). After a  number of unsuccessful attempts, a 
breakthrough came in 1981 when ESCs were isolated from murine embryos 
(Evans et al., 1981, Martin, 1981), before they were isolated from non-human 
primate embryo’s in 1995 (Thomson et al., 1995). In 1998 James A. Thomson 
used human embryos, produced by in vitro fertilisation (IVF), to isolate and 
culture the first human-derived ESCs (Thomson et al., 1998). The cells were 
obtained from the inner cell mass (ICM) of the blastocyst stage embryo, isolated 
by immunosurgery and cultured on irradiated mouse embryonic fibroblasts 
(MEF). Cells were grown as colonies and individual undifferentiated colonies 
were manually selected and dissociated into clumps until the cell line was 
established. Five different hESC lines were derived, two having a normal XX 
karyotype (H7 and H9) and 3 having a normal XY karyotype (H1, H13 and H14). 
These cells, generated in 1998, are still used in research today and are widely 
regarded as the ‘gold standard’ hESC lines.  
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Originally, hESC lines were cultured on MEF feeder layers, and in serum 
containing medium, in order to culture the cells whilst maintaining their 
undifferentiated state (Thomson et al., 1998). Using animal derived serum and 
cells to culture the hESCs, however, raised concerns about the transfer of non-
human pathogens, and limits the potential use of these cells in a clinical setting. 
Therefore, efforts were made to advance the culture conditions to a clinically 
acceptable standard, and following good manufacturing practice (GMP). MEF 
feeder layers secrete a number of soluble factors required for the maintenance 
of pluripotency and, in mouse ESCs (mESC) culture, it was discovered that 
feeder layers could be replaced by the addition of leukaemia inhibitory factor 
(LIF) into the culture medium (Williams et al., 1988). LIF does not, however, 
have the same effect on hESC culture. The earliest feeder-free culture systems 
were established using Matrigel cell matrix and in MEF-conditioned medium 
(MEF-CM), containing the soluble factors secreted by MEFs to support 
pluripotency (Xu et al., 2001). Subsequently, Xu et al. were also able to show 
that hESCs can be maintained in serum replacement non-conditioned medium 
supplemented with basic fibroblast growth factor (bFGF), based on their 
expression of the receptors for a number of FGFs (Xu et al., 2005). 
In addition to the original 5 lines, a large number of other hESC lines have now 
been generated. Between lines there exists considerable heterogeneity, with 
differences in gene expression signatures (Abeyta et al., 2004), differentiation 
propensity (Osafune et al., 2008) and population doubling time all 
demonstrated, possibly reflecting differences in derivation method and timing, 
initial culture conditions, or underlying genetics of the source embryos. Despite 
this, there are a number of criteria which any hESC line must meet (Hoffman et 
al., 2005). This includes expressing a number of pluripotency associated cell 
surface antigens and internal transcription factors such as stage specific 
embryonic antigens 3 and 4 (SSEA3; SSEA4), tumour receptor antigens 1-60 and 
1-81 (Tra1-60; Tra1-81), octamer-binding transcription factor 4 (Oct4; encoded 
by the Pou5f1 gene), Nanog, and SRY-box 2 (Sox2). Another definitive test of 
hESC pluripotency is often considered to be the ability to form derivatives of the 
three germ layers in immunocompromised mice in vivo (Allegrucci et al., 2007). 
Other properties these cells must possess include a capacity for indefinite self-
renewal, and a normal karyotype.  
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Despite their promise, there are numerous caveats that must be addressed 
before such strategies can be considered for routine use clinically. Firstly, there 
are a number of ethical concerns, including the destruction  of fertilised 
embryos, which must be taken into account when using these cells (de Wert et 
al., 2003). Secondly, ensuring all pluripotent cells are removed from the 
transplanted cell population is essential, as the presence of undifferentiated 
cells increases the potential of teratoma formation. Another caveat is their 
immunogenicity. In a similar way to tissue and organs, transplantation of hESCs 
is an allogeneic process, and rejection by the host is a very real prospect. 
Several studies have shown varying degrees of immune response elicited by 
these cells, with some reports even suggesting that hESCs are immune-privileged 
(Li et al., 2004, Drukker et al., 2006). Circumvention of rejection may be 
possible via the generation of hESC banks containing immunophenotyped lines, 
although this requires a large time and economic investment (Jacquet et al., 
2013). It is estimated that generation of 150 hESC lines from random donors 
would only match 38% of the UK population (Taylor et al., 2005). Despite these 
safety concerns, however, the first clinical trials using hESC-derived cell types 
have commenced. A recently published trial, evaluating hESC-derived retinal 
pigment epithelium in the treatment of patients with age-related macular 
degeneration and Stargardt’s macular dystrophy (Schwartz et al., 2015), 
provided evidence of safety, graft survival and possible biological activity. 
1.5.2 Induced pluripotent stem cells 
One way in which to overcome the issue of hESC immunorejection is via the use 
of autologous cells. In 2007, Shinya Yamanaka and his team successfully 
reprogrammed both mouse (Takahashi et al., 2006) and human (Takahashi et al., 
2007) adult fibroblasts to pluripotency by transduction of four defined factors; 
Oct4, Sox2, Klf4 and c-Myc. The pluripotent cells generated, known as induced 
pluripotent stem cells (iPSCs) are similar to hESCs in morphology, proliferation, 
surface antigens (SSEA3, SSEA4, Tra1-60 and Tra1-81) and gene expression (Oct4, 
Nanog, Sox2), and are able to produce cells from all 3 germ layers both in vitro 
and in in vivo teratoma formation assays. Although hESCs are still considered the 
‘gold standard’ in terms of developmental biology, these cells have the potential 
to provide patient- and disease-specific autologous cells for transplantation. 
Additionally, iPSCs can be used as excellent in vitro models of disease. For 
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example, it has been demonstrated that iPSCs generated from patients with long 
QT syndrome type 2, a disease characterised by abnormal ventricular 
repolarisation, and subsequently differentiated to cardiomyocytes can be used 
to test drug potency and toxicity (Itzhaki et al., 2011, Matsa et al., 2011). 
Moreover, as the method of iPSC derivation does not require the use of human 
embryos, using these cells circumvents the ethical issues faced with the use of 
hESCs. 
An overview of iPSC derivation and potential uses can be seen in Figure 1.3. 
 
Figure 1.3 – Derivation and potential uses of hiPSC. 
Human iPSC are generated via reprogramming of terminally differentiated adult cells e.g. 
fibroblasts, using a number of factors, including Oct4, Sox2, Klf4 and c-Myc. Once reprogrammed, 
they can be differentiated into any cell of the three germ layers. Differentiated cells then have a 
variety of uses including autologous cell therapies, in vitro disease modelling and drug screening.  
1.5.3 Regulation of pluripotency 
As stated previously, there are two main characteristics of pluripotent stem 
cells; their ability to self-renew indefinitely, and their pluripotency – the ability 
to generate cells from the mesoderm, ectoderm and endoderm. During in vivo 
development, pluripotency is a characteristic of the ICM of the preimplantation 
blastocyst, existing transiently. In vitro, however, these cells maintain their 
pluripotency indefinitely (section 1.5.1). Although well studied, the mechanisms 
governing pluripotency in these cells are still relatively poorly understood.  
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Thus far, research has identified a group of key transcription factors, playing 
essential roles in maintenance and control of pluripotency – Oct4, Sox2 and 
Nanog. Indeed, these factors are used in the reprogramming of somatic cells to a 
pluripotent state (section 1.5.2). Much of the original work was performed in 
mESCs, before the derivation of hESCs in 1998, with many of the mechanisms 
conserved between the two systems. 
A member of the POU (Pit-Oct-Unc) transcription factor family and encoded by 
the Pou5f1 gene, the role of Oct4 was first demonstrated during embryonic 
development in mice. In vivo, the expression of Oct4 mRNA and protein is 
restricted to pluripotent cells within the gastrulating embryo, and in germ cells 
(Rosner et al., 1990), and in vitro to ESCs (Okamoto et al., 1990), and was found 
to be rapidly downregulation during differentiation and specification of cells to 
specific germ layers (Okamoto et al., 1990, Pesce et al., 1998). Indeed, 
introduction of a homozygous Oct4-/- mutation results in peri-implantation 
lethality, and cells no longer progress to become mature ICM cells, revealing an 
essential role for Oct4 in the establishment of ICM pluripotency (Nichols et al., 
1998). In hESCs in vitro, knockdown of Oct4 results in rapid changes in 
morphology, a marked reduction in growth rate and cell surface marker 
expression, including down regulation of SSEA3, SSEA4, and Tra1-60 (Hay et al., 
2004, Matin et al., 2004). Cells deficient in Oct4 also show a clear upregulation 
of differentiation-associated markers, particularly genes associated with 
differentiation to trophoectoderm (Niwa et al., 2000, Matin et al., 2004), 
endoderm (Hay et al., 2004) and mesoderm (Rodriguez et al., 2007). 
Upregulation of Oct4 was also shown to induce changes in genes associated with 
mesodermal and endodermal differentiation (Niwa et al., 2000, Rodriguez et al., 
2007), thus implying a critical amount of Oct4 is required to efficiently regulate 
pluripotency. Additionally, RNAi-induced silencing of Oct4 induced a change in 
>1000 genes, with both positive (e.g. pluripotency-associated TFs) and negative 
(e.g. mesoderm, endoderm and ectoderm-associated genes) regulation of 
different gene sets, many of which are implicated in the strict regulation of 
pluripotency (Babaie et al., 2007).  
Oct4 interacts with other TFs, in order to activate and repress the expression of 
specific genes. One such protein, with which Oct4 can heterodimerise, is Sox2, a 
member of the SRY-related HMG box (Sox) family, which encodes transcription 
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factors with a single HMG DNA-binding domain. Similary to Oct4, Sox2 is 
expressed in the pluripotent cells in the developing embryo and in mESCs and 
hESCs in vitro. Inhibition of Sox2 expression results in embryonic lethality in 
vivo, as no ICM develops (Avilion et al., 2003), and in hESC in culture resulted in 
the loss of pluripotency, indicated by changes in morphology and surface marker 
expression (Fong et al., 2008). Furthermore, hESCs, in which Sox2 has been 
knocked down, are most likely to differentiate towards the trophectoderm, with 
significant upregulation in genes associated with this cell lineage (Adachi et al., 
2010). Cells in which Sox2 was transiently overexpressed observed a very similar 
phenotype, suggesting that tight regulation of Sox2 is needed in order to 
maintain pluripotency. 
The last of the three key transcription factors is Nanog. A homeodomain TF, 
Nanog was identified in mESCs, using in silico digital differentiation display, and 
found to be enriched in undifferentiated cells (Mitsui et al., 2003). mESC lacking  
Nanog acquired morophological changes, and differentiated towards 
extraendoderm lineages, and Nanog null embryos were epiblast deficient, 
showing that Nanog is essential for the maintenance of a pluripotent state 
(Mitsui et al., 2003). Hyslop et al. confirmed this is hESCs, whereby RNAi-
mediated silencing of human Nanog induced activation of a number of 
extraembryonic endoderm associated genes such as GATA4 and GATA6, and 
trophoectoderm-associated genes (Hyslop et al., 2005). It was also shown that 
Nanog was expressed in the ICM of blastocyst stage pre-implantation human 
embryos, but not in some of the earlier-stage embryos, demonstrating a role for 
Nanog in the maintenance of pluripotency.  
Most interestingly, genome-scale location analysis showed that main protein-
coding and miRNA genes are targeted by all three of these transcription factors 
(Boyer et al., 2005). Oct4, Sox2 and Nanog were found to co-occupy the 
promoter region of 353 different genes, with binding sites occurring in close 
proximity. The three factors were found to regulate pluripotency by binding and 
transcriptionally activating genes with roles in pluripotency, including Oct4, 
Sox2, Nanog and STAT3, and binding and transcriptionally inactivating genes that 
promote development, such as HOXB1and PAX6. The binding sites for the three 
TFs are in close proximity in co-occupied promoter regions, and the presence of 
Nanog was shown to increase the efficiency with which the Oct4-Sox2 
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heterodimer forms (Boyer et al., 2005, Rodda et al., 2005). Indeed, targeted 
down regulation of any one of these three factors results in a decrease in the 
expression of the other two. Thus, a synergy exists between these three factors, 
forming an autoregulatory loop (Figure 1.4), and working to regulate a large 
number of differentiation and pluripotency associated genes.  
 
Figure 1.4 –Pluripotency-associated transcription factors form an autoregulatory loop. 
Schematic showing the autoregulatory function of the three main pluripotency-associated 
transcription factors. Blue boxes show genes, red circles show proteins/TFs, dotted arrows 
represent translation. Adapted from Boyer et al. (2005). 
1.6 Endothelial differentiation of pluripotent stem cells 
To date, there have been a large number of protocols published, demonstrating 
the ability of hESC and hiPSCs to differentiated into various cell types in vitro, 
including hepatocytes (Hannan et al., 2013), neural progenitors (Dhara et al., 
2008), cardiomyocytes (Mummery et al., 2012) and smooth muscle (Cheung et 
al., 2011), and these have been extensively reviewed. However, in terms of 
vascular regeneration and stimulation of angiogenesis, hPSC-derived endothelial 
cells (hPSC-ECs) are thought to have the greatest potential, although methods of 
derivation still remain suboptimal. 
1.6.1 In vitro differentiation of pluripotent stem cells to 
endothelium 
Thus far, there have been a large number of publications describing protocols 
for the derivation of ECs from hPSCs, and these have been reviewed extensively 
(Descamps et al., 2012). Within this, there are two main approaches which have 
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been taken when generating hESC-ECs; 3D embyroid body (EB)-based culture 
systems and 2D monolayer culture systems. 
Endothelial-associated genes, including Pecam-1 (CD31), VE-Cadherin (CD144) 
and CD34, are increased during spontaneous EB-based differentiation of hESCs 
(Levenberg et al., 2002). However, the efficiency of these differentiations is 
low, with only ~2% of cells expressing CD31 on their cell surface when analysed 
by FACS. Other studies showed that addition of VEGF into the system can 
increase the numbers of cells expressing CD31 and CD144 (Nourse et al., 2010), 
and although these cells can be isolated and cultured to obtain higher 
percentages of CD31+ cells (Levenberg et al., 2002), more direct differentiation 
systems have been investigated to increase initial hPSC-EC generation efficiency.  
3D EB-based direct differentiation protocols have been efficient in generating 
hESC-EC or hiPSC-ECs. These protocols are efficient, generating anywhere 
between 5-50% hPSC-ECs or hPSC-EC precursors in the first instance, before 
sorting and further culture to obtain cultures of 100% functional hPSC-ECs 
(Rufaihah et al., 2011, Costa et al., 2013, White et al., 2013). Rufaihah et al. 
used hiPSCs to generate cells which were positive for CD31, CD144, endothelial 
nitric oxide synthase (eNOS) and von Willibrand Factor (vWF), and were able to 
perform functionally as ECs in terms of acetylated low-density lipoprotein 
(acLCL) incorporation and tubule formation assays. When hiPSC-ECs were 
transplanted into a murine model of hind limb ischemia, there was a significant 
increase in both blood perfusion and capillary density, possibly as a result of 
detected higher levels of angiogenic cytokines, such as Angiopoetin-1 and VEGF-
A and -C (Rufaihah et al., 2011). Another published EB-based EC differentiation 
assay involved the isolation of KDR+ (CD309; VEGFR2) precursor cells on day 6 of 
differentiation. On day 6, approximately 44% of cells were positive for KDR, and 
only 12 or 13% of these expressed CD31 or CD144 respectively. When isolated 
cells were plated onto fibronectin (FN), cultured in endothelial medium, they 
exhibited a high proliferative capacity and after 14 days contained 97% or 93% 
CD144+CD31+ cells when hESCs or hiPSCs were used respectively. Like the 
previous study, cells derived using this protocol displayed a cobblestone-like 
morphology, were functional in in vitro assays, and were able to form functional 
capillaries which linked with the endogenous circulatory system in a murine 
matrigel plug assay (White et al., 2013). Similarly, Costa et al. isolated 
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CD34+KDR+ endothelial precursors on day 6 of an EB-based differentiation 
system, and continued their culture in a monolayer where, by day 12 of 
differentiation, cells uniformly expressed CD31, CD144, KDR, CD34 and other EC 
markers. Again, these cells were able to form tubules in vitro and incorporate 
acLDL, and the study also demonstrated a high degree of transcriptional 
similarity between hESC-ECs and post-natal ECs (Costa et al., 2013). 
Recently, studies have focused on both increasing hESC-EC differentiation 
efficiency, i.e. the percentage of ECs generated, and scalability, i.e. the number 
of ECs generated. Although highly efficient, 3D EB-based culture systems are 
difficult to scale up to produce clinically relevant numbers of cells due to 
methods of EB formation, and because of this, monolayer-based protocols have 
also been investigated. An early 2D monolayer protocol used a co-culture 
system, whereby H9 hESCs were plated onto MEF and in hESC differentiation 
medium (Wang et al., 2007). Using this protocol, cells were shown to upregulate 
endothelial-associated CD31 and downregulate pluripotency-associated genes 
such as Oct4. However, the percentage of CD34+ cells before selection was low 
(~5-10%), and the use of MEFs results in the inability of this protocol to be 
clinically transferrable. Kane et al. developed a fully defined, feeder- and 
serum-free 21 day monolayer-based protocol, yielding approximately 80% 
CD144+CD31+ cells in the SA461 and SA121 hESC lines. These cells expressed high 
levels of endothelial-associated genes, and performed functionally in wound 
healing assays in vitro and in a murine model of hind limb ischemia in vivo (Kane 
et al., 2010). Recently, a method for simultaneous derivation of ECs and 
pericytes from hiPSCs was published (Orlova et al., 2014a, Orlova et al., 2014c). 
The protocol is a fully defined, monolayer-based protocol, allowing for easy 
large scale adaptation. Differentiation efficiency was consistent amongst 
different hPSC lines, including both hESC and hiPSC, with 10-30% of cells 
expressing CD31 (Pecam-1) and CD34, which were also show to express 
comparable levels of other endothelial markers, including CD144 and CD309 
(KDR; VEGFR2). The cells could be isolated and expanded, and analysis showed 
cells were able to perform functionally in an in vivo zebrafish xenograft model, 
and form interactions with pericytes – derived simultaneously – in vitro, 
promoting further differentiation of pericytes to smooth muscle cells. 
Furthermore, Patsch and colleagues also described a highly efficient monolayer-
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based system for the derivation of ECs from hPSCs, which they developed 
alongside a protocol for VSMC differentiation (Patsch et al., 2015). Using two 
hESC lines (SA001 and Hues9) and two hiPSC lines, it was demonstrated that 
between 61.8% and 88.8% of generated cells were CD144+, when assessed by flow 
cytometry. Additionally, the CD144+ cells also expressed other endothelial-
associated cell surface markers, including CD31, KDR, CD34, CD105 and von 
Willibrand factor (vWF). The group also showed that the CD144+ hPSC-ECs could 
be purified on day 6, using magnetic activated cell sorting (MACS), to obtain 
virtually pure (~96%) hPSC-EC cultures. Moreover, analysis of the transcriptional 
signature and metabolomics profiles revealed high levels of similarity between 
the generated CD144+ hPSC-ECs and primary vascular cells. 
Encouragingly, the studies described, using in vivo assays, showed largely 
positive results, with transplantation of hESC-ECs resulting in an increase in 
revascularisation and angiogenesis. These data are promising for the potential 
translation of these technologies into the clinic, as possible treatments for PAD 
and CLI. 
1.6.2 In vivo development of the vasculature 
During embryonic development in vivo the vascular and hematopoietic systems 
are thought to be closely linked, with the first ECs originating from the lateral 
and posterior mesoderm, before migrating towards the yolk sac, where they 
differentiate into ECs and hematopoietic cells (HCs) (Medvinsky et al., 2011). 
The close relationship between the developing endothelial and hematopoietic 
systems led to the suggestions that they share a common mesodermal ancestor – 
the hemangioblast – and this common progenitor was observed in vitro in studies 
involving murine ESCs (Nishikawa et al., 1998). Another theory, however, 
suggests that the first hematopoietic stem cells (HSCs) are derived from ECs with 
hematopoietic potential, known as hemogenic endothelium (HE). In vivo studies 
have shown, using time lapse imagining in both mouse and zebrafish, that HCs 
originate from VE-Cadherin (CD144) expressing ECs in the dorsal aorta (Zovein et 
al., 2008, Bertrand et al., 2010, Boisset et al., 2010, Kissa et al., 2010). It has, 
however, been demonstrated that these two separate hypotheses can be merged 
to form a single linear developmental process, stating that hemangioblasts 
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generate HCs via the formation of intermediate hemogenic endothelial 
populations (Lancrin et al., 2009). 
1.6.2.1 In vitro formation of hemogenic endothelium 
As well as direct hPSC-EC differentiation systems, there have been a number of 
publications showing simultaneous derivation of ECs and hematopoietic cells 
through a common HE progenitor, mimicking conditions in vivo.  
Originally, the Vodyanik group had demonstrated the ability of both hESCs and 
hiPSCs to differentiate to EC and hematopoietic cells simultaneously in vitro 
(Vodyanik et al., 2006, Choi et al., 2009). Cells were co-cultured with mouse 
bone marrow stromal cell line OP9 for 8 days, after which time both CD43+ 
hematopoietic cells and CD31+CD43- ECs were detected. Recently, Choi et al. 
attempted to identify and classify HE populations present within the OP9 hPSC 
differentiation system (Choi et al., 2012). By day 5 of differentiation 3 distinct 
CD144+ cell populations were identified; CD144+CD235a+CD43+CD41+, 
CD144+CD73+ and CD144+CD73-CD235a-CD43-. All 3 of these subsets exhibited a 
similar endothelial phenotype, and were functional, capable of acLDL uptake. 
CD117 (c-Kit), a angiohematopoietic progenitor marker, was expressed at 
different levels in the different CD144+ subpopulations, with the highest 
expression in the CD144+CD73+ cells, the lowest in the 
CD144+CD235a+CD43+CD41+ cells, and an intermediate level in the CD144+CD73-
CD235a-CD43- cells. Further functional and phenotypic analysis allowed for their 
definition of the following EC populations; HE progenitors are CD144+CD73 −
CD235a/CD43−CD117intermediate with primary endothelial characteristics but can 
generate blood and endothelial cells, and CD144+CD73+CD235a/CD43- non-HE 
progenitors, which have all the functional and phenotypic characteristics of 
endothelial cells. Extensive functional characterisations of EC populations, 
including in vivo assays, were, however, not performed within this study. 
The assay developed by Choi et al. involves co-culture with the OP9 mouse bone 
marrow stromal cell line, introducing an undefined factor into the system. 
Recently, a system, using fully defined conditions, generating both distinct 
hemogenic and arterial vascular endothelium has been published (Ditadi et al., 
2015), although cells are cultured on feeders before being transferred to 
51 
 
 
Matrigel – an undefined cell matrix – 24 hrs prior to differentiation. In this 
protocol, a previously defined CD34+CD43- population, with the additional cell 
surface profile of CD31+CD144+KDR+CD117low and the ability to generate T-
lymphoid, erythroid and myeloid cells (Kennedy et al., 2012), were isolated and 
cultured on Matrigel in hematopoietic supportive conditions. It was 
demonstrated that these cells underwent endothelial to hematopoietic transition 
(EHT) and formed CD45+ hematopoietic cells, which were then able to undergo 
further definitive hematopoiesis. Definitive venous and arterial ECs were 
identified from the CD34+CD43- fraction as CD73hiCD184- and CD73medCD184+ 
fractions respectively. Both of these cells types were shown to form functional 
vessels when transplanted into immunocompromised mice, subcutaneously in a 
Matrigel plug. 
Combinations of direct and indirect differentiation systems are valuable tools for 
studying the mechanisms driving development of ECs in vitro and in vivo.  
1.7 MicroRNAs 
The historical central dogma of molecular biology explains that DNA codes for 
mRNAs, which in turn code for the specific amino acid sequences making up all 
of the proteins existing with a cell. Protein-coding genes, however, comprise 
only a very small fraction of the genome (Lander et al., 2001). A large portion of 
the remaining DNA codes for non-coding and regulatory RNAs, including 
ribosomal RNAs (rRNA), transfer RNAs (tRNA), small nucleolar RNAs (snoRNA), 
small interfering RNAs (siRNA), long-non coding RNAs (lncRNA) and microRNAs 
(miRNA; miR) – an extensively studied set of regulatory RNAs. 
First discovered as regulators of development in C.Elegans (Lee et al., 1993, Lee 
et al., 2001), miRNAs have been shown to regulate a large number of important 
biological processes (Bartel, 2004). Existing as single stranded RNA molecules, 
approximately 22 nucleotides (nt) in length, miRNAs are non-coding RNAs, which 
exert post transcriptional control on the expression of their specific target 
messenger RNAs (mRNAs) (Wightman et al., 1993). It is hypothesised that there 
are over 1,000 miRNAs existing within the human genome, each one working to 
control the translation of a whole network of mRNAs. Since their discovery in 
1993, large numbers of miRNAs and their functions in various processes have 
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been identified and described, with the current version of miRbase, the public 
repository for all published miRNA sequences, containing over 24,500 miRNA 
loci, processed to produce over 30,000 mature miRNA products from 206 
different species (Kozomara et al., 2014). Patterns of miRNA expression are 
generally tissue specific, and dysregulation of miRNAs can lead to cellular 
dyfunction. Indeed, miRNAs have been implicated in a number of different 
diseases, including cancer (Iorio et al., 2012) and metabolic diseases (Rottiers et 
al., 2012), as well as CVD (Ono et al., 2011). 
1.7.1 miRNA biogenesis 
Although it was originally believed miRNAs would be transcribed by RNA 
polymerase III, in a similar fashion to other small RNAs such as tRNAs and the 
small nuclear RNA (snRNA) U6, it was subsequently discovered that miRNAs are 
transcribed in the nucleus by RNA polymerase II (Cai et al., 2004, Lee et al., 
2004). This initial transcript is known as the primary miRNA (pri-miRNA), and 
contains an imperfect hairpin approximately 80nt in length, which in turn 
contains the mature miRNA sequence (Lee et al., 2002), flanked by single 
stranded RNA regions. It has also been demonstrated that multiple miRNA stem 
loops, existing in close proximity within the genome, may be transcribed 
together as one pri-miRNA (Mourelatos et al., 2002, Baskerville et al., 2005), 
known as a miRNA cluster. Recently, however, the existence of pri-miRNAs 
containing only a single miRNA has also been shown, suggesting that splicing may 
play a role in the uncoupling of clustered miRNAs previously thought to be co-
transcribed and co-expressed (Ramalingam et al., 2014). Pri-miRNAs can be very 
large (>1kb) and can contain both a 5’ cap and poly(A) tail, much like classical 
mRNAs.  
Once transcribed, the pri-miRNA must undergo further processing in the nucleus. 
This processing is performed by Drosha, an RNase III type enzyme (Lee et al., 
2003), along with its cofactor DiGeorge syndrome critical region gene 8 (DGCR8; 
known as Pasha in flies and worms) (Gregory et al., 2004, Han et al., 2004, 
Landthaler et al., 2004), a double stranded RNA binding protein, shown to play 
an major role in the recognition and binding of pri-miRNAs by this 
microprocessor complex. The DGCR8 protein contains two double-stranded RNA-
binding domains (dsRBDs), which have previously been shown to bind the pri-
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miRNA (Han et al., 2006). More recently, it has also been demonstrated that the 
DGCR8 protein also uses a heme-binding domain to directly bind pri-miRNAs at 
the basal and apical junction of the hairpin (Quick-Cleveland et al., 2014). Once 
bound, the Drosha-DCGR8 microprocessor complex cleaves the hairpin  ~11nt 
from the ds-ssRNA junction (Zeng et al., 2005), resulting in a short miRNA 
precusor, with stem loop structure and ~70nt in length, termed pre-miRNAs. 
Cleavage of the pri-miRNA by Drosha results in a 2nt overhang on the 3’ end of 
the stem loop, thereby allowing for recognition by exportin 5 (EXPO5) (Lee et 
al., 2002, Lund et al., 2004). EXPO5 binds pre-miRNAs, in the presence of its co-
factor Ran-GTP, to allow for their export from the nucleus to the cytoplasm for 
further processing (Yi et al., 2003, Bohnsack et al., 2004). 
Once in the cytoplasm, the pre-miRNAs are then bound by the RNA induced 
silencing complex (RISC)-loading complex (RLC), consisting of Argonaute protein 
2 (Ago2), Dicer – another RNase III endonuclease (Grishok et al., 2001, Hutvagner 
et al., 2001, Knight et al., 2001) previously shown to be involved in generating 
small interfering RNAs (siRNAs) (Bernstein et al., 2001), and the cofactors TAR 
RNA binding protein (TRBP) and protein activator of pkt (PACT) (Chendrimada et 
al., 2005, Lee et al., 2006, MacRae et al., 2008). 
Human Dicer (hDicer) recognises the 5’ phosphate at the end of the pre-miRNA 
stem loop, as well as the 2nt overhang at the 3’ end (Park et al., 2011, Feng et 
al., 2012). Once bound, Dicer cleaves both strands of the duplex, to produce an 
imperfect double-stranded mature miRNA duplex ~22nts in length. Dicer then 
dissociates from the complex, and the mature miRNA is transferred to the Ago2 
protein and incorporated into the RNA-induced silencing complex (RISC), a 
process mediated by heat shock protein 90 (HSP90) in humans. The HSP90-Ago2 
complex hydrolyses ATP, keeping the Ago2 in an open state to allow for the 
binding of the dsmiRNA molecule (Iwasaki et al., 2010, Johnston et al., 2010).  
The dsmiRNA duplex is then unwound and a single strand of the duplex targeted 
for degradation. Although the mechanism behind this unwinding is still unclear, 
recent evidence suggests that the amino-terminal (N) domain of the Ago2 
protein supports this step (Kwak et al., 2012). It was originally shown that the 
strand of the duplex containing the less stable 5’ end was preferentially loaded 
into the Ago2 protein, with the other ‘passenger’ or ‘star’ (miRNA*) strand 
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targeted for degradation (Khvorova et al., 2003). However, recent studies have 
shown important functional roles for these classical miRNA* strands, suggesting 
that they are also actively incorparated into the RISC (Yang et al., 2011, Shan et 
al., 2013, Yang et al., 2013, Mitra et al., 2015). This has lead to new 
nomenclature for miRNAs, with miRNA names suffixed with either -3p or -5p to 
denote their location within the pre-miRNA stem loop. 
Recently, it has also been suggested that a number of miRNAs may be processed 
by Dicer-independent pathways. miR-451 was shown to be produced through an 
alternative pathway, whereby pre-miRNA-451 is recognised, loaded and cleaved 
directly by Ago2 (Cheloufi et al., 2010, Cifuentes et al., 2010, Yang et al., 2010). 
This  yields a ~30nt precursor, which is then further processed to form the 23nt 
miR-451. The mechanism of this method of processing is still poorly understood, 
although recent data suggests a role for eIF1A, which may augment Ago2-
mediated miRNA-guided RNAi and Dicer-independent miRNA biogenesis via direct 
interation with Ago2 (Yi et al., 2015). 
The classical miRNA biogenesis process is summarised in Figure 1.5.  
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Figure 1.5 – MiRNA biogenesis 
MiRNAs are transcribed in the nucleus and processed by Drosha and DCGR8 before being 
exported to the cytoplasm. Once in the cytoplasm pre-miRNAs undergo further processing by Dicer 
to form a double-stranded miRNA duplex. A single strand of this miRNA duplex is then 
incorporated into RISC, which then acts to inhibit mRNA expression, either by inhibition of 
translation or by targeting the mRNA for degradation (Grant et al., 2013).  
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1.7.2 miRNA function 
Once incorparated into the RISC, miRNAs work to guide the Ago2 to specific 
target mRNAs. Often, the specific miRNA binding sites are located within the 3’ 
untranslated region (UTR) of the gene, a phenomenon which was first observed 
in C.Elegans, when it was realised that the lin-14 mRNA contained multiple 
conserved sites, which were complementary to the small RNA lin-4 (Lee et al., 
1993, Wightman et al., 1993). The binding of the miRNA to the mRNA target is 
determined by a region known as the miRNA ‘seed’ sequence - nucleotides 2-8  
at the 5’ end of the mature miRNA, which act to control target specificity (Lewis 
et al., 2003). Once bound the miRNA-RISC acts to control the expression of 
mRNAs in one of 2 ways; either inhibition of translation, or targeting of the 
mRNA for degradation (Guo et al., 2010), depending on the level of 
complementarity between the seed sequence and the binding site in the 3’ UTR. 
In cases where the Watson-Crick base pairing between the miRNA seed and 
mRNA target sequence is perfectly complementary, Ago2 can catalyse mRNA 
cleavage. Other AGO proteins, which can also be incorparated into the RISC 
(Ago1, 2 and 4), do not possess this catalytic activity but can still be involved in 
miRNA-guided gene repression via the inhibition of translation. Recent studies 
have suggested that translational inhibition is the main form of repression at 
early time points, with mRNA degradation contributing more at later time points 
(Bethune et al., 2012). 
As well as the Ago2 protein, miRNA-guided repression of mRNAs is mediated and 
assisted by a number of other proteins. The GW182 protein has been shown to 
directly interact with Ago proteins, via an N domain containing multiple glycine-
tryptophan (GW) repeats. GW182 also contain a bipartite silencing domain (SD) 
within their carboxy-terminal and mid-regions. This SD has been shown to be 
required for efficient silencing and is thought to function through an interation 
with poly(A)-binding protein C (PABPC), a protein which binds to the poly(A) tail 
at the 3’ end of the target mRNA (Fabian et al., 2009, Zekri et al., 2009). This 
interation has been proposed to induce silencing of the target mRNA in two 
different ways. Firstly, GW182 binding to PABPC inhibits the interaction of 
PABPC with the cap-binding complex, preventing circularisation of the mRNA, 
and therefore inhibiting translation. Recently, however, it has also been 
proposed that PABPC and the poly(A) tail may be involved in stimulating the 
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interaction between the Ago-GW complexes and the target mRNA, supported by 
evidence which shows gene silencing efficiency correlates with the length of the 
poly(A) tail and the number of PABPCs associated (Moretti et al., 2012). 
Although its main function is in the mediation of translational repression, it has 
also been hypothesised that GW182 may be involved in the destabilisation, and 
subsequent decay, of the target mRNA, via recruitment of the deadenylase 
CCR4-NOT complex (Behm-Ansmant et al., 2006, Wu et al., 2006, Piao et al., 
2010).  
Using both biochemical and  proteomic appraoches, further studies have also 
identified a number of proteins thought to interact with AGO proteins (Meister 
et al., 2005). Proteins can be indirectly associated with AGO proteins through 
binding to the same mRNA, subseqeuntly affecting the miRNA-RISC binding and 
gene repression. One example of this is Importin 8 (IPO8). IPO8 was identified to 
be an AGO binding partner, and two distinct roles for this protein have 
subsequently been elucidated. Firstly, IPO8 was shown to be involved in the 
loading of Ago2-miRNA complexes onto target mRNAs in the cytoplasm 
(Weinmann et al., 2009). Secondly, IPO8 controls the import of mature miRNAs 
into the nucleus, via its association with Ago2 in the miRNA-RISC (Wei et al., 
2014). Management of this import may suggest a role for IPO8 in the control of 
miRNA-guided repression of miRNA biogenesis. 
While most miRNA-mediated gene repression is induced through binding to the 3’ 
UTR of the target mRNAs, studies have also shown that  miRNAs can bind to the 
5’ UTR or in coding regions in order to exert their affect (Lytle et al., 2007). 
Interestingly, it has also been shown that miRNAs can also upregulate their 
targets, for example miR-10a, which has been shown to bind to the 5’UTR of 
ribosomal protein mRNAs to enhance their translation (Orom et al., 2008). This 
data suggests more complex mechanisms of miRNA regulation than originally 
hypothesised. 
1.8 Endothelial-associated miRNAs 
As an important component of the vascular wall, endothelial cells (EC) play a 
major role in maintenance of vascular integrity, particular with relation to 
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angiogenesis and wound repair post-injury, as well as in vasculogenesis during in 
vivo development and embryogenesis (Wang et al., 2008c).  
As in most cell types, miRNAs have been implicated in EC function and 
proliferation, as well as in the regulation of angio- and vasculogenesis. Global 
reduction of miRNAs, via conditional knockdown of the miRNA processing Dicer 
using siRNAs in vitro, altered the expression of several important regulators of 
endothelial biology and angiogenesis including vascular endothelial growth factor 
receptor 2 (VEGFR2; KDR) and endothelial nitric oxide synthase (eNOS), as well 
reducing proliferation and tubule formation capacity (Suarez et al., 2007). In 
vivo, Dicer silencing was also shown to reduce postnatal angiogenesis in response 
to angiogenic cytokines, such as VEGF (Suarez et al., 2008). Combined transient 
silencing of both Dicer and Drosha processing enzymes reduced the sprout 
forming and angiogenic properties of ECs, although only silencing of Dicer had 
significant effects on angiogenic potential in vivo (Kuehbacher et al., 2007). 
Several miRNAs have been identified to play a role in the regulation of function, 
proliferation and growth of vascular ECs (Jakob et al., 2012). These include miR-
126, miR-10a, the let-7 cluster, the pro-angiogenic miR-17-92 cluster and the 
anti-angiogenic miR-221 and -222. MiRNAs identified to play key roles in the 
regulation of angiogenesis may be important therapeutic targets in the 
treatment of a range of ischemic diseases, as well as in the regulation of 
angiogenesis during cancer and tumour progression. 
1.8.1 miR-126 
One of the most studied and extensively characterised EC miRNAs is miR-126, 
the -3p arm of the miR-126 stem loop. Early miRNA profiling studies found that 
miR-126 was enriched in tissues with a high vascular component, and expression 
patterns in zebrafish also showed the expression of miR-126 to be confined to 
the vascular system (Lagos-Quintana et al., 2002, Wienholds et al., 2005). 
Studies showed that miR-126 was expressed in primary human umbilical vein ECs 
(HUVEC), as well as in a number of EC lines (Harris et al., 2008, Wang et al., 
2008c), and miR-126 was also found to be the most highly enriched miRNA in ECs 
generated from differentiating mESC (Fish et al., 2008). Generation of miR-126 
null mice resulted in approximately 40% embryonic lethality, exhibiting a large 
number of vascular defects, including severe systemic oedema, haemorrhage 
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and vessel rupture, and knockdown in zebrafish using pri-miR-126-specific 
morpholinos resulted in comprised blood vessel integrity, haemorrhages and 
compromised endothelial tube formation. Taken together, this data suggested a 
role for miR-126 in the maintenance of endothelial and vascular integrity during 
development. Knockdown of miR-126 also resulted in a decrease in angiogenesis 
during ex vivo and in vivo assays. To exert its angiogenic affects, miR-126 was 
also shown to augment MAP kinase pathway activation in response to angiogenic 
factors such as FGF and VEGF in vitro, with knockdown of the miRNA resulting in 
a reduction in FGF and VEGF-mediated migration, possibly through defective 
reorganisation of the actin cytoskeleton (Fish et al., 2008, Wang et al., 2008c).  
It was subsequently demonstrated that miR-126 exerts its angiogenic effects 
through the targeting of the sprouty-related protein Spred-1 (Figure 1.6), a 
negative regulator of the Ras/MAP kinase pathway (Wakioka et al., 2001), and 
phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2), a negative regulator of 
PI3 kinase (Ueki et al., 2003, Sessa et al., 2012). A role for miR-126 in the 
regulation of vascular inflammation has also been elucidated, via its targeting 
and repression of vascular cell adhesion molecule-1 (VCAM-1), an intercellular 
adhesion molecule expressed by ECs. VCAM-1 expression is upregulated during 
vascular inflammation, where it functions to mediate EC:leukocyte adhesion. 
Reduced expression of miR-126, in tumour necrosis factor-α (TNF-α) stimulated 
ECs, increases the expression of VCAM-1, in turn enhancing leukocyte adherence 
and, ultimately, vascular inflammation (Harris et al., 2008).  
MiR-126 is located within intron 7 of epidermal growth factor-like domain 7 
(Egfl7), a gene which is highly expressed in ECs, and the expression of both 
strands of the miR-126 stem loop (miR-126-3p and -5p) mirrors the expression of 
Egfl7 (Harris et al., 2010). This suggested that miR-126 is processed from the 
pre-mRNA-Egfl7 transcript. A 5’ region upstream of the Egfl7/miR-126 locus was 
then found to regulate expression of miR-126, and in silico analysis subsequently 
revealed two Ets binding sites (EBS) within this region. The Ets factors are a 
family of transcription factors, and several members, including Ets-1 and -2, 
have been shown to play important roles in vasculo- and angiogenesis (Dejana et 
al., 2007). Ets-1 and -2 were found to bind to the Egfl7/miR-126 5’ region to 
activate transcription in ECs, therefore suggesting that these transcription 
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factors play an important role in the regulation of miR-126 expression and, 
therefore, the regulation of it angiogenic affects (Harris et al., 2010).  
1.8.2 miR-17-92 cluster 
The miR-17-92 cluster, consisting of miR-17, -18a, -19a/b, -20a and -92a, has 
also been extensively studied in the context of ECs and angiogenesis. Originally, 
it was discovered that this cluster plays a role in the augmentation of tumour 
angiogenesis. Expression of this cluster was found to be upregulated in 
colonocytes co-expressing K-Ras and c-Myc, two proto-oncogenes. In this system 
the miRNAs target the anti-angiogeneic thrombospondin-1 (Tsp1) and the related 
protein connective tissue growth factor (CTGF), to cause an increase in 
angiogenesis, and cells transduced with the miR-17-92 cluster formed larger, 
better-perfused tumours (Dews et al., 2006). In contrast to this, however, 
Doebele et al. demonstrated that the overexpression of individual members of 
the cluster, specifically miR-17, -18a, -19a and -20a, resulted in reduced 
angiogenic sprouting, whereas inhibitors of the same miRNAs caused an increase 
in angiogenesis in vitro, suggesting an anti-angiogenic role for this cluster 
(Doebele et al., 2010). This ties in with previous work showing that miR-92a 
targets several proangiogenic proteins, including integrin subunit alpha 5, to 
exert an anti-angiogenic effect, with overexpression of this miRNA blocking 
angiogenesis in vivo and in vitro (Bonauer et al., 2009). More recently, it was 
shown that histone deacetylase 9 (HDAC9) displays a proangiogenic affect, 
regulated through the transcriptional repression of the miR-17-92 cluster (Kaluza 
et al., 2013). Taken together, this data suggests a varied role for the miR-17-92 
cluster in the context of EC function and angiogenesis. 
1.8.3 miR-210 
Reduced miR-210 expression has been shown to inhibit EC growth and induce 
apoptosis, suggesting a proangiogenic role for this miRNA. In hypoxic conditions, 
it was found that the level of miR-210 was increased in HUVECs when compared 
to cells in normoxic conditions (Fasanaro et al., 2008). In normoxic ECs in vitro, 
overexpression of miR-210 simulated the formation of capillary-like structures on 
matrigel, and VEGF-mediated migration. Knockdown of this miRNA inhibited 
these same functions, and also inhibited cell growth and caused an increase in 
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apoptosis. In silico analysis revealed Ephrin-A3 (EFNA3), a gene post-
transcriptionally downregulated by hypoxia, as a potential target for miR-210, 
and luciferase assays using the 3’UTR of the EFNA3 mRNA confirmed this. 
Downregulation of this gene was proven to be necessary for miR-210-regulated 
angiogenesis. Lou et al. further elucidated the mechanism of miR-210 and its 
role in angiogenesis by investigating the role of this microRNA in regulating 
angiogenesis in response to brain ischemic injury. miR-210 was significantly 
upregulated in adult rat ischemic brain cortexes in vivo, where the expression of 
Notch-1 signalling molecules, which facilitate the migration of endothelial cells, 
were also increased. Using lentiviral-mediated overexpression, it was shown that 
miR-210 activated the Notch signalling pathway, facilitating the migration of 
endothelial cells and inducing in vitro capillary formation (Lou et al., 2012). 
Recently, this has also been shown in the normal adult mouse brain, where 
overexpression of miR-210, using stereotactic injection of a lentiviral vector, 
increased neurogenesis and angiogenesis, associated with a local increase in the 
levels of VEGF (Zeng et al., 2014). Overall, data suggests that miR-210 could be 
used as a therapy, or a therapeutic target for the modulation of angiogenesis in 
the treatment of ischemic diseases. Indeed, miR-210 has been used as a therapy 
in vivo to enhance wound healing, and tissue repair, processes in which 
angiogenesis plays a key role (Kawanishi et al., 2014, Usman et al., 2015). 
1.8.4 miR-10 
Interestingly, it was also suggested that miR-10 may play a role in angiogenesis, 
after it was discovered that heparin, an anti-thrombotic drug, impairs 
angiogenesis through the inhibition of miR-10b, therefore inducing upregulation 
of its mRNA target HoxD10 (Shen et al., 2011). Indeed, further investigation 
showed an increase in the expression of miR-10a in CD144+VEGFR2+ ECs 
generated from mESCs when compared to CD144-VEGFR2- non-ECs (Hassel et al., 
2012). Knockdown of all four miR-10 isoforms (a-d) during zebrafish development 
resulted in an impairment in angiogenesis and the development of the 
intersegmental vessels, whereas overexpression lead to enhanced angiogenic 
potential in vivo. In vitro experiments demonstrated the direct targeting of the 
3’UTR of Flt1, also known as VEGFR1, and its soluble splice variant sFlt1 by miR-
10, with miR-10 depletion leading to an increase in Flt-1 expression both in vivo 
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and in vitro. Flt-1 binds VEGF and is thought to function to inhibit angiogenesis 
by sequestering VEGF to prevent binding to VEGFR2 (Hassel et al., 2012). 
1.8.5 miR-221 and -222 
Just as important as miRNAs with potential proangiogenic functions, miRNAs with 
anti-angiogenic functions may also be useful targets in the control of 
angiogenesis in a disease setting, such as in the regulation of tumour 
angiogenesis during cancer, as well as in cardiovascular and ischemic diseases. 
Similarly to those involved in the positive regulation of angiogenesis, anti-
angiogenic miRNAs function via the targeting of an array of angiogenic-
associated mRNAs, as previously described in section 1.8.2 (Figure 1.6).  
Located intergenically, miR-221 and -222 are transcribed as a cluster, and have 
been shown to share an identical seed sequence. Both of these miRNAs have 
been described as anti-angiogenic, and were shown to regulate c-kit, the 
receptor for stem cell factor (SCF), at the protein level (Poliseno et al., 2006). 
SCF is an angiogenic factor, which has been shown to promote survival, 
migration and capillary formation of HUVECs in vitro (Matsui et al., 2004). 
Overexpression of miR-221 and -222 caused a reduction in survival, migration 
and capillary formation in vitro mediated through a reduction in the levels of c-
kit. Another study showed that miR-221 and -222 regulate the expression of 
eNOS, with overexpression of these miRNAs inhibiting the increase in eNOS 
expression observed after Dicer knockdown (Suarez et al., 2007).  
It has also been shown that miR-221 indirectly up-regulates GAX, a potential 
master regulator of EC angiogenic phenotype (Gorski et al., 1993), in order to 
inhibit angiogenesis (Chen et al., 2010). It was hypothesised that this 
upregulation was mediated through the downregulation of an intermediate 
protein, and this was subsequently discovered to be ZEB2, a zinc-finger nuclear 
factor which primarily acts as a transcriptional repressor (van Grunsven et al., 
2003). 
1.8.6 Other notable pro- and anti- angiogenic miRNAs 
Similarly to miRNAs already mentioned, other angiogenesis-regulating miRNAs 
also function via the direct or indirect targeting of growth factors and their 
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receptors (Figure 1.6). One such miRNA is the proangiogenic miR-296, which was 
found to be upregulated when human brain microvascular ECs were treated with 
angiogenic factors, and also shown to be expressed at higher levels in primary 
highly angiogenic ECs derived from human brain tumours, when compared to 
normal brain endothelial cells (Wurdinger et al., 2008). In this context miR-296 
was found to target hepatocyte growth factor-regulated tyrosine kinase 
substrate (HGS), a protein involved in the mediation of the degradation of a 
number of growth factor receptors, including platelet derived growth factor 
receptor β and VEGFR2, therefore increasing the levels of signalling by 
angiogenic factors (Takata et al., 2000, Ewan et al., 2006).  
Moreover, miR-15b and -16, along with miR-20a and -20b, are also thought to 
exert their antiangiogenic effects via the targeting of VEGF (Hua et al., 2006). 
Although the study was performed in a human nasopharyngeal carcinoma cell 
line, all of four of these miRNAs were downregulated in response to hypoxia, in 
contrast to the concomitant upregulation of VEGF. As well as VEGF, other 
angiogenic factors were also found to be targets of all or some of these miRNAs, 
including COX2, c-MET and uPAR. These data suggest a role for these four 
miRNAs in the regulation of angiogenesis, and this has been supported by 
evidence in a number of other studies (Sun et al., 2013, Xue et al., 2015). In the 
same study which originally identified the previous four miRNAs (-15, -16, -20a 
and -20b), miR-378 was also shown to regulate the expression of VEGF (Hua et 
al., 2006), although not through direct binding to its predicted 3’ UTR target 
sequence. Further studies showed a proangiogenic role for miR-378, through its 
propensity to cause an increase in cell survival and a decrease in apoptosis, in a 
similar way to miR-210 and the miR-17-92 cluster (Lee et al., 2007). In the U87 
human cancer cell line, miR-378 was shown to target both Suppressor of Fused 
(SuFu) and Tumour Suppressor Candidate 2 (Fus-1), two tumour suppressor 
genes, to control blood vessel growth and tumour survival. These studies were 
all performed using cancer cell lines, however, and as stated previously, miRNA 
expression patterns and profiles are tissue and cell-type specific. The 
angiogenic-regulating behaviours of these miRNAs have not yet been 
recapitulated in the context of the vasculature and human ECs. 
MiR-100, a miRNA expressed in both ECs and vascular smooth muscle cells 
(VSMCs), was also found to be downregulated during hypoxia, much like miR-15 
64 
 
 
and -16. In vivo, miR-100 was significantly downregulated after the induction of 
hind limb ischemia in mice, and it was found to control angiogenic sprouting and 
the proliferation of vascular cells in vitro (Grundmann et al., 2011). Mammalian 
target of rapamycin (mTOR), a gene previously demonstrated to be involved in 
angiogenesis and proliferation of ECs in response to hypoxia (Humar et al., 
2002), was found to be a direct target of miR-100 (Wang et al., 2008a) and this 
was confirmed in the context of ECs, indicating a role for this miRNA in the 
negative regulation of EC angiogenesis. More recently, this has also been shown 
in the context of graft-verus-host disease (GvD), whereby miR-100 antagonism 
increased neovascularisation and, therefore, increased disease severity 
(Leonhardt et al., 2013). 
A global knock out of miRNA processing enzymes in human ECs also lead to the 
identification of miR-27b and let-7f as possible proangiogenic miRNAs 
(Kuehbacher et al., 2007). Knockdown of Dicer and Drosha processing enzymes 
lead to a reduction in the expression of these two miRNAs, shown to be highly 
expressed in ECs, and treatment of cells with selective inhibitors of miR-27b and 
let-7f caused a decrease in sprout forming capacity. In silico analysis revealed 
Tsp1, an antiangiogenic protein also shown to be a target of the miR-17-92 
cluster (Section 1.8.2), as a predicted target of let-7f. Dicer and Drosha 
knockdown caused a significant increase in the levels of Tsp1, although specific 
knockdown of let-7f only trigged a small increase in the levels of Tsp1, 
confirming that this antiangiogenic protein may be a shared target of a number 
of important proangiogenic miRNAs. 
Finally, GAX, previously shown to be indirectly regulated by the antiangiogenic 
miR-221 (Section 1.8.5), was verified as a direct target of miR-130a. As stated 
previously, GAX has been implicated in the inhibition of angiogenesis in vascular 
ECs, and suppression of this gene by miR-130a suggests a role in the positive 
regulation of angiogenesis for this miRNA. In the same study, a genome wide 
search for other genes containing at 3’ UTR miR-130a binding site also identified 
another antiangiogenic homeobox gene, HOXA5, enhancing the proposal that 
miR-130a may play an important role in the regulation of the angiogenic 
phenotype in vascular ECs (Chen et al., 2008b).  
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Taken as a whole, the studies and findings reported show a significant role for 
miRNAs in the control of vascular EC function and angiogenic phenotype. 
Utilising knowledge gained from these studies may be critical in the 
development of novel therapies, not only for the treatment of ischemic diseases, 
such as PAD, CLI, CHD and stroke, but also in the context of cancer and 
regulation of tumour angiogenesis. It is now essential to elucidate exact 
mechanisms of action, in order to determine crucial signalling pathways and 
whether it is preferable to directly target key miRNAs, or the pathways which 
they regulate. 
The function and mechanisms of a number of angiogenesis-regulating miRNAs are 
summarised in figure 1.4.
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Figure 1.6 – miRNAs play an important role in the regulation of angiogenesis. 
A summary of published miRNAs, and their mRNA targets, involved in the regulation of angiogenesis. Antiangiogenic miRNAs are shown in red and pro-angiogenic 
miRNAs in green. (Scott et al., 2013) 
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1.9 miRNAs and pluripotent stem cells 
MiRNAs are essential for vertebrate development. Indeed, the discovery of the 
original miRNAs in C.elegans demonstrated a role in early embryonic 
development and developmental timing (Lee et al., 1993, Wightman et al., 
1993). Dicer-1 depletion in the developing zebrafish embryo using targeted 
morphlinos, resulted in developmental arrest with a decrease in miRNA 
accumulation after 1 week (Wienholds et al., 2003). Knockout of this processing 
enzyme in murine embryos was similar, and resulted in embryonic lethality 
(Bernstein et al., 2003). Profiling of both mouse and zebrafish embryos also 
showed that miRNAs are differentially expressed throughout embryonic 
development, signifying their importance during development, lineage 
specification and maintenance (Wienholds et al., 2005, Mineno et al., 2006).  
The integral role played by miRNAs in embryonic development, has implicated 
them in both regulation of pluripotency and differentiation of PSCs. Since their 
discovery, many studies have probed the function of these short non-coding 
RNAs in both ESCs and iPSCs, with the hope of finding master regulators of the 
pluripotent phenotype and in commitment to specific lineages, with the 
prospect of driving in vitro PSC reprogramming and differentiation. 
1.9.1 Pluripotency-associated miRNAs 
MiRNAs, along with other TFs, signalling pathways and epigenetic changes, are 
involved in a complex network, acting to control both pluripotency and 
differentiation in hPSCs. Early profiling studies used both mESC and hESC lines to 
identify miRNAs expressed in pluripotent conditions, with data showing a distinct 
set of miRNAs, enriched in these cells, unlike any other adult tissue or cell line 
(Houbaviy et al., 2003, Suh et al., 2004, Stadler et al., 2010).  
Specifically expressed at high levels in hPSCs, the miR-302 cluster is located on 
chromosome 4, contains 10 miRNA sequences, all located within a ~700bp 
region; -3p and -5p forms of miR-302a, -302b, -302c, -302d and -367. Four of the 
eight miR-302 (miR-302a, -b, -c and -d) members in this cluster are highly 
homologous in their mature forms, with the greatest levels of sequence 
similarity existing at the 5’ end – the location of the miRNA ‘seed’ sequence. 
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Homology in this region suggests the existence of a number of shared target 
mRNAs (Suh et al., 2004). When tested in a number of different hESC cell lines, 
the miR-302 cluster was shown to be consistently down-regulated during early 
differentiation, in a similar manner to pluripotency-associated genes, such as 
Oct4 (Stadler et al., 2010). Analysis of the miR-302 promoter region revealed 
binding sites for 3 pluripotency-associated TFs, Oct4, Sox2 and Nanog, and it was 
subsequently discovered that Oct4/Sox2 function as transcriptional activators of 
the miR-302 cluster. Inhibition of the miR-302 cluster in hESCs using anti-miRs 
resulted in an increase in cells in the G1 phase of the cell cycle, a phenomenon 
observed in differentiated cell types. This affect was shown to be mediated 
through the translational repression of Cyclin D1 by the miR-302 cluster, a 
protein expressed at low levels in hESCs (Card et al., 2008). Oct4 and miR-302 
also work together to regulate the activity of NR2F2 (COUP-TFII), a member of 
the NR2F, COUP-TF, nuclear orphan receptor family of transcription factors. 
NR2F2 is silenced transcriptionally by Oct4 and post-transcriptionally by miR-302 
in hPSCs. However, when Oct4 and miR-302 levels decline during hPSC 
differentiation, NR2F2 becomes transcriptionally activated and in turn acts to 
transcriptionally repress Oct4 expression, thus reducing the levels to miR-302, 
providing positive feedback for the tight regulation of pluripotency and 
differentiation within these cells (Rosa et al., 2011). Most recently, Zhang et al. 
showed that in addition to its roles in cell cycle control, the miR-302 cluster also 
works to regulate apoptosis in hESCs (Zhang et al., 2015). These affects were 
mediated through the targeting and down regulation of BNIP3L/Nix (a BH3-only 
proapoptotic gene), and upregulation of BCL-xL, preventing apoptosis in these 
cells.  
The murine homolog of the miR-302 cluster (miR-302), however, has a much 
lower abundance in mES cells. In these cells, it is the miR-290 cluster, a 2.2kb 
region encoding 6 miRNA stem loops (miR-290, -291, -292, -293, 294 and -295), 
which is highly expressed (Houbaviy et al., 2003). In human cells, the miR-371-
373 cluster (containing miR-371, -372 and -373) is homologous to the mouse miR-
290 cluster and, similarly, is expressed at high levels in pluripotent hESCs (Suh et 
al., 2004, Stadler et al., 2010). Yet, unlike miR-302 and miR-290, it was 
discovered that this cluster of miRNAs were expressed at lower levels in hiPSCs 
than in hESCs, suggesting that robust expression of this cluster may not be 
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critical for pluripotency (Wilson et al., 2009). Both miR-372 and -373 possess the 
same ‘seed’ sequence as the miR-302 family, suggesting shared targets for these 
miRNAs. The ‘seed’ sequence in many pluripotency-associated miRNAs appears 
near identical and, in fact, comprehensive profiling suggests the miRNA 
signature in hESCs is dominated by one ‘seed’ sequence (Laurent et al., 2008). 
Numerous profiling studies have observed high expression of the miR-17 family in 
pluripotent hESC, while they were rapidly down-regulated in response to various 
differentiation cues (Suh et al., 2004, Stadler et al., 2010). Encompassing miR-
17, -18a, -18b, -20a, -20b and -93, the miR-17 family possess the same, or a very 
similar, conserved pluripotent seed sequence, and are contained within 3 
paralogous clusters in the genome; the miR-17-92, miR-106a-92 and miR-106b-25 
clusters, all located on different chromosomes (Hayashita et al., 2005).  
In particular, the miR-17-92 cluster has been shown to play a possible role in 
self-renewal. Comprising miR-17, -18a, 19a/b, -20a and -92a, the miR-17-92 
cluster is expressed in a number of cancers, as well as in pluripotent hESCs, 
where expression is controlled by c-Myc. In the presence of c-Myc, the 
expression of the miR-17 cluster is increased, resulting in a decrease in 
expression of one target, E2F1, therefore tightly regulating c-Myc mediated 
proliferation (O'Donnell et al., 2005). Smith et al. confirmed the regulation of 
the cluster by c-Myc in pluripotent cells, and demonstrated a role for the miR-
17-92 cluster in cell cycle control in murine iPSCs, via the regulation of a number 
of cell cycle control genes such as Rb2/p30 (Wang et al., 2008b, Smith et al., 
2010).  
Indeed, miRNAs are such potent regulators of pluripotency that numerous studies 
have demonstrated their ability to reprogram both mouse and human cells to 
pluripotency to generate iPSCs. Particularly, studies have focused on the use of 
the miR-302 cluster. Originally, it was shown that this cluster of miRNAs, when 
over expressed in human skin cancer cells, was able to reprogram the cells to an 
ES-like pluripotent state (Lin et al., 2008). Further studies showed that 
transfecting miR-200c, miR-302 and miR-369 family double stranded (ds) mature 
miRNAs in combination allowed for efficient reprogramming of mouse and human 
adipose stromal cells (ASCs) and human dermal fibroblasts (HDFs) (Miyoshi et al., 
2011). In both of these studies showed increases in the pluripotency markers in 
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the transfected cells, and an ability to differentiate into multiple cell lineages. 
Hu et al. also demonstrated that reprogramming efficiency was greatly increased 
when miR-302 was used alongside four other factors (Oct4, Klf4, Sox2 and C-Myc) 
in human ASCs, although this study was unable to produce iPSCs using miR-302 
alone (Hu et al., 2013). miRNA reprogramming methods do not require vector-
based gene transfer and could, therefore, hold significant potential for future 
applications in biomedical research, regenerative medicine and cell therapies. 
1.10 miRNAs and differentiation 
Pluripotent stem cell differentiation is governed by a complex network of genes, 
signalling pathways and non-coding RNAs.  In particular, miRNAs have been 
implicated in hESC differentiation in vitro (Bar et al., 2008). Knock down of the 
miRNA processing enzyme Dicer has been shown to have a significant effect on 
the ability of mESCs to differentiate in vivo and in vitro (Kanellopoulou et al., 
2005, Murchison et al., 2005).  
Studies have also identified a number of specific miRNAs highly expressed during 
differentiation of pluripotent cells, and playing vital roles in both unspecific and 
specific differentiation and lineage commitment. In 2009, miR-145, a smooth 
muscle cell associated miRNA expressed at very low levels in pluripotent cells, 
was identified as a regulator of general differentiation. Exerting its affects 
through its ability to bind and supress the expression of the pluripotency factors 
Oct4, Sox2 and Klf4, knockdown of miR-145 in differentiating hESCs resulted in a 
significant reduction in differentiation (Xu et al., 2009). Additionally, it was also 
shown that Oct4 binds to the promoter region of miR-145 during pluripotency to 
repress its expression, forming a double negative feedback loop. Upon 
differentiation the miR-145 promotor is derepressed and miR-145 is upregulated, 
allowing for the downregulation of pluripotency factors.  
In mESCs, the miR-17 family members, miR-17-5p, miR-20a, miR-93 and miR-
106a are differentially expressed during differentiation, as well as in vivo in the 
developing mouse embryo (Foshay et al., 2009). Modulation of miR-93 and miR-
20 in vitro demonstrated a role for this family of miRNAs in differentiation to 
specific germ layers, with miR-93 having possibly the most potent affect. 
Subsequently, it was shown that this family of miRNAs bind the 3’ UTR of STAT3 
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during ESC differentiation, a mechanism possibly conserved between species. 
STAT3 is expressed at high levels in pluripotent cells, although is it not necessary 
for self-renewal. It is, therefore, likely that downregulation of this gene by the 
miR-17 family is needed for the onset of differentiation. 
1.10.1 miRNA regulation of hESC-EC differentiation 
Specifically, differential expression of various miRNAs has been documented 
during hESC-EC differentiation. Silencing of the Dicer processing enzyme during 
hESC-EC differentiation in vitro was shown to significantly decrease the 
percentage of cells positive for two endothelial markers, VE-Cadherin (CD144) 
and Pecam-1 (CD31), 10 and 14 days post-induction of differentiation (Kane et 
al., 2012). 
It has also been reported that there is an increase in the expression of 
angiogenesis-associated miRNAs (e.g. miR-126, miR-210, let-7f) during a 10 day 
hESC-EC differentiation protocol, coinciding with an increase in endothelial-
associated genes and an increase in the angiogenic abilities of the cells both in 
vitro and in vivo (Kane et al., 2010). Although it has previously been shown that 
miR-126 does not contribute towards endothelial lineage commitment during 
differentiation, despite its wide functional role in ECs (Fish et al., 2008). Anti-
angiogenic miRNAs, such as miR-221 and -222, were also shown to be 
downregulated in these differentiated hESC-derived ECs (Kane et al., 2010). 
Furthermore, when the miRNA-ome of these differentiated cells was studied in 
more detail, miR-181a, -181b and -99b were observed to be expressed at 
significantly higher levels in hESC-ECs than in pluripotent hESCs (Kane et al., 
2012). Modulation of their expression in vitro significantly increased percentage 
of cells expressing Pecam-1 and VE-cadherin, as well as inducing a significant 
increase in the production of nitric oxide (NO). Transplantation of hESC-derived 
ECs overexpressing miR-181b or miR-99b, were shown to significantly improve 
therapeutic angiogenesis in an in vivo mouse model of peripheral ischemia. 
Mechanisms of action and identification of targets of these miRNAs were not 
elucidated during this study, although a role for miR-181a in vascular 
development, through its targeting of Prox-1, had previously been described 
(Kazenwadel et al., 2010). MiR-181b has also been reported to be expressed in 
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vascular endothelium, with a possible role in EC activation and vascular 
inflammation (Sun et al., 2012).  
Due to their previously defined role in endothelial cell function and 
neovascularisation, as well as their high expression in hESCs, it was also 
hypothesised that the miR-17-92 cluster may play a role in endothelial 
differentiation and commitment. Treguer et al. used mESCs and miPSCs to study 
the expression of this cluster during differentiation. Although all miRNAs in the 
cluster were expressed at high levels in undifferentiated cells, it was discovered 
that they are differentially regulated during differentiation. miR-17, -18, -19 and 
-20 were upregulated during mESC-EC differentiation, whereas miR-92a was 
downregulated during differentiation (Treguer et al., 2012). Antagomir inhibition 
of the individual members of the cluster, however, did not appear to have any 
effect on mESC-EC differentiation, suggesting these individual miRNAs are not 
essential for differentiation. 
Two miRNAs, miR-200c and -150, were also shown to play a role in endothelial 
lineage specification and differentiation, both during hESC-EC differentiation 
and during chick embryo vasculogenesis. Knock down of these miRNAs caused a 
decrease in the levels of endothelial associated genes in mixed cell populations 
in vitro, as well as impairment in blood vessel formation or vasculogenesis in an 
in vivo chick embryo model. It was discovered that the 3’ UTR of the 
transcriptional repressor zinc-finger E-box-binding homeobox 1 (ZEB1) contained 
two highly conserved binding sites for miR-200c and one highly conserved 
binding site for miR-150, and it was subsequently confirmed that this gene is a 
shared target of the two miRNAs (Luo et al., 2013). ZEB1 was shown to directly 
repress the transcriptional activity of a number of EC specific genes, including 
CD144, endothelial nitric oxide synthase (eNOS) and Von Willebrand factor 
(vWF). Taken together, this suggested that both miR-150 and -200c regulate the 
expression of endothelial-associated genes during hESC-EC differentiation via the 
targeting and repression of ZEB1.  
Other studies in murine stem cells have also suggested roles for specific miRNAs 
in EC commitment and differentiation from ESCs, including miR-10, which has 
been shown to be upregulated during specification of mESC to mesoderm (Hassel 
et al., 2012). Experiments in miPSCs have also suggested a role for miR-21 in the 
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regulation of endothelial lineage differentiation, through the control of 
transforming growth factor β2 (TGFβ2) (Di Bernardini et al., 2014). In this study 
phosphate and tensin homolog (PTEN) was identified as a direct target of miR-
21. During differentiation to ECs, PTEN is inhibited by miR-21, therefore 
resulting in an increase in the phosphorylation of Akt, which in turn induces 
TGFβ2 to drive EC differentiation, hypothesised to occur possibly through the 
activation of Twist1 (Xue et al., 2012).  
Novel miRNAs, with no identified role in EC function, have also been recognised 
as having a potential role in hESC-EC differentiation and commitment. During 
hESC-EC differentiation, miR-6086 and -6087 were shown to downregulated the 
expression of CD144 and endoglin respectively (Yoo et al., 2012), and miR-5739 
was shown to potentially regulate the expression of endoglin within the same 
system (Yoo et al., 2011b).  
Although a large number of miRNAs have been identified as being differentially 
regulated, in the context if hESC-EC differentiation and EC lineage commitment, 
exact mechanisms for many still remain unknown. Changes in expression of 
specific miRNAs may, however, be a consequence of differentiation, rather than 
a cause. Distinguishing between these phenomenon, and identifying key miRNAs 
with roles in hESC-EC differentiation, may be crucial in the development of 
regenerative therapies.  
1.11 Control of pluripotency and differentiation by other 
regulatory non-coding RNAs 
Recently, another genre of non-coding RNAs, long non-coding RNAs (lncRNA) 
have been implicated hESC differentiation (Klattenhoff et al., 2013) and control 
of pluripotency (Wang et al., 2013, Lin et al., 2014). Much larger than miRNAs, 
lncRNAs are classified as non-coding RNAs >200 nts in length, and recent studies 
have identified large numbers of lncRNAs contained within mammalian genomes 
(Guttman et al., 2009, Derrien et al., 2012), although biological functions have 
only been elucidated for a select few. Similarly to mRNAs, they are transcribed 
by RNA polymerase II, are spliced, polyadenylated and have a 5’ cap, although, 
unlike mRNAs, they lack protein coding potential.  
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The functions and mechanisms of lncRNAs, are still widely under investigation. 
Whereas miRNAs mainly function through binding to the 3’ UTR of target genes, 
lncRNAs can function through a variety of different mechanisms. They can be 
nuclear or cytoplasmic, and their location is associated with their mechanism of 
action. Most nuclear lncRNAs function via the guiding of chromatin modifiers to 
specific genomic loci, whereas cytoplasmic lncRNAs have various functions, 
including modulation of translational control (Carrieri et al., 2012, Yoon et al., 
2012) and modulation of mRNA stability. Most interestingly, lncRNAs can act as a 
competing endogenous control RNA (ceRNA) or miRNA sponge (Poliseno et al., 
2010), suggesting lncRNAs work in synergy with miRNAs, adding extra levels of 
regulation in the control of cell phenotype and function by non-coding RNAs.  
Numerous lncRNAs have been identified with potential roles in the control and 
regulation of pluripotency. Originally identified to modulate reprogramming 
during the derivation of hiPSCs (Loewer et al., 2010), the large intergenic non-
coding RNA RoR (Regulator of Reprogramming) was found to act as an 
endogenous miRNA sponge to regulate the pluripotency-associated genes Oct4, 
Nanog and Sox2 (Wang et al., 2013). Wang et al. showed that linc-RoR binds 
miR-145, a key differentiation regulating miRNA, to prevent degradation of the 
critical pluripotency genes and regulate hPSC self-renewal. Additionally, a 
genome wide screen identified two novel lncRNAs (AK028326 and AK141205), 
directly controlled by the pluripotency factors Oct4 and Nanog, involved in the 
regulation of pluripotency and differentiation in mESCs (Sheik Mohamed et al., 
2010). TUNA, another lncRNA, was also discovered to control pluripotency and 
differentiation towards neural lineages in mESCs (Lin et al., 2014). 
In terms of cardiovascular development and differentiation, Klattenhoff et al. 
identified Braveheart, a lncRNA expressed in pluripotent mESCs. Braveheart was 
found to be critical for cardiovascular lineage commitment, specifically in 
promotion of cardiac cell fate, via the regulation of a number of cardiovascular-
related transcription factors, including Mesp1 (Klattenhoff et al., 2013). 
Recently, RNA sequencing analysis of transcripts differentially regulated in 
specific populations during hESC-EC differentiation, including pluripotent hESCs, 
mesoderm committed cells, early cardiovascular progenitors, committed 
vascular progenitors and vascular endothelial cells, identified three specific 
lncRNAs, each with specific roles in governing pluripotency, cardiovascular 
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commitment and endothelial cell identity; TERMINATOR, ALIEN and PUNISHER 
respectively (Kurian et al., 2015).  
Collectively, data from miRNA and lncRNA studies shows a vital role for non-
coding RNAs in pluripotent cells, both in the regulation of pluripotency and the 
control of differentiation and commitment to specific lineages.  
1.12 Project Aims 
The aims of this thesis were to generate and characterise protocols for the 
derivation of hESC-ECs, therefore allowing for identification and investigation of 
differential expression of miRNAs within the system, and in-depth probing of 
their mechanisms of action. Gaining insight into these mechanisms would allow 
us to understand how miRNAs drive commitment of pluripotent cells towards 
specific lineages, with particular focus on mesoderm and vascular endothelium. 
Specifically, these aims included:  
1. To develop, optimise and characterise differentiation protocols for the 
derivation of endothelial cells from hESCs. 
2. To identify miRNAs differentially regulated throughout hESC-EC 
differentiation. 
3. To modulate miRNA expression during hESC-EC differentiation, thereby 
allowing for the elucidation of functional role(s) of specific miRNAs. 
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2.1 General laboratory practice 
Laboratory reagents and equipment were of the highest commercially available 
standard. All chemicals, unless otherwise stated, were purchased from Sigma-
Aldrich, Dorset, UK. Hazardous chemicals were handled and disposed of in 
compliance with Control of Substances Hazardous to Health (COSHH) guidelines. 
Laboratory coats, nitrile powder-free gloves and fume hoods were used where 
appropriate. 
2.2 General cell culture techniques 
All cell culture was performed in standard biological safety class II vertical 
laminar flow cabinets under sterile conditions. Cabinets were cleaned before 
and after use with 1% virkon and 70% ethanol. Cells were cultivated in a 
humidified incubator at 37°C with a constant atmosphere of 5% CO2.  
2.2.1 Culture of HEK293Ts 
Human Embryonic Kidney (HEK) 293T cells (ATCC, Teddington, UK) were cultured 
as a monolayer in 150 cm2 vented-cap cell culture flasks (Corning, Poole, UK) 
and maintained in Minimum Essential Media (MEM), supplemented with 10% 
foetal calf serum  (FCS), 100 µg/mL penicillin, 100 µg/mL streptomycin, 2 mM L-
Glutamine (all Gibco, Paisley) and 1 mM sodium pyruvate (Sigma). Cell culture 
medium was replenished every 2-3 days, or in line with cell growth and cells 
were passaged when 70% confluent to avoid over growth. 
To passage, culture medium was removed and cells were washed with PBS. 2-3 
mL 1x citric saline was then added to each flask, and cells were incubated at 
37°C, 5% CO2 for 2-3 min. When the majority of cells had lifted from the bottom 
of the flask, an equal volume of serum-containing cell culture medium was 
added in order to neutralise the reaction. Cells were then collected and pelleted 
by centrifugation at 1,500 rpm for 5 mins. The supernatant was then discarded 
and cells were resuspended in an appropriate volume of fresh culture medium 
before they were distributed amongst flasks.  
For virus preparation (section 2.9.1) HEK293Ts were passaged at a ratio of 1:2 24 
hours prior to triple transfection of lentivirus producing plasmids.  
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When cells were needed at specific densities, e.g. titration of lentivirus particles 
(section 2.9.3), cells were counted using a haemocytometer prior to seeding in 
appropriate cell culture vessel. 
2.2.2 Human pluripotent stem cell culture 
Human embryonic stem cells (hESCs) were cultured as a monolayer in feeder- 
and serum-free conditions, with media replaced every 24-48 hours. This study 
focused on the use of 2 different hESC lines; the original Wisconsin lines H1 and 
H9 (Thomson et al., 1998) (WiCell, Madison, USA) Cells were tested for 
Mycoplasma using MycoAlert™ Mycoplasma detection kit (Lonza) and routinely 
and independently tested for karyotypic abnormalities. 
2.2.2.1 Maintenance and passage of hESCs 
H1 and H9 hESC lines were maintained in StemPro® hESC SFM culture medium 
(Life technologies), a medium specialised for the growth and expansion of hESCs 
and consisting of DMEM/F12 with GlutMAX™ medium, 1x StemPro® hESC 
supplement and 1.8% bovine serum albumin (BSA). Medium was then further 
supplemented with 0.1 mM 2-mercaptoethanol (Gibco, Paisley) and 20 ng/mL 
basic fibroblast growth factor (bFGF). When confluency reached 80-90%, cells 
were passaged mechanically using the StemPro® EZPassage tools (Invitrogen). 
EZPassage tools create a grid-like pattern of hESC cell colonies, which can then 
be lifted and transferred to new tissue culture vessels at a split ratio of 1 in 6. 
Tissue culture vessels were pre-coated with either CELLstart™ (Life 
Technologies) or recombinant Vitronectin (Life Technologies), protocols for 
coating plates are shown in table 2.1. 
Matrix Volume Concentration
Incubation 
time
Incubation 
Temperature
CELLstart 750µL/well N/A 2hr 37°C
Recombinant 
Vitronectin
0.5-1mL/well 5µg/mL 1hr Room temperature
Gelatin 2mL/well 0.1% Solution 1hr Room temperature
 
Table 2.1 – Protocols for coating tissue culture plates with various matrices 
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2.2.2.2 Cryo-preservation and recovery of cells 
Cells were treated as described in section 2.2.2.1. Culture medium containing 
small colonies, produced from the use of the StemPro® EZPassage tool, was 
added, at a ratio of 1:1 (v/v), to a ‘freezing medium’ mixture. The ‘freezing 
medium’ comprised 60% cell culture medium, 30% knock out serum replacement 
(KOSR) and 10% dimethyl sulfoxide (DMSO). 1 mL of the mixture, containing cells 
and freezing medium mix, was then added to 1 cryovial. Cryovials were then 
placed in a Nalgene® Mr.Frosty freezing container, and placed at -80°C. The 
freezing container contains isopropanol (2-propanol), ensuring a critical 1°C/min 
cooling rate, required for successful cryopreservation of cells. Cells were 
subsequently transferred to liquid nitrogen tanks for long term storage. 
For recovery from liquid nitrogen, cells were thawed quickly in a water bath at 
37°C, before being immediately transferred to a 15 mL flacon. 10 mL pre-
warmed culture medium was then added, dropwise. Cells were then centrifuged 
at 1,200 rpm for 3 min, and resuspended in culture medium containing 10µM Y-
27632, a rho-kinase inhibitor shown to improve stem cell survival (Watanabe et 
al., 2007). Culture medium was replaced the next day to remove remaining Y-
27632. 
2.3 Differentiation of human pluripotent stem cells 
2.3.1 Endothelial differentiation of hESC  
Endothelial differentiation of hESC was performed using an embyroid body (EB)-
based method. On d0, hESCs (90-100% confluent, 8 days post-passage) were 
taken to single cell suspensions using StemPro® Accutase (Life Technologies) or 
TrypLE Select™ (Gibco, Paisley). Cells were counted and 10,000 cells placed into 
each well of the inner 60 wells of a Corning® 96-well clear round bottom ultra-
low attachment microplate (Corning), or 96-well clear round bottom microplate 
coated with 5% pluronic F-127 (Sigma-Aldrich) (Ungrin et al., 2008), with 100 µL 
Stemline II medium (Sigma), supplemented with BMP4, Wnt3a (both R&D 
Systems), Activin A, VEGF (both Peprotech) and Y-26732 (Millipore) at 
concentrations shown in Table 2.2. To coat plates with 5% pluronic F-127, 50 µL 
solution was added to each well and plates were incubated at room temperature 
for 30 min, before being removed prior to the addition of cells (Table 2.1). 
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BMP4 VEGF Wnt3A Activin A Y-26732
0 Stemline II 10ng/mL 10ng/mL 10ng/mL 5ng/mL 10µM
2 Stemline II 40ng/mL 60ng/mL 20ng/mL 10ng/mL N/A
3-7
LONZA-EBM2 with 
EGM-2 bullet kit
N/A 50ng/mL N/A N/A N/A
Cytokine Concentration 
Day Media
 
Table 2.2 – Cytokine concentrations used on specific days of hESC-EC differentiation 
 
2 days after EB formation 16.6 µL of Stemline II medium, supplemented with 
BMP4, VEGF, Activin a and Wnt3A, was added to each well in the 96-well plate, 
giving final cytokine concentrations shown in Table 2.2. On d3, EBs were 
collected, washed in PBS and resuspended in 3mL Endothelial Growth Medium-2 
(EGM-2, Lonza) containing 50 ng/mL VEGF. The EGM-2 medium used is produced 
from the addition of the EGM-2 bullet kit to the Endothelial Basal Medium-2 
(Lonza), without the addition of the VEGF and FBS components. EBs were 
transferred into 6-well plates coated with 0.1% gelatin (Sigma). Medium was 
then changed (2 mL LONZA EGM-2 with 50 ng/mL VEGF) every 2 days until 
appropriate analysis time point was reached. Some earlier differentiations were 
performed using 6-well ultra-low attachment dishes (Corning) and StemPro® 
EZPassage tools for EB formation (as described in hematopoietic differentiation, 
section 2.3.3). 
2.3.2 MACSorting of hESC-ECs and further outgrowth 
After 7 days of endothelial differentiation, CD144+ cells were sorted using 
magnetic activated cell sorting (MACS), in order to allow for further culture of 
hESC-ECs (Figure 2.1). MACS was performed as follows, using commercially 
available microbeads, columns, magnets and holders from Miltenyi Biotec. Media 
was removed and cells were washed briefly with PBS, before dissociation to 
single cells using TrypLE Select™. Once collected, single cells were resuspended 
in MACS buffer; PBS, pH 7.2, 0.5% bovine serum albumin (BSA), passed through a 
40 µm nylon mesh (Fisherbrand) to ensure removal of cell clumps, and counted 
to determine total cell number. Cells were then centrifuged at 300 x g for 5 min, 
and the resulting pellet resuspended in 80 µL of MACS buffer per 107 total cells.  
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Figure 2.1 – Overview of MACSorting  
Cells were magnetically labelled using MACS microbeads conjugated antibodies, before being 
passed through a column within a magnetic field. Labelled cells will bind to the column, and those 
which are unlabelled will pass through. Labelled cells were then be collected by removal of the 
column from the magnetic field (Adapted from Miltenyi Biotec). 
20 µL of CD144 microbeads, per 107 total cells, was then added and the mixture 
incubated at 4°C for 15-30 min. Cells were then washed using 1-2 mL MACS 
buffer and centrifuged at 300 x g for 5 min, to remove any excess or unbound 
CD144 microbeads, and the resulting pellet resuspended in 500 µL MACS buffer. 
A cell separation column (LS column) was placed in a MidiMACS™ separator and 
prepared for use by rinsing with 3 mL MACS buffer. The MidiMACS™ separator 
contains a powerful permanent magnet which applies a high-gradient magnetic 
field to a MACS column, allowing for cells labelled with even small amount of 
magnetic microbeads to bind to the column (Figure 2.1). Once the column was 
prepared, the cell suspension was then applied to the column and the flow 
through collected. The column was washed 3 times with 3 mL MACS buffer, the 
flow through collected and combined with that from the cell suspension. This 
flow through contains CD144- cells from the mixture, as they are unlabelled and 
have therefore been unable to bind to the MACS column. To collect the CD144+ 
cells, the column was removed from the MidiMACS separator and the 
magnetically labelled cells were flushed out using 5 mL MACS buffer. 
Flow cytometry was performed to ensure efficient purification of CD144+ cells. 
Sorted cells were then plated onto gelatin coated 6-well tissue culture plates at 
a density of 1x105 cells per well and cultured for a further 7 days in LONZA EGM-
2 media with FBS component added and supplemented with 50ng/mL VEGF. 
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2.3.3 Differentiation of hESC to hemogenic endothelium 
Differentiation of cells to early hemogenic endothelium was performed using the 
first 10 days of a defined serum- and feeder-free EB-based hematopoietic 
differentiation protocol (Mountford lab). On d0 EBs are formed by removing 
medium from the wells and washing cells in PBS. 3 mL/well Stemline II medium 
(Sigma-Aldrich), supplemented with BMP4, VEGF, Activin A, Wnt3A and Inhibitor 
VIII, was added, and cells were cut into rough squares using a StemPro® 
EZPassage tool. Cells were then removed from the well and transferred to a 
Corning® 6-well ultra-low attachment plate (Corning) at a 1:3 ratio. A further 
1.5 mL media, containing d0 cytokines, was then added to each well, resulting in 
a final volume of 3 mL/well. At d2, cells had formed EBs and a further addition 
of 0.5mL Stemline II medium, supplemented with BMP4, VEGF, Inhibitor VII, 
Wnt3A, Activin A, FGFα, SCF and β-Estradiol, was made. On d3 cells were 
collected and dispersed, using Tryple Select. Single cells were then resuspended 
in Stemline II medium, counted, and seeded at 2x105 cells per well in a standard 
6-well plate, in 3 mL/well Stemline II medium, with appropriate cytokines 
added. A further 0.5 mL media, supplemented with specific cytokines, was 
added on day 5, before a complete media change was then performed on d7. On 
day 9, a final addition of 0.5 mL media and cytokines was made, before cells 
were harvested for analysis on d10. Stemline II medium was used for all stages of 
differentiation, and concentrations of all cytokines added are shown in table 
2.3. 
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BMP4 VEGF Wnt3A Activin A Inhibitor VIII FGFα SCF β-Estradiol IGF2 TPO Heparin IBMX
0 10ng/mL 10ng/mL 10ng/mL 5ng/mL 2µM - - - - - - -
2 20ng/mL 30ng/mL 10ng/mL 5ng/mL 2µM 10ng/mL 20ng/mL 0.4ng/mL - - - -
3 20ng/mL 30ng/mL - - - 10ng/mL 30ng/mL 0.4ng/mL 10ng/mL 10ng/mL 5ng/mL 50µM
5 20ng/mL 30ng/mL - - - 10ng/mL 30ng/mL 0.4ng/mL 10ng/mL 10ng/mL 5ng/mL 50µM
7 20ng/mL 30ng/mL - - - 10ng/mL 30ng/mL 0.4ng/mL 10ng/mL 10ng/mL 2.5ng/mL 50µM
9 10ng/mL 15ng/mL - - - 5ng/mL 15ng/mL 0.2ng/mL 5ng/mL 5ng/mL 1.25ng/mL 25µM
Day Media
Stemline II
Cytokine Concentration
 
Table 2.3 – Final concentration of cytokines in Stemline II medium on specific days of differentiation to hemogenic endothelium. 
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2.4 Functional analysis of hESC-ECs  
2.4.1 Matrigel Tubule Assay 
Growth-factor reduced Matrigel™ (BD Biosciences) was thawed overnight at 4°C. 
Once thawed, 75 µL Matrigel™ was added to each well of a 96-well cell culture 
dish, ensuring an even spread across the surface and removing any bubbles. 
Plates were then incubated at 37°C for ≥30 min to ensure setting of the matrix.  
hESC-ECs were taken to a single cell suspension using TryPLE select and 
resuspended in Lonza EGM-2 medium supplemented with 50 ng/mL VEGF. 75 µL 
medium containing 2x104 cells was added to each well, and cells were incubated 
for 24 h at 37°C and 5% CO2. After 24 h cells were removed from the incubator 
and assessed for their ability to form tubules. Cells were imaged using an EVOS® 
XL Core Cell Imagine System (Life Technologies). 
2.5 Gene and miRNA expression analysis 
2.5.1 Extraction of total RNA from cells 
Extraction of total RNA, including miRNA, from cultured cells was performed 
using the Qiagen miRNeasy mini kit, with as per manufacturer’s instructions. An 
on-column DNase treatment was also performed during the extraction via the 
use of the accompanying RNase-free DNase Set (Qiagen). 
Culture medium was removed and cells were washed using PBS. For one well of a 
6 well plate, 700 µL QIAzol lysis reagent was added to the cells, either directly 
on the plate, or after dissociation using TrypLE Select™. Samples were 
homogenised by pipetting up and down using, and the lysate transferred to a 1.5 
mL microcentrifuge tube. Lysates were then either directly processed or stored 
at -80°C until required.  
When required, cell lysates were placed at RT for 5 min, before the addition of 
140 µL chloroform. Samples were mixed and incubated at RT for a further 3 min, 
before being centrifuged at 12,000 x g at 4°C for 15 min. Centrifuging the 
sample allows for separation into three different phases; an upper, aqueous 
phase, containing total RNA, a middle interphase, containing DNA and a lower, 
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organic phase, containing proteins. The aqueous phase was then removed and 
transferred to a new 1.5 mL microcentrifuge tube. 1.5 volumes of 100% ethanol 
was added to each sample and mixed thoroughly. Samples were then transferred 
to RNeasy spin columns, and centrifuged at 8,000 x g for 15 s, and the flow 
through discarded. This allows total RNA to bind to the column, whilst phenol 
and other contaminants are efficiently washed away. 350 µL RWT buffer was 
then added and columns were centrifuged again at 8,000 x g for 15 s at RT. 
At this stage an on-column DNase digest was performed, allowing for removal of 
any contaminating genomic DNA in the sample. To do this, DNase was prepared 
according to manufacturer’s instructions and 10 µL of enzyme mixed with 70 µL 
RDD buffer per sample. 80 µL of the DNase/RDD buffer mix was then added to 
directly onto each column and left to incubate for 15 min at RT. After 15 min, a 
further 350 µL of RWT buffer was added and columns were centrifuged for 15 s 
at 8,000 x g at RT.  
Samples were then washed twice with 500 µL RPE buffer, the first with a 15 s 
spin and the second with a 2 min spin, both at 8,000 x g at RT. RNeasy spin 
columns were then transferred to clean 2 mL collect tubes and centrifuged at 
full speed for 1 min. This spin ensures removal of residual ethanol and avoids 
carryover of buffer RPE which may interfere with downstream reactions. Total 
RNA was then eluted by passing 30-50 µL nuclease-free water through the spin 
column for 1 min at 8,000 x g. The eluate was then collected and passed through 
the column again to obtain an optimal RNA yield.  
RNA concentration was determined using a NanoDrop 1000 spectrophotometer 
(Thermo Scientific), and samples stored at -80°C until required. 
2.5.1.1 RNA quality control 
Quality control of RNA was performed using the Agilent® 2100 Bioanalyser or 
Agilent 2200 TapeStation instrument. 
The Aligent® 2100 Bioanalyser is used to measure the quality of RNA, via the 
calculation of an RNA integrity number (RIN), calculated based on the presence 
or absence of degradation productions within the sample. This was used to test 
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RNA samples before analysis using TLDA card (see section 2.5.3.1), samples with 
a RIN value of 7 or more are deemed of a high quality. For analysis using the 
Aglient® bioanalyser, 1 µL of RNA was used for each sample. First, the Agilent 
gel was prepared by centrifuging 550 µL of gel matrix through a spin column at 
1500 x g for 10 min. Once passed through the column, 65 µL of the matrix was 
transferred to a new Eppendorf, and 1 µL of RNA 6000 Nano dye concentrate was 
added and mixed well. The mix was then centrifuged at 13,000 x g for 10 min. 
An RNA 6000 nano chip was then placed into the chip priming station, and 9 µL 
of the gel-dye mix was added to the specified well, and spread evenly through 
the chip using the 1 mL syringe attached to the chip priming station. A further 9 
µL of gel-dye mix was then added to two other wells on the nano chip. 5 µL of 
RNA 6000 Nano marker was then added to all wells, including the 12 sample 
wells and the ladder well. 1 µL of sample was added to each sample well, with a 
maximum of 12 samples per chip, and 1 µL of RNA ladder added to the marked 
‘ladder’ well. The chip was then vortex mixed for 60 s at 2400 rpm, before being 
inserted into the Agilent® 2100 bioanalyser and immediately run.  
For miRNA microarray (section 2.5.4) RNA quality control was performed using 
an Agilent® 2200 Tapestation, following the standard operating procedures at 
Sistemic Ltd. Similarly to the Agilent® 2100 Bioanalyser system, this instrument 
provides a readout of RNA quality, via the calculation of a RIN value. Briefly, all 
reagents were allowed to equilibrate to room temperature and vortex mixed 
before use, and RNA samples thawed on ice. 5 µL sample buffer was added to 1 
µL of sample RNA, or RNA ladder. All samples were vortex mixed for 1 min at 
2,000 rpm, and briefly centrifuged, before samples were then denatured. To do 
this, tubes were heated to 72°C for 3 min, followed 2min incubation on ice. 
Samples were then loaded into the Agilent® 2200 TapeStation and analysis was 
performed. 
2.5.2 Reverse transcription polymerase chain reaction (RT-PCR) 
In order to analyse cellular gene and miRNA expression levels, cDNA 
(complementary DNA) must first be created from total RNA.  
For gene expression analysis, cDNA was  generated using TaqMan® Reverse 
Transcription Reagents (Life technologies). Each reaction contained 200-1000 ng 
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RNA (consistent within experiments), and the following reagents: 1x reverse 
transcription buffer, 5.5 mM MgCl2, 0.5 mM of each dNTP, 2.5 µM random 
hexamers, 0.4 U/µL RNase inhibitor enzyme and 1.25 U/µL Multiscribe™ Reverse 
Transcriptase. Nuclease-free H2O was then added to give a final reaction volume 
of 20 µL, and samples were put through the following temperature cycle in a 
thermal cycler: 10 min at 25°C to allow for annealing of primers, 30 min at 48°C 
for reverse transcription, and 5 min at 95°C to inactivate the reverse 
transcriptase. Samples were then removed from the thermal cycler and placed 
at -20°C until required. 
When performing miRNA analysis, cDNA was generated using the TaqMan® 
miRNA Reverse Transcription kit (Life Technologies). Reactions contained 5ng 
total RNA, and the following reagents: 1 x reverse transcription buffer, 0.25 
U/µL RNase inhibitor, 3.33 U/µL Multiscribe™ Reverse Transcriptase, 1 mM of 
each dNTP (all provided with the kit), 1 x TaqMan® miRNA reverse transcription 
primers (provided with TaqMan® assays, Life Technologies). H2O was then added 
to make a final reactioin volume of 7.5 µL. Synthesis was then performed using 
the following thermal cycling conditions: 16°C for 30 min to allow for the 
binding of the miRNA primers, 42°C for 30 min for the reverse transcription, and 
85°C for 5 min to allow for inactivation of the reverse transcription enzyme. 
Samples were then removed from the thermal cycler and stored at -20°C until 
required. Reverse transcription of an endogenous control miRNA (RNU48) was 
also performed, in order to allow for normalisation of changes in miRNA 
expression.  
Non-template controls (NTC), whereby H2O was added to in the place of RNA, 
were performed for each experiment. For the miRNA RT-PCR, one NTC was 
performed for each miRNA primer used.  
2.5.3 mRNA and miRNA TaqMan® real-time PCR  
Quantitative real time-PCR (qRT-PCR) is a technique which can be used for the 
quantification of a specific mRNA or miRNA within a sample. TaqMan® qRT-PCR 
assays are labelled with a 5’ fluorescent reporter dye, such as VIC or FAM, and a 
quencher molecule at the 3’ end. When the TaqMan® probe is intact, 
fluorescence released from the 5’ dye is transferred to the 3’ quencher molecule 
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by a phenomenon known as fluorescence resonance energy transfer (FRET). 
However, during the amplification process, if the target sequence is present in 
the sample, the probe anneals and the quencher is cleaved via the action of the 
Taq DNA polymerase – present in the reaction mixture. The Taq polymerase 
enzyme contains a 5’ nuclease domain, which allows degradation of DNA bound 
to the target, downstream of DNA synthesis. This results in the degradation of 
the TaqMan® probe, and cleavage of the 3’ quencher molecule, therefore 
preventing FRET and allowing for the detection of the reporter fluorophores. 
The strength of the fluorescence is increased with each amplification cycle, and 
is relative to the amount of a specific mRNA or miRNA within a sample. The 
fluorescence signal can be normalised to that of a reference or ‘housekeeping’ 
gene – a gene which should maintain relatively stable expression levels 
throughout a sample set. This allows for comparison of expression levels 
between samples. For gene expression analysis, Ubiquitin protein C (UBC) was 
selected as a stable housekeeping gene using a human endogenous control array 
and, unless otherwise stated, was used as a reference gene throughout the 
studies. GAPDH was used during TLDA card analysis. RNU48 was used as an 
endogenous control for all miRNA expression experiments. 
For mRNA expression, qRT-PCR was performed using TaqMan® Gene Expression 
assays and TaqMan® Universal Master Mix II (both Life Technologies) in 
accordance with the manufacturer’s instructions. Reactions were performed in 
384-well plates, and contained 1 x Taqman® assay (5 µL), and 1 x TaqMan® 
master mix (0.5 µL), as well as 1.5 µL cDNA (section 2.5.2) and 3 µL nuclease-
free H2O – giving a total reaction volume of 10 µL. 
miRNA expression qRT-PCR was performed using TaqMan® miRNA RT-PCR probes 
(provided in same assay as reverse transcription primers), and TaqMan® 
Universal Master Mix II in accordance with the manufacturer’s instructions. Each 
reaction contained 5 µL TaqMan® mastermix, 0.5 µL miRNA probe, 3.83 µL 
nuclease-free H2O and 0.67 µL cDNA from miRNA reverse transcription, and were 
performed in 384-well plates.  
Both mRNA and miRNA expression was measured using ABI Prism Applied 
Biosystems 7900HT sequence detection system. Samples were subject to 10 min 
at 95°C to allow for denaturing, before undergoing 40 cycles of denaturing at 
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95°C for 15 s, followed by 60 s at 60°C for primer and probe annealing and 
primer extension. 
Data was then analysed using the comparative CT method, also known as 2
-ΔΔCT 
method (Livak et al., 2001). The number of cycles taken for the reporter dye 
emissions to reach a specific level is known as the cycle threshold (CT). The ΔCT 
is the difference between the CT of the gene of interest (GOI) and the CT of the 
housekeeper or reference gene, therefore allowing for expression to be 
normalised to total RNA content. The mean ΔCT of all biological replicates for 
the same GOI was calculated, and then used to calculate the ΔΔCT, which shows 
the difference in gene expression between a sample and control or non-
treatment group. 2-ΔΔCT is then used to calculate the fold increase or decrease in 
gene expression between a sample and the control group, whose value is equal 
to 1.  
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Gene name Alternative name Assay ID
UBC Hs01871556_s1
GAPDH Hs02758991_g1
PECAM-1 CD31 Hs00169777_m1
CDH5 VE-Cadherin; CD144 Hs00901463_m1
POU5F1 Oct4 Hs00999632_g1
NANOG Hs04399610_g1
SOX2 Hs01053049_s1
T Brachyury Hs00610080_m1
MESP1 Hs01001283_g1
MIXL1 Hs00430824_g1
SPN CD43 Hs01872322_s1
 
Table 2.4 – List of gene expression TaqMan assays used. 
 
 
miRNA
Alternative 
names
miR Base 
Identifier
Assay 
number
miR-10a-5p miR-10a MIMAT0000253 000387
miR-126-3p miR-126 MIMAT0000445 002228
miR-143-3p miR-143 MIMAT0000435 002249
miR-143-5p miR-143* MIMAT0004599 002146
miR-145-3p miR-145* MIMAT0004601 002149
miR-145-5p miR-145 MIMAT0000437 002278
miR-302a-3p miR-302a MIMAT0000684 000529
miR-302b-3p miR-302b MIMAT0000715 000531
miR-451a miR-451 MIMAT0001631 001141
miR-483-3p - MIMAT0002173 002339
miR-483-5p - MIMAT0004761 002338
RNU48 - - 001006  
Table 2.5 – List of miRNA TaqMan assays used. 
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2.5.3.1 TaqMan® Low Density Array cards (TLDA) 
TaqMan® Low Density Array (TLDA) cards use the same chemistry as previously 
described for TaqMan® qRT-PCR (section 2.5.3), but allow for higher through put 
screens. In this format, lyophilized TaqMan® assays are stored on 384-well micro 
fluid cards, therefore allowing for a large number of reactions to be performed 
with relatively low amounts of sample. Cards allow for a maximum of 8 samples 
to be run simultaneously, for up to 48 different genes. For each sample, 30-1000 
ng DNA (consistent between experiments) was diluted into 55 µL nuclease-free 
H2O and added to 55 µL TaqMan® master mix. 100 µL of this mixture was then 
added directly to one port of on the TLDA card.  Cards were then centrifuged to 
ensure even distribution of sample cDNA between wells, and data was collected 
using the ABI Prism Applied Biosystems 7900HT sequence detection system.   
Data was then analysed using the 2-ΔΔCT method as previously described (section 
2.5.3). Details of assays on custom TLDA cards are given in Table 2.6. 
This technology, in the form of a human endogenous control array (Life 
Technologies), was also used to help identify UBC as a suitable housekeeper 
gene for gene expression analysis studies.  
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Gene name Protein name Alternative name Assay ID
18S 18S ribosomal RNA Hs99999901_s1
ACTC1 Alpha actin Hs00606316_m1
AFP Alpha-fetoprotein Hs00173490_m1
B2M Beta-2 microflobulin Hs99999907_m1
BMP4 Bone morphogenic protein 4 Hs00370078_m1
CDX2 Hs00230919_m1
CER1 Cerberus Hs00193796_m1
CGA Chorionic gonadotropin alpha Hs00174938_m1
CXCR4 Hs00607978_s1
CYP26A1 Cytochrome P450 26A1 Hs00175627_m1
DES Desmin Hs00157258_m1
DKK1 Dickkopf-related protein 1 Hs00183740_m1
FN1 Fibronectin Hs00277509_m1
FOXA2 Forkhead box protein A2 HNF-3B Hs00232764_m1
FOXC1 Forkhead box C1 Hs00559473_s1
FZD5 Frizzled-5 Hs00258278_s1
GAPDH
Glyceraldehyde 3-phosphate 
dehydrogenase
Hs99999905_m1
GATA2 GATA binding protein 2 Hs00231119_m1
GATA4 Transcription factor GATA-4 Hs00171403_m1
GATA6 Transcription factor GATA-6 Hs00232018_m1
GDF15 Growth differentiation factor 15 Hs00171132_m1
GJA1 Gap junction alpha-1 protein Cx43 Hs00748445_s1
GSC Goosecoid Hs00418279_m1
HAND1 
Heart- and neural crest 
derivatives-expressed protein 1
Hs00231848_m1
HNF1B 
Hepatocyte nuclear factor 1 
homeobox B
TCF2
Hs00172123_m1
INS Insulin Hs00355773_m1
ISL1 Insulin gene enhancer protein ISL-1 ISLET1 Hs00158126_m1
ITGB5 Integrin beta-5 Hs00609896_m1
KDR Kinase insert domain receptor
CD309; VEGFR2; 
FLK1 
Hs00911700_m1
MESP1 Mesoderm posterior 1 homolog Hs00251489_m1
MIXL1 Hs00430824_g1
MSX1 Msh homeobox 1 Hs00427183_m1
MYL2 Myosin regulatory light chain 2 MLC-2 Hs00166405_m1
NANOG Hs02387400_g1
NES Nestin Hs00707120_s1
NKX2-2 Homeobox protein Nkx-2.2 Hs00159616_m1
NKX2-5 Homeobox protein Nkx-2.5 Hs00231763_m1
PAX6 Paired box protein Pax-6 AN2 Hs00240871_m1
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PDX1 
Pancreatic and duodenal 
homeobox 1
IPF1 Hs00426216_m1
PECAM1 
Platelet endothelial cell 
adhersion moecule
CD31 Hs00169777_m1
POU5F1 
POU domain, class 5, 
transcription factor
OCT4 Hs00742896_s1
SNAI1 Zinc finger protein SNAI1 SNAIL Hs00195591_m1
SOX17 SRY (Sex detemining Y)-Box 17 Hs00751752_s1
SOX2 SRY (Sex detemining Y)-Box 2 Hs00602736_s1
SOX7 SRY (Sex detemining Y)-Box 7 Hs00846731_s1
SST Somatostatin Hs00174949_m1
T Brachyury Hs00610080_m1
 
Table 2.6 –TaqMan probes on custom TLDA cards used for gene expression analysis.  
GAPDH, 18S and B2M were used as housekeeper genes. 
 
2.5.4 miRNA microarray 
Total RNA extraction was performed using the Qiagen miRNeasy mini kit, as 
described in section 2.5.1. Concentration and quality control of collected RNA 
was determined using the NanoDrop and Agilent® 2200 Tapestation respectively. 
The Tapestation platform allows for a read out of RNA quality as given by the 
RIN value, to ensure data collect was of the highest quality, RNA was tested to 
ensure RIN values of >7 (see section 5.3.3). All RNA samples were then diluted to 
the working concentration of 50 ng/µL. Before running on the array, samples 
were also randomised to ensure equal distribution of biological replicated 
between microarray slides. 
Samples were then processed for analysis. To do this, two kits were used; the 
miRNA Spike-In kit and the miRNA Complete Labelling and Hybridisation kit (both 
Agilent Technologies). The miRNA Spike-In kit contains a mix of ten in vitro 
synthesised, polyadenylated transcripts in predetermined ratios. These 
transcripts hybridise to control probes on the Agilent microarray, and allow for 
distinguishing of significant biological data from processing errors. Two different 
Spike-In solutions are provided in the kit, and both are used in the analysis; the 
Labelling Spike-in, added during the labelling reaction, and the Hybridisation 
(Hyb) Spike-In, added during the hybridisation reaction. To prepare the Spike-In 
solutions, serial dilutions of both Spike-In mixtures were performed. Briefly, 2 µL 
of the Labelling Spike-In, prepared as per the manufacturer’s instructions, was 
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added to 198 µL of nuclease-free H2O and mixed thoroughly. 2 µL of this dilution 
was then added to 198 µL nuclease-free H2O and mixed thoroughly to give the 
working dilution of the Labelling Spike-In. This process was repeated with the 
Hyb Spike-In. 
Once the Spike-In solutions were prepared, samples underwent Labelling and 
Hybridisation, performed using the aforementioned miRNA Complete Labelling 
and Hybridisation kit. 2 µL of each RNA samples (100 ng total) was added to 
individual 1.5 mL microcentrifuge tubes and maintained on ice to avoid 
degradation. Samples were then dephosphorylated using the Calf Intestine 
Alkaline Phosphatase (CIP) enzyme. The CIP Master Mix was prepared as shown 
below and kept on ice until needed: 
Reagent      Amount per reaction (µL) 
10X Calf Intestinal Phosphatase Buffer         0.4  
Labelling Spike-In            1.1  
Calf Intestinal Phosphatase          0.5 
Total               2.0 
2 µL CIP Master Mix was added to each sample tube and gently mixed by 
pipetting. Tubes were then incubated at 37°C for 30 min to allow for 
dephosphorylation.  Samples then underwent denaturation using DMSO. 2.8 µL 
DMSO was added to each sample, before incubation at 100°C for between 5-10 
mins. Samples were transferred immediately to an ice-water bath, thus ensuring 
samples remain properly denatured, before moving immediately onto labelling 
of samples. Immediately prior to use, the Ligation Master Mix was prepared as 
described below: 
Reagent      Amount per reaction (µL) 
10X T4 RNA Ligase Buffer           1.0  
Cyanine 3-pCp            3.0 
T4 RNA Ligase            0.5 
Total               4.5 
After preparation, 4.5 µL of Ligation Master Mix was added to each sample, 
gently mixed by pipetting and briefly centrifuged. Samples were then incubated 
for 2 h at 16°C to allow for efficient labelling.  
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Micro Bio-Spin P-6 Gel Columns (Bio-Rad) were then employed to purify labelled 
RNA samples. This allows for removal of DMSO and excess Cyanine 3-pCp from 
samples. Before use, columns were inverted several times to ensure 
resuspension of the settled gel and to remove any air bubbles. The tip of each 
column was removed, and columns were placed into a 2 mL collection tube. The 
green cap of each column was removed allowing the buffer, hydrating the Bio-
Gel on the column, to drain through. Once evenly drained, flow through was 
discarded and tubes containing columns were centrifuged for 2 min at 1000 x g. 
Columns were then placed into a new 1.5 mL RNase-free microcentrifuge tube. 
38.7 µL of nuclease-free H2O was added to each sample, to give a total reaction 
volume of 50 µL. All 50 µL of sample was then carefully added to a column, 
ensuring the gel bed was not disturbed. Samples were then centrifuged at 1000 x 
g for 4 min, eluting the purified sample, which appears slightly pink. Columns 
were then discarded and samples kept on ice. Samples were then dried using a 
vacuum concentrator with heater. Before proceeding with the hybridisation 
reaction, it was ensured that all samples were completely dry. 
Once all samples had undergone labelling, hybridisation was performed. Dried 
samples were resuspended in 17 µL nuclease-free H2O, before the addition of 1 
µL Hyb Spike-In solution, 4.5 µL 10x Gene Expression Blocking Agent and 22.5 µL 
2x Hi-RPM Hybridisation Buffer. Tubes were incubated at 100°C for 5 min and 
then transferred to ice for a further 5 min. Samples were then immediately 
loaded into one well of a gasket slide, in an Agilent SureHyb chamber base. 
Gasket slides were loaded with 8 samples, before the SurePrint G3 Human v16 
miRNA 8x60K microarray slides were placed, active side down, onto the gasket 
slide, ensuring correct alignment of both slides. This was then clamped into 
place and each assembled chamber placed into an oven on a rotating rack. 
Samples were hybridised overnight (~20 h) at 55°C and 20 rpm. After 
hybridisation, slides were washed thoroughly, and placed into a slide holder. 
Slides were then processed using the Agilent C Scanner, and data was extracted 
using the Agilent Feature Extraction Software. 
2.6 Immunocytochemistry (ICC) 
Media was aspirated and cells were washed with PBS. Ice cold 100% methanol 
was added and cells were placed at -20°C for 15 min. Methanol was aspirated 
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and cells were washed once again in PBS. For blocking, 750 µL 10% normal goat 
serum (NGS) was added to each well of a 6 well plate and cells were incubated 
for 1 h at RT on a shaker. After incubation, cells were washed twice using PBS-
Tween20 (PBS-T); 0.5 mL Tween-20 in 49.5 mL PBS. Primary antibodies were 
diluted in 1% NGS at a pre-optimised dilution, 1 mL primary antibody was added 
to each well and cells were incubated overnight at 4°C. The primary antibody 
was then removed and cells were washed 3 times in PSB-T. 800 µL of the 
appropriate secondary antibody, diluted in 1% NGS, was then added to each well 
and cells incubated for 1 h at room temperature. Secondary antibodies were 
then aspirated and cells washed in PSB-T another 3 times. Once the last wash of 
PBS-T has been performed, cells were washed twice in PBS and all PBS was 
aspirated. Prolong gold with DAPI was then added to each well and a coverglass 
was applied, ensuring all bubbles were removed, before leaving the cells to set 
for 1 h at 4°C. Imaging was then performed using Zeiss Axiovert 200M. 
2.7 Flow Cytometry 
Cells were prepared for analysis by flow cytometry by dissociating to single cells 
using TrypLE Select™ (Gibco, Paisley). Cells were washed using PBS and 
resuspended in FACS sheath fluid (BD Biosciences) or in FACS buffer; 2 mM EDTA, 
1% KOSR, PBS. Cells were counted and 1x105 cells were transferred to a reaction 
tube. Antibodies were then added to each reaction tube, with amount varying 
with the conjugate used; 1 µL allophycocyanin (APC) and brilliant violet 421 
(BV421), 2 µL phycoerythrin (PE), 3 µL fluorescein isothiosyanate (FITC), APC-Cy7 
and peridinin-chlorophyll proteins (PerCP)-Cy5.5. The antibody-cell mixture was 
incubated in the dark at 4°C for 30 min. Cells were washed with 2 x 3 mL FACS 
sheath fluid, and resuspended in 200 µL of sheath fluid. Samples were then 
analysed using the BD Biosciences FACSCanto II with FACSDiva software and 
either a 2-laser (red – 633-nm, and blue – 488-nm) or 3-laser (red, blue and 
violet - 405-nm) configuration. Unstained and matched isotype control samples 
were used as negative controls and used to set gates for positive and negative 
populations, and 10,000 events were collected for each sample. 
Compensation was performed using single-stained samples for each fluorophore 
and calculated using the FACSDiva software. For samples with GFP virus 
compensation set up was performed manually. For large, multi-colour 
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experiments, fluorescence minus one (FMO) controls were used to ensure 
compensation settings were correct. 
Analysis of flow cytometry data was performed using FlowJo analysis software 
(Tree Star). Antibodies used for flow cytometry are shown in Table 2.7. 
Target Antigen Species Raised in Conjugate Supplier
SSEA3 Rat Alexa fluor® 647 BD Biosciences
SSEA3 Mouse PE BD Biosciences
SSEA4 Mouse APC BD Biosciences
Tra1-60 Mouse PE BD Biosciences
CD56 Mouse PE BD Biosciences
CD326 Mouse APC BD Biosciences
CD326 Mouse FITC BD Biosciences
CD144 Mouse PE BD Biosciences
CD144 Mouse APC eBiosciences
CD31 Mouse FITC BD Biosciences
CD31 Mouse PE BD Biosciences
CD31 Mouse APC R&D Systems
CD43 Mouse PE-Cy7 BD Biosciences
CD309 Mouse PE BD Biosciences
CD117 Mouse PerCP-Cy5.5 BD Biosciences
CD117 Mouse PerCP-eFlour® 710 eBiosciences
CD235a Mouse BV421 BD Biosciences
CD73 Mouse APC BD Biosciences
 
Table 2.7 – Antibodies used for flow cytometric analysis. 
 
2.7.1 Fluorescence Activated Cell Sorting (FACS)  
For FACSorting, cells were prepared in the same was as described for flow 
cytometry (see above), with the addition of a step whereby cells were passed 
through a 40 µm cell strainer (Fisher) after resuspension, before staining. Cells 
were stained with APC-conjugated CD326 (EpCAM) and PE-conjugated CD56 
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(NCAM) antibodies (both BD biosciences). FACSorting was performed using either 
BD Biosciences FACS Aria™ or FACS Aria III™. Cells for FACSorting were gated for 
Live/Dead using 7-AAD, and sorting performed until ≈1x106 cells were collected. 
Compensation was performed using single-stained samples.  
2.8 General DNA cloning techniques 
Eukaryotic expression plasmids were employed to create miRNA overexpressing 
lentiviruses for hESC transduction. All plasmids used in this study encoded 
ampicillin resistance. Cloning of miRNA fragments into pcDNA3.3 was performed 
using the pcDNA™3.3-TOPO® TA Cloning Kit (Life Technologies). 
2.8.1 Genomic DNA extraction 
Extraction of genomic DNA from cells was performed using the QIAamp DNA Mini 
and Blood Mini Kit (Qiagen) as per manufacturer’s instructions. Briefly, cells 
were collected, pelleted and resuspended in 200 µL PBS. 20µL proteinase K was 
then added to each sample, followed by 200 µL of buffer AL and then pulse-
vortexed for 15secs. Tubes were placed at 56°C for 10 min before 200 µL 
ethanol was added and samples were mixed again by pulse vortexing. This 
mixture was then added to a QIAamp Mini spin column and centrifuged at 6,000 
x g for 1 min. The QIAamp Mini spin column contains a silica membrane onto 
which the DNA is adsorbed. The conditions of the lysate and during wash steps 
ensure removal of proteins and other contaminants from the column, whilst still 
allowing the binding of DNA. Samples were washed via the addition of 500 µL 
buffer AW1 and centrifuged again at 6,000 x g for 1 min. A second wash was 
performed using 500 µL buffer AW2 and centrifuging at 16,000 x g for 3 min, 
followed by a further centrifugation step of 16,000 x g for 1 min to remove any 
remaining contaminants. The spin column was then placed in a 1.5 mL Eppendorf 
and DNA was eluted using 50 µL of nuclease-free H2O. Concentration of DNA was 
then measured using the Nanodrop and stored at -20°C until required.  
2.8.2 Polymerase chain reaction (PCR) 
Standard reaction mixes and thermal cycling protocols are shown below. 
Protocols were optimised when standard conditions were unsuccessful. PCR 
primers (shown in table 2.8) were designed using OligoPerfect™ Designer 
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(Invitrogen, Life Technologies) software and purchased from Eurofins. Reactions 
were performed using Platinum®Taq DNA Polmerase (Invitrogen, Life 
Technologies) as shown below: 
Per reaction: 
Reagent     Amount per reaction (µL)     
10 x Buffer     5 
10 mM dNTP mix    1 
50 mM MgCl2     1.5 
Primer mix (10 µM of F and R)  1 
Betaine     5 
Taq Polymerase    0.2 
H2O         Up to 50µL total reaction volume 
 
Thermal cycling conditions: 
1: 95°C for 2 min 
2:  95°C for 30 s 
3: 55°C for 30 s    x30 
4: 72°C for 1 min 
5: 72°C for 10 min 
6: 12°C forever 
Primer name miRNA(s) to amplify 5' Addition Primer sequence
miR-145 F miR-145 ATGCCTCGAG GAGCAATAAGCCACATCCG
miR-145 R
miR-145; miR-
143/145 cluster
ATGCACGCGT TCCAGGGACAGCCTTCTTC
miR-143 F
miR-143; miR-
143/145 cluster
ATGCCTCGAG TGGTCCTGGGTGCTCAAAT
miR-143 R miR-143 ATGCACGCGT ATGGACACACTGGGGTACACA
 
Table 2.8 – Sequence of primers used for PCR amplification of miR-145, miR-143 and miR-
143/145 cluster.  
A mix of 10µM of forward (F) and reverse (R) primers were used in each reaction. 
 
2.8.3 Restriction digest 
Restriction digests were performed as diagnostic tools, and for the insertion of 
specific DNA sequences (inserts) into plasmid backbones for expression. 
Reactions were performed using restriction endonucleases (all used in this study 
from New England Biosciences), in either a 20 µL reaction (for diagnostic 
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purposes) or in a larger, 250 µL reaction for digestion and purification of plasmid 
or insert DNA. 
Small 20 µL reactions contained 500 ng DNA, 0.5 µL of each specific restriction 
endonuclease, 0.2 µL BSA, 2 µL buffer (matched for the activity of each enzyme) 
and were made up to 20 µL total volume using nuclease-free H2O. Samples were 
incubated at 37°C for ≈2 h. DNA gel electrophoresis was performed to visualise 
DNA and asses digests.  
For insertion of specific sequences into a plasmid backbone, both plasmid and 
insert were digested using the same restriction endonucleases to ensure the 
creation of compatible ends for ligation. 10 µg of DNA was added to each 
restriction digest, with 2 µL of each enzyme, 2.5 µL BSA, 25 µL of buffer and the 
total volume made to 250 µL using nuclease free H2O. Samples were incubated 
overnight at 37°C. Purification was subsequently performed using DNA gel 
electrophoresis and gel extraction (section 2.8.4). 
2.8.4 DNA gel electrophoresis 
Gel electrophoresis allows for the separation of DNA molecules based on size. An 
appropriate percentage agarose gel was chosen (0.8-2.5% w/v) based on 
fragment sizes and agarose was dissolved and electrophoresed in 1 x Tris-Borate 
EDTA (TBE) buffer (Gibco, Paisley). Ethidium bromide (1 ng/100mL) was added 
to molten agarose before gels were poured. Gels were run in BIO-RAD 
electrophoresis tanks and using a BIO-RAD Power Pac 300, at a constant voltage 
of 30-100 V. Samples were mixed with 6 x blue/orange loading dye and loaded 
onto the gel along with appropriate DNA marker ladders (100 bp or 1 Kb) 
(Promega, Southampton, UK). Bands were visualised using trans UV illumination 
on a ChemiDoc XRS+ Imaging System. 
2.8.4.1 Gel extraction and purification 
In order to perform further ligation of digested plasmids and inserts, restriction 
endonuclease digested DNA was purified using gel extraction using the Wizard® 
SV Gel and PCR Clean-Up System (Promega, Southampton, UK). This kit is based 
on the ability of DNA to bind to silica membranes in the presence of chaotropic 
salts. Following electrophoresis, DNA bands were excised, placed in a 15 mL 
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falcon and 10 µL Membrane Binding Solution was added per 10 mg of gel slice. 
Falcons were incubated at 65°C and vortexed until gel was completely dissolved. 
The dissolved gel mixture was then transferred to an SV Minicolumn in a 
collection tube, and incubated at room temperature for 1 min. columns were 
then centrifuged at 16,000 x g for 1 min. Flow through was discarded and this 
was repeated until all of the gel mixture had been passed through the column. 
700 µL of Membrane Wash Solution was then added and columns centrifuged at 
16,000 x g for 1 min. This was repeated with 500 µL of Membrane Wash Solution, 
with a longer 5 min centrifugation. Tubes were finally centrifuged at 16,000 x g 
for 1 min to remove any residual ethanol – present in the Membrane Wash 
Buffer. DNA was then eluted from the column using 50 µL nuclease-free H2O, and 
centrifuging at 16,000 x g for 1 min. Eluate was collected and passed through 
the column again to ensure highest possible recovery. 
2.8.5 Dephosphorylation and ligation 
Dephosphorylation of plasmid DNA was performed in order to prevent 
circularisation during ligation. This was performed using Antartic Alkaline 
Phosphatase (New England Biolab UK Ltd, Hertfordshire, UK), following the 
manufacturers’ protocol. Briefly, 500 ng of plasmid DNA was added to 2 µL 
Antartic Phosphatase enzyme, 1 µL 10 x Antartic Phosphatase buffer and made 
up to 10 µL total using nuclease free H2O. Reactions were incubated at 37°C for 
15 min, followed by 10 min incubation at 65°C to deactivate the enzyme.  
Ligation of inserts into dephosphorylated plasmid was performed using T4 DNA 
ligase (New England Biolabs UK Ltd, Hertfordshire, UK) as per manufactures’ 
instructions. Reactions were performed at a variety of molar ratios to ensure 
successful ligation of inserts into plasmid backbone. Ratios of 1:1 and 1:3 of 
plasmid:insert were routinely used, with a negative control of 1:0. Molar ratios 
were calculated using the following equation: 
(
ng of vector x Kb of insert
Kb of vector
) x molar ratio = ng of insert  
50 ng of dephosphorylated plasmid vector was added to each reaction, along 
with the calculated amount of insert DNA, 1 µL T4 DNA ligase enzyme, 2 µL 10 x 
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T4 ligase buffer were added to a 0.5 mL microcentrifuge tube and reaction made 
up to 20 µL total using nuclease-free H2O. Samples were incubated at 16°C 
overnight. Ligation success was probed using restriction endonuclease digest 
(section 2.8.3) and sequencing (section 2.8.6). 
2.8.6 Sequencing 
Sequencing of cloned plasmids and inserts were routinely performed to check 
the cloning efficiency. DNA sequences were analysed using dideoxy sequencing. 
300 ng of plasmid DNA was used in each sequencing reaction, along with 2 nM of 
forward or reverse sequencing primers, 0.5 µL Ready Reaction Mix (Applied 
Biosystems, UK) and 3.5 µL Sequencing Buffer. The reaction was then made up 
to a final volume of 20 µL using nuclease-free H2O. Samples were then subject to 
25 PCR cycles at the following conditions: 
1: 96°C for 50 s 
2: 50°C for 20 s    x25 
3: 60°C for 3 min 
The PCR products were then cleaned using CleanSEQ (Agencourt Bioscience 
Corporation, MA, USA) following the manufacturers’ protocol. 20 µL of 
sequencing products were then loaded into optically clear barcoded 96-well PCR 
plates for capillary electrophoresis, which was performed on a 48-capillary 
Applied Biosystems 3730 Genetic Analyser with 36 cm capillaries.   
2.8.7 Plasmid purification 
2.8.7.1 Transformation of competent bacteria 
Successfully cloned expression plasmids were transformed into chemically 
competent bacteria. One Shot® TOP10 chemically competent Escherichia coli (E. 
coli) (Invitrogen, Life Technologies) were used as hosts in this study, and 
transformations were performed as per the manufacturer’s instructions. A vial of 
One Shot® bacteria was thawed on ice. Once thawed, 1-5 µL (10 pg-100 ng) of 
plasmid DNA was added, mixed gently and incubated on ice for 30 min. Cells 
were then heat-shocked in at water bath at 42°C for 30 s, before being removed 
and immediately incubated on ice for 2 min. 250 µL of S.O.C medium was then 
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added, and the tube was shaken, horizontally, for 1 h at 200 rpm and 37°C in a 
shaking incubator. Varying amount of the plasmid-media mix was then spread 
onto pre-warmed Luria agar (Sigma) culture plates containing 100 µg/mL 
ampicillin, and incubated overnight at 37°C. Bacterial colonies were then 
selected and grown overnight in 10 mL Luria broth (LB), before they were 
screened using diagnostic restriction digests, DNA electrophoresis and plasmid 
sequencing (described in sections 2.8.3, 2.8.4 and 2.8.6). 
2.8.7.2 Small scale DNA purification 
Small scale DNA purification was performed using the PureLink® Quick Plasmid 
Miniprep Kit (Invitrogen, Life Technologies), and 2-3 mL transformed E.coli in LB 
medium from overnight culture. Bacteria were harvested by centrifugation at 
6,000 x g for 5 mins, and the supernatant discarded. The cell pellet was then 
resuspended in 250 µL resuspension buffer R3 (50 mM Tris-HCl, pH 8.0; 10 mM 
EDTA) containing RNase A (100 µg/mL). 250 µL lysis buffer L7 (200 mM NaOH, 1% 
w/v SDS) was then added and the sample was mixed by inverting the tube until 
the mixture was homogenous. The mix was then incubated at room temperature 
for 5 min, and then centrifuged at 12,000 x g for 10 min. The supernatant was 
then loaded onto a spin column – a silica membrane column which selectively 
binds plasmid DNA - in 2 mL wash tube and centrifuged at 12,000 x g for 1 min. 
500 µL of wash buffer W10 was added to the column, incubated at room 
temperature for 1 min and then centrifuged at 12,000 x g for 1 min. 700 µL of a 
second wash buffer W9 was then added to the column, and again centrifuged at 
12,000 x g for 1 min. The flow through was discarded and the column was 
centrifuged again at 12,000 x g for 1 min to remove any remaining ethanol 
contamination. The spin column was transferred to a new 1.5 mL Eppendorf and 
plasmid DNA was then eluted from the column using 50 µL nuclease-free H2O. 
The water was added to the column, incubated for 1 min at room temperature, 
and then centrifuged at 12,000 x g for 2 min. DNA concentration was measured 
using the Nanodrop (Thermo Scientific) and stored at -20°C until required.  
2.8.7.3 Large scale DNA purification 
The PureLink® HiPure Plasmid Maxiprep Kit was used to perform large scale DNA 
purification. A 10 mL ‘starter’ culture, made using a single colony, was added to 
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a further 450-500 mL LB medium containing 100 µg/mL ampicillin and incubated 
overnight in a shaking incubator at 37°C and 170 rpm. Bacteria were first 
collected by centrifugation at 6,000 x g for 5 min at 4°C, in a Beckman Coulter 
Avanti J-26XP. All supernatant was discarded and the pelleted cells were 
resuspended in 10 mL resuspension buffer R3 (50 mM Tris-HcL, pH 8.0; 10 mM 
EDTA) containing RNase A (100 µg/mL) until homogenous. 10 mL lysis buffer L7 
(0.2 M NaOH; 1% w/v SDS) was then added and mixed gently by inversion until 
the sample is thoroughly mixed and completely homogenous. The mixture was 
then incubated at room temperature for 5 min to ensure sufficient lysis, the SDS 
in the solution acts a detergent to disrupt the bacterial membrane and NaOH 
denatures chromosomal DNA and proteins. To neutralise the lysis, 10 mL 
precipitation buffer N3 (3.1 M potassium acetate, pH 5.5) was added, and the 
sample immediately mixed by inverting the tube until the mixture is 
homogenous. The precipitated lysate was then centrifuged at 20,000 x g for 20 
min. The clarified supernatant was then added to a HiPure Column, pre-
equilibrated using equilibriation buffer EQ1 (0.1 M sodium acetate, pH 5.0; 0.6 M 
NaCl; 0.15% (v/v) Triton® X-100), and allowed to drain by gravity flow. The 
HiPure columns use an anion-exchange resin to bind DNA. The negatively 
charged phosphates on the backbone of the DNA will interact with the positive 
charges on the surface of the resin. Temperature, salt concentration and pH of 
solutions all influence the binding of the DNA. Once all of the clarified 
supernatant has passed through the column, 60 mL wash buffer W8 (0.1 M 
Sodium acetate, pH 5.0; 825 mM NaCl). The moderate salt conditions, which 
occur on the column during washing with W8, allow for plasmid DNA to remain 
bound, whilst RNA, proteins and other impurities are removed. Plasmid DNA was 
then eluted from the column using 15 mL elution buffer E4 (100 mM Tris-HCl, pH 
8.5, 1.25 M NaCl). 10.5 mL isopropanol (2-propanol) was used to precipitate the 
DNA, before the mixture was centrifuged at 15,000 x g for 30 min at 4°C. The 
pelleted DNA was then washed in 4 mL 70% ethanol, and 4 x 1 mL aliquoted into 
4 x 1.5 mL eppendorfs. Eppendorfs were centrifuged at full speed for 5 min at 
4°C and all supernatant was removed. Pellets were then allowed to air dry, 
either on the bench top at room temperature, or at 37°C. Once dried, DNA 
pellets were combined in a total of 200 µL nuclease-free H2O and centrifuged at 
full speed for 1 min, to remove any remaining impurities. Finally, the 
supernatant was transferred to a clean 1.5 mL Eppendorf. DNA concentration 
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was measured using the Nanodrop (Themo Scientific) and stored at -20°C until 
required.  
2.8.7.4 Glycerol stocks 
700 µL of overnight bacterial cultures were combined with 300 µL glycerol 
solution for long term storage of successfully transformed bacterial cultures. The 
bacteria-glycerol mixture was then stored at -80°C. Recovery of bacterial from 
these stocks was performed by thawing, followed by streaking for single colonies 
on ampicillin containing agar plates. 
2.9 Lentivirus production 
Lentiviral vectors were second-generation, self-inactivation (SIN), HIV-1 based 
and produced as previously described (Demaison et al., 2002). 
2.9.1 Production of Lentivirus via triple transfection method 
Lentiviral vectors were produced using a transient triple transfection protocol, 
whereby HEK293Ts were transfected with 3 different plasmids, required for viral 
production; the expression plasmid (pHR’SIN-cPPT-SFFV-MCS-WPRE; pSFFV Lenti 
MCS) containing the desired gene under the control of the spleen focus-forming 
virus (SFFV) promoter (a kind gift of Prof. Adrian Thrasher, Institute of Child 
Health, University College London, London, UK), a packaging plasmid 
(pCMVΔ8.74) which contains Gag, Pol, Tat and Rev, and a plasmid endcoding the 
enveloped of vesicular stomatitis virus (VSVg) (pMDG). Polyethylenimine (PEI; 
Sigma-Aldrich) was used as the transfection reagent. Lentivirus preparations 
were performed in batches of 6 or 12 T150 flasks and cells were prepared as 
previously described (section 2.2.1). 
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Figure 2.2 – Plasmid map for pSFFV Lenti MCS. 
Plasmid map showing the sequence of the pSFFV Lenti MCS. Features are shown, as are unique 
restriction sites.  
For each T150 flask, 2 mixes were prepared; one containing the 3 plasmids for 
transfection, and one containing the PEI. Each DNA mix contained 50 µg 
expression plasmid, 17.5 µg PMDG and 32.5 µg pCMVΔ8.74, in 5 mL Opti-MEM 
reduced serum medium with GlutaMAX™ supplement (Gibco, Paisley), and was 
filtered using a 0.22 µm sterile filter. 5 mL Opti-MEM containing 1 µL PEI was 
then sterile filtered and added directly to the DNA mixture. Tubes containing 
DNA and PEI were then incubated in a tissue culture cabinet, at room 
temperature, avoiding exposure to light, for 20 min.  This allows for the 
formation of DNA:PEI complexes, which have endosomolytic activity, and are 
protected from lysosomal degradation.  
Culture medium was removed from HEK293Ts and cells were gently washed with 
5 mL Opti-MEM medium. This was then removed and 10 mL of medium containing 
DNA:PEI complexes were added to the flask. Cells were incubated for 4 h at 
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37°C and 5% CO2. After 4 h Opti-MEM was removed, replaced with 20 mL fresh 
complete culture medium (section 2.2.1) and cells were returned to the 
incubator. Lentiviral particles are produced and released into the medium by the 
cells after successful transfection of the 3 plasmids. Medium was collected after 
48 h, replaced with 10 mL fresh complete culture medium and filtered using a 
0.22 µm sterile filter unit. Cells were cultured for a further 24 h, when medium 
was collected, filtered and combined with the medium removed at 48 h.  
2.9.2 Concentration of Lentivirus 
After collection, lentivirus was concentrated using ultracentrifugation. Briefly, 
media collected from triple-transfected cells was dispensed into Beckman 14 x 
95 mm (14 mL) plastic tubes (Beckman Coulter), loaded into a SW-32.1 Ti rotor 
buckets and placed into the SW32 Ti rotor (Beckman Coulter). 
Ultracentrifugation was then then performed at 23,000 rpm for 1 h at 4°C in an 
Optima L-80 XP Ultracentrifuge (Beckman Coulter).  Supernatant was discarded 
and this process was repeated until all virus-containing medium had been used. 
Excess media was removed from all tubes before 100 µL Opti-MEM® reduced 
serum medium with GlutaMAX™ supplement (Gibco, Paisley) was added to each 
tube, and incubated for 1 h at 4°C. Pelleted lentivirus was then resuspended in 
the OptiMEM, and the virus was aliquoted and stored at -80°C until required. 
2.9.3 Calculation of lentiviral titre 
The concentration of produced lentivirus, in particle infectious units per mL 
(PIU/mL), was determined using a TaqMan® qRT-PCR based method, which 
detects linear, double-stranded DNA pre-integration complexes as previously 
described (Butler et al., 2001). The sequence of the primers used was as follows; 
forward (F) - 5’-TGTGTGCCCGTCTGTTGTGT-3’, reverse (R) – 5’-
GAGTCCTGCGTCGAGAGAGC-3’. The probe used was FAM labelled with a TAMRA 
quencher, with the following sequence; 5’-(FAM)-CAGTGGCGCCCGAACAGGGA-
(TAMRA)-3’.  
HEK293T cells were cultured and seeded into a 12-well plate, at a density of 
5x104 cells per well and left overnight. Lentivirus was serially diluted and added 
to each well at decreasing concentrations. Virus was allowed to transduce cells 
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for 72 h. After 72 h, cells were washed and 200 µL PBS was added to each well. 
Cells samples in PBS were stored at -20°C and underwent a freeze thaw prior to 
DNA extraction performed using the QIAamp Mini and Blood Mini kit as described 
in section 2.8.1. Concentrations of samples were determined using the Nanodrop 
and samples were diluted to 250 ng/µL using nuclease-free H2O.  
To titrate samples, serial dilutions of the expression plasmid, used to make the 
lentivirus, were performed to generate a standard curve of 1x1013 to 1x104 
plasmid copies.  To prepare the most concentrated standard, plasmid was 
diluted in nuclease-free H2O, using the following calculation was performed: 
1: Molecular weight of one copy of expression plasmid 
Size of plasmid (bp)x (Size of 1 bp (660 Daltons)
Avogadro′s constant
= g per molecule 
Daltons = g/mole 
Avogadro’s constant = 6.023x1023 molecules/mole 
2: Determine the copy number of plasmids in 1mL stock 
Concentration of stock plasmid (g/mL)
g per molecule
= no. molecules per mL 
3: Preparation of top standard (1x1013 copies) 
no. of molecules per mL
1x1013
= initial dilution factor for top standard 
1000
initial dilution factor for top standard
=  µL of plasmid stock needed to make 1mL 1x1013 standard 
A reaction master mix was prepared and 11.5 µL was added to each well of a 
384-well PCR plate, with each well containing the following: 
2x TaqMan® Universal Master Mix  2 µL 
Primer/Probe mix    3.125 µL 
Nuclease-free H2O    2.125 µL 
109 
 
 
1 µL of DNA standard or DNA samples collected from lentiviral titre was added to 
each well, and reactions were performed in technical triplicate. The samples 
were then run on the ABI Prism Applied Biosystems 7900HT sequence detection 
system as previously described (section 2.5.3). 
Titre was calculated by plotting cycle threshold (cT) values for standards, and 
solving the equation of the line for each virus titration sample. This generates a 
value of copies of plasmid DNA in each sample. The number of cells whose DNA 
would have been included in 250 ng DNA was also calculated: 
concentration of DNA collected x 50 µL = total ng DNA collected 
total ngDNA collected
ng DNA in 1 µL
× 100 = % of total DNA added for 250 ng 
5x104
% of total DNA added for 250 ng 
= no. cells used for 250 ng DNA 
The number of copies of plasmid DNA in each sample, plus the number of cells 
whose DNA was included in 250 ng were then used to calculate the number of 
copies of plasmid per cell: 
Copies of plasmid in sample x no. of cells used in 250 ng = copies of plasmid per cell 
And this was subsequently used to calculate PIU/mL: 
copies of plasmid per cell × (
dilution factor of virus stock used × 1000
µL virus added to cells
) = PIU/mL 
 
2.10 Lentiviral transduction of hESCs 
Unless stated, all viral infections were performed using a multiplicity of 
infection (MOI) of 10. The MOI describes the ratio of virus to cells, where an MOI 
of 10 is the addition of 10 viral particles per cell, and is calculated as follows: 
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Cell no.× MOI
viral titre
= µL virus to add 
2.10.1 Monolayer transduction 
Titration of EGFP lentivirus was performed using a monolayer transduction 
protocol. hESCs were passaged enzymatically using TryPLE select (Gibco, 
Paisley) and plated out in 12-well tissue culture dishes, coated with CellStart 
matrix, at a density of 1x105 cells per well and in the presence of Y-27632 (ROCK 
inhibitor). Cells were incubated overnight at 37°C and 5% CO2. Virus was then 
added to the culture medium at the correct MOI and incubated for a further 24 
h. After 24 h virus containing medium was removed and replaced with fresh 
culture medium. Cells were cultured for a further 48 h, before they were 
harvested and analysed.  
2.10.2 Transduction of hESCs in suspension 
Transduction of hESCs in suspension was performed for overexpression studies 
during hESC-EC differentiation. To do this, hESCs were taken to a single cell 
suspension using TryPLE Select as previously described. Cells were counted and 
added to 1 mL Stemline II medium in a 15 mL falcon. Virus was then added at 
the correct MOI and cells were incubated at 37°C for 30 min. Mixing was 
performed at intervals of 10 min to ensure a homogenous mixture of virus and 
cells.  
After 30 min incubation cells were added to Stemline II containing d0 cytokines 
and hESC-EC differentiation was performed as previously described (2.3.1). 
All viral transduction experiments were performed using the following negative 
controls; non-transduced, EGFP-pSFFV lentivirus and pSFFV-‘empty’ lentivirus, 
where pSFFV-‘empty’ contained the pSFFV expression plasmid without an insert. 
2.11 Statistical analysis 
Unless stated, values are presented as mean ± the standard error of the mean 
(SEM). qRT-PCR results are expressed at relative quantification (RQ) calculated 
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using 2-ΔΔcT (see section 2.5.3), and error is expressed as RQ max and RQ min, 
determined by the calculation of RQ using ΔΔCT ± SEM. 
Statistical analysis was performed using GraphPad Prism 5 Software (California, 
USA). Student’s t-test was used to perform comparisons when 2 groups were 
present, or one-way analysis of variance (ANOVA), followed by a Tukey’s post 
hoc  t-test, in experimental conditions with more than 2 groups. In conditions 
where multiple readings were taken from the same sample set, paired or 
repeated measures tests were used. Statistical significance was accepted as 
p<0.05. 
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Chapter 3 Development and characterisation of a 
direct hESC-EC differentiation 
protocol. 
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3.1 Introduction 
It has been suggested that hPSC-derived ECs, may hold the key to the 
development of a long term cell-based therapy for the treatment of a wide 
range of ischemic diseases, such as PAD, CLI, CHD and stroke. It is believed that 
these cells are able to stimulate angio- and vasculogenesis in vivo, and this has 
been demonstrated in a number of different publications, with cells generated 
using a variety of hPSC-EC differentiation protocols (Kane et al., 2010, Orlova et 
al., 2014a, Patsch et al., 2015).  
Thus far, there have been a number of protocols published describing the 
generation of ECs from hPSCs; either hESCs (hESC-ECs) or hiPSCs (hiPSC-ECs), 
and these have been reviewed extensively (Descamps et al., 2012). Many early 
publications used undefined systems, containing serum-supplemented or 
conditioned medium (Levenberg et al., 2002) or co-culture with stromal cell 
lines, any of which make the protocol unsuitable for use in a clinical setting. 
Additionally, undefined culture can lead to introduction of unknown factors, 
thus making it difficult to study exact mechanisms and pathways involved in 
specific differentiation and culture systems. Therefore, studies have focused on 
the development of protocols using more defined conditions. Differentiation 
efficiency in many of these protocols has, however, been poor, with generation 
of <10% hPSC-ECs. Recently, a number of publications have demonstrated more 
efficient generation of these cells (Orlova et al., 2014a, Orlova et al., 2014c, 
Patsch et al., 2015). Development of efficient differentiation protocols is 
essential for the translation of any cell-based therapy, due to the large numbers 
of cells which may be needed for each treatment.  
Gaining further understanding of mechanisms of both differentiation and 
commitment will allow for the development of more efficient protocols. 
Signalling pathways, molecules or non-coding RNAs involved in differentiation, 
may be manipulated in order to drive differentiation, and produce higher 
number of hPSC-ECs for potential transplantation. In order to study mechanisms 
of mesodermal and early endothelial commitment, and to determine the role of 
specific factors within this differentiation system, there has also been a focus on 
the identification of progenitor cell populations, existing within these in vitro 
hPSC-EC differentiation systems. Early mesodermal progenitor (MP) populations 
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are, thus far, poorly defined and various studies have suggested an array of cell 
surface marker profiles, describing these distinct populations (Evseenko et al., 
2010, Drukker et al., 2012, Kurian et al., 2015).  
One study, published in 2010, suggested that these MP cells can be described as 
cells negative for the cell surface marker epithelial cell adhesion molecule 
(EpCAM; CD326) and positive for neural cell adhesion molecule (NCAM; CD56), 
also known as CD326-CD56+ (Evseenko et al., 2010). During early embryogenesis, 
epithelial-to-mesenchymal transition (EMT) plays an important role in 
gastrulation and lineage specification and, specifically, has been shown play a 
key role in the generation of mesoderm in several experimental organisms 
(Nakaya et al., 2008). Specifically, FGF, Wnt and TGFβ signalling, have been 
shown to contribute to mesoderm formation via EMT in vivo (Ciruna et al., 2001, 
Kemler et al., 2004, Ben-Haim et al., 2006). It was therefore, hypothesised that 
the earliest stage of mesoderm formation during hESC differentiation in vitro 
may also be associated with this process. CD56 had previously been shown to be 
upregulated during EMT in human epithelial breast carcinoma cells, and this 
upregulation was associated with a loss of E-cadherin and epithelial cell 
adhesion molecule (Lehembre et al., 2008). Similarly to epithelial cells, hESCs 
express adhesion molecules such as E-Cadherin and CD326, that may possibly 
play roles in the maintenance of hESC pluripotency (Lu et al., 2010). In hESC 
culture, CD326 is localised to Oct4 positive cells, and becomes downregulated 
during differentiation, with knockdown causing an increase in mesoderm-
associated markers in pluripotent cells (Lu et al., 2010, Ng et al., 2010b). 
Evseenko et al. demonstrated that CD326-CD56+ cells, occurring at day 3.5 of a 
general hESC-mesoderm differentiation protocol, represent a multipotent 
mesoderm-committed progenitor population, capable of differentiating towards 
hematopoietic, endothelial, mesenchymal, smooth muscle and cardiomyocyte 
lineages, whilst lacking the ability to differentiate to endo- or ectodermal 
lineages (Evseenko et al., 2010). These cells, herein known as mesoderm 
progenitors (MP), were described as possible precursors to previously described, 
more lineage-restricted, mesodermal progenitor cell types. 
Experiments within this chapter were designed to develop and characterise an 
efficient hESC-EC differentiation protocol, generating immature vascular ECs 
directly from hESCs. Using the marker profile published by Evseenko et al., we 
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also wanted to probe early MP populations, existing within the direct hESC-EC 
differentiation system (Evseenko et al., 2010). Identified populations could then 
be used for investigation and interrogation of factors, mechanisms and pathways 
involved in hESC-EC commitment, thus allowing for manipulation of the system 
and the potential to increase differentiation efficiency by driving hESCs toward 
an EC phenotype. 
3.2 Aims 
The aims of this chapter were as follows: 
 To develop and characterise a direct hESC-EC differentiation protocol. 
 To assess hESC-ECs produced using this newly developed direct hESC-EC 
differentiation protocol. 
 To identify and characterise a multipotent MP cell population, existing 
within this direct hESC-EC differentiation system 
  
116 
 
 
3.3 Results 
3.3.1 Development of a direct hESC-EC differentiation protocol 
Originally, a 6-well based differentiation protocol was developed for direct 
generation of hESC-ECs (Figure 3.1). In this protocol hESCs were taken at d0, and 
mechanically cut into clumps using a StemPro® EZPassage tool, before being 
transferred into a Corning Ultra Low Attachment 6-well cell culture plate in 3mL 
Stemline II media. On day 3, EBs were collected and dispersed using Tryple 
Select, before they were plated onto 0.1% gelatin in 2mL LONZA EGM-2 medium 
containing 50ng/mL VEGF. Although able to generate CD31+CD144+ hESC-ECs at 
high efficiency (Figure 3.1), preliminary experiments suggested that the 
robustness of this protocol was poor, and reproducibility between experiments 
and hESC lines was low.  
 
Figure 3.1 – Preliminary analysis of H1 d7 hESC-ECs. 
H1 pluripotent hESCs were differentiated using a 6-well hESC EC differentiation protocol. Cells 
were harvested on d7, stained using antibodies against pluripotent (SSEA3, Tra1-60; centre) and 
endothelial (CD31, CD144; right) surface antigens. Dot plots show representative images.  
Cytokines were added to the differentiation system at specific time points and 
concentrations as described in section 2.3.1. The cocktail of cytokines and 
growth factors given to cells in the differentiation medium, including BMP4, 
VEGF, Wnt3A and Activin A, were used to drive the cells towards a mesodermal 
fate. These specific factors, and their associated signalling pathways, have been 
implicated in development of the mesoderm or vascular system in vivo (Winnier 
et al., 1995, Dyson et al., 1997, Liu et al., 1999, Coultas et al., 2005), and have 
all been used extensively to recapitulate this phenomenon in vitro (Lindsley et 
al., 2006, Evseenko et al., 2010, Cerdan et al., 2012, Orlova et al., 2014c). 
Additionally, LONZA EGM-2 medium also contains a number of cytokines and 
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growth factors, including human Epidedermal Growth Factor (hEGF), R3-Insulin-
like Growth Factor-1, Ascorbic Acid, Hydrocortisone and human Fibroblast 
Growth Factor-Beta (hFGF-β), which support the maturation and expansion of 
hESC-ECs after d3.  
To increase the levels of reproducibility between experiments, changes were 
made in the method used to create the EBs. Previously, EBs had been formed 
using mechanically cutting the cells into clumps, before transferring into ultra-
low attachment 6 well plates, in the presence of Y-27632, a Rho kinase inhibitor. 
Optimisation involved standardising the size of the EBs, by using a spin EB 
protocol to form them in 96-well round-bottom tissue culture plates coated with 
5% Pluronic F-127 (Ungrin et al., 2008). Cells were counted, and each EB was 
formed from 10,000 cells (Figure 3.2B). Unlike in previous versions of the 
differentiation protocol, d3 cells were not dispersed, and instead EBs were 
collected, washed and plated directly onto gelatin, where cells were cultured to 
allow outgrowth from the EB (Figure 3.2B). Once optimised, the newly 
developed 96-well direct differentiation protocol was then characterised. 
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Figure 3.2 – Direct hESC-EC differentiation. 
Pluripotent hESCs were dispersed to single cells at d0, allowed to form size controlled EBs and 
kept in this form until d3. EBs were then collected and plated out onto 0.1% gelatin, where they 
were cultured until d7, shown in the schematic (A). Specific combinations of cytokines were used at 
various time points, and this is described in detail in section 2.3.1. Bright field images of cells 
during at d0 (left), d3 (centre) and d7 (right) of hESC-EC differentiation are shown in B. Images are 
representative of each time point, and were taken at 10x magnification and scale bars represent 
250 µm. 
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3.3.2 Characterisation of hESC-ECs generated via a direct hESC-
EC differentiation protocol 
Originally, the H9 hESC cell line was differentiated using the 96-well direct 
hESC-EC differentiation protocol. Cells were harvested at d0, 3, 5 and 7, stained 
using antibodies against a number of different endothelial and pluripotent cell 
surface markers, and analysed by flow cytometry. Data presented in Figure 3.3A 
shows a significant increase in the percentage of total cells positive for two 
endothelial associated markers, CD31 (Pecam-1) and CD144 (VE-Cadherin), 
known as CD31+CD144+ hESC-ECs, with approximately 35% of cells expressing this 
cell surface profile by d7. The CD31+CD144+ cells exist as a distinct population, 
and this can be seen in the dot plots shown in Figure 3.3C. A concomitant 
decrease in pluripotency-associated markers was also observed, with on average 
less than 10% of cells expressing Tra1-60 on d7, significantly lower than on d0, 
where >90% of cells express this surface marker (Figure 3.4). Quantitative results 
obtained from FACS analysis were further validated using immunocytochemistry 
(ICC). Using this technique, it was possible to visualise cells staining positive for 
both CD144 and CD31 (CD31+CD144+), with the majority of staining occurring at 
the surface of positive cells (Figure 3.3E).  
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Figure 3.3 – Analysis of endothelial – associated surface markers during H9 hESC-EC differentiation. 
H9 hESCs were subjected to direct hESC-EC differentiation, and cell surface markers analysed at d0, 3, 5 and 7. Flow cytometry was used to analyse expression of 
the endothelial markers CD144 (PE-conjugated) and CD31 (APC-conjugated) (A-B). Dot plots shown are representative. Histogram shows average percentage of total 
cells at each time point from n=3 experiments, ± SEM. Repeated measures ANOVA, * = p<0.05, ** = p<0.01, *** = p<0.001 when compared to d0 pluripotent control. 
d7 hESC-ECs were also subjected to analysis by immunocytochemistry (C). VE-cadherin/CD144 is shown in red, Pecam-1/CD31 in green and DAPI in blue. 
121 
 
 
Figure 3.4 – Analysis Tra1-60 expression during H9 hESC-EC differentiation. 
Cells were also stained for the pluripotency-associated marker Tra1-60 (PE-conjugated). Graph (A) 
shows average percentage of total cells at each time point from n=3 experiments, ± SEM. 
Repeated measures ANOVA, * = p<0.05, ** = p<0.01, *** = p<0.001 when compared to d0 
pluripotent control. Flow cytometry histograms (B) shown are representative of all samples from 
that specific time point.  
Total RNA samples were also collected from d0 hESCs, d1, 2 and 3 EBs and d5 
and 7 heterogeneous hESC-EC populations. Samples were then subject to qRT-
PCR gene expression analysis, interrogating the mRNA expression profiles of cells 
throughout hESC-EC differentiation. The expression levels of pluripotency-
associated genes, such as Nanog, Oct4 and Sox2, stayed constant during the first 
3 days of hESC-EC differentiation, before a significant decrease was observed at 
d5 and 7, following the replating of EBs onto gelatin coated plates in endothelial 
supportive media. The lowest levels of pluripotency-associated gene expression 
were observed at d7, with cells continuing to lose their pluripotent phenotype 
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throughout the duration of hESC-EC differentiation (Figure 3.5A). A concomitant 
upregulation of CD31 and CD144, both endothelial-associated genes, was also 
observed throughout hESC-EC differentiation. These genes were shown to be 
significantly upregulated by d5 and 7, with the greatest upregulation observed 
on d7, where genes went from almost absent (cT value ~35) to much more highly 
expressed (cT value ~25) (Figure 3.5B). These changes in expression from almost 
absent result in large RQ values (~1,500 and ~7,000 for CD31 and CD144 
respectively), which are not true reflections of the actual fold changes (Figure 
3.5). 
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Figure 3.5 – Gene expression analysis of direct hESC-EC differentiation. 
Pluripotency- (A) and endothelial-associated (B) gene expression was profiled throughout H9 
hESC-EC differentiation using qRT-PCR. Cells were harvested from d0 hESCs, d1, 2 and 3 EBs, 
and d5 and 7 hESC-ECs and RNA extracted for analysis. Repeated measures ANOVA with Tukey 
post hoc t-test, * = p<0.05, ** = p<0.01, *** = p<0.001 when compared to d0 pluripotent control. 
Data shown is RQ ± RQ max, relative to UBC reference gene. RQs calculated from n=3 biological 
replicates. Y-axis on endothelial gene expression graph is expressed as a Log scale. 
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To ensure reproducibility of the newly developed differentiation protocol, 
experiments were also performed using the H1 hESC cell line, another of the 
original hESC lines derived by Thomson et al. in 1998 (Thomson et al., 1998). 
Although hESC-EC differentiations performed with this second cell line were less 
efficient, experiments produced approximately 20-30% CD31+CD144+ hESC-ECs by 
d7 (Figure 3.6A). Similar to the results observed when using the H9 hESC line, 
the percentage of total cells expressing both endothelial-associated cell surface 
markers was increased from d5 of differentiation, with the highest levels 
observed on d7, and was accompanied by a decrease in the number of cells 
expressed Tra1-60, when analysed by flow cytometry (Figure 3.6B). The 
CD31+CD144+ cells again existed as a distinct population, with most cells staining 
positive for CD144 co-expressing CD31, although the opposite was not always 
true, with 10% of cells expressing only CD31 (Figure 3.6C). Analysis of gene 
expression profiles by qRT-PCR also validated results previously shown in H9 
hESCs, with results demonstrating a decrease in the levels of pluripotency-
associated genes, including Nanog, Oct4 and Sox2, throughout differentiation, 
again with the greatest downregulation occurring on d7 (Figure 3.6D). Significant 
upregulation of endothelial-associated CD31 and CD144 was also show in d5 and 
d7 hESC-ECs (Figure 3.6E),  with a large induction ofCD144 and CD31 expression 
by d7. These data demonstrate the ability to efficiently and reproducibly 
generate CD31+CD144+ hESC-ECs from different cell lines using this direct hESC-
EC differentiation protocol. 
Both the gene expression and flow cytometric data show the emergence of 
CD31+CD144+ immature vascular ECs from d5 of direct hESC-EC differentiation, 
when experiments were performed using the H1 or H9 hESC line. The percentage 
of cells expressing endothelial markers continues to increase until d7, with a 
concomitant increase in the expression of these same two markers (CD31 and 
CD144) at the RNA level. Therefore, for all subsequent experiments, d7 was 
chosen as the ‘end point’ of our direct hESC-EC differentiation, and the term 
hESC-EC will herein refer to this population. 
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Figure 3.6 – hESC-EC differentiation in H1. 
Cells were subjected to endothelial differentiation, and d0 H1 hESCs, d3 EBs and d5 and 7 hESC-
ECs samples collected and analysed. Cells were stained using PE-conjugated anti-CD144 and 
APC-conjugated CD31 to assess differentiation efficiency. Average percentages of cells expressing 
CD31 and CD144 (A) and Tra1-60 (B) are shown in histograms. C shows representative dot plots 
for CD31 and CD144 at d0 and 7. n=2 experiments. Gene expression analysis for pluripotent 
(Oct4, Nanog, Sox2; D) and endothelial (CD144 and CD31; E) associated genes was also 
performed using RNA from the same time points. Graphs show RQ ± RQ max, n=3 experiments. Y-
axis of endothelial gene graph is shown in Log scale. Repeated measures ANOVA with Tukey’s 
post hoc comparisons, * = p<0.05, ** = p<0.01, *** = p<0.001 when compared to d0 pluripotent 
control. 
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3.3.3 Purification and expansion of CD144+ hESC-ECs 
For further analysis of immature vascular ECs, magnetic activated cell sorting 
(MACS) was used to isolate and purify CD144+ cells, as described in section 2.3.2. 
It was previously observed, using flow cytometry, that almost 100% of cells 
expressing CD144 were also positive for CD31 (Figure 3.4C and Figure 3.6C). A 
number of d7 cells, however, stained positive for CD31, but not CD144. 
Therefore, sorting of immature vascular ECs from the d7 heterogeneous hESC-EC 
population was performed using a single CD144 MACS selection protocol, 
described in detail in section 2.3.2. Briefly, cells were harvested and incubated 
in the presence of anti-CD144 antibodies conjugated to the surface of small 
magnetic beads. During the incubation, beads would bind CD144+ hESC-ECs, 
whereas cells negative for CD144 would remain free in solution. CD144+ cells 
were then selected for by passing the entire cell suspension through a column 
within a magnetic field; CD144+ cells bound to magnetic beads would be trapped 
inside the column, whereas unbound cells would pass straight through. The 
column could then be removed from the magnetic field, and a pure population 
of CD144+ hESC-ECs collected. 
D7 hESC-ECs were harvested, MACSorted and the resultant positive and negative 
fractions analysed using flow cytometry. Cells were stained for CD144 and CD31, 
to ensure high levels of purity and confirm the efficiency of a single CD144 
selection to isolate CD31+CD144+ hESC-ECs. Analysis showed high levels of purity 
in the CD144+ fraction (approximately 99%) (Figure 3.7B), whereas <10% of cells 
were CD31+CD144+ in the CD144- fraction. Once purified, CD144+ and CD144- cells 
were replated into 6-well plates, pre-coated with 0.1% gelatin, at a density of 
1x105 cells per well. Cells were cultured for a further 7 days, taking them to 
d14, in endothelial-supportive Lonza EGM-2 media, containing the FBS 
component and supplemented with 50ng/mL VEGF. At d14, there were clear 
morphological differences between the cells cultured from the d7 CD144+ 
fraction, and those from the CD144- fraction (Figure 3.7C). CD144- cells 
appeared to be much smaller and densely packed, and appeared to grow at a 
much faster rate. Conversely, the cells cultured from the CD144+ fraction formed 
a homogenous monolayer of cells, which begin to adopt a ‘cobblestone-like’ 
morphology. Analysis of the cells using flow cytometry revealed that only very 
low percentages of d14 cells, cultured from the CD144- fraction, were  
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Figure 3.7 –  Sorting and further culture of CD144
+
 hESC-ECs 
H9 hESCs were subjected to direct hESC-EC differentiation. MACSorting of CD144
+
 cells was 
performed on d7, and cells were analysed, replated and cultured for a further 7 days (A). Flow 
cytomeric analysis was performed to assess the purity of cells at each step (B). Dot plots shown 
are representative of each time point. Both CD144
+
 and CD144
- 
fractions were plated out onto 
gelatin at a density of 1x10
5
 cells per well. Cells were cultured for a further 7 days in LONZA EGM-
2 containing the FBS component and supplemented with 50ng/mL VEGF. Morphological analysis 
of cells was performed on d14 (C).  n=4, representative images are shown. Scale bars represent 
100µm. 
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CD31+CD144+, whereas almost 100% of cells cultured from the CD144+ fraction 
were positive for both endothelial markers (Figure 3.7B). Data presented here, 
demonstrated the potential scalability of this protocol, with expansion of pure 
CD31+CD144+ populations possible. 
3.3.4 Tubule formation capacity of d14 CD144+ IVECs 
In order to assess the function capacity of cells produced using our direct hESC-
EC differentiation, Matrigel tubule formation assays were performed. Previous, 
unsuccessful attempts were made to assess EC function using heterogeneous d7 
hESC-ECs and MACSorted d7 CD144+ hESC-EC. Tubule formation assays were, 
therefore, performed using purified d14 CD144+ immature vascular ECs (IVECs). 
Cells were plated out onto matrigel at a density of 2x104 cell per well in a 96-
well plate, in Lonza EGM-2 media supplemented with 50 ng/mL VEGF and tubule 
formation was assessed after 24 h (described in more detail in section 2.4.1).  
After 24 h, the d14 CD144+ IVECs were able to form tubules, in a similar way to 
the human umbilical vein endothelial cells (HUVEC), which were used as a 
positive control. Pluripotent H9 hESCs were used as a negative control, and were 
unable to stick down and form tubules on the Matrigel matrix. This data 
demonstrated the angiogenic and tubule forming capacities of the cells 
generated using this newly developed, direct hESC-EC differentiation protocol. 
 
Figure 3.8 – Tubule formation capacity of d14 CD144
+
 IVECs. 
CD144
+
 d7 hESC-ECs were MACSorted, replated and cultured for a further 7 days to obtain d14 
CD144
+
 IVECs. Cells were then harvested and plated onto matrigel to assess their tubule formation 
capacity (right panel). HUVEC (centre) and pluripotent H9 hESCs (left) were used as positive and 
negative controls, respectively. n=3 experiments. Scale bars represent 250 µm. 
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3.3.5 Identification and characterisation of a CD326lowCD56+ 
progenitor population 
To study mechanisms involved in early commitment of hESCs to mesoderm, as 
well as their subsequent commitment to the vascular endothelium, analysis was 
performed to identify an early stage mesoderm progenitor population (MP) 
existing within direct hESC-EC differentiation. As described previously, Evseenko 
et al. identified a population with the cell surface marker profile CD326-CD56+ 
(Evseenko et al., 2010). The study demonstrated that this population was 
transient, appearing on d3.5 of a general mesodermal differentiation, and was 
also multipotent, capable of differentiating into a number of different 
mesodermal cell types, including haematopoietic cells, cardiomyocytes and 
smooth muscle. 
To assess the existence of this CD326-CD56+ MP population within the direct 
hESC-EC differentiation system, time course experiments were performed, using 
both H1 and H9 hESC lines. It was hypothesised that these cells would appear at 
a comparable time point in our hESC-EC system, as a similar cytokine mixture 
and timing was used to induce mesodermal differentiation, and this would be 
before the emergence of more mature EC markers at d5 and d7. Therefore, d0 
hESCs, d3 EBs, and d5 and 7 hESC-ECs were harvested, stained using PE-
conjugated mouse anti-human CD56 and FITC-conjugated mouse anti-human 
CD326, and subjected to analysis by flow cytometry.  
Analysis of the cells by flow cytometry showed that the percentage of 
pluripotent hESCs expressing CD326 was at a level similar to previous studies, 
where it has been suggested to play a role in the maintenance of pluripotency 
(Lu et al., 2010). CD56 was, however, not expressed on the surface of any d0 
hESCs (Figure 3.9A and B). Throughout differentiation, it was observed that cells 
underwent a transition, whereby the CD326, present on the surface of the cell, 
was gradually lost. Coupled with this, cells began to acquire expression of CD56. 
The emergence of a CD326lowCD56+ population was observed on d3 of hESC-EC 
differentiation when experiments were performed using either H1 or H9 hESCs 
(Figure 3.9A-D), before the appearance of the more mature EC markers CD31 
and CD144 (Figure 3.4 and Figure 3.6). The CD326lowCD56+ MP population 
accounted for approximately 30-50% of cells on d3 during H9 hESC-EC 
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differentiation (Figure 3.9A and C) and 10% of cells during H1 hESC-EC 
differentiation (Figure 3.9B and D), demonstrating its reproducibility across 
distinct hESC cell lines. The percentage of MP cells, present at d3, was largely 
representative of the overall differentiation efficiency; experiments with higher 
percentages of CD326lowCD56+ cells on d3 often also had higher percentages of 
CD31+CD144+ hESC-ECs on d7. Flow cytometric analysis of d5 and 7 showed that 
these CD326lowCD56+  MP cells are present on these days, in the heterogeneous 
hESC-EC populations, although a distinct population of cells are present which 
have lost both CD326 and CD56 (Figure 3.9A and B).  
As well as analysis of cell surface markers, profiling of mesoderm-associated 
genes was performed using mRNA qRT-PCR. Total RNA was collected from d0 
pluripotent hESCs, d3 EBs, and d5 and 7 heterogeneous hESC-ECs (cells from d1 
and 2 EBs were also harvested in experiments performed with H9 hESCs), and 
the expression of 3 mesoderm-associated genes, Brachyury (T), Mesp1, and 
Mixl1, was investigated (Figure 3.10A and B). Expression of these genes was low 
in d0 pluripotent hESCs, and in the d7 hESC-EC samples. All three of these 
mesoderm-associated genes were significantly upregulated in samples from d3 
EBs; Brachyury 1426-fold in H9 and 384-fold in H1, Mesp1 164-fold in H9 and 252-
fold in H1 and Mixl1 348-fold in H9 and 272-fold in H1. In H9s, it was observed 
that this increase was gradual, as expression was also significantly upregulated 
in both d1 and d2 EB samples, although fold changes were much lower (Figure 
3.10A). This peak of expression coincided with the emergence of the 
CD326lowCD56+ MP population, supporting the hypothesis that these cells 
represent the initiation of mesodermal lineage commitment, occurring within 
this hESC-EC in vitro differentiation system. 
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Figure 3.9 – Identification of a previously published CD326
low
CD56
+
 mesoderm progenitor 
population in direct hESC-EC differentiation. 
Flow cytometry was used to profile the expression of a previously published CD326
low
CD56
+
 
mesoderm progenitor cell population, existing within hESC-EC differentiation. Cells were harvested 
at d0, 3, 5 and 7 and stained using PE-conjugated anti-CD56 and FITC-conjugated anti-CD326 
antibodies. This population was found to exist in both differentiating H9 (A and C) and H1 (B and D) 
hESC cell lines. Dot plots show representative samples from d0, 3 and 7 and graphs show mean 
percentage of total cells with error bars (C only) showing SEM. Repeated measures ANOVA with 
Tukey’s post hoc comparisons, * = p<0.05, ** = p<0.01, *** = p<0.001 when compared to d0 
pluripotent control. H9, n=3. H1, n=2. 
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Figure 3.10 – Analysis of mesoderm-associated genes during H9 and H1 hESC-EC 
differentiation. 
Expression profiles of mesoderm-associated genes (Mixl1, Brachyury and Mesp1) during direct 
hESC-EC differentiation were assessed using qRT-PCR. H9 (A) and H1 (B) hESCs were 
differentiated and samples collected for RNA analysis. Repeated measures ANOVA with Tukey’s 
post hoc comparisons, * = p<0.05, ** = p<0.01, *** = p<0.001 when compared to d0 pluripotent 
control. Data shown is RQ ± RQ max, relative to UBC reference gene. Y-axis shown as Log scale. 
n=3.  
 
As the CD326lowCD56+ MP population was still present in d5 and 7 hESC-EC 
samples, 3-colour staining was performed in order to assess co-expression of 
CD326, CD56 and CD144 (Figure 3.11 and Figure 3.12). Samples were collected 
from d0 hESCs, d3 EBs and d5 and 7 hESC-ECs from direct endothelial 
differentiation using H1 hESCs. Interestingly, it was observed that all CD144+ 
cells, both at d5 and d7, were negative for CD326, with negligible levels of cells 
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staining for both markers (Figure 3.11). As CD326 has been suggested to play a 
role in the maintenance of pluripotency, this finding supports previous data, 
showing a loss of pluripotency-associated markers, at both mRNA and protein 
levels, occurring throughout hESC-EC differentiation. Distinct CD326low/- 
populations were then assessed for CD144 expression (Figure 3.12). As shown 
previously (Figure 3.4 and Figure 3.6), no CD144+ cells were detected in any of 
the d3 samples, when approximately 20% of cells present were CD326lowCD56+, 
but as differentiation progressed there was an increasing percentage of cells 
displaying CD144 at d5 (≈18%) and d7 (≈31%). On d5, 42% of CD326lowCD56+ cells 
expressed CD144, with all CD144 cells present at this time point also staining for 
CD56 (Figure 3.11).  By d7, however, the majority of CD326lowCD56+ cells were 
negative for CD144, also apparent from analysis of CD56 and CD144 co-
expression (Figure 3.11). In contrast, >90% of CD326-CD56- cells, a population 
only observed at this time point, stained positive for CD144 (Figure 3.12).  
 
Figure 3.11 – Co-expression of CD144 and CD326 or CD56 on d3, 5 and 7. 
Cells were harvested at d3, 5 and 7 during H1 hESC-EC differentiation, stained using 3 different 
antibodies; PE conjuated anti-CD56, APC conjugated anti-CD144 and FITC conjugated anti-CD326 
and analysed using flow cytometry. Co-expression of CD144 with CD326 (top panel) and CD56 
(bottom panel) is shown in dot plots. Gates were determined using matched isotype and unstained 
controls and compensation calculated using singly stained samples. n=1. 
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Figure 3.12 – CD144 staining of d3, 5 and 7 CD326
low
CD56
+
. 
d3, 5 and 7 H1 hESC-ECs were stained using PE conjuated anti-CD56, APC conjugated anti-
CD144 and FITC conjugated anti-CD326 and analysed using flow cytometry. CD326
low
CD56
+
 
populations were gated at each time point (red lines) and cells analysed for CD144 expression. 
Compensation was performed using singly stained controls. Numbers on histograms represent 
percentage of cells in specified gate. n=1. 
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Taken together, this data demonstrates the presence of a CD326lowCD56+ MP 
population, existing transiently during hESC-EC differentiation. This population 
also occurs alongside the peak of mesoderm associated genes, substantiating the 
claims that this population is a multipotent MP cell population. Further 
characterisation of this population using 3-colour flow cytometry also suggests 
that CD31+CD144+ ECs may emerge from these MPs, as all CD144+ cells on d5 of 
hESC-EC were also positive for CD56, before the cells lose this marker on d7, 
although experimental n numbers would need to be increased to confirm this. 
3.3.6 Isolation and further characterisation of the CD326lowCD56+ 
population 
In order to further investigate the phenotype of these cells, fluorescence 
activated cell sorting (FACS) was used to isolate the CD326lowCD56+ MP 
population. Pure samples were then collect, cells were lysed and total RNA was 
extracted, before analysis was performed using TaqMan® mRNA qRT-PCR. 
Heterogeneous d3 samples (approximately 35-60% CD326lowCD56+), were 
collected from direct hESC-EC differentiation performed using H9 hESCs, and 
subjected to FACS to isolate the CD326lowCD56+ MP cells, as well as the 
CD326highCD56- cells, hereafter known as the negative cell fraction (NCF). Purity 
of cells after FACS was high, with >97% CD326lowCD56+ cells in the MP fraction 
and <3% CD326lowCD56+ in the NCF sample. Example data collect from these FACS 
experiments are shown as dot plots in Figure 3.13. 
 
Figure 3.13 – FACSorting of CD326
low
CD56
+
 progenitor populations. 
Representative example of dot plots obtained before and after FACSorting of CD326
low
CD56
+
. H9 
hESCs were harvested at d3, and stained with PE-conjugated anti-CD56 and APC-conjugated anti-
CD326 before they were subjected to sorting using a BD Aria I or III. Dot plots shown above show 
the heterogenous d3 population before FACSorting, and the 2 post-sort populations; 
CD326
low
CD56
+
 and the ‘negative’ cells. n=4. 
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Gene expression analysis was then performed, using TaqMan® qRT-PCR, for a 
number of pluripotent- (Nanog, Sox2, Oct4) (Figure 3.14A), mesodermal- 
(Brachyury (T), Mesp1, Mixl1) (Figure 3.14B), and endothelial- (CD31, CD144) 
(Figure 3.14C) associated genes. As previously observed (Figure 3.4 and Figure 
3.6), the expression level of pluripotency-associated genes was significantly 
decreased as hESC-EC differentiation progressed, when compared to levels seen 
in d0 pluripotent hESCs. Surprisingly, levels of Nanog and Oct4 were found to be 
significantly lower in the d3 MP samples than in the NCF. This suggests a rapid 
loss of pluripotency in MP cells (<3 days), compared to cells in the NCF, 
supporting claims that this population of cells are already committed, either just 
to the mesoderm or to a more defined cell type, e.g. ECs. 
It was originally hypothesised that mesoderm-associated genes would be 
expressed at significantly higher levels in the CD326lowCD56+ MP population than 
in the NCF population. Evseenko et al. used microarray analysis to demonstrate a 
significant upregulation of mesoderm-associated genes, such as Brachyury, 
Mixl1, KDR, MESP1, MESP2 and SNAI2, in CD326-CD56+ cells compared to d0 
hESCs (Evseenko et al., 2010). Using qRT-PCR, analysis showed a significant 
upregulation of Brachyury, Mesp1 and Mixl1 in the d3 CD326lowCD56+ MP cells, 
when compared to d0 pluripotent control (Figure 3.14B). However, although 
observed expression levels of these genes significantly higher in MP cells, they 
were also seen to be significantly upregulated in the NCF.  Furthermore, 
mesoderm-associated gene expression was either significantly lower (Brachyury, 
or unchanged (Mixl1 and Mesp1) in d3 CD326lowCD56+ MPs when compared to 
levels seen in the d3 NCF cells. One explanation for this is that the cells have 
already passed the peak of mesodermal gene expression, as they begin to 
express CD56 on their surface, whilst losing the expression of CD56. There may 
possibly exist an earlier MP population within our d3 heterogeneous EBs, which is 
as yet undefined, and this may contribute to the high levels of Brachyury, Mesp1 
and Mixl1 in this population. 
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Figure 3.14 – Expression of pluripotency-, mesodermal- and endothelial-associated genes in 
FACSorted CD326
low
CD56
+
 cells. 
mRNA expression of pluripotent- (A), mesodermal-  (B) and endothelial- (C) associated genes in 
samples from H9 hESCs during direct hESC-EC differentiation, including d0 pluripotent hESCs, 
heterogeneous d3 EB, FACSorted d3 CD326
low
CD56
+
 MP and NCF, and d7 hESC-EC samples. 
Repeated measures ANOVA with Tukey’s post hoc compairsons, * = p<0.05, ** = p<0.01, *** = 
p<0.001, when compared to d0 pluripotent control unless indicated. Data shown is RQ ± RQ max, 
calculated relative to UBC reference gene. n=4.MP – mesoderm progenitor, NCF – negative cell 
fraction. 
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Expression of endothelial-associated genes (CD31, CD144), was shown to 
increase as cells progressed through hESC-EC differentiation, consistent with 
previous results (Figure 3.14C). The fold change in expression of these genes was 
higher in d3 MPs (CD31 5-fold, CD144 5-fold) than in the d3 NCF (CD31 4-fold, 
CD144 4-fold) when compared to d0 pluripotent hESCs, although this difference 
was non-significant. The increase in endothelial-associated genes, coupled with 
the rapid decrease in pluripotency genes and lower expression of mesoderm-
associated genes than expected, may suggest that the CD326lowCD56+  MP cells 
are more committed than previously thought, and that there may exist a subset 
of these cells, or of the NCF cells, which represent an even more primitive 
multipotent MP population. 
To ascertain a more in depth gene expression profile of these cells, TaqMan® 
Low Density Array (TLDA) cards were used analyse the expression of a larger 
number of genes. TLDA cards allow for higher throughput screening of up to 48 
genes in 8 different samples and, in this study, were designed to profile 
mesoderm- and endoderm-associated genes, as well as a number of pluripotent 
and ectoderm-associated genes.  
Cards contained a number of previously profiled genes, including Nanog, Oct4 
(POU5F1), Sox2, CD31 (Pecam-1), Mesp1, Mixl1 and Brachyury (T). Expression of 
these genes was similar to that seen when analysed using qRT-PCR (Figure 3.14). 
Pluripotency-associated genes (Nanog, Oct4, Sox2) were shown to significantly 
decrease during differentiation, and also to be expressed at significantly lower 
levels in the CD326lowCD56+ MPs than in NCF cells (Table 3.1). Mesp1 and Mixl1 
were shown to be significantly upregulated in both MPs and NCF, although there 
was no significant difference in expression between the two groups on d3 (Figure 
3.14B; Table 3.1). Mesoderm-associated Brachyury, however, was shown to be 
expressed at significantly higher levels in the NCF than in the CD326lowCD56+ MPs 
(Figure 3.14B; Table 3.1). Like during previous profiling qRT-PCR profiling, the 
endothelial-associated CD31 was significantly upregulated during hESC-EC 
differentiation. However, unlike during previous analysis, CD31 was observed to 
be expressed at significantly higher levels in CD326lowCD56+ cells, than in d3 
NCFs (Figure 3.14C; Table 3.1). Taken together, this data supports claims that 
these cells have already lost their pluripotency and committed to the mesoderm, 
or possibly further to specific cell lineages. In this system, these cells may not 
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be as immature as had been suggested by Evseenko et al. and may, in fact, 
already be beginning to acquire a more committed phenotype. 
RQ P-value RQ P-value Y/N P-value
POU5F1 0.011 *** 0.124 *** Y ***
FZD5 0.032 *** 0.109 *** Y **
NANOG 0.003 *** 0.379  n/s Y ***
SOX2 0.003 *** 0.027 *** Y **
GATA2 90.05 *** 10.6 *** Y ***
ACTC1 12.39 *** 0.678 n/s Y ***
HAND1⁺ 1 N/A 0.146 ***
KDR 15.18 *** 4.5 *** Y ***
MESP1 303.91 *** 575.25 *** N n/s
MIXL1 331.79 *** 477.67 *** N n/s
NKX2.5 170.89 *** 51.57 *** Y **
PECAM1 18.83 ** 1.1 n/s Y **
SNAI1 6.68 *** 10.61 *** N n/s
SOX7 53.64 *** 1.71 n/s Y ***
T 388.48 *** 2295.39 *** Y ***
DKK1 338.5 *** 151.89 *** N n/s
CER1 97.46 *** 17.91 ** N n/s
CXCR4 3.16 * 2.01 n/s N n/s
FOXA2 2.95 n/s 12.79 * N n/s
GATA4 366.14 *** 172.06 *** N n/s
GATA6 570.15 *** 447.14 *** N n/s
GSC 49.14 ** 56.67 ** N n/s
SOX17 91.36 *** 106.2 *** N n/s
NES 1.15 n/s 0.559 * Y **
NKX2.2
PAX6
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Table 3.1 – TLDA card analysis of d3 MP and NCFs during hESC-EC differentiation. 
mRNA expression of a larger number of genes in FACSorted d3 CD326
low
CD56
+
 MP and NCF 
samples from H9 hESC-EC differentiation. Repeated measures ANOVA with Tukey’s post hoc 
comparisons, * = p<0.05, ** = p<0.01, *** = p<0.001, when compared to d0 pluripotent control 
unless indicated. ⁺ = no expression in d0 hESCs, direct comparison made between d3 
CD326
low
CD56
+
  MPs and NCFs. Data shown is RQ, calculated relative to GAPDH reference gene. 
n=3. MP – mesoderm progenitor, NCF – negative cell fraction, n/s – non significant. 
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Figure 3.15 – Histograms of selected gene expression from TLDA card analysis. 
Histograms showing mRNA expression in d0 pluripotent hESCs, FACSorted d3 CD326
low
CD56
+
 
MP and NCF samples and d7 hESC-ECs from H9 differentiation for selected genes from TLDA 
card analysis. Repeated measures ANOVA with Tukey’s post hoc comparisons, * = p<0.05, ** = 
p<0.01, *** = p<0.001, when compared to d0 pluripotent control unless indicated. Data shown is 
RQ ± RQ max, calculated relative to GAPDH reference gene. n=3. MP – mesoderm progenitor, 
NCF – negative cell fraction. 
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Frizzled class receptor 5 (FZD5), thought to be the receptor for Wnt5A and 
previously seen to be downregulated during differentiation of embryonal 
carcinoma cell lines (Walsh et al., 2003), was shown to be significantly 
downregulated during hESC-EC differentiation (Figure 3.15A; Table 3.1), in a 
similar way to other pluripotency-associated genes. 
VEGFR2 (KDR; CD309; Flk1), a mesoderm-associated gene also commonly used to 
identify early endothelial progenitors, was significantly upregulated during hESC-
EC differentiation (Figure 3.15B). Interestingly, this gene was expressed at 
higher levels in the CD326lowCD56+ MP cells (15-fold increase) than in the NCF (5-
fold increase), when compared to d0 pluripotent control. Another gene shown to 
be upregulated to significantly higher levels in the MP cells (54-fold) than in the 
NCF (2-fold), is Sox7 (Figure 3.15C; Table 3.1). A member of the Sry-related HMG 
box gene family, Sox7 is involved in cardiovascular development, and has been 
shown to control transcription in hemogenic endothelium, where it has been 
shown to bind and activate the expression of CD144 maintaining the endothelial 
phenotype of these cells (Costa et al., 2012). Recently, it has even been shown 
that Sox7 is directly regulated by ETV2, activating transcriptional networks, and 
therefore playing a role in EC development and angiogenesis (Behrens et al., 
2014). A member of the same family as Sox7, Sox17 was also shown to be 
upregulated in MPs (91-fold) and, together with Sox18, has been shown to work 
alongside Sox7 in the development of the cardiovascular system. Coupled with 
the increase in other more mature endothelial-associated markers (CD31; Figure 
3.14C), the expression of these genes in CD326lowCD56+ MP cells supports the 
hypothesis that these cells have committed towards a mesodermal lineage, and 
are possibly already starting to become specified towards an EC phenotype.  
Other mesoderm-associated genes, such as BMP4, NKX2.5 and GATA4 were also 
found to be expressed at higher levels in the isolated CD326lowCD56+ population 
than in the NCF cells (Figure 3.15D-F; Table 3.1). BMP4 has previously been 
shown to be involved in specification to the mesodermal lineage (Winnier et al., 
1995, Zhang et al., 2008), although upregulation in this case may be in response 
to treatment with high concentrations of this protein during d0-3 of hESC-EC 
differentiation (Figure 3.2A). HAND1, also shown to be involved in mesodermal 
lineage specification (Barnes et al., 2010, Maska et al., 2010) and whose 
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expression was not detected in d0 pluripotent hESCs, was expressed at 
significantly higher levels in d3 MP cells than in the NCF (Table 3.1).  
The d3 NCF samples were shown to express Sox17 (106-fold increase), FoxA2 (13-
fod increase) and GSC (Goosecoid) (57-fold increase) at higher levels than the 
CD326lowCD56+ MP cells, which did not show a significant upregulation of FoxA2 
(3-fold increase) (Table 3.1; Figure 3.15G). All three of these genes have been 
shown to be involved in formation of endoderm and mesendoderm, a bipotent 
progenitor with both mesodermal and endodermal potential (Tada et al., 2005, 
Wang et al., 2011). This may suggest the presence of a population of 
mesendodermal or endodermal progenitor cells, present in the NCF on d3. These 
cells also have lower levels of HAND1 and BMP4, both of which are associated 
with a more definitive mesodermal phenotype (Table 3.1; Figure 3.15D).  
As expected, expression of ectoderm-associated genes was largely undetected in 
all tested samples (Table 3.1). Though the mRNA Nestin, an ectoderm-associated 
gene, was detected in all samples, its expression was low and was found to be 
largely unchanged throughout differentiation, although a significant 
downregulation was observed in the NCF cells when compared to d0 pluripotent 
hESCs (Table 3.1; Figure 3.15H).  
Collectively, the gene expression profile of these cells suggests a definitive 
mesoderm progenitor either existing as a CD326lowCD56+ population or existing as 
a smaller population within this specific cell fraction, on d3 of direct hESC-EC 
differentiation.  
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3.4 Discussion 
In summary these experiments shown the development of a differentiation 
protocol for the generation of IVECs from hESCs, known as hESC-ECs. Through 
optimisation of an original 6-well format assay, an efficient 96-well EB-based 
method was developed, producing sufficient numbers of CD31+CD144+ cells by d7 
of differentiation. Isolation, culture and expansion of these cells was also 
possible, resulting in a pure population of CD31+CD144+ IVECs by d14, which were 
functional, as demonstrated by their ability to form tubules when plated on a 
Matrigel cell matrix. 
Numerous studies have been previously published, describing various methods 
for the derivation of ECs from hESC and hiPSCs. While some protocols have 
attempted to be clinically relevant (Kaupisch et al., 2012, Orlova et al., 2014a), 
many others still involve the use of undefined ECM or serum-containing medium, 
or require co-culture of cells with stromal cell lines (Rufaihah et al., 2011, Choi 
et al., 2012). In a recent publication, describing a highly efficient hPSC-EC 
differentiation protocol, despite using fully defined medium, Patsch and 
colleagues used the undefined cell matrix Matrigel for both the culture and 
differentiation of cells (Patsch et al., 2015). The undefined nature of these 
conditions raises concerns about transfer of non-human pathogens and 
contaminants, and therefore differentiation protocols involving the use of serum 
or stromal cell lines cannot be easily adapted for clinical use as a cell therapy. 
Additionally, these undefined reagents can introduce unknown factors, which 
cannot be monitored and may contribute to differentiation via a variety of 
signalling pathways. Furthermore, due to the nature of their production, there 
can be inherent batch to batch variability in these reagents, reducing the 
reproducibility of differentiation experiments.  Here, a newly developed, fully 
defined, efficient, serum- and feeder-free protocol for hESC-EC differentiation 
has been presented. Although reagents used within these studies are not 
compliant with good manufacturing practice (GMP), the practices and 
regulations required to conform to guidelines recommended by specific agencies 
for the production and licensing of various products, all have the potential to be 
made GMP-compliant.  
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Initially, hESC-EC differentiation experiments had been performed using a 6-well 
methodology, but this lacked reliability and consistency between experiments 
and cell lines. One explanation for this may have been intra- and inter-
experimental differences observed in the formation of EBs. Classically, the 
formation of stem cell aggregates, or EBs, has been used to induce the 
simultaneous formation of mesoderm, endoderm and ectoderm from ESCs and 
iPSCs, thus demonstrating their pluripotency (Itskovitz-Eldor et al., 2000). In 
recent years, EB culture has been adapted in many studies to incorporate 
cytokines and growth factors which specifically drive cells towards different 
lineages from this early stage. Use of factors such as BMP4, Activin A, Wnt3A and 
VEGF, as demonstrated in the presented study, have been shown to direct 
differentiation toward a mesodermal and endothelial cell fate. Recently, studies 
have also demonstrated the use of glycogen synthase kinase 3 (GSK3) inhibitors 
in this context (Bao et al., 2015, Patsch et al., 2015). GSK3 is inhibited by Wnt 
signalling and, therefore, the use of GSK3 inhibitors mimics this to drive 
mesodermal development. Despite development of this direct approach, 
however, many of these differentiation protocols include crude methods of EB 
formation, whereby size and density are not controlled, such as partial digestion 
or, as in this hESC-EC protocol, mechanical cutting of pluripotent cell 
monolayers, yielding colonies and aggregates of an assortment of sizes. A 
number of studies have shown that EB size can influence both lineage 
differentiation of cells, and the reproducibility of cell differentiation 
experiments in vitro (Ng et al., 2005, Bauwens et al., 2008). Therefore, a 
number of methods have been developed to produce EBs of controlled size and 
density (Ng et al., 2005, Burridge et al., 2007). Ungrin and colleagues were able 
to develop a robust method for the development of size controlled EBs from 
hESCs, using Pluronic F-127 coated 96- or 384-well round bottomed cell culture 
vessels, and a centrifugation step (Ungrin et al., 2008). The 96-well spin EB-
based technique was then adapted to increase reliability and efficiency of direct 
hESC-EC differentiation. Although the formation of the EBs using a 96-well spin 
EB-based method, adopted for direct hESC-EC differentiation in the presented 
studies, is more time consuming and technically demanding than the original 6 
well protocol, the use of this method increased reproducibility and robustness of 
our direct hESC-EC experiments. Percentages of CD31+CD144+ hESC-ECs produced 
by d7 were not only consistent between experiments, but also between different 
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cell lines. Further analysis could be performed to confirm that EBs formed using 
the 96-well spin EB-based methodology were consistent in size and density. 
Although efficient, EB-based differentiation methods, particularly those using 
centrifugation to form spin-EBs, have often been criticised for the difficulties 
associated with adaptation for scaling up EC production. 2D monolayer protocols 
are easily scalable, and have been shown to easily generate large numbers of 
hESC-ECs (Kane et al., 2010, Orlova et al., 2014a, Patsch et al., 2015). Here, it 
has been demonstrated that d7 CD144+ hESC-ECs can be isolated, replated and 
expanded, with ~100% of cells CD31+CD144+ after 7 days of further culture. 
Further optimisation of this would allow for generation of even larger numbers 
of cells, as protocols could be scaled up to larger culture vessels, such as T25, 
T75 or even T150 culture flasks.  
Extensive characterisation of hESC-EC differentiation, profiling marker 
expression at the protein and mRNA levels using flow cytometry and qRT-PCR, 
revealed a significant increase in the percentage of CD31+CD144+ cells at d7. 
This was coupled with significant decreases in the numbers of cells expressing 
the pluripotency marker Tra1-60 and the levels of pluripotency-associated TFs, 
such as Nanog and Oct4. Despite this, the specific phenotype of the resultant 
hESC-ECs generated was not investigated. For more in depth characterisation of 
these cells, markers of arterial, venous and lymphatic vessels could be profiled. 
Mature endothelium is heterogeneous, both in structure and function, with a 
variety of cell markers present amongst a diversity of different EC types (Aird, 
2007). Arterial cells have been shown to express markers such as ephrinB2, Hey2 
and neurophilin-1, whereas EphB4, a receptor for ephrinB2, and COUP-TFII have 
been described as venous cell markers (Wang et al., 1998, Herzog et al., 2001, 
Fischer et al., 2004, You et al., 2005, Korten et al., 2013). Recently, Orlova and 
colleagues demonstrated the presence of arterial and venous markers on the 
surface of hPSC derived ECs, as well as the presence of lymphatic endothelial 
markers, such as vascular endothelial growth factor receptor 3 (VEGFR3) and 
lymphatic vessel hyaluronan receptor 1 (LYVE1) (Orlova et al., 2014a, Orlova et 
al., 2014b). From this, it was concluded that these cells have an embryonic 
phenotype, with the potential to further differentiate into various EC types, 
although this was not experimentally validated. Further characterisation of 
hESC-ECs, produced using the direct hESC-EC differentiation, would determine 
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whether these cells also possess this embryonic phenotype, or whether they 
have already begun to acquire a more specialised EC characteristics. This would 
introduce the possibility of driving EC differentiation and maturation towards 
specific EC types, thus allowing for generation of an optimum cell type for 
specialised angiogenic cell therapies. 
CD31+CD144+ cells, obtained on d14 of hESC-EC differentiation, after hESC-ECs 
had been isolated and expanded, were able to perform functionally in vitro. It 
was demonstrated that cells were able to form tubules when plated onto 
Matrigel cell matrix, similarly to mature HUVECs. Recently published guidelines 
from the American Heart Association have, however, suggested that the Matrigel 
tubule assay is not a suitable in vitro representation of angiogenesis, due to the 
observation that other cell types, for example, VSMCs and fibroblasts, also form 
similar structures when plated on this matrix (Simons et al., 2015). Therefore, 
an alternative model of in vitro angiogenesis, for example a 3D vascular tubule 
formation or sprouting assay (Koh et al., 2008), should be performed using these 
cells. A number of additional in vitro assays, such as measurement of endothelial 
nitric oxide production and acetylated LDL (Ac-LDL) uptake, and in vivo 
experiments, such as angiogenic potential of cells in a murine model of hind 
limb ischemia, could have also been performed (Kane et al., 2010). Orlova et al. 
described two novel assays to determine the functional capacity of ECs 
generated from hPSCs, including 2D co-culture with hESC-derived pericytes to 
model endothelia-pericyte interactions in vitro and measurement of vascular 
competence in a zebrafish xenograft in vivo model (Orlova et al., 2014a). A 
recent study by Patsch and colleagues demonstrated the barrier function of 
generated hPSC-ECs by measuring cellular impedance, a measurement of cell 
growth behaviour. Using this assay, hPSC-ECs were shown to form tight 
monolayers, and the impedance was decreased with the addition of the 
vasoactive agent Thrombin (Patsch et al., 2015). Additionally, Patsch also 
performed assays to measured barrier-tightness using trans-endothelial electrical 
resistance (TEER), and hPSC-EC:leukocyte binding after stimulation with 
inflammatory cytokines. Time constraints prevented further investigation into 
the functional capabilities of the cells generated from the presented hESC-EC 
differentiation protocol; however, there are numerous experiments which may 
be performed going forward. 
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By day 7 of hESC-EC differentiation, only 20-50% of cells are CD31+CD144+, 
leaving questions over the identity of the remaining 50-80% of cells. These cells 
are no longer pluripotent, as is demonstrated by the low numbers of cells 
staining positive for Tra1-60, and the low expression of Nanog, Oct4 and Sox2 at 
the transcript level. Recently, a protocol for the simultaneous generation of ECs 
and pericytes from hPSCs has been published, with the pericytes existing in the 
CD31- fraction of differentiating cells (Orlova et al., 2014c), and one possibility 
is that cells similar to these are being generated. Another option is that the 
remaining cells are supportive of differentiation, and without them cells would 
not receive the correct environmental stimulus to encourage endothelial 
specification, although this has not been validated and further in vitro 
characterisation would be needed to verify either of these explanations.   
These studies also demonstrated the presence of a previously published 
CD326lowCD56+ mesoderm progenitor population, existing at d3 of direct hESC-EC 
differentiation. Gene expression profiling revealed that, even at this early time 
point, these cells have rapidly lost their pluripotency, demonstrated by the loss 
of Nanog, Oct4 and Sox2 at the mRNA level, something which is not observed to 
the same extent in the NCF cell samples. High percentages of cells still express 
Tra1-60 on their surface at d3, however, and experiments to identify which 
fraction – the CD326lowCD56+ MPs or NCF – still express this marker, could be 
performed to further validate these findings. Additionally, levels of pluripotency 
associated mRNAs will be modulated more quickly than protein levels and, 
therefore, it is not wholly unexpected that Tra1-60 is still expressed on the 
surface of these cells after downregulation of Oct4, Nanog and Sox2. Similarly to 
previously published results, we observed an upregulation of mesoderm-
associated genes in CD326lowCD56+ MP cells, when compared to d0 pluripotent 
hESCs (Evseenko et al., 2010). Unlike this study, however, Evseenko and 
colleagues did not report the differences in gene expression between isolated 
MPs and NCFs. From this data, it is possible to speculate the existence of 
another, potentially less committed, mesodermal or mesendodermal progenitor 
within the NCF, due to the significant upregulation of mesoderm-associated 
genes within these samples. Moreover, genes associated with the endothelial 
lineage, for example CD31, were shown to be upregulated in the d3 
CD326lowCD56+ MPs, demonstrating that these cells may already be starting to 
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commit towards the EC lineage, or that cells are being primed for differentiation 
in this direction. The cardiac-associated gene NKX2.5 was also found to be 
expressed at significantly higher levels in the CD326lowCD56+ cells than the NCF. 
Although shown to be involved in mesodermal specification, primarily NKX2.5 
has been associated with heart development. Furthermore, CER1 was also highly 
upregulated in the d3 MPs, although there was no significant difference in 
expression when compared to the NCF. Similar to NKX2.5, CER1 has previously 
been shown to be involved in cardiac mesoderm formation in differentiating 
ESCs (Liu et al., 2014) and in the antagonism of both Nodal and BMP to drive 
cardiomyocyte commitment of cardiovascular progenitors (Cai et al., 2013). It 
may, therefore, be hypothesised that the large increase in the expression of 
these genes in CD326lowCD56+ progenitors indicates that these cells are primed 
for further mesodermal differentiation, possibly towards cardiovascular lineages. 
Evseenko et al. also demonstrated the multipotent potential of their isolated 
CD326-CD56+ progenitors, showing their ability to differentiate to hematopoietic, 
endothelial, mesenchymal, smooth muscle and cardiac cells (Evseenko et al., 
2010). Due to time constraints, experimental validation of this multipotency in 
CD326lowCD56+ cells from direct hESC-EC differentiation has not yet been 
performed. This would be needed in order to confirm the phenotype of these 
cells. Additionally, experiments to further elucidate the surface marker profile 
of these cells may be performed. The profile of these cells is still highly 
debatable, and a number of other studies have isolated similar cell populations 
using alternative cell surface antigens. One study, performed using co-culture 
with OP9 stromal cell lines, identified two distinct populations of mesoderm 
progenitors (Choi et al., 2012). The first, defined as APLNR+PDGFRα+, was shown 
to be a more primitive mesoderm progenitor. The second, a more committed 
mesoderm progenitor, was described as KDRbrightAPLNR+PDGFRαlow/- or 
hematovascular mesodermal precursors (HVMP). These cells were shown to be 
distinct from the APLNR+PDGFRα+ cells, and were possibly equivalent to 
embryonic angioblasts, with the potential to form both ECs and hematopoietic 
cells. In addition to this, Drukker et al. used a flow cytometry-based large scale 
screen to identify novel cell surface markers, to define specific populations of 
cells representative of primitive endodermal, mesodermal, vascular endothelial 
and trophoblast progenitors from hPSCs (Drukker et al., 2012). In this study, 
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cells positively expressing Receptor Tyrosine Kinase-Like Orphan Receptor 2 
(ROR2+) were shown to express mesoderm-associated mRNAs, such as Brachyury 
and Mesp1, and could generate differentiated mesoderm tissues. Similarly to the 
CD326lowCD56+  identified in direct hESC-EC differentiation, ROR2+ cells were 
shown to express pluripotency genes at lower levels (~50-fold reduction) when 
compared to undifferentiated pluripotent control cells. That study also 
identified a CD87+ vascular endothelial progenitor cell fraction, expressing a 
gene profile similar to that of human microvascular ECs, and able to form 
tubules on matrigel. It may, therefore, be of interest to further investigate the 
specific surface marker profile of the CD326lowCD56+ MPs. 
Identification of the CD326lowCD56+ MP will allow in depth characterisation of the 
first stages of commitment and differentiation. Specifically, use of the MP 
population will allow for miRNA profiling, via the use of microarray technology, 
to monitor differential expression of these non-coding RNAs within this system. 
As previously stated, miRNAs have been shown to play important roles in the 
differentiation of hPSC to ECs (Kane et al., 2012, Luo et al., 2013), and it is, 
therefore, hypothesised that they will also play central roles in emergence of 
mesodermal and endothelial populations within this hESC-EC differentiation 
system. 
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Chapter 4 Development and characterisation of 
an indirect hESC-EC differentiation 
protocol 
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4.1 Introduction 
First demonstrated almost 100 years ago (Jordan, 1916), it is now commonly 
accepted that the development of the vascular and hematopoietic systems are 
closely linked during in vivo embryogenesis. Definitive hematopoietic stem cells 
(HSCs) originate in the aorta-gonad-mesonephros (AGM) region of the developing 
embryo (Medvinsky et al., 1996). Clusters of hematopoietic cells have been 
identified attached to the ventral endothelial lining in the aorta of developing 
vertebrates (Tavian et al., 1996, Taoudi et al., 2007), suggesting this is the site 
of HSC emergence, a hypothesis supported by extensive work performed showing 
a clear relationship between ECs and HSCs in the AGM (Zovein et al., 2008). 
Studies have focused on the presence of small populations of specialised 
bipotent precursor cells, with characteristic endothelial phenotype and the 
ability to generate hematopoietic cells (HCs) and HSCs (Zovein et al., 2008). This 
process, whereby ECs undergo a phenotypic switch to HCs, is known as the 
endothelial-to-hematopoietic transition (EHT). The term hemogenic endothelium 
(HE) has been coined to describe these specialised ECs, responsible for the 
generation of HC via EHT.  
Jaffredo and colleagues were amongst the first to demonstrate this phenomenon 
in vivo, whereby CD45- ECs in the developing chick embryo were tagged using 
Dil-conjugated Ac-LDL, a molecule specifically endocytosed by ECs. Just 1 day 
later, populations of LDL+CD45+ cells were present as both clusters and single 
cells, suggesting a phenotypic switch from endothelial to HC (Jaffredo et al., 
1998, Jaffredo et al., 2000). The same process has been subsequently 
documented in a number of other in vivo systems of vertebrate development 
(Bertrand et al., 2010, Boisset et al., 2010). Data obtained from lineage tracing 
of endothelium, via the utilisation of an inducible VE-cadherin Cre line, was also 
used to support this model (Zovein et al., 2008). 
In vitro generation and differentiation of HE has also been studied. In 1998, 
Nishikawa et al. identified this population during the differentiation of mESCs to 
HCs (Nishikawa et al., 1998). Within this differentiation system, they identified 
the diverging point of endothelial and hematopoietic lineages, and showed that 
a Flk1+CD144+CD45- progenitor cell population exhibited hemoangiogenic 
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potential. The hemogenic capacity of specialised HE cells, generated from 
differentiating mESCs, has also been observed using continuous single-cell 
imaging (Eilken et al., 2009). Using this technology, Eilken et al. demonstrated 
that mESC-derived mesodermal cells, differentiated via coculture with OP9 
stromal cells, give rise to HE colonies. These HE cells were observed to first 
adopt an EC identity, with cells negative for the HC marker CD45, while 
expressing CD144, forming tight junctions with adjacent cells, assuming and EC-
like morphology and with the ability to uptake Ac-LDL. During EHT, these cells 
lose their endothelial phenotype, migrate from their EC colonies, gain CD45 
expression, morphologically transform to blood cells and begin to proliferate as 
suspension cells. HE cells were unable to generated SMCs or cardiomyocytes, 
confirming that they are not early multipotent mesoderm progenitor cells, and 
their lack of CD45 expression contradicts suggestions that these cells may be 
bipotent blood and endothelial precursors expressing molecules from both 
lineages.  
Studies have also been performed to identify HE populations within hPSC 
differentiation systems, as described in detail in section 1.6.2.1 (Choi et al., 
2012, Ditadi et al., 2015). Using an OP9 co-culture system, Choi et al. were able 
to identify a CD144+CD73 −CD235a/CD43 −CD117intermediate cell population, with 
primary EC characteristics and the ability to further generate HCs and mature 
ECs (Choi et al., 2012). A more defined system was employed by Ditadi and 
colleagues, who identified a CD34+CD43-CD31+CD144+KDR+CD117low population, 
able to undergo EHT to form CD45+ HCs, which could then undergo further 
definitive hematopoiesis (Ditadi et al., 2015). These cells were also shown to 
form both venous and arterial ECs, both of which were able to form functional 
vessels during an in vivo Matrigel plug assay. 
The development of multiple differentiation protocols, providing distinct routes 
for the generation of hESC derived ECs, will allow for more in depth study of 
mechanisms involved in the commitment of cells to specific lineages. Pathways 
and molecules, identified as playing key roles in endothelial commitment during 
more direct hESC-EC differentiation assays, can be verified in an independent 
system for the generation of the same ECs. This will, therefore, result in the 
elucidation of mechanisms involved specifically in hESC-EC differentiation and 
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commitment, and identification of processes more generally involved in 
differentiation or specification of cells to the mesodermal lineage. Many 
previous publications documenting the existence of HE in vitro have focused on 
the development of HCs and HSCs from these progenitors. In the present study, 
experiments were designed to optimise generation of CD31+CD144+ hESC-ECs, 
switching cells from a bipotent HE to a more mature EC phenotype via the 
manipulation of culture conditions. Derivation of an equivalent population of 
CD144+CD31+ ECs using a distinct differentiation protocol would allow for 
validation of any miRNAs, identified as having potential roles in endothelial 
differentiation and commitment, in an independent system, specifically one 
routed through the formation of HE progenitors. This indirect hESC-EC 
differentiation system will also allow for the determination of miRNA specificity; 
it is highly likely miRNAs differentially expressed in hESC-ECs but not hESC-HC 
and hESC-HSCs from the same culture are EC-specific. 
4.2 Aims 
The aims of this chapter were as follows: 
 Characterise hypothesised hemogenic endothelial progenitor cells, 
existing within a defined hematopoietic differentiation protocol. 
 Develop and optimise a protocol for production of hESC-ECs from these 
hemogenic endothelial progenitors. 
 Determine the existence of CD326lowCD56+ progenitor cells within this 
indirect hESC-EC differentiation. 
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4.3 Results 
4.3.1 Preliminary characterisation of adherent cells in a defined 
hematopoietic differentiation system 
Previously, a 30-day, defined hematopoietic differentiation protocol had been 
developed in the lab of Dr J. Mountford, and it described in detail in section 
2.3.3. In the presented studies, experiments used the first 10 days of this 
differentiation system. Briefly, cells were mechanically cut into clumps at d0, 
using the StemPro® EZ Passage tool, before being placed into 6-well ultra-low 
attachment plates, where they were allowed to form EBs. After 3 days EBs were 
collected and dispersed, before they were plated out into 6-well culture plates 
or T25 culture flasks at specific densities, where they were maintained until 
d10. Cells were cultured in Stemline II hematopoietic expansion medium of 
specific mesodermal- and hematopoietic-cytokines (Figure 4.1A).  
After EB dispersal on d3, cells become adherent, undergo a low level of 
expansion and, between d7-10, begin to ‘bud’, producing suspension cells. This 
phenomenon was observed in experiments using both H1 and H9 hESCs (Figure 
4.1B). Adherent cells can form colonies, and appear morphologically similar to 
ECs, whereas the suspension cells have a HC morphology, appearing round and 
shiny when viewed using a phase contrast brightfield microscope (Figure 4.2). It 
was, therefore, hypothesised that these adherent cells, giving rise to budding 
hematopoietic progenitor (HP) suspension cells from d7, were a population of 
specialised bipotent HE cells, existing during hPSC-hematopoietic 
differentiation.  
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Figure 4.1 – Schematic and morphological analysis of d7 and d10 of a defined 
hematopoietic differentiation protocol. 
Pluripotent hESCs were mechanically passaged at d0, transferred to ultra-low attachment culture 
dishes, and allowed to form EBs. EBs were collected and dispersed on d3, where they were 
cultured until d10, as shown in the schematic (A). Cytokine mix I = BMP4, VEGF, Activin A, Wnt3A 
and Inhibitor VIII. Cytokine mix II = Cytokine mix I + FGFα, SCF and β-Estradiol. Cytokine mix III = 
BMP4, VEGF, FGFα, SCF, β-Estradiol, IGF2, TPO, Heparin and IMBX. Specific concentrations of 
cytokines are described in detail in section 2.3.3. Morphological analysis (B) of H1 (top panels) and 
H9 (bottom panels) hESCs was performed on d7 (left panels) and d10 (right panels) of 
hematopoietic differentiation. Images were taken at 10x magnification and scale bars represent 100 
µm. 
  
B d7 d10 
H1  
H9  
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Figure 4.2 – d7 adherent and budding cells during hematopoietic differentiation. 
Phase contrast image clearly demonstrating the presence of adherent and budding cells on day of 
hematopoietic differentiation. Differentiation shown performed using RC9b hESC line. 
Representative image, 10x magnification. 
Taking the first 10 days of this protocol as a window for the emergence of a HE 
population, a panel of endothelial- and hematopoietic-associated makers for was 
devised for analysis using flow cytometry. In these initial studies, performed 
using H1 hESCs, 2-colour flow cytometry was employed to gain insight into the 
cell surface marker profile of both suspension and adherent cells, from days 7 
and 10 of hematopoietic differentiation. This would allow for preliminary 
identification and characterisation of any possible HE progenitor populations, 
existing within this culture system. Primarily, five different antibody 
combinations were used, each containing one PE-conjugated and one APC-
conjugated antibody (Table 4.1).  
Table 4.1 – 2-colour flow cytometry antibody combinations. 
Antibody combinations used for initial flow cytometry studies. More information on antibodies is 
provided in Section 2.7, Table 2.7. 
Combination (Figure 
4.3) 
APC-conjugated PE-conjugated 
A CD34 CD45 
B CD235a CD71 
C CD43 CD31 
D CD144 CD31 
E CD235a CD144 
157 
 
 
First, cells were analysed for a number of hematopoietic cell surface markers; 
CD34 and CD45, CD235a (Glycophorin A) and CD71, and CD43 and CD31 (Figure 
4.3A-C). The combination of CD34 and CD45 is associated with HP cells, with the 
presence of CD45 on CD34+CD45+ cells discriminating from CD34+CD45- 
endothelial progenitor populations (Case et al., 2006). As would be expected, 
the d10 suspension samples contained the highest percentage of CD34+CD45+ 
cells (~26%), suggesting these cells are moving toward a HP phenotype (Figure 
4.3A). Approximately 47% of d7 suspension cells stained positive for CD34, 
however, there was no expression (<0.5%) of CD45 in any cells from this sample 
(Figure 4.3A). Publications have previously suggested that CD34+CD45- cells may 
represent an early or emerging population of HP cells (Venditti et al., 1999), 
although it could also be suggested that CD34+CD45- cells may express CD235a, 
and therefore have progressed beyond the HSC phenotype, and become a more 
defined HC. This would, therefore, explain the presence of a large CD34+CD45- 
population in the d10 suspension samples (approximately 28%).  
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Figure 4.3 – 2-colour flow cytometric analysis of HE markers in a defined hematopoietic 
differentiation system. 
Suspension and adherent cells were harvested at d7 and d10 of hematopoietic differentiation using 
H1 hESCs, and stained using a variety of endothelial and hematopoietic antibodies. Plots above 
are representative of that sample group. Gates were determined using matched isotype controls for 
each sample group. n=3. 
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Both populations of adherent cells (d7 and d10) showed higher levels of 
expression of CD34 than the suspension cells, both in terms of total percentage 
of cells expressing this markers and fluorescence intensity. Although CD34 is 
commonly used to identify early HP cells, it is also expressed on the surface of 
vascular ECs and circulating endothelial progenitor cells (Civin et al., 1984, Fina 
et al., 1990, Urbich et al., 2004), giving a possible explanation for the high 
levels of expression in these cells. There was no expression of CD45 (<0.5%) in d7 
adherent cells, supporting claims these cells may be early HP cells or have a 
more EC phenotype. In the d10 adherent cell population, however, ~11% of cells 
stained positive for CD45. This may be due to the presence of contaminating 
suspension cells, not removed during washing, or CD34+CD45+ cells in this sample 
group may represent those cells currently in the process of ‘budding’ and, 
therefore, still attached to the adherent cells on the culture surface.  
The combination of CD235a, a cell surface antigen whose expression is restricted 
to erythroid precursors and circulating red blood cells, and CD71 (also known as 
Transferrin receptor) antibodies, allowed for identification of potential erythroid 
precursors (Chasis et al., 1992, Marsee et al., 2010). On d7, high levels of 
adherent and suspension cells expressed CD235a (89.5% and 99.7% respectively), 
although the intensity was brighter in suspension cells and there was the 
existence of a small (10.4%) CD235a- population in the adherent cell sample 
(Figure 4.3B). At d10, however, high percentages of the suspension cells (77.8%) 
were CD235a+CD71+ suggesting a large proportion of hematopoietic commitment 
in these cells. Approximately 40% of d10 adherent cells had the CD235a+CD71+ 
marker profile, although, again, this could be due to contaminating or ‘budding’ 
suspension cells present in the sample (Figure 4.3B). A substantial percentage of 
d10 adherent cells were negative for both CD235a (56.5%), with 31.3% expressing 
neither CD235a nor CD71. Lastly, CD43, a marker of hematopoietic commitment 
(Vodyanik et al., 2006), was used in combination with CD31, expressed on the 
surface of leukocytes and HSCs (Baumann et al., 2004). In the d7 suspension 
sample, almost all cells (>99%) were CD43+CD31+. By d10, a high percentage of 
suspension cells were still highly double positive for these two markers (~88%), 
but some cells had lost or were losing expression of CD31 (11.6% CD43+CD31-) 
(Figure 4.3C). In adherent cells, although the majority of cells were still 
CD43+CD31+ (89.9% and 64.7% at d7 and 10 respectively), there was a distinct 
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population of CD43-CD31+ cells, which increased in size between d7 and d10 
(from 8.7% to 25%) (Figure 4.3C). Although present on the surface of HSCs and 
leukocytes, CD31 has classically been associated with ECs, involved in EC 
adhesion and present at cell-cell junctions (Muller et al., 1989, Albelda et al., 
1990). This suggests that the populations of CD43-CD31+, present in the adherent 
cell samples, may represent an emerging population of ECs or, more likely, HE 
progenitors. 
The EC surface marker combination of CD31 and CD144, a marker classically 
used in the identification of vascular ECs (Breier et al., 1996) (Figure 4.3D), was 
then employed to investigate this further. This marker combination had been 
previously used to measure the numbers of hESC-ECs generated during direct 
hESC-EC differentiation as described previously (Chapter 3). Although the 
highest percentage of CD31+CD144+ cell overall was observed in the d7 adherent 
sample, a smaller CD31+CD144high population was also present, which increased 
in size by d10 in the adherent, and was not present in either suspension cell 
sample. In fact, only a small percentage of cells expressed CD144 at all in the 
d10 suspension sample, as it appears all cells were losing or had lost expression 
of this marker. These results suggested a more EC or HE phenotype in both 
adherent cell samples, and a more HP or HSC phenotype in the suspension cells.  
To verify this, cell were finally stained for a combination of CD144 and CD235a 
(Figure 4.3E). This combination of an endothelial (CD144) and a hematopoietic 
(CD235a) surface marker, is the basis of the HE marker profile described by Choi 
et al. (Choi et al., 2012), and would allow for more definitive identification of 
HE. Choi et al. suggest that HE cells are CD144+CD235a-, and populations 
matching this profile were observed in both d7 and d10 adherent samples (23.8% 
and 34.8% respectively). By d10, adherent cells expressing either CD235a or 
CD144 were mutually exclusive, with no cells expressing both of these markers. 
In both sets of suspension cells, almost all cells were CD144-CD235a+ (92% and 
84.6% on d7 and d10 respectively), suggesting the absence of EC or HE 
populations within these non-adherent cellular fractions. This was in contrast to 
the previous combination (Figure 4.3D), where >50% of cells were positive for 
CD144 in both d7 samples (compared to 47% and 5.38% in adherent and 
suspension in the CD235a/CD144 combination), and almost 40% in d10 suspension 
cells (compared to 4% in the CD235a/CD144 combination). This may be due to 
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antibody variability, antibodies used were from different companies (Table 2.7), 
and different fluorophores were used; APC–conjugated anti-CD144 with CD31 and 
PE-conjugated anti-CD144 with CD235a. One explanation may be that suspension 
cells express low levels of CD144; the bright APC fluorophore may show this as 
positively staining for CD144, whereas the PE antibody may show this as CD144 
negative. This explains the presence of the CD31+CD144high population in the 
CD31/CD144 combination, which correlates to the CD144+ cells in the d7 and 10 
adherent samples when stained with CD144 and CD235a (Figure 4.3D-E). 
Taken together, these data suggest a possible HE progenitor population, existing 
within the adherent cells, both at d7 and d10 of hematopoietic differentiation. 
4.3.2 Multi-colour flow cytometry to identify HE populations 
within a defined hematopoietic differentiation system 
To gain a more in depth surface marker profile of these possible HE progenitors, 
a larger, 6-colour flow cytometry panel was devised (Table 4.2), based on the 
definition of HE progenitors previously published by Choi and colleagues (Choi et 
al., 2012). Utilising a combination of hematopoietic and endothelial cell surface 
markers, Choi et al. defined these cells as CD144+CD73 − CD235a/CD43 −
CD117intermediate and this was the profile investigated in this study, with the 
addition of CD31. The panel of antibodies used, and their conjugated 
fluorophores are shown in Table 4.2. 
Antibody Fluorophore Excitation (nm) Emission (nm)@ 
CD144 PE 488 578 
CD31 FITC 488 520 
CD43 PE-Cy7 488 785 
CD117 PerCP-Cy5.5 488 695 
CD73 APC 640 660 
CD235a BV421 405 421 
Table 4.2 – 6-colour flow cytometry antibody panel. 
Table shows antibodies used in 6-colour flow cytometry panel and their conjugated fluorophores. 
Excitation and maximum emission wavelengths for each fluorophore are also shown. BV421 = 
Brilliant Violet 421 (BD Biosciences). 
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Figure 4.4 – 6-colour flow cytometric analysis of d7-10 adherent cells.Adherent cells were harvested d7, 8, 9 and 10 of hematopoietic differentiation using H1 hESCs, 
stained and analysed using flow cytometry. Plots above are representative of that sample group. Gates were determined using matched isotype controls for each 
sample group, compensation was performed using singly stained controls and FMO controls were performed at each time point. n=3. 
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Suspension and adherent cells were harvested at d7, 8, 9 and 10, and stained 
using the antibodies shown in Table 4.2. Using the same basis as Choi and 
colleagues, cells were first gated for CD144+CD235a- populations (Figure 4.4). 
Using this population, events were then analysed for expression of CD43, 
representing cells committed to the hematopoietic lineage, CD31, an endothelial 
marker, CD73, also an established EC marker (Thomson et al., 1990) and CD117 
(c-Kit), a marker of early stage angiohematopoietic progenitors (Choi et al., 
2012). The numbers of adherent cells in the CD144+CD235a- population 
decreased throughout differentiation, with the lowest numbers of cells present 
on d10, and the highest on d7, where approximately 24% of cells fit this 
description. Within the CD144+CD235a- population, at all time points (d7-d10), 
almost all events were also CD31 positive, implying that these cells are 
CD31+CD144+CD235a-(Figure 4.4). The co-staining of all cells for two EC markers, 
suggests a predominantly EC phenotype in the CD144+CD235a- cells, similar 
previously published definitions of HE (Nishikawa et al., 1998, Zovein et al., 
2008, Choi et al., 2012, Ditadi et al., 2015), and in concurrence with data 
collected by Choi et al. Unlike previously published data, however, CD117 
staining was not observed on any cells throughout this experiment (Figure 4.4), 
including in the non-CD144+CD235a- cell fraction (data not shown). 
The expression of CD73, however, was variable. CD31+CD144+CD235a- Adherent 
cells from d7 were mixed in terms of CD73, with those expressing the highest 
levels of CD31 also expressing CD73 (CD31+CD73+), possibly indicative of a more 
mature EC phenotype (Figure 4.4). 35% of cells at this time point, however, were 
CD31+CD73-. As differentiation progressed, larger percentages of cells were seen 
to co-express CD31 and CD73, and the CD31+CD73- population was reduced in 
size (16.2% by d10). This may indicate a loss of HE cells from d7-10, as medium 
becomes more supportive of HP suspension cells. CD43 staining, signifying cells 
committed to a hematopoietic fate, was also variable in the 
CD31+CD144+CD235a- cells (Figure 4.4). At d7, the majority of 
CD31+CD144+CD235a- cells were also CD43- (approximately 60%), with a decrease 
in the size of this population as differentiation progressed (approximately 35-45% 
on d8-10). Choi et al. hypothesised that HE cells were negative for both CD43 
and CD73. To therefore investigate this hypothesis, cells were analysed for co-
expression of CD43 and CD73. A population of CD31+CD144+CD235a-CD43-CD73- 
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cells was present only in d7 adherent cell samples (Figure 4.4; red gate), before 
being lost by d8-10 time points. Taken together, alongside previously published 
data, these results suggest that the CD31+CD144+CD235a-CD43-CD73- population 
may be a HE population, equivalent to the CD144+CD73 − CD235a/CD43 −
CD117intermediate cells identified by Choi.  
As well as the adherent cells, suspension cells were also harvested at the same 
time points (d7, 8, 9 and 10) and analysed using the same panel of cell surface 
markers (Table 4.2). In suspension samples, however, CD144+CD235a- cells were 
not present at any time point (Figure 4.5). Profiles were similar between all four 
samples, with the majority of cells (>75%) possessing the surface marker profile 
CD144-CD235a+. All of the cells were also positive for both CD43 and CD31, whilst 
staining negative for CD73, giving the profile CD31+CD144-CD235a+CD43+CD73-. 
This, therefore, confirmed suggestions that these cells are a population of 
emerging HPs, and do not contain the HE population.  
165 
 
 
 
Figure 4.5 – CD235a/CD144 staining of d7-10 suspension cells. 
Suspension cells were harvested d7, 8, 9 and 10 of hematopoietic differentiation using H1 hESCs, stained and analysed using flow cytometry. Plots above are 
representative of that sample group. Gates were determined using matched isotype controls for each sample group. n=3. 
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To further characterise these cells, total RNA samples were also collected from 
d0 hESCs, d7,8 9 and 10 adherent cells and d7 and d10 suspension cells. Samples 
were then subjected to gene expression profiling using Taqman® qRT-PCR, 
examining the levels of endothelial, hematopoietic and pluripotent genes (Figure 
4.6). CD144, CD31 and CD34, all endothelial-associated genes, are significantly 
upregulated in all time points after d0, including at the d3 EB stage (Figure 4.6. 
Specifcally, CD144 is highly upregulated to similar levels in all of the adherent 
cell samples, and in the d7 suspension cells. In the d10 suspension cells, 
however, the levels of CD144 mRNA expression were significantly lower than in 
all adherent cell samples and the d7 suspension cells. This suggests that 
suspension cells lose the expression of CD144 between d7 and d10, as cells 
become more committed to a hematopoietic cell fate. The expression pattern of 
CD31 was similar, with a significant upregulation in levels of this gene in all 
samples when compared with d0 pluripotent hESCs (Figure 4.6A). In contrast to 
CD144, however, CD31 was also upregulated to the same levels in d10 suspension 
cells, as in the rest of the samples. As stated previously, CD31 is also expressed 
on the surface of leukocytes, and erythroid progenitors (Baumann et al., 2004), 
and, therefore, high expression in the d10 suspension cells, combined with low 
CD144 expression indicates that these cells are of a more hematopoietic fate. 
This is further confirmed by the expression profiles of CD34, also associated with 
both endothelial and hematopoietic cell types, and CD43 (Figure 4.6B). CD34 
was, again, significantly upregulated in all time points after d0. The highest 
levels of expression were observed in d8-10 adherent cells, although there was 
no significant difference in levels in all suspension and adherent time points, 
possibly due to the expression of this gene in both HPs, and vascular ECs and 
circulating EPCs. In terms of hematopoietic gene expression, the highest levels 
of CD43 were observed in the d10 suspension cells (Figure 4.6B), with 
significantly lower expression in the adherent cell samples. Higher levels of 
expression in the d7 and d10 suspension cells, coupled with CD144, CD31 and 
CD34 expression, shows that these cells are beginning to move toward the 
hematopoietic lineage by d7, with the levels of commitment increased further 
by d10, supporting flow cytometry data (Figure 4.3, Figure 4.4). In contrast, 
adherent cells show a predominantly EC phenotype, with lower levels of 
hematopoietic-associated genes, although CD43 is still upregulated in these cells 
when compared to d0 hESCs and d3 EBs. 
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Figure 4.6 – Gene expression analysis of suspension and adherent cells in a defined 
hematopoietic differentiation system. 
Expression profiles of endothelial- (CD144, CD31 and CD34) (A), pluripotent- (Nanog and Sox2) 
(B) and hematopoietic- (CD43) (C) associated genes in adherent cells from d7-10 and suspension 
cell from d7 and d10 during hematopoietic differentiation of H1 hESCs, determined using qRT-
PCR. Repeated measures ANOVA with Tukey post hoc t-test, * = p<0.05, *** = p<0.001 vs. H1 d0 
hESCs, ## = p<0.01, ### = p<0.001 vs. d10 suspension cells. Data shown is RQ ± RQ max, 
relative to UBC. n=3. 
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Levels of pluripotent genes were also assessed in these samples. Both Nanog and 
Oct4, pluripotency-associated TFs, were found to be significantly downregulated 
during differentiation (Figure 4.6C). Nanog was significantly downregulated by 
d3, and both genes were expressed at near-undetectable levels by d7, 
demonstrating, as would be expected, a loss in pluripotency as hESCs 
differentiate, becoming committed toward specific lineages. 
The results collected from the qRT-PCR analysis of the cell samples are 
consistent with the flow cytometry data and, taken together, these data suggest 
that the d7 adherent cells possess the most EC or HE phenotype. 
4.3.3 Optimisation of an indirect hESC-EC differentiation protocol 
Following the identification and characterisation of a possible CD31+CD144-
CD235a+CD43+CD73- HE progenitor population, it was hypothesised that the 
phenotype of these cells may be controlled by cell culture conditions. Currently, 
during hematopoietic differentiation, adherent cells from d7 are kept in culture 
conditions supportive of hematopoietic expansion. Therefore, if placed into 
endothelial supportive conditions cells would be driven toward an EC fate and, 
thus, this protocol may be use as an additional, indirect, method of hESC-EC 
generation. 
To examine this hypothesis, and to optimise the day on which cells are 
transferred to endothelial-supportive conditions, suspension cells were removed 
from the culture system. Remaining adherent cells were washed to limit 
suspension cell carry over, and medium was replaced with the EC-supportive 
Lonza EGM-2, containing the FBS component and supplemented with 50 ng/mL 
VEGF. Cells were placed into endothelial conditions on d7, 8 or 9 and cultured 
for 3, 2 or 1 day until d10 (d7+3, d8+2 and d9+1, respectively). D10 was chosen 
as an end point, as this is the time at which, during hematopoietic 
differentiation, suspension cells at d10 are removed and their culture continues 
without the adherent cells. After 10 days, the resultant cells were photographed 
for morphological analysis, harvested for analysis by flow cytometry and total 
RNA samples taken for gene expression profiling. A schematic detailing the 
experimental design is shown in Figure 4.7. 
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Figure 4.7 – Schematic of indirect hESC-EC differentiation system. 
Cytokine mix I = BMP4, VEGF, Activin A, Wnt3A and Inhibitor VIII. Cytokine mix II = Cytokine mix I + FGFα, SCF and β-Estradiol. Cytokine mix III = BMP4, VEGF, 
FGFα, SCF, β-Estradiol, IGF2, TPO, Heparin and IMBX. Specific concentrations of cytokines are described in detail in section 2.3.3. 
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By d10, cultures which had been in endothelial-supportive conditions for 3 days 
(d7+3) contained fewer suspension cells than those in medium for 1 or 2 day; 
(d9+1 and d8+2, respectively (Figure 4.8A). Adherent cells cultured in 
endothelial-supportive conditions for 1, 2 and 3 days (d9+1, d8+2 and d7+3), had 
expanded to a confluent, homogenous monolayer by d10, with a morphology 
similar to that of mature ECs. In contrast to this, however, d10 adherent cells, 
cultured in only medium and cytokines supporting hematopoietic differentiation, 
did not form a confluent monolayer, clumped together, and displayed high levels 
of budding, producing larger amounts of suspension cells.  
In order to characterise the cells produced, d7+3, d8+2 and d9+1 samples were 
subjected to the 6-colour flow cytometry antibody panel detailed in section 
4.3.2 (Table 4.2). This would determine whether hESC-ECs had been generated 
and, if so, whether they were still HE, or whether they had gained a more 
definitive EC marker profile. In this experiment, d10 adherent cells, continually 
cultured in hematopoietic conditions until they were harvested, were used as a 
comparison. Firstly, samples were assessed for the percentage of CD31+CD144+ 
cells, the criteria used to determine levels of hESC-ECs generated during direct 
differentiation (Chapter 3). There was a significant increase in the proportion of 
cells expressing these two markers in d7+3 samples (up to 80%), when compared 
with d0 pluripotent controls (Figure 4.8A, Figure 4.9). On average, percentages 
of CD31+CD144+ cells were also increased in d8+2 (approximately 50%) and d9+1 
samples (approximately 40%), although not significantly (Figure 4.9), however, 
this may be due to variability between experimental replicates. The percentage 
CD31+CD144+ decreased when cells had spent less time in the endothelial-
supportive conditions, with the highest levels at d7+3 and the lowest at d9+1. In 
d10 adherent cells, numbers of CD31+CD144+ were very low (Figure 4.8B, Figure 
4.9), although this varied with the success of the hematopoietic differentiation 
to d7. Differentiations producing high numbers of budding cells and, 
subsequently, suspension cells, resulted in lower levels of CD31+CD144+ d10 
adherent cells. High numbers of suspension cells may result in culture conditions 
favouring further generation of suspension cells, no longer supporting adherent 
cells, therefore causing a reduction in the numbers of CD31+CD144+ HE cells. This 
initial data suggest that transfer of cells to endothelial-supportive conditions at 
d7 is optimum for the generation of hESC-ECs. 
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Figure 4.8 – Optimisation of a newly developed indirect hESC-EC differentiation system. 
Adherent cells were put into endothelial medium on d7, d8 or d9 of hematopoietic differentiation and cultured until d10 (d7+3, d8+2 and d9+1, respectively). 
Morphological analysis of cells was performed (B). Adherent d10 cells shown have had suspension cells removed for clearer analysis. Brightfield images were taken at 
10x magnification, scale bars represent 100 µm. n=3.  On d10, cells were also harvested, stained using PE-conjugated anti-CD144 and FITC-conjugated anti-CD31 (as 
part of a larger 6-colour panel), and analysed using flow cytometry (A). Compensation was performed using single-stained controls and FMO controls performed to 
ensure correct compensation.  
hESC-EC d7+3 hESC-EC d8+2 hESC-EC d9+1 Adherent d10  A 
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Figure 4.9 –Average percentage of CD31
+
CD144
+
 hESC-ECs  
Histogram of CD31/CD144 flow cytometry data, combined from n=3 different indirect hESC-EC 
differentiation optimisation experiments (A). Average percentages of double positive cells are 
plotted with SEM. Repeated measures ANOVA with Tukey’s post hoc comparisons, * = p<0.05. 
To further investigate the surface marker profile of the generated d7+3 hESC-
ECs, CD31+CD144+ were gated and analysed for the expression of further 
endothelial (CD73) and hematopoietic (CD235a, CD43) markers. Shown in Figure 
4.10, CD31+CD144+ cells were mainly negative for both hematopoietic markers 
CD43 and CD235a, similarly to the CD31+CD144+CD235a-CD43-CD73- HE progenitor 
population, suggesting a largely EC phenotype in these cells. Additionally, and 
unlike the HE progenitor population identified on d7, 100% of these cells are also 
positive for CD73, an EC surface marker, indicating that these cells possess a 
more committed EC phenotype than the bipotent HE progenitor cells, verifying 
that these cells are hESC-ECs and not HE cells. 
 
Figure 4.10 – Further analysis of surface marker expression in CD31
+
CD144
+
 d7+3 cells. 
After initial analysis, d7+3 CD31
+
CD144
+
 were further gated and analysed for their expression of 
further EC (CD73) and HC (CD235a,  CD43) markers. Red gate indicates cells included in further 
analysis. Dot plots shown are representative of multiple experiments, gates drawn based on 
negative isotype and unstained control samples. Compensation performed using singly stained 
controls.   n=3. 
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To allow for further characterisation of the phenotypic profile of these cells, 
total RNA was also collected from d7+3, d8+2 and d9+1 samples, as well as 
pluripotent d0 hESCs and suspension and adherent cells from d10 of 
hematopoietic differentiation. Pluripotent (Nanog, Oct4), hematopoietic (CD43) 
and endothelial (CD144, C31 and CD34) genes were all profiled using Taqman® 
qRT-PCR (Figure 4.11). As observed previously, Nanog and Oct4 were 
significantly down regulated during differentiation, as hESCs lose their 
pluripotency and become committed to specific lineages and cell types (Figure 
4.11A). CD43 was significantly upregulated in all samples compared to d0 
pluripotency cells (Figure 4.11B). Additionally, significantly higher levels of CD43 
were detected in the HP-containing d10 suspension samples, than in d7+3, 8+2, 
9+1 or d10 adherent cells. Levels were also significantly higher in d9+1 and d10 
adherent samples than in d7+3 cells. Profiling of endothelial-associated genes 
showed that, although significantly upregulated in all samples when compared to 
d0 pluripotent controls, the highest levels of expression were in d7+3 and d8+2 
(Figure 4.11C). Specifically, levels of CD144, CD31 and CD34 were all 
significantly higher in the d7+3 cells than in the d10 suspension cells. Combined 
with data from flow cytometric analysis, these findings suggest that the addition 
of endothelial-supportive conditions to adherent cells on d7 generates high 
percentages of committed hESC-ECs. The resultant hESC-ECs, express high levels 
of EC markers and low levels of hematopoietic and pluripotent markers when 
assessed using qRT-PCR and flow cytometry. Cells appeared similar to mature 
ECs, demonstrating a ‘cobblestone-like’ morphology, and were no longer 
‘budding’, therefore ceasing generation of HP suspension cells. Furthermore, it 
was observed that, in contrast to the d7 CD31+CD144+CD235a-CD43-CD73- HE 
cells, d7+3 cells expressed the endothelial marker CD73, suggesting they were 
more committed to an EC fate than the bipotent HE progenitors. Thus, d7+3 
conditions were chosen as optimum for the indirect generation of hESC-ECs, and 
were henceforth used as an endpoint in this differentiation system. 
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Figure 4.11 – Gene expression profiling of generated hESC-ECs. 
Pluripotent- (A), hematopoietic-  (B) and endothelial- (C) associated gene were analysed in 
samples from H1 hESCs during direct hESC-EC differentiation, including d0 pluripotent hESCs, 
d7+3, d8+2 and d9+1 hESC-EC and d10 adherent and suspension samples. Data shown is RQ ± 
RQ max, calculated relative to UBC.  Repeated measures ANOVA with Tukey’s post hoc 
comparisons, *** = p<0.001, vs. H1 d0 hESCs, # = p<0.05, ## = p<0.01, ### = p<0.001 vs. d10 
suspension cells, ϕ = p<0.05 vs. d7+3 hESC-ECs. n=3. 
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After assessing hESC-EC generation, levels of pluripotency associated cell surface 
markers were also assessed in the newly generated hESC-EC differentiation 
protocol. This would ensure that there are no pluripotent cells contaminating 
d7+3 samples. In order to fully assess this, levels of two pluripotency-associated 
cell surface markers were measured using flow cytometry; Tra1-60 and SSEA3 
(Figure 4.12). Approximately 80% of cells were Tra1-60+SSEA3+ in the d0 H1 
control (Figure 4.12A-B), indicative of high levels of pluripotency, as would be 
expected. By d7, however, levels were significantly reduced, with <1% of cells 
positive for either Tra1-60 or SSEA3, and levels were similar in d7+3 and d10 
adherent (cultured in hematopoietic conditions) cell samples. This, together 
with the presented gene expression data, confirms a loss of pluripotency during 
differentiation, with no pluripotent cells detected after d7. 
 
Figure 4.12 – Analysis of pluripotency associated cell surface markers in H1 indirect hESC-
EC differentiation. 
Cells at various time points during indirect hESC-EC differentiation were assed 
for expression of Tra1-60 and SSEA3, two pluripotency-associated markers, using 
flow cytometry. Histogram (A) shows average percentages of cells expressing 
both of these markers at the indicated time points, error bars represent SEM. 
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Dot plots (B) give representative examples of staining in each sample group. n=3. 
Repeated measures ANOVA with Tukey’s post hoc comparisons, ** = p<0.01 vs H1 
d0 hESCs.To ensure reproducibility and robustness of the newly developed 
indirect hESC-EC differentiation protocol, experiments were repeated using the 
H9 hESC line (Figure 4.13, Figure 4.14). D7+3 hESC-ECs and d10 suspension and 
adherent cells (from hematopoietic differentiation) were assessed by flow 
cytometry for the expression of CD31 and CD144. Similarly to differentiations 
performed with H1s, there was a significant increase in the proportion of 
CD31+CD144+ cells in d7+3 samples, with on average 66% of cells expressing both 
of these EC-associated markers. Lower numbers of cells expressed these markers 
in the d10 adherent cells, whereas in the suspension sample no cells stained 
positive for CD144. Morphological analysis of d7+3 cells (Figure 4.13C) showed 
that cells expanded to form a homogenous monolayer when cultured in these 
endothelial-supportive conditions. 
Moreover, cells were also analysed for the expression of the pluripotency 
associated markers SSEA3 and Tra1-60 (Figure 4.14). Again, similarly to samples 
from H1 indirect hESC-EC differentiations, these markers were expressed at high 
levels in d0 H9 hESCs (72.1%), before being downregulated. In d7+3 and d10 
adherent samples, <1% of cells were Tra1-60+SSEA3+, suggesting that, similarly to 
differentiations performed with H1 hESCs, there are no pluripotent cells 
remaining at this time point. 
Together, these data suggest that the newly developed indirect hESC-EC 
differentiation protocol is efficient, generating high levels of CD31+CD144+ cells 
after 10 days (d7+3) and low levels of Tra1-60+SSEA3+ cells. The protocol is also 
reproducible and robust, having been tested in multiple hESC cell lines. 
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Figure 4.13 – Indirect hESC-EC differentiation in H9 hESCs. 
After optimisation, indirect hESC-EC differentiation was performed using H9 hESCs. d7+3 hESC-
ECs were harvested, stained for CD31 and CD144 and analysed using flow cytometry. 
Hematopoietic differentiation was also continued from d7 and adherent and suspension cells from 
d10 were stained for comparison. Average percentages of CD144
+
CD31
+
 are presented in the 
histogram, error bars are SEM (B). Brightfield imaging of d7+3 cells show a similar morphology to 
H1 d7+3 hESC-ECs (C). Image shown taken at 10x magnification, scale bar represents 100 µm. All 
dot plots shown are representative for sample group. n=3. Statistical comparisons (B), repeated 
measures ANOVA with Tukey’s post hoc comparisons, ** = p<0.01 vs H9 d0 hESCs. 
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Figure 4.14 – Assessment of pluripotency markers in H9 indirect hESC-EC differentiation. 
d0 hESCs, d7+3 hESC-EC and d10 adherent cells were also stained for pluripotent markers using 
PE-conjugated anti-Tra1-60 and APC-conjugated anti-SSEA3 (D). All dot plots shown are 
representative for sample group.  
4.3.4 Identification of a CD326lowCD56+ MP population during 
indirect hESC-EC differentiation 
The first 3 days of the hematopoietic differentiation protocol, and subsequently 
indirect hESC-EC differentiation, is similar to the first 3 days of direct generation 
of hESC-ECs. It was believed that mesodermal commitment occurs between d0-3 
of hematopoietic differentiation, when cells are cultured as EBs (Figure 4.1A). A 
transiently existing CD326lowCD56+ MP population was previously identified on d3 
of direct hESC-EC differentiation, as described in section 3.3.5 (Evseenko et al., 
2010). The CD326lowCD56+ expression profile is based on cells undergoing EMT 
during generation of the mesodermal germ layer (Lehembre et al., 2008, 
Evseenko et al., 2010, Lu et al., 2010). Therefore, experiments were performed 
to determine whether this population also existed at the equivalent time point 
within the newly developed indirect hESC-EC differentiation.  
Cells were harvested at a variety of time points, including d3 EBs, and the 
expression of CD326 and CD56 was assessed using flow cytometry (Figure 4.15A-
B). As observed previously, H1 pluripotent hESCs highly express CD326 (<96%) but 
not CD56 (Figure 4.15A). By the d3 EB stage of differentiation, however, a 
number of cells have begun to lose expression of CD326, and this is coupled with 
a gain of the CD56 cell surface marker. This resultant population is the 
previously identified CD326lowCD56+ MP population, and represents, on average, 
approximately 40% of cells at d3 (Figure 4.15B), a significant increase when 
compared to d0 pluripotent controls. 
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Figure 4.15 – Identification of CD326
low
CD56
+
 MPs during hematopoietic and indirect hESC-
EC differentiation. 
Indirect hESC-EC differentiation was probed to assess the existence of the previously identified 
CD326
low
CD56
+
 mesoderm progenitor population. Cells were stained for CD326 and CD56 and 
analysed using flow cytometry on d0, in adherent d7 cells and in suspension and adherent cells at 
d10 (A). Average percentage of CD326
low
CD56
+
 cells in each sample group is shown in the 
histogram (B). RNA was collected at the same time points, as well as d7+3 hESC-ECs, and 
analysed for the expression of mesoderm-associated Brachyury and Mesp1 (C). Data shown is RQ 
± RQ max, calculated relative to UBC.  Repeated measures ANOVA with Tukey’s post hoc 
comparisons, * = p<0.05, ** = p<0.01, *** = p<0.001, vs. H1 d0 hESCs, ## = p<0.01, ### = 
p<0.001, vs. d3 EBs. No exp = undetectable expression when analysed by Taqman qRT-PCR. 
n=3. 
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After d3, however, the percentage of CD326lowCD56+ cells decreases, and by d10 
the majority of cells (<50%) were negative for either of these markers. The 
presence of the CD326lowCD56+ MP population at d3 also coincides with the peak 
mesoderm-associated gene expression. Levels of Brachyury and Mesp1 were 
measured using Taqman® qRT-PCR, and were found to be significantly 
upregulated in d3 EB samples (Figure 4.15C). These genes were then significantly 
downregulated at later time points, as cells become committed toward HE, EC 
and HP phenotypes. These data verify the existence of a CD326lowCD56+ MP 
population within the newly developed indirect hESC-EC differentiation. This 
also supports claims that these cells are multipotent, as they can produce both 
EC and HCs within this culture system.  
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4.4 Discussion 
Previously published work, centred on the formation of a common hematopoietic 
and endothelial progenitor, has focused on the generation of HSCs and HPs (Choi 
et al., 2012, Ditadi et al., 2015). This study focuses on the derivation of hESC-
ECs from a common HE progenitor population. Data presented here describes the 
development of an indirect hESC-EC differentiation protocol, efficiently 
generating large numbers of CD31+CD144+ hESC-ECs by d10. Through the 
characterisation of a pre-existing CD31+CD144+CD235a-CD43-CD73- HE population, 
present during a defined hPSC-hematopoietic differentiation, an efficient 
protocol for hESC-EC generation was optimised. By d10, including 7 days in 
hematopoietic-supportive condition followed by 3 days in EC growth medium, 
production of suspension cells had ceased and cells had expanded to form a 
confluent homogenous adherent monolayer. These cells expressed the 
endothelial markers CD144, CD31 and CD73, and were negative for both 
hematopoietic (CD235a and CD43) and pluripotent-associated (Tra1-60 and 
SSEA3) markers, when analysed using flow cytometry. This was additionally 
verified when the gene expression profile of these cells were assessed.  
Unlike the previously shown direct hESC-EC differentiation, this indirect protocol 
does not employ a 96-well spin-based technique for EB formation. Instead, cells 
are mechanically cut into clumps and transferred to ultra-low attachment 6-well 
plates, where they spontaneously form EBs and, in contrast to direct hESC-EC 
differentiation, this does not appear to affect experimental reproducibility in 
this system. Formation of EBs using the previously described 96-well spin-based 
method is time consuming and difficult to adapt for scaling up EB production, 
the 6-well EB-formation method, however, does not have this problem, and is 
much more scalable. Additionally, using the newly developed indirect hESC-EC 
differentiation system, high percentages of CD31+CD144+ were generated. On 
average, these percentages were higher than those generated using the direct 
hESC-EC differentiation protocol. Previously, generation of hESC-ECs via the 
formation of HE has been relatively inefficient, although studies have focused on 
mechanisms and generation of HSCs and HP cells (Choi et al., 2012, Ditadi et al., 
2015), with Choi et al. showing only ~6% of cells expressing CD144 by d5. 
Percentages of CD31+CD144+ hESC-ECs generated by d10 in the present study are 
comparable to the numbers produced by Patsch and colleagues, who recently 
182 
 
 
described a direct differentiation protocol, generating both ECs and VSMCs from 
hPSCs (both iPSCs and ESCs), which generated high percentages (up to 80%) of 
CD144+ cells (Patsch et al., 2015), although this high percentage was only 
obtained after sorting and further culture of generated ECs. In other recently 
published studies, performed by Orlova et al., only 10-30% of cells were 
CD31+CD34+ ECs by d10, substantially less than the numbers generated using the 
indirect hESC-EC differentiation (Orlova et al., 2014a, Orlova et al., 2014c).  
The indirect hESC-EC differentiation protocol also has scope for production of 
large numbers of pure CD31+CD144+ hESC-ECs. Numerous studies, including those 
presented in Chapter 3, have previously shown that low percentages of hESC-ECs 
can be isolated from heterogeneous mixes of cells, usually generated at the end 
of differentiation protocols, replated and cultured. Via isolation, using either 
MACS or FACS, and further expansion of cells, near pure populations (>95%) of 
hESC-ECs have been generated (Levenberg et al., 2002, White et al., 2013, 
Orlova et al., 2014a, Orlova et al., 2014c). In contrast, during indirect hESC-EC 
differentiation, cells were simply plated out at a density of 5x105 cells in a T25 
culture flask on d3, and by d10 a confluent monolayer, of approximately 80% 
CD31+CD144+ hESC-ECs, had formed. Additional experiments could be performed 
to assess whether further culture of these cells increases purity, or whether 
expansion is possible after depletion of non-CD31+CD144+ hESC-ECs. The protocol 
could also be optimised to scale up the size of the culture vessel used, resulting 
in the generation of greater hESC-EC numbers. Specific EC phenotypes of 
generated cells could also be investigated, as Ditadi and colleagues 
demonstrated distinct populations of arterial and venous ECs, present in their 
differentiation, routed through the formation of a common HE precursor (Ditadi 
et al., 2015). As described previously (Section 3.4), further characterisation of 
both surface markers and transcription factors, present in the CD31+CD144+ d7+3 
hESCs could be performed to determine the exact phenotype of these cells on 
d10.  
Although CD31+CD144+ hESC-ECs, generated using the indirect differentiation 
protocol, were extensively characterised using flow cytometry and gene 
expression profiling, no functional studies were performed. To fully validate the 
EC phenotype of these cells, a number of in vitro or in vivo functional assays 
must be performed, as described in detail in Section 3.4. Recently published 
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studies have suggested that classical EC functional assays are perhaps no longer 
appropriate, and have therefore used alternatives, such as co-culture with hPSC-
derived pericytes, zebrafish xenograft, analysis of trans-endothelial electrical 
resistance and barrier formation via the measurement of cellular impedance 
(White et al., 2013, Orlova et al., 2014a, Orlova et al., 2014c). Time constraints, 
however, prevented thorough functional characterisation of CD31+CD144+ hESC-
ECs, generated using the indirect protocol. 
This study also demonstrated that the HE profile, previously identified by Choi 
and colleagues in their undefined, OP9 co-culture-based differentiation, also 
identifies a population of progenitor cells existing within a more defined 
hematopoietic differentiation system (Choi et al., 2012). As stated previously, 
undefined conditions, such as the use of serum and stromal cell co-culture, 
introduce non-human pathogens, contaminants and unknown factors into 
differentiation systems. Defined systems, therefore, are not only advantageous 
in terms of downstream clinical relevance, but also allow for precise control of 
the extracellular environment, and exact knowledge of factors added to the 
system. The HE population defined by Ditadi and colleagues had a similar surface 
marker profile to the one described in this study and by Choi et al., with the 
addition of CD34+, CD184- and KDR+, and without determining the expression of 
CD235a (Ditadi et al., 2015).  
Both previous publications, describing the formation of HE from hPSCs, have 
identified multiple other progenitor populations existing within their specific 
differentiation systems. Choi et al., identified seven specialised populations, 
each of which possessed defining characteristics, such as 
CD144+CD73+CD235a/CD43-CD117high non-HEP cells, which possess a mainly EC 
phenotype, and CD144+CD73-CD43lowCD235a+CD41a-CD117- angiogenic 
hematopoietic progenitors, primarily a HP cell possessing hematopoietic 
function, but capable of generating ECs (Choi et al., 2012). Experiments could 
be performed to further elucidate the exact profile and phenotype of other cell 
populations, existing as adherent cells on d7 of hematopoietic and indirect hESC-
EC differentiation. This may include characterisation by flow cytometry, 
isolation and further culture, gene expression profiling and performance of 
functional assays to test for hematopoietic and EC function, such as analysis of 
the colony forming potential of cells and AcLDL uptake.  
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Further work could also be performed to demonstrate the direct production of 
suspension cells from the hypothesised bipotent HE progenitor population. 
Previous work used live cell imaging and time lapse photography to visualise the 
formation of CD43+ and CD45+ hematopoietic suspension cells from CD144+ 
adherent HE cells (Choi et al., 2012, Ditadi et al., 2015), and this technique 
could be utilised to also demonstrate this in the presented differentiation 
system.   
The expression of Runx1, a transcription factor indispensable for the emergence 
of HSCs, could also be investigated in the cell population from this 
differentiation system. Although Ditadi et al. found that Runx1 was not 
expressed in HE cells, and that expression only occurs post-EHT (Ditadi et al., 
2015), other studies have shown its expression in HE and during EHT (Chen et 
al., 2009a, Ng et al., 2010a). Additionally, in a murine model of HE 
development, it was demonstrated that an enhancer, located intronically in 
Runx1, also marks HE and HSCs, suggesting an important role for this axis in HE 
and HSC differentiation (Ng et al., 2010a). Colleagues in Edinburgh are currently 
working on Runx1 reporter lines, which could possibly be used to observe the 
expression of this gene in HE and HSCs in this system. Specifically, these cells, 
alongside live cell imaging techniques, could be utilised to monitor the 
emergence of Runx1 positive cells from HE progenitors.  
One major difference between the progenitor defined in this study and the one 
identified by Choi and colleagues, is the presence of CD117, also known as c-kit, 
a receptor tyrosine kinase which binds and recognises the ligand SCF 
(Lennartsson et al., 2012), a cytokine added in the hematopoietic and indirect 
hESC-EC differentiation protocols. CD117 and its ligand have long been known to 
play important roles in hematopoiesis. CD117 is found expressed on the surface 
of HSCs and HPs and is responsible for the inhibition of apoptosis in human 
erythroid progenitor cells through activation of phosphoinositide 3-kinase (PI3K) 
(Ogawa et al., 1991, Broudy, 1997, Sui et al., 2000). Another study, documenting 
properties and differences of four hESC lines, additionally demonstrated that 
CD117 is expressed at varying levels in H1 hESCs maintained in a feeder-free 
culture system (Carpenter et al., 2004). During this study, however, expression 
of CD117 was not detected on any of the cells profiled, including suspension, 
adherent and d0 pluripotent hESCs (Figure 4.4). Both previously published 
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methods for the derivation of HE from hPSCs, describe HE cells as expressing low 
or ‘intermediate’ levels of the CD117 surface marker, with Choi an colleagues 
suggesting its expression can be used to distinguish between HE and non-HE 
progenitors (Choi et al., 2012, Kennedy et al., 2012, Ditadi et al., 2015). 
Although multiple CD117 antibodies were tested, this may suggest an antibody 
problem in the presented research and a positive control sample should have 
been used in order to ensure this was working correctly. Alternatively, the lack 
of CD117 expression may be due to internalisation of the receptor on SCF 
binding. Historical studies have demonstrated that upon SCF binding, CD117 is 
activated, internalised and then degraded via the ubiquitin/endosomal pathway, 
with reappearance on the cell surface requiring protein synthesis (Broudy et al., 
1998, Jahn et al., 2002). High concentrations of SCF are added from d3 of 
hematopoietic and, subsequently, indirect hESC-EC differentiation. Therefore, 
to further investigate and validate the expression of CD117 within the HE and HP 
populations, techniques other than flow cytometry, which relies on the staining 
of cell surface antigens, must be used. Immunocytochemistry would allow for 
visualisation of internalised receptors in these cell populations. As a result, 
definitive conclusions involving the expression of CD117 in populations, occurring 
throughout the described hematopoietic and indirect hESC-EC differentiations, 
cannot be made. 
Here, the presence of the previously characterised CD326lowCD56+ MP 
population, during indirect hESC-EC and hematopoietic differentiation, was also 
confirmed. This further strengthened the argument that these cells are an early 
progenitor cell population, occurring just as cells commit to the mesodermal 
germ layer (Evseenko et al., 2010) or slightly later, when cells have already 
started to move toward an EC or HE cell fate (Chapter 3). Although the presence 
of this progenitor was shown in two differentiation systems, both involve the 
generation of hESC-ECs, and closely related hematopoietic cells. Therefore, it 
would be beneficial to investigate the presence of these progenitors in other 
mesodermal differentiation systems, such as during the generation of 
cardiomyocytes from hPSCs, these cells could also be isolated and their ability to 
generate cells of different lineages assessed (discussed in more detail in section 
3.4). Furthermore, on average the percentages of CD326lowCD56+ cells, present 
on d3 of indirect hESC-EC differentiation, are higher than those observed in the 
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direct system, making it easier to study these cells, and mechanisms involved in 
their formation, within this differentiation system. 
Optimisation and characterisation of this protocol, along with the identification 
of the CD326lowCD56+ MP, will allow for analysis and elucidation of possible 
mechanisms, including signalling molecules and non-coding RNAs, with roles in 
endothelial lineage commitment. Mechanisms identified from in depth analysis 
of the direct hESC-EC differentiation protocol can be validated in this, distinct, 
differentiation system. This will allow for distinguishing of mechanisms involved 
in specific endothelial lineage commitment, mesodermal commitment or those 
involved generally in loss of pluripotency and differentiation.  
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during hESC-EC differentiation   
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5.1 Introduction 
The discovery of numerous classes of non-coding RNAs has challenged the 
traditional central dogmas of molecular biology, introducing new levels of cell-
type specific gene regulation. As previously stated, a variety of these non-coding 
RNAs, including miRNAs and lncRNAs, have been implicated in the differentiation 
and commitment of pluripotent cells to a variety of lineages, as well as in 
regulation and maintenance of pluripotency. Specifically, a number of 
publications have identified miRNAs and lncRNAs playing important roles in 
differentiation and commitment to the endothelial lineage (Hassel et al., 2012, 
Kane et al., 2012, Klattenhoff et al., 2013, Kurian et al., 2015).  
Currently there are 1881 human miRNA stem loop sequences recorded on 
miRBase, an online database of published miRNA sequences and annotation 
(Kozomara et al., 2014), with each of these stem loops giving rise to two 
individual mature miRNAs, the -5p and -3p strands.  Although highly sensitive for 
quantitative profiling of individual mRNA and miRNAs, qRT-PCR methods are low-
throughput, and so cannot be used to investigate genome-wide miRNA profiles. 
Therefore, in order to gain unbiased and global analysis of miRNA expression, 
studies have employed the use of large scale microarray screens (Liu et al., 
2004, Thomson et al., 2004, Liu et al., 2008). This technology involves the use of 
40-60-mer oligonucleotide probes, synthesised to target specific mature miRNA 
sequences. Briefly, miRNAs, contained within the RNA sample, are labelled with 
fluorescent tag. These miRNAs are then allowed to hybridise to the 
aforementioned oligonucleotide probes, which are bound to an array surface. 
Arrays are washed to remove unbound RNA, and fluorescence is then read using 
specialised microarray scanners. Frequently, the array surface is known as a 
‘chip’ or ‘slide’, and each one can run multiple samples simultaneously, 
therefore, allowing for high-throughput screening of large numbers of samples. 
To date, vast numbers of studies using this technology have been published, with 
applications ranging from analysing specific miRNA expression signatures in a 
range of tissue types (Liu et al., 2004), to monitoring changes which occur during 
the onset and development of various disease states, including cardiovascular 
disease and cancer (Lu et al., 2005, Chen et al., 2008a, Fichtlscherer et al., 
2010). 
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Indeed, numerous studies have also utilised microarray technology to identify 
miRNAs with potential roles in the commitment and differentiation of hPSCs to 
ECs (Yoo et al., 2011b, Kane et al., 2012, Luo et al., 2013, Yoo et al., 2013). 
Initially, this method of genome-wide profiling was used to demonstrate possible 
roles for miR-181a, -181b and -99b in a fully-defined monolayer hESC-EC 
differentiation system (Kane et al., 2012). In this study, Kane and colleagues 
demonstrated that the expression levels of these three miRNAs were increased 
in a differentiation-dependent manner. Additionally, it was also shown that 
lentiviral-mediated overexpression of miR-181a, -181b, -99b or all three miRNAs 
in combination, increased the efficiency of hESC-EC differentiation. Despite this, 
however, the authors did not describe any mRNA targets, or mechanisms of 
action for these miRNAs. Therefore, there is no conclusive evidence to suggest 
that upregulation of miR-181a, -181b and -99b is due to specific roles for these 
miRNAs in hESC-EC differentiation, and not just as a consequence of the 
development of an EC phenotype.  
More recently, microarray technology was used to identify two other mature 
miRNAs with possible roles in commitment of hPSCs to the endothelial lineage; 
miR-150 and miR-200c (Luo et al., 2013). In this study, samples were taken at 
days 0, 3, 6 and 9 during hESC-EC differentiation, and subjected to analysis by 
microarray, whereby it was discovered that miR-150 and -200c were significantly 
upregulated during hESC-EC differentiation. Modulation of these miRNAs showed 
that inhibition and overexpression causing significant decreases and increases in 
EC-associated genes, respectively. Further investigation allowed Luo to 
demonstrate that these miRNAs exerted their effects through their common 
target, ZEB1. In addition to identification of novel miRNAs, Luo et al. also used 
the microarray screen to demonstrate hESC-EC differentiation-dependent 
increases in previously published angiogenic and endothelial-associated miRNAs, 
as well as significant decreases in the pluripotency-associated miR-302 family. 
These studies demonstrate how miRNA technology can be used effectively to 
identify potential miRNAs of interest, via the profiling of samples taken from 
different time points. However, both of the aforementioned studies have 
focused on miRNA which may drive the production of ECs from hPSCs, and 
neither focused on early mesodermal differentiation. As published data suggest 
an integral role for miRNAs during development, it was hypothesised that 
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miRNAs are heavily involved in the specification of pluripotent cells to specific 
germ layers. Using the previously defined CD326lowCD56+ MP population, 
appearing on d3 of hESC-EC differentiation, the presented study aimed to 
identify and characterise miRNAs involved in early mesodermal and endothelial 
commitment. 
5.2 Aims 
The aims of this chapter were as follows: 
 To profile miRNAs differentially regulated during direct hESC-EC 
differentiation. 
 Validation of chosen miRNAs in both direct and indirect hESC-EC 
differentiation. 
 Create and optimise lentiviral vectors for the overexpression of miRNAs. 
 To modulate the expression of these miRNA using lentiviral vectors, 
during hESC-EC differentiation and in pluripotent cells.  
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5.3 miRNA microarray screen 
Microarray analysis was performed in conjunction with Sistemic Ltd. (West of 
Scotland Science Park, Glasgow, UK), using the Agilent SurePrint Human miRNA 
Microarray platform. SurePrint G3 Human v16 miRNA 8x60K microarray slides 
were used, with each slide containing 8 individual arrays. These slides contain 
60-mer Agilent SurePrint synthesised probes for 1,199 human miRNAs, with 
sequence data sourced from the miRBase public database (Kozomara et al., 
2014). Samples were prepared and analysed on the array as described in section 
2.5.4. 
5.3.1 Normalisation and Data Analysis 
Data collected from the array was then normalised using the AgiMicroRNA 
method (Lopez-Romero, 2011). Analysis was performed using R statistical 
analysis software (htps://www.R-project.org) and Sistemic Ltd. proprietary 
algorithms.  
Statistical significance was calculated using paired Student’s t-tests to compare 
specific groups. miRNAs were considered to be significantly changed if the 
calculated fold change was greater than or equal to 1.5, with a False Discovery 
Rate (FDR) of less than 0.05. 
5.3.2 Experimental Design 
In order to profile miRNAs differentially regulated during hESC-EC differentiation 
total RNA was taken from cells harvested at d0 H9 hESCs, d3 FACSorted 
CD326lowCD56+ MPs, d3 non-CD326lowCD56+ NCF cells and d7 samples containing 
hESC-ECs (Figure 5.1). The experiment was designed to document significant 
changes in miRNAs occurring at these specific time points during hESC-EC 
differentiation, in order to identify miRNAs with roles in commitment of cells to 
mesodermal (d3) and endothelial (d7) lineages. RNA from these 4 sample groups 
were collected from 4 separate hESC-EC differentiation experiments, with 
differentiations performed on cells from consecutive passages of H9 hESCs. All 4 
of these experimental replicates were then analysed. To collect d3 samples, 
cells were FACSorted to collect two different fractions; CD326lowCD56+ MPs and 
the non-CD326lowCD56+ NCF. 8 plates of EBs (approximately 768 individual EBs) 
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were pooled to ensure sufficient material for high quality RNA preparation, with 
samples containing less than 1x106 cells after FACSorting not used in the screen. 
Additionally, d3 heterogeneous samples, taken before FACSorting, were taken 
from the same experiment, although this was not run on the array and only used 
during Taqman® qRT-PCR of identified miRNAs.  
 
Figure 5.1 – miRNA microarray experimental design. 
An n=4 samples were collected from 4 different H9 hESC-EC differentiation experiments. Total 
RNA was collected from pluripotent d0 H9 hESCs, d3 CD326
low
CD56
+
 MPs, d3 non-
CD326
low
CD56
+
 NCF and d7 cells. 
Briefly, comparisons of data were made between all groups (d3 MPs, d3 NCFs 
and d7) and d0 H9 hESCs, in order to identify miRNAs significantly changed 
throughout the course of hESC-EC differentiation. miRNAs identified to be 
significantly up- or downregulated during differentiation may play important 
roles in the regulation of proteins and factors involved in the commitment of 
cells to an EC phenotype. Moreover, using these comparisons expression of 
previously published and characterised miRNAs, such as the pluripotency-
associated miR-302 family and endothelial-associated miR-126 and miR-10a, may 
be investigated and validated within the presented direct hESC-EC 
differentiation system. 
Additionally, comparisons were made between the two d3 sample groups, 
profiling changes in miRNA expression between the CD326lowCD56+ MPs, a 
population committed to the mesoderm and possibly endothelial lineages, and 
the NCF samples, suggested to contain a number of other populations, including 
mesendodermal and endodermal progenitors. It was hypothesised that miRNAs 
with large differences in expression levels between these two groups may play 
specific roles in mesodermal and endothelial lineage commitment.  
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Figure 5.2 – Schematic of comparisons performed 
Comparisons between groups are represented by arrows in the above schematic.  
5.3.3 Quality control 
5.3.3.1 RNA Quality control 
For the collection of high quality results from the microarray screen, RNA quality 
was tested to ensure it was of sufficiently high quality. As stated previously, only 
samples with an RNA integrity number or RIN >7 were used for further analysis. 
RIN values range between 1 and 10, with a RIN of 10 signifying high quality RNA. 
This was assessed by running samples on the Agilent 2200 Tapestation as 
described in section 2.5.4. Agilent analysis also produced electrophoresis plots 
or a ‘virtual gel’ (Figure 5.3, Table 5.1) and electropherograms (Figure 5.4) for 
each sample.  Electropherograms for each sample show distinct peaks 
representing 18S and 28S ribosomal RNA (rRNA), indicative of high quality RNA, 
these two bands are also visible in Figure 5.3. All RNA samples used in this study 
achieved a RIN value of >9, with 6 samples obtaining RINs of 10 (Figure 5.3, 
Table 5.1). 
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Figure 5.3 – Agilent Tapestation analysis of RNA quality. 
Electrophoresis plots for all 16 samples with corresponding RIN values shown below. Arrows 
indicate 18S and 28S rRNA bands. Sample labels are shown across the top, with corresponding 
sample names shown in Table 5.1. 
 
Sample Name Gel Label 
d0 n=1 A1 
d0 n=2 B1 
d0 n=3 C1 
d0 n=4 D1 
d3 CD326lowCD56+ MP n=1 E1 
d3 CD326lowCD56+ MP n=2 F1 
d3 CD326lowCD56+ MP n=3 G1 
d3 CD326lowCD56+ MP n=4 H1 
d3 non-CD326lowCD56+ NCF n=1 A2 
d3 non-CD326lowCD56+ NCF n=2 B2 
d3 non-CD326lowCD56+ NCF n=3 C2 
d3 non-CD326lowCD56+ NCF n=4 D2 
d7 n=1 E2 
d7 n=2 F2 
d7 n=3 G2 
d7 n=4 H2 
Table 5.1 – Array samples and corresponding Tapestation gel labels. 
Labels correspond to those shown in Figure 5.3. 
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Figure 5.4 – Typical Tapestation electropherogram. 
A representative electropherogram generated by samples when analysed using the Agilent 2200 
Tapestation system. Blue lines indicate (from left to right) the lower marker and the 18S and 28S 
rRNAs, used for RIN value calculation. Trace shown is for d0 2 sample (B1 in Figure 5.3). 
 
5.3.4 Differentiation Quality Control 
hESC-EC differentiation samples to be run on the array were also subjected to 
analysis by flow cytometry to ensure successful differentiations. D0 H9 hESCs, d3 
heterogeneous EBs and d7 cells were harvested and stained to look at 
percentages MP (CD326lowCD56+) endothelial (CD31+CD144+) , and pluripotent 
(Tra1-60+SSEA3+) cells at each of these time points (Figure 5.5). 
Levels of CD326lowCD56+ MP cells were found to be low in d0 pluripotent cells, 
before increasing significantly to approximately 60% in the d3 heterogeneous EB 
samples (Figure 5.5A). Additionally, by d7 the percentage of cells with this 
surface marker profile had decreased to <20%. This demonstrates a peak in MP 
cell numbers at d3 of hESC-EC differentiation, hypothesised to be the point at 
which cells have committed to mesoderm, in line with previous data (Chapter 3).  
To measure differentiation efficiencies, the levels of CD31+CD144+ hESC-ECs and 
Tra1-60+SSEA3+ pluripotent cells were measured at these same time points. As 
demonstrated previously, a significant increase CD31+CD144+ expressing cells, 
coupled with a significant decrease in the numbers of cells expressing Tra1-60 
and SSEA3, was observed throughout direct hESC-EC differentiation (Figure 5.5B-
C). The lowest levels of Tra1-60+SSEA3+ cells were observed in d7 samples, 
where on average <5% of cells stained for these two markers, similar to previous 
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results (Chapter 3). D7 samples also contained the highest percentages of 
CD31+CD144+ hESC-ECs (Figure 5.5B). The percentages of CD31+CD144+ hESC-ECs 
obtained during these 4 differentiations (approximately 15%) was lower than had 
been previously observed (Chapter 3) and ideally differentiations would have 
been repeated to obtain samples with a higher CD31+CD144+ hESC-EC content. 
Due to time and financial constraints, specifically involved in the FACSorting of 
d3 cells, however, miRNA microarray analysis proceeded using these samples. 
Taken together, this data demonstrates that hESC-EC differentiations, from 
which samples were collected for miRNA microarray analysis, were successful. 
Changes in cell surface marker expression were similar to those seen during 
characterisation of the protocol (Chapter 3). Corresponding RNA samples were 
subsequently processed for use during the microarray screen as described in 
section 2.5.1.  
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Figure 5.5 – Flow cytometric analysis of hESC-EC differentiation samples used in 
microarray screen. 
D0 pluripotent H9 hESCs, heterogeneous d3 (taken before FACSorting) and d7 cells were also 
harvested and subject to analysis by flow cytometry to examine Tra1-60
+
SSEA3
+
, CD326
low
CD56
+
 
and CD31
+
CD144
+
 populations. N=4 experiments. Statistical significance was calculated using a 
repeated measures ANOVA, with Tukey’s post hoc comparisons. *** = p<0.001 vs d0 H9 hESCs, 
and ## = p<0.01, ### = p<0.001 when compared to d3 heterogeneous samples. 
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5.3.4.1 FACSorting 
Fluorescence activated cell sorting (FACS) was performed using samples 
collected on d3 of direct hESC-EC differentiation. CD326lowCD56+ MPs were 
isolated from heterogeneous samples and the remaining cells, hereby known as 
NCF, were also collected. After sorting, small samples of collected cells were 
run back through the machine, ensuring purification of cells was successful 
(Figure 5.6). The purity of cells after sorting was high, with >95% CD326lowCD56+ 
in sorted samples, compared to approximately 65% in d3 heterogeneous samples 
(Figure 5.6 left and centre panels). Additionally, <1% of cells in the NCF samples 
were CD326lowCD56+, with the majority of cells in this fraction having retained 
the CD326highCD56- profile, previously demonstrated to be associated with hESCs 
(Evseenko et al., 2010). Dot plots obtained from samples are shown in Figure 
5.6. 
Once obtained samples were lysed using QIAzol lysis reagent and processed for 
analysis as described in sections 2.5.1 and 5.3.3.1. 
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Figure 5.6 – FACSorting of d3 CD326
low
CD56
+
 MP cells for miRNA microarray. 
Dot plots showing staining of CD326 and CD56 in d3 samples before and after FACSorting. Left 
panel shows staining in heterogeneous samples, centre panel shows staining in cells collected in 
the CD326
low
CD56
+
 fraction during FACS, and the far right panel shows staining in the NCF after 
FACS. Circular gate labelled ‘CD326lowCD56+’ indicates CD326
low
CD56
+
 MP population in that 
specific sample group, with the associated number showing percentage of total cells located within 
the gate. Numbers on left hand side indicate experimental n number.  
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5.4 Results 
5.4.1 miRNA profiling – array 
5.4.1.1 Principle component analysis 
Principle component analysis (PCA) is a mathematical model which performs 
linear transformations on variables within a data set to produce variables known 
as principle components (PC). Performing this analysis allows for identification 
of patterns within a data set, highlighting global similarities and differences 
between specific samples and sample groups. This, in turn, allows for the 
plotting of multidimensional PCA maps, an analytical tool used for visualisation 
of these identified similarities and differences. PCA maps for data sets are 
shown in Figure 5.7. 
Here, it was demonstrated that the 4 samples from each of the 4 individual 
groups (d0 H9 hESCs, d3 CD326lowCD56+ MPs, d3 NCFs and d7 hESC-ECs) cluster 
together and separately from the other groups (Figure 5.7A), suggesting 
differences in overall miRNA expression profiles between all groups. The 
pluripotent d0 H9 hESCs cluster very tightly together, on the left hand side of 
the map, away from the other 3 groups (Figure 5.7A, red dots). This further 
validates previous suggestions, made during differentiation characterisation 
(Chapter 3), that cells rapidly lose their pluripotent phenotype during hESC-EC 
differentiation. D7 samples, containing the CD31+CD144+ hESC-ECs, also 
clustered quite tightly together, away from all other samples (Figure 5.7A, light 
blue data points). Again, this suggested that these cells have a distinct miRNA 
profile, with large differences when compared to the other sample groups. In 
particular, these cells have lost all pluripotency and committed specifically to 
the endothelial lineage, apparent on the PCA map due to the clustering of the 
d7 samples furthest away from the d0 pluripotent cells.  
Both d3 samples (CD326lowCD56+ MPs and NCF), however, clustered relatively 
close together when viewed on the PCA map, although individual samples from 
the groups clustered together (Figure 5.7A, royal blue and green data points). 
This indicated that, while distinct from d0 and d7 samples, these samples may 
share a number of similarities in their miRNA expression profile. An additional 
PCA was also performed just using the two d3 CD326lowCD56+ MP and NCF  
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Figure 5.7 – Principle component analysis. 
Data collected from the Agilent SurePrint miRNA microarray were subjected to PCA. Each dot 
represents one sample, with colours showing different groups. Groups are as follows: 1/Red – d0 
H9 hESCs, 2/Green – d3 CD326
low
CD56
+
 MPs, 3/Royal blue – d3 NCF, 4/Light blue – d7. Top 
panel (A) shows PCA performed including all 16 samples, bottom panel (B) shows analysis of only 
d3 CD326
low
CD56
+
 MP and d3 NCF samples.  
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samples (Figure 5.7B). Using this map, the clustering of samples from these 
groups was clearly separate, although it is still clear that there is some level of 
similarity between the two. As described previously (Chapter 3), data has 
suggested that both of these groups contain multipotent progenitor populations, 
with the CD326lowCD56+ fraction containing mesodermal and possible EC 
progenitors, and the NCF possibly containing a mix of mesodermal, endoderm 
and mesendodermal progenitors, which may explain the close clustering of these 
two groups. Furthermore, the close spacing of these groups on the PCA map also 
suggested that there would only be a small number of differentially expressed 
miRNAs between these two sample groups. It could be hypothesised, therefore, 
that any miRNA whose expression is significantly different between these two d3 
sample groups may play an important role in lineage specification, specifically to 
the mesoderm and subsequently to the endothelium. 
5.4.1.2 Pluripotency-associated miRNAs 
After global analysis and comparisons of sample groups, groups of previously 
characterised miRNAs were examined to assess their expression within the direct 
hESC-EC differentiation system. Initially, the expression of pluripotency-
associated miRNAs was analysed. Consisting of 10 individual highly homologous 
mature miRNAs (including -3p and -5p strands from 5 different miRNA stem 
loops), it has been well documented that miRs from the miR-302 cluster are 
expressed at high levels in hESCs, with specific roles in the maintenance or 
pluripotency and control of cell cycle (Houbaviy et al., 2003, Card et al., 2008, 
Rosa et al., 2011, Zhang et al., 2015), discussed in more detail in section 1.8.1. 
The ‘lead’ strands of all 5 miRNAs in this cluster (miR-302a-3p, -302b-3p, -302c-
3p, -302d-3p and -367-3p) were detected in all samples run on the miRNA 
microarray screen (Figure 5.8). All 5 were significantly downregulated in the d7 
hESC-EC samples, and expressed at lower levels in d3 CD326lowCD56+ MPs than in 
the NCF samples. These results were subsequently verified using Taqman® qRT-
PCR (Figure 5.9). Due to the similar expression profiles of all miR-302 cluster 
miRNAs in the microarray screen, only miR-302a (Figure 5.9A) and -302b (Figure 
5.9B) were validated using this method. Both of these miRNAs were significantly 
downregulated in heterogeneous and CD326lowCD56+ MP d3 samples, but not in  
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Figure 5.8 – Microarray analysis of pluripotency-associated miRNAs. 
Previously published pluripotency-associated miRNA profiles were assessed using data from the 
miRNA microarray. Specifically, miRNAs from the miR-302 family were analysed; miR-302a (A), -
302b (B), -302c (C), -302d (D) and miR-367 (E), with the -3p strands of all of these miRNAs 
previously defined as the ‘lead’ strand. Each individual data point in the dot plots represent the 
value obtained from 1 sample on the microarray, with values plotted as normalised intensities, 
determined as described in section 5.3.1. Bars represent the mean for each sample group. n=4 
samples.  
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Figure 5.9 – qRT-PCR validation of pluripotent-associated miRNA. 
After analysis by miRNA microarray, samples were subject to analysisby Taqman® qRT-PCR to 
validate findings. Total RNA from d0 hESCs, heterogeneous and FACSorted samples from d3, and 
heterogeneous and MACSorted samples from d7 was analysed for expression of 2 miRNAs from 
the miR-302 family; miR-302a and -302b. Histograms show RQ ± RQ Max, calculated against 
RNU48 reference RNA. Significance calculated using a repeated measures ANOVA with Tukey 
post hoc comparison; * = p<0.05, ** = p<0.01, *** = p<0.001 vs. d0 pluripotent control. n/s = non-
significant, MP = CD326
low
CD56
+
 mesoderm progenitor, NCF = negative cell fraction. n=4. 
the NCF. This is in line with previous data (Chapter 3), showing pluripotency-
associated genes, such as Nanog and Oct4, are downregulated to significantly 
lower levels in the CD326lowCD56+  MP cells than in the NCF. Taken together, 
these data support the hypothesis that these MP cells have lost their 
pluripotency, and have, or are beginning to, commit toward the mesoderm, or 
possibly an even more mature cell phenotype.  Additionally, these miRNAs were 
even further downregulated by d7 of hESC-EC differentiation (Figure 5.9). Total 
RNA was also collect from MACSorted CD144+ and CD144- d7 hESC-ECs, and miR-
302a was expressed at significantly lower levels in CD144+ cells than in CD144-, 
although the expression levels in both sample groups was still significantly 
downregulated when compared to d0 pluripotent hESCs. This may suggest that, 
although cells in both sample groups have lost pluripotency, the CD144+ cells 
have already begun to develop a more mature EC phenotype. 
Downregulation of miR-302a (Figure 5.10A) and -302b (Figure 5.10B) was also 
observed during indirect hESC-EC differentiation, when total RNA samples were 
analysed using Taqman® qRT-PCR. Although a significant reduction in expression 
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was observed for both miRNAs in all d7 and d10 samples, including d7+3 hESC-
ECs, downregulation occurred more slowly in this differentiation system (Figure 
5.10). No significant downregulation was observed by d3 of indirect hESC-EC 
differentiation, though only heterogeneous d3 samples were analysed. Isolation 
of CD326lowCD56+ MP cells may have revealed a significant downregulation in 
these two miRNAs, in concurrence with observations in the direct hESC-EC 
system. Taken alongside previous gene expression data, this confirms the loss of 
pluripotency in cells during both indirect and direct hESC-EC differentiation.   
 
Figure 5.10 – Expression of miR-302a and -302b during indirect hESC-EC differentiation. 
The expression of miR-302a (A) and -302b (B) were also profiled during indirect hESC-EC 
differentiation. Total RNA was collected from d0 H1 hESCs, heterogeneous d3 samples, 
suspension and adherent samples at d7 and 10, and d7+3 hESC-ECs, and analysed using qRT-
PCR. Histograms show RQ ± RQ Max, relative to RNU48 reference RNA. Repeated measures 
ANOVA with Tukey post hoc comparisons used to calculate significance, *** = p<0.001 vs. d0 
hESCs. n=4. 
5.4.1.3 Endothelial-associated miRNAs 
In addition to those associated with pluripotent cells, the expression profiles of 
miRNAs previously identified to have a role in EC function and phenotype were 
also analysed using data collected from the microarray screen. Lead strands of 
miR-126 (Figure 5.11A) and miR-10a (Figure 5.11B) were found to be significantly 
upregulated in the d7 hESC-EC samples. Both of these miRNAs have been shown 
to play roles in the regulation of angiogenesis and EC function, and are 
upregulated during differentiation of PSCs to ECs (Kane et al., 2010, Hassel et 
al., 2012).  
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Figure 5.11 – Profile of endothelial-associated miRNAs during direct hESC-EC differentiation. 
miRNAs previously identified to play a role in EC function and development were analysed using microarray (A-B) and qRT-PCR (C-D) analysis. N=4 H9 direct hESC-
EC differentiation samples were analysed to profile the expression of miR-126 (A and C) and miR-10a (B and D). Dot plots (A-B) show normalised intensity values for 4 
individual samples run on miRNA microarray screen, with the line representing the mean value. Histograms (C-D) show RQ ± RQ Max calculated using RNU 48 
reference gene. Repeated measures ANOVA with Tukey post hoc comparisons used to calculate significance; *** = p<0.001 vs. d0 pluripotent control. MP = 
CD326
low
CD56
+
 mesoderm progenitor, NCF = negative cell fraction. 
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Additionally, both of these miRNAs were observed to be expressed at higher 
levels in the CD326lowCD56+ MPs than in the NCF samples, showing a similar 
expression pattern to EC-associated genes such as CD31 and CD144 (Chapter 3). 
This, therefore, supports the previously stated hypothesis that the MP cells have 
already started to commit toward an EC phenotype, losing their multipotency 
and, therefore, their ability to differentiate into any mesodermal cell type, 
although further experiments would be needed to confirm this.  
These data were, once again, verified using qRT-PCR. Using this method of 
miRNA profiling, miR-126 was only significantly upregulated by d7 of hESC-EC 
differentiation, when cells begin to acquire a more mature EC phenotype, and 
not in any of the d3 samples. Like miR-302a and b, the expression of these 
miRNAs was also examined in total RNA samples obtained from MACSorted 
CD144+ and CD144- d7 cells from direct hESC-EC differentiation. Interestingly, 
miR-126 was expressed at significantly higher levels (approximately 300-fold 
increase compared to pluripotent hESCs) in CD144+ hESC-ECs when compared to 
CD144- d7 cells (approximately 30-fold increase compared to d0 pluripotent 
hESCs). This further validates claims that the CD31+CD144+ cells are committed 
toward an EC fate.  
The expression profile of miR-10a was different from that of miR-126. Overall, 
miR-10a was shown to be upregulated throughout hESC-EC differentiation. 
Additionally, a significant upregulation was observed in all d3 samples, 
heterogeneous, CD326lowCD56+ MPs and NCF (approximately 5000, 8000 and 
1500-fold upregulation in each of these samples, respectively) when compared 
to d0 hESCs. Although not significantly different from d3 NCF samples, the 
highest levels of miR-10a upregulation were seen in the MPs, consistent with the 
hypothesis that, even at this early stage in differentiation, MPs have already 
started to gain an EC phenotype. At d7, although there was no significant 
difference between heterogeneous, CD144+ and CD144- hESC-ECs, the highest 
level of expression was recorded in the heterogeneous samples (Figure 5.11D). 
Surprisingly, the lowest levels of miR-10a were observed in the d7 CD144+ cells, 
in contrast to data shown by Hassel et al., who demonstrated that miR-10a was 
significantly enriched in CD144+CD309+ cells derived from mESCs (Hassel et al., 
2012). This may be due to large amounts of variation in expression between 
experimental replicates, or it may be a species difference. Alternatively, 
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however, the pattern of miR-10a expression observed here may suggest a role 
for this miRNA in endothelial commitment, and the formation of endothelial 
precursors.  
 
Figure 5.12 – miR-126 and -10a during indirect hESC-EC differentiation. 
The endothelial-associated miR-126 (A) and miR-10a (B) were profiled in RNA samples from 
indirect H1 hESC-EC differentiation. Histograms show RQ ± RQ Max calculated relative to the 
RNU48 reference RNA. Repeated measures ANOVA with Tukey’s post hoc comparisons was used 
to calculate significance; * = p<0.05 ** = p<0.01, *** = p<0.001 vs d0 hESCs unless comparisons 
specified. Samples from n=4 differentiation experiments.  
In the indirect hESC-EC differentiation system, both endothelial-associated 
miRNAs, miR-126 (Figure 5.12A) and miR-10a (Figure 5.12B), were shown to be 
significantly upregulated throughout differentiation, with the highest levels of 
expression observed by d10. Similarly to the direct hESC-EC differentiation 
system, miR-126 was not detected at d3, whereas miR-10a was shown to be 
significantly upregulated even at this early time point. Taken together with 
previous data, and that published by Hassel and colleagues (Hassel et al., 2012), 
it could be suggested that miR-10a plays a role in early EC development, 
whereas miR-126 is more important in mature EC function.  
Both miR-126 and miR-10a were expressed at higher levels in the adherent cells 
than in suspension cells, with significant differences in miR-126 at d7 and d10 
(Figure 5.12A) and in miR-10a in d10 samples (Figure 5.12B). Furthermore, the 
highest levels of expression for both miRNAs were observed in d7+3 hESC-ECs 
(Figure 5.12), strengthening data showing that these cells have developed a 
more mature EC phenotype than the d7 HE cells (Chapter 4).  
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5.4.1.4 EC differentiation associated miRNAs 
As stated previously, a number of miRNAs have also been implicated in hESC-EC 
differentiation. Data collected from the miRNA microarray screen was then used 
to examine the expression of these miRNAs within the presented direct hESC-EC 
differentiation system. Previously, Kane et al. had demonstrated the 
upregulation of 3 different miRNAs, miR-181a, -181b and -99b, during generation 
of hESC-ECs using a 21 day monolayer differentiation protocol (Kane et al., 
2012). Within the direct hESC-EC differentiation system, these 3 miRNAs were 
significantly upregulated, with the highest level of expression occurring on d7, 
alongside the appearance of CD31+CD144+ hESC-ECs (Figure 5.13). The lead 
strands of miR-181a (Figure 5.13A) and miR-181b (Figure 5.13B) were shown to 
have the same expression profile, as well as similar levels of expression, during 
direct hESC-EC differentiation. Both members of the miR-181 family, these 
miRNAs are highly homologous, and are transcribed as one, poly-cistronic 
transcript from two different alleles within the genome and, therefore, it is not 
unexpected that this is the case. High homology between miRNAs suggests 
shared mRNA targets and, therefore, implicates these miRNAs in similar cellular 
pathways.  
miR-99b, however, is not a member of the miR-181 family, and exhibits a 
different expression pattern when profiled during direct hESC-EC differentiation. 
Unlike the other EC-associated miRNAs, miR-99b was undetected in all 4 samples 
from the d0 pluripotent hESC, d3 CD326lowCD56+ MP and d3 NCF groups, before 
being significantly upregulated at d7 (Figure 5.13C).  
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Figure 5.13 – Expression miR-181a, -181b and 99b 
miR-181a (A), -181b (B) and -99b (C) were previously described to play a role in hESC-EC 
differentiation by Kane et al. (2012). Expression profiles of these miRNAs were then examined 
using data obtained from the microarray screen. The -5p strand of all of these miRNAs has been 
previously defined as the ‘lead’ strand. Each individual data point in the dot plots represent the 
value obtained from 1 sample on the microarray, with values plotted as normalised intensities, 
determined as described in section 5.3.1. n=4 samples.  
Unlike miR-126 and miR-10a, none of the miRNAs described by Kane and 
colleagues were upregulated in d3 CD326lowCD56+ MPs, when compared to NCF 
samples (Figure 5.11 and Figure 5.13). In fact, miR-181a and -181b were 
expressed at higher levels in the NCF samples and miR-99b, as previously stated, 
as undetected in all samples until d7. Collectively, this suggests that these three 
miRNAs may not be essential for EC commitment and differentiation. Instead, 
upregulation is merely correlates with EC commitment and the appearance of 
hESC-ECs, with these miRNAs playing roles in mature EC function and 
angiogenesis. Indeed, a recent publication has demonstrated a role for both miR-
181a and -99b in the regulation of mRNAs associated with hypertension in human 
microvascular ECs (Kriegel et al., 2015), and miR-181b has been previously 
shown to be involved in the regulation of NF-κB signalling in the vascular 
endothelium (Sun et al., 2012). 
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In 2013, Luo and colleagues also used a microarray screen to identify potential 
miRNA candidates involved in EC differentiation (Luo et al., 2013). Using this 
technology and a variety of follow-up experiments, Luo demonstrated the 
involvement of miR-150 and miR-200c in EC differentiation from hESCs, through 
their shared target ZEB1. When profiled in the presented direct hESC-EC 
differentiation system, however, the expression pattern of these miRNAs did not 
match this previously published data. In contrast, neither the lead nor passenger 
(-5p and -3p, respectively) strand of miR-150 was detected in any of the samples 
analysed using the microarray screen. Additionally, the lead strand of miR-200c 
was shown to be expressed at lower levels in all 4 samples from the d3 
CD326lowCD56+ MP and d7 groups, than in d0 pluripotent hESC and d3 NCF 
samples (Figure 5.14).  
 
Figure 5.14 – miR-200c expression during direct hESC-EC differentiation. 
Luo et al. (2013) previously described the involvement of miR-200c in the differentiation of hESCs 
to ECs. The expression profile of this miRNA was, therefore, analysed in the direct hESC-EC 
differentiation using data collected from the microarray screen. Each individual data point in the dot 
plots represent the value obtained from 1 sample on the microarray, with values plotted as 
normalised intensities, determined as described in section 5.3.1. d7 hESC-EC samples are total 
RNA collected from all cells present on d7 of direct hESC-EC differentiation. n=4 samples. 
5.4.1.5 Other notable mesoderm-associated miRNAs 
Due to the unbiased and global nature of microarray technology, data for other, 
previously characterised, groups of miRNAs was collected. Specifically, the 
expression levels of miRNAs, identified to play roles in the differentiation and 
function of other mesodermal cell types such as cardiomyocytes, skeletal muscle 
and hematopoietic cells, were assessed. Data collected from TLDA cards (shown 
in Chapter 3) showed higher expression of genes associated with other 
mesodermal cell types, such as NKX2.5, in the d3 MP cells when compared with 
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NCF samples. It was, therefore, hypothesised that miRNAs associated with other 
cells of the mesoderm would be expressed in a similar way. 
Existing as a cluster within the genome, miR-1 and miR-133 are transcribed 
together and have been widely shown to be specifically expressed in the skeletal 
and cardiac muscle (Zhao et al., 2005). miR-1 has specifically been implicated in 
heart development, playing roles in cardiogenesis and cardiac cell fate 
decisions, with miR-133 involved in the specification of cells to skeletal muscle 
(Ivey et al., 2008). Previously (chapter 3), it was shown that genes associated 
with cardiac development, such as NKX2.5, were significantly upregulated in d3 
MP cells, when compared to the NCF samples (Table 3.1). Therefore, the 
expression of these cardiac-associated miRNAs was assessed. Data from the 
microarray screen recorded no expression of either miR-1 or miR-133 in samples 
from any time point (d0, d3 MP, d3 NCF or d7 hESC-ECs). Interestingly, this is in 
contrast to previously published data, showing the miR-1 and miR-133 promote 
mesoderm formation from human and mouse ESCs, and prevent the induction of 
endo- and ectodermal lineage specification (Ivey et al., 2008). Coupled with 
previous gene and miRNA expression data, this supports the hypothesis that d3 
CD326lowCD56+ MP cells, even at this early stage, may already be committed 
toward and EC phenotype, possibly due to the specialised culture conditions. 
This, therefore, explains the absence of miRNAs from other mesodermal 
lineages, as downregulation and degradation may have already occurred at this 
early stage in EC commitment.  Furthermore, Ivey et al. used an undefined hESC 
differentiation protocol to induce the formation of mesoderm and cardiac 
lineages. As stated previously, the use of undefined reagents within hESC 
differentiation protocols introduces unknown factors into systems. Induction of 
miR-1 and miR-133 may be more specific to later cardiac and skeletal muscle 
specification, with early expression induced in this undefined system due to 
stimulation by one of these unknown factors and, therefore, explaining why 
these miRNAs are undetectable in samples from the presented defined hESC-EC 
differentiation.  
Additionally, miR-451a, a miRNA associated with erythropoiesis in vivo (Dore et 
al., 2008, Patrick et al., 2010), was only detected in one d7 sample, out of all of 
those run on the array.  Dore and colleagues demonstrated an upregulation of 
miR-451 during induction of erythroid maturation of human CD34+ cells and 
213 
 
 
murine erythroleukemia cells, as well as being expressed in mouse blood (Dore 
et al., 2008). The miR-451 transcript is bi-cistronic, and also codes for miR-144, 
additionally shown by Dore to be upregulated during eythroid maturation. 
Similarly, miR-144 was not detected in any of the 16 samples analysed in the 
microarray screen. As these miRNAs are associated with erythropoiesis, a process 
occurring later in lineage and cell type specification, it would not be expected 
to detect either miR-144 or miR-451 in these samples. Instead, these results 
demonstrate that the developed direct hESC-EC differentiation pathway is 
completely independent from the indirect pathway, with no upregulation of 
common hematopoietic-associated miRNAs.  
5.4.1.6 Pairwise comparisons to identify novel miRNAs 
In order to identify novel miRNAs, which may play a role in early mesodermal 
and endothelial commitment and specification of hESCs during hESC-EC 
differentiation, analysis focused on miRNAs differentially expressed between d3 
CD326lowCD56+ MPs and d3 NCF samples. As described previously (section 5.3.1), 
a paired T-test was performed to make a direct comparison between these 
groups. Only miRNAs with a fold change (FC) >1.5 and a false discovery rate 
(FDR) <0.05 were deemed to be differentially expressed, with fold changes 
generated for d3 CD326lowCD56+ MPs, relative to d3 NCF samples. 
Direction of expression 
change (vs d3 NCF) 
Number of differentially 
expressed miRNAs 
Upregulated 21 
Downregulated 30 
Table 5.2 – miRNAs differentially expressed between d3 CD326
low
CD56
+
  and NCF samples. 
Differentially expressed miRNAs are defined as having a FDR<0.05 and FC>1.5. 
Although over 1,000 miRNAs were profiled using the Agilent® microarray screen, 
only a small subset of 51 were found to be differentially expressed between d3 
MP and NCF samples (Table 5.2,  
Upregulated Downregulated 
miRNA Fold 
change 
FDR miRNA Fold 
change 
FDR 
hsa-miR-483-3p 28.17 0.025 hsa-miR-105-5p -17.72 0.025 
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hsa-miR-145-5p 12.81 0.032 hsa-miR-429 -8.67 0.015 
hsa-miR-10b-5p 5.54 0.022 hsa-miR-200a-3p -7.26 0.021 
hsa-miR-132-3p 5.54 0.034 hsa-miR-203a -6.86 0.013 
hsa-miR-10a-5p 5.41 0.039 hsa-miR-139-5p -6.18 0.036 
hsa-miR-372-3p 4.67 0.036 hsa-miR-767-5p -6.15 0.048 
hsa-miR-455-5p 4.52 0.047 hsa-miR-200c-3p -4.65 0.042 
hsa-miR-373-3p 4.43 0.025 hsa-miR-525-3p -4.46 0.007 
hsa-miR-371a-3p 3.94 0.026 hsa-miR-141-3p -4.39 0.014 
hsa-miR-145-3p 3.64 0.032 hsa-miR-515-3p -4.27 0.007 
hsa-miR-155-5p 3.05 0.023 hsa-miR-181d-5p -4.12 0.023 
hsa-miR-378a-3p 2.84 0.027 hsa-miR-519b-3p -4.06 0.009 
hsa-miR-455-3p 2.77 0.023 hsa-miR-516b-5p -3.98 0.005 
hsa-miR-193a-5p 2.70 0.032 hsa-miR-522-3p -3.92 0.020 
hsa-miR-23b-3p 2.39 0.025 hsa-miR-135b-5p -3.52 0.011 
hsa-miR-629-5p 2.30 0.015 hsa-miR-183-5p -3.31 0.023 
hsa-miR-373-5p 2.28 0.048 hsa-miR-96-5p -3.13 0.023 
hsa-miR-3651 1.94 0.014 hsa-miR-551b-3p -3.12 0.019 
hsa-miR-126-3p 1.87 0.036 hsa-miR-210-3p -3.01 0.048 
hsa-miR-20a-5p 1.58 0.025 hsa-miR-518b -2.88 0.013 
hsa-miR-365a-3p 1.55 0.025 hsa-miR-519c-3p -2.87 0.027 
   hsa-miR-526-5p -2.59 0.014 
   hsa-miR-520g-3p -2.59 0.048 
   hsa-miR-520b -2.44 0.045 
   hsa-miR-182-5p -2.29 0.023 
   hsa-miR-181a-5p -1.92 0.025 
   hsa-miR-1247-5p -1.91 0.049 
   hsa-miR-517a-3p -1.75 0.048 
   hsa-miR-205-5p -1.66 0.033 
   hsa-miR-517b-3p -1.58 0.007 
Table 5.3). Of these 51 miRNAs, 21 were found to be upregulated and 30 
downregulated. Within the upregulated miRNAs were miR-126-3p, which was 
shown to be expressed ≈1.9-fold higher in the MPs, and miR-10a-5p, expressed 
≈5.4-fold higher in MPs than in NCF samples ( 
Upregulated Downregulated 
miRNA Fold FDR miRNA Fold FDR 
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change change 
hsa-miR-483-3p 28.17 0.025 hsa-miR-105-5p -17.72 0.025 
hsa-miR-145-5p 12.81 0.032 hsa-miR-429 -8.67 0.015 
hsa-miR-10b-5p 5.54 0.022 hsa-miR-200a-3p -7.26 0.021 
hsa-miR-132-3p 5.54 0.034 hsa-miR-203a -6.86 0.013 
hsa-miR-10a-5p 5.41 0.039 hsa-miR-139-5p -6.18 0.036 
hsa-miR-372-3p 4.67 0.036 hsa-miR-767-5p -6.15 0.048 
hsa-miR-455-5p 4.52 0.047 hsa-miR-200c-3p -4.65 0.042 
hsa-miR-373-3p 4.43 0.025 hsa-miR-525-3p -4.46 0.007 
hsa-miR-371a-3p 3.94 0.026 hsa-miR-141-3p -4.39 0.014 
hsa-miR-145-3p 3.64 0.032 hsa-miR-515-3p -4.27 0.007 
hsa-miR-155-5p 3.05 0.023 hsa-miR-181d-5p -4.12 0.023 
hsa-miR-378a-3p 2.84 0.027 hsa-miR-519b-3p -4.06 0.009 
hsa-miR-455-3p 2.77 0.023 hsa-miR-516b-5p -3.98 0.005 
hsa-miR-193a-5p 2.70 0.032 hsa-miR-522-3p -3.92 0.020 
hsa-miR-23b-3p 2.39 0.025 hsa-miR-135b-5p -3.52 0.011 
hsa-miR-629-5p 2.30 0.015 hsa-miR-183-5p -3.31 0.023 
hsa-miR-373-5p 2.28 0.048 hsa-miR-96-5p -3.13 0.023 
hsa-miR-3651 1.94 0.014 hsa-miR-551b-3p -3.12 0.019 
hsa-miR-126-3p 1.87 0.036 hsa-miR-210-3p -3.01 0.048 
hsa-miR-20a-5p 1.58 0.025 hsa-miR-518b -2.88 0.013 
hsa-miR-365a-3p 1.55 0.025 hsa-miR-519c-3p -2.87 0.027 
   hsa-miR-526-5p -2.59 0.014 
   hsa-miR-520g-3p -2.59 0.048 
   hsa-miR-520b -2.44 0.045 
   hsa-miR-182-5p -2.29 0.023 
   hsa-miR-181a-5p -1.92 0.025 
   hsa-miR-1247-5p -1.91 0.049 
   hsa-miR-517a-3p -1.75 0.048 
   hsa-miR-205-5p -1.66 0.033 
   hsa-miR-517b-3p -1.58 0.007 
Table 5.3), as stated previously (section 5.4.1.3). 
Upregulated Downregulated 
miRNA Fold 
change 
FDR miRNA Fold 
change 
FDR 
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hsa-miR-483-3p 28.17 0.025 hsa-miR-105-5p -17.72 0.025 
hsa-miR-145-5p 12.81 0.032 hsa-miR-429 -8.67 0.015 
hsa-miR-10b-5p 5.54 0.022 hsa-miR-200a-3p -7.26 0.021 
hsa-miR-132-3p 5.54 0.034 hsa-miR-203a -6.86 0.013 
hsa-miR-10a-5p 5.41 0.039 hsa-miR-139-5p -6.18 0.036 
hsa-miR-372-3p 4.67 0.036 hsa-miR-767-5p -6.15 0.048 
hsa-miR-455-5p 4.52 0.047 hsa-miR-200c-3p -4.65 0.042 
hsa-miR-373-3p 4.43 0.025 hsa-miR-525-3p -4.46 0.007 
hsa-miR-371a-3p 3.94 0.026 hsa-miR-141-3p -4.39 0.014 
hsa-miR-145-3p 3.64 0.032 hsa-miR-515-3p -4.27 0.007 
hsa-miR-155-5p 3.05 0.023 hsa-miR-181d-5p -4.12 0.023 
hsa-miR-378a-3p 2.84 0.027 hsa-miR-519b-3p -4.06 0.009 
hsa-miR-455-3p 2.77 0.023 hsa-miR-516b-5p -3.98 0.005 
hsa-miR-193a-5p 2.70 0.032 hsa-miR-522-3p -3.92 0.020 
hsa-miR-23b-3p 2.39 0.025 hsa-miR-135b-5p -3.52 0.011 
hsa-miR-629-5p 2.30 0.015 hsa-miR-183-5p -3.31 0.023 
hsa-miR-373-5p 2.28 0.048 hsa-miR-96-5p -3.13 0.023 
hsa-miR-3651 1.94 0.014 hsa-miR-551b-3p -3.12 0.019 
hsa-miR-126-3p 1.87 0.036 hsa-miR-210-3p -3.01 0.048 
hsa-miR-20a-5p 1.58 0.025 hsa-miR-518b -2.88 0.013 
hsa-miR-365a-3p 1.55 0.025 hsa-miR-519c-3p -2.87 0.027 
   hsa-miR-526-5p -2.59 0.014 
   hsa-miR-520g-3p -2.59 0.048 
   hsa-miR-520b -2.44 0.045 
   hsa-miR-182-5p -2.29 0.023 
   hsa-miR-181a-5p -1.92 0.025 
   hsa-miR-1247-5p -1.91 0.049 
   hsa-miR-517a-3p -1.75 0.048 
   hsa-miR-205-5p -1.66 0.033 
   hsa-miR-517b-3p -1.58 0.007 
Table 5.3 – Differentially expressed miRNAs and their changes in expression between d3 
CD326
low
CD56
+
 and NCF samples. 
Where differential expression is defined as a fold change > 1.5, and a FDR < 0.05. FDR = false 
discovery rate. 
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Interestingly, three different miRNA stem loops were shown to have both -3p 
and -5p strands upregulated in CD326lowCD56+ MPs, when compared to NCF 
samples ( 
Upregulated Downregulated 
miRNA Fold 
change 
FDR miRNA Fold 
change 
FDR 
hsa-miR-483-3p 28.17 0.025 hsa-miR-105-5p -17.72 0.025 
hsa-miR-145-5p 12.81 0.032 hsa-miR-429 -8.67 0.015 
hsa-miR-10b-5p 5.54 0.022 hsa-miR-200a-3p -7.26 0.021 
hsa-miR-132-3p 5.54 0.034 hsa-miR-203a -6.86 0.013 
hsa-miR-10a-5p 5.41 0.039 hsa-miR-139-5p -6.18 0.036 
hsa-miR-372-3p 4.67 0.036 hsa-miR-767-5p -6.15 0.048 
hsa-miR-455-5p 4.52 0.047 hsa-miR-200c-3p -4.65 0.042 
hsa-miR-373-3p 4.43 0.025 hsa-miR-525-3p -4.46 0.007 
hsa-miR-371a-3p 3.94 0.026 hsa-miR-141-3p -4.39 0.014 
hsa-miR-145-3p 3.64 0.032 hsa-miR-515-3p -4.27 0.007 
hsa-miR-155-5p 3.05 0.023 hsa-miR-181d-5p -4.12 0.023 
hsa-miR-378a-3p 2.84 0.027 hsa-miR-519b-3p -4.06 0.009 
hsa-miR-455-3p 2.77 0.023 hsa-miR-516b-5p -3.98 0.005 
hsa-miR-193a-5p 2.70 0.032 hsa-miR-522-3p -3.92 0.020 
hsa-miR-23b-3p 2.39 0.025 hsa-miR-135b-5p -3.52 0.011 
hsa-miR-629-5p 2.30 0.015 hsa-miR-183-5p -3.31 0.023 
hsa-miR-373-5p 2.28 0.048 hsa-miR-96-5p -3.13 0.023 
hsa-miR-3651 1.94 0.014 hsa-miR-551b-3p -3.12 0.019 
hsa-miR-126-3p 1.87 0.036 hsa-miR-210-3p -3.01 0.048 
hsa-miR-20a-5p 1.58 0.025 hsa-miR-518b -2.88 0.013 
hsa-miR-365a-3p 1.55 0.025 hsa-miR-519c-3p -2.87 0.027 
   hsa-miR-526-5p -2.59 0.014 
   hsa-miR-520g-3p -2.59 0.048 
   hsa-miR-520b -2.44 0.045 
   hsa-miR-182-5p -2.29 0.023 
   hsa-miR-181a-5p -1.92 0.025 
   hsa-miR-1247-5p -1.91 0.049 
   hsa-miR-517a-3p -1.75 0.048 
   hsa-miR-205-5p -1.66 0.033 
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   hsa-miR-517b-3p -1.58 0.007 
Table 5.3); miR-145, miR-455 and miR-483, although miR-483-5p FDR was >0.05 
(≈0.09). Recently, an increasing number of studies have demonstrated a role for 
classical ‘passenger’ or ‘star’ strand miRNAs (Yang et al., 2011). Furthermore, 
publications have shown that both the -5p and -3p strand of a single miRNA stem 
loop can exhibit the same expression pattern (Mitra et al., 2015), and possibly 
play similar regulatory roles (Shan et al., 2013, Yang et al., 2013). It was, 
therefore, hypothesised that these three identified miRNA stem loops play 
important regulatory roles during hESC-EC differentiation and commitment. 
Further work was then performed to validate the findings from the miRNA 
microarray and investigate this resultant hypothesis. 
5.4.1.7 miR-143/145 cluster 
As miR-145 is transcribed as a cluster alongside miR-143, in a cluster know as 
miR-143/145. The miR-143/145 cluster is a poly-cistronic transcript, processed 
to produce 4 distinct mature miRNAs (Figure 5.15A); miR-143-3p, miR-143-5p (*), 
miR-145-5p and miR-145-3p (*) and, therefore, expression of all 4 miRNAs 
contained within this cluster were investigated. Similarly to miR-145-5p and -3p, 
miR-143-3p, the classically known ‘lead’ strand of the miRNA, was demonstrated 
to be expressed at higher levels (≈2-fold) in d3 CD326lowCD56+ MPs when 
compared with NCF samples, although the FDR was >0.05. miR-143-5p, however, 
was not detected in any of the samples run on the microarray screen. 
Assessment of miRNA profiles throughout the duration of direct hESC-EC 
differentiation demonstrated an additional increase in the expression of miR-
145-5p (Figure 5.15A), -145-3p (Figure 5.15B) and -143-3p (Figure 5.15C) by d7 
(Figure 5.15). The increase in expression in d3 CD326lowCD56+ MPs, coupled with 
the increase at d7, suggested a possible role for these miRNAs in early 
mesodermal and endothelial commitment.  
Taqman® qRT-PCR was then used to confirm the expression pattern of these 
miRNAs. Initially, pri-miR-143 and pri-miR-145 levels were assessed. As described 
previously, pri-miRNAs are the stem loop structures containing both the -3p and 
-5p miRNA strands (Figure 5.15A), before processing by Drosha and Dicer. As 
would be expected from miRNAs transcribed together, both pri-miRNAs were 
demonstrated to exhibit a similar expression pattern, with both being 
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significantly upregulated during hESC-EC differentiation (Figure 5.16). Pri-miR-
145 was upregulated to slightly higher levels (approximately 150-fold) than pri—
miR-143 (approximately 100-fold) at d7 when compared with d0 pluripotent 
hESCs. As both miRNAs are transcribed together, the difference in the levels of 
expression may suggest a more prominent role for the mature miR-145 miRNAs 
within this system, as pri-miR-143 may be targeted for degradation. 
Additionally, both pri-miRNAs were shown to be expressed at significantly higher 
levels in d3 MPs than the NCF samples (Figure 5.16A and B). 
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Figure 5.15 – Microarray profiling of miR-143/145 cluster during hESC-EC differentiation. 
miR-143 and -145 are transcribed together in a cluster, which is processed to produce 4 mature 
miRNAs (A). 3 of the miRNAs in this cluster were detected in the microarray screen, miR-145-5p 
(B), miR-145-3p (C) and miR-143-3p (D). Dot plots show normalised expression data for n=4 
samples in each group, with lines representing the mean value.  
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Figure 5.16 – qRT-PCR for pri-miR-143 and -145 during direct hESC-EC differentiation. 
Total RNA collected from d0 H9 hESCs, d3 heterogeneous, d3 CD326
low
CD56
+
 MP, d3 NCF and 
d7 samples were analysed for expression of pri-miR-143 (A) and -145 (B), the stem loop structures 
existing before processing (Figure 5.15A).  Histograms show RQ ± RQ Max calculated relative to 
the UBC reference gene. Repeated measures ANOVA with Tukey’s post hoc comparisons was 
used to calculate significance; * = p<0.05 ** = p<0.01, *** = p<0.001 vs d0 hESCs, # = p<0.05, ### 
= p<0.001 vs d3 MP. Samples from n=4 differentiation experiments. 
Once expression profiles obtained from the microarray screen were validated for 
the two pri-miRNAs, expression levels of mature miRNAs from the miR-143/145 
cluster were also analysed using qRT-PCR. Although only three of the four 
miRNAs were detected in data from the microarray screen (miR-143-3p, -145-5p, 
-145-3p), all four mature miRNAs from the cluster were validated 
experimentally. As all other miRNAs from the miR-143/145 cluster had the same 
expression pattern, it was hypothesised that miR-143-5p, classically known as 
the ‘passenger’ strand of miR-143, would be regulated in the same way.  
Analysis by Taqman® qRT-PCR is more sensitive than the microarray screen, and 
will therefore detect expression of miRNAs which may have been previously 
missed, such as miR-143-5p. Indeed, when profiled it was demonstrated that all 
4 mature miRNAs exhibited the same expression pattern, with all significantly 
upregulated in d7 samples when compared to d0 pluripotent controls (Figure 
5.17A-D). The previously defined ‘lead’ strands (mi-145-5p and miR-143-3p), 
were shown to have the highest levels of upregulation (Figure 5.17A and C), 
although the passenger strands were also shown to be highly upregulated 
(approximately 100 and 30-fold for miR-145-3p (Figure 5.17B) and miR-143-5p 
(Figure 5.17D), respectively). Moreover, all four miRNAs were upregulated in the 
d3 MP samples, when compared to d0 hESCs, and their expression was 
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significantly higher in these samples than in those from the NCF. Overall, these 
data allude to a possible role for the miR-143/145 cluster in regulation of hESC 
differentiation and commitment to mesodermal and early endothelial lineages.  
 
Figure 5.17 – qRT-PCR validation of miR-143/145 cluster expression. 
Expression profiles of miR-145-5p (A), -145-3p (B)  and -143-3p (C) were analysed in total RNA 
samples used for the microarray screen, plus a heterogeneous d3 samples, using Taqman® qRT-
PCR. Additionally, the expression of the remaining miRNA in the cluster, miR-143-5p (D), was also 
examined. Histograms show RQ ± RQ Max calculated relative to the RNU48 reference RNA. 
Repeated measures ANOVA with Tukey’s post hoc comparisons was used to calculate 
significance; * = p<0.05 ** = p<0.01, *** = p<0.001 vs d0 hESCs, # = p<0.05, ### = p<0.001 vs d3 
MP. Samples from n=4 differentiation experiments. MP = mesoderm progenitor, NCF = negative 
cell fraction. 
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After validation in direct hESC-EC differentiation, expression levels were 
examined in total RNA samples from indirect hESC-EC differentiation. Analysis of 
these miRNAs in a linked, but independent, system allowed for initial 
investigations into their specificity; whether they are involved in general 
mesodermal, hemogenic endothelial or specifically EC specification of hESCs. 
Similarly to direct differentiation, all four of the mature miRNAs from the 
cluster share the same expression pattern, and are significantly upregulated 
throughout differentiation and, therefore, during commitment of cells to an EC 
phenotype (Figure 5.18A-D).  
 
Figure 5.18 – qRT-PCR analysis of miR-143/145 expression during indirect hESC-EC 
differentiation. 
Total RNA samples collected during indirect hESC-EC differentiation were assessed for the 
expression of miR-145-5p (A), -145-3p (B), -143-3p (C) and -143-5p (D).  Histograms show RQ ± 
RQ Max calculated relative to the RNU48 reference RNA. Repeated measures ANOVA with 
Tukey’s post hoc comparisons was used to calculate significance; * = p<0.05 ** = p<0.01, *** = 
p<0.001 vs d0 hESCs, unless indicated.  
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The highest levels of expression for all four of the miRNAs appeared to be in d10 
adherent or d7+3 hESC-EC samples, with a significant increase in expression in 
these groups when compared to d0 pluripotent hESCs (Figure 5.18). Additionally, 
although still higher than levels seen in d0 pluripotent controls, expression of 
the miR-143/145 cluster was lower in d10 suspension cells than adherent or d7+3 
samples, and this difference was significant for miR-145-5p (Figure 5.18A). This 
may suggest that the miR-143/145 cluster has a role in differentiation to both 
hematopoietic and endothelial lineages, or in general mesodermal 
differentiation. High levels of upregulation at all time points after d3, but at 
slightly lower levels in d10 suspension cells, may suggest that these miRNAs are 
involved in endothelial specification, and their presence in d7 and d10 adherent 
cells is due to the presence of HE progenitors and ECs (as detailed in chapter 4). 
All miRNAs, with the exception of miR-143-5p (Figure 5.18D), were shown to be 
significantly upregulated by d3, although all samples were heterogeneous d3 
samples (Figure 5.18A-C), containing all cells present in EBs at this time point 
during indirect hESC-EC differentiation. Previous data (Chapter 4) showed that, 
although a high percentage of cells (≈40%) were CD326lowCD56+ MPs, there were 
a large number of non-CD326lowCD56+ MPs present at d3. Therefore, isolation and 
collection of total RNA from a purified CD326lowCD56+ MP cell population, in a 
similar way to that shown during direct hESC-EC differentiation, would be 
necessary to fully determine differences in expression between d0 pluripotent 
cells and d3 MPs, as well as between MP and NCF samples at d3. Although no 
significant difference is present between d0 and d3 for miR-143-5p in these 
samples, the heterogeneity may mask changes and, if d3 MP and NCF samples 
were isolated, large differences may become apparent. 
Taken together, these data show that all four miRNAs from the miR-143/145 
cluster have similar expression levels, and may all be regulated by the same 
mechanisms during hESC-EC differentiation. This, therefore, led to the 
hypothesis that this cluster plays an important role in mesodermal, 
hematoendothelial or endothelial specification of hESCs.  
225 
 
 
5.4.1.8 miR-483 
Array data also suggested a potential role for the miR-483 stem loop in hESC-EC 
differentiation and mesodermal specification. A significant difference in 
expression of miR-483-3p was observed between d3 CD326lowCD56+ MP and NCF 
samples. The miR-483-5p strand, although not deemed to be significantly 
changed, had one of the largest fold changes, expressed ≈9-fold higher in MPs 
than in NCF samples. Large variations in miR-483-5p expression in NCF samples 
may explain the high FDR value (0.087). When normalised intensities from the 
microarray screen (calculated as described in section 5.3.1) were plotted for all 
samples at all time points, it was observed that expression of this miRNA was 
increased throughout the duration of hESC-EC differentiation (Figure 5.19A-B). 
Moreover, both miR-483-3p (Figure 5.19A) and -5p (Figure 5.19B) exhibit a 
similar pattern of expression, with the exception of in d0 pluripotent hESCs, 
where miR-483-3p is undetected. 
 
Figure 5.19 – miR-483 stem loop expression. 
miR-483-3p (A) and miR-483-5p (B) were expressed at significantly higher levels in d3 
CD326
low
CD56
+
 MP cells than in d3 NCF samples when assessed using microarray technology. 
Dot plots show expression of these two miRNAs during d0-7 of direct hESC-EC differentiation. 
Individual points on the graphs represent values for each of the 4 samples in each group, with the 
line representing the mean value.  
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These findings were subsequently validated using qRT-PCR, in samples from both 
direct and indirect hESC-EC differentiation experiments. Both miR-483-3p and -
5p were shown to be significantly upregulated in hESC-EC samples generated 
using the direct (Figure 5.20A-B) and indirect (Figure 5.20C-D) differentiation 
protocols, although the levels of upregulation were higher in samples taken from 
the direct system. Differences between the d3 MP and NCF fractions were also 
consistent with data collected from the microarray, when expression was 
validated using qRT-PCR. Levels of both miRNAs were shown to be significantly 
upregulated in d3 MPs (approximately 30 and 5-fold for miR-483-5p and -3p, 
respectively), when compared to d0 pluripotent hESCs, and also expressed a 
significantly higher level than in cells contained in the NCF samples (Figure 
5.20A-B). 
Similar differences in both -5p and -3p strand expression, combined with 
significantly higher levels of both miRNAs in MP cells, when compared to d3 NCF 
samples, led to the hypothesis that both strands of this miRNA stem loop are 
involved in the commitment and differentiation of hESCs the mesodermal and 
endothelial lineages. Data collected from the indirect differentiation system, 
showing significantly higher expression of both mature miRNAs in d7+3 hESC-ECs, 
than in d10 suspension HC cells, suggests that miR-483 specifically plays a role in 
endothelial specification, and not in hematopoietic specification. This is further 
supported by the observation that the levels of both miRNAs appear to decrease 
from d7 to d10 in suspension cells, as they become more committed to a 
hematopoietic phenotype (as described in chapter 4), although this difference is 
not significant (Figure 5.20C-D). 
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Figure 5.20 – qRT-PCR validation of miR-483 expression during hESC-EC differentiation. 
Both strands of the miR-483 stem loop, -5p (A, C) and -3p (B, D), were assessed for expression in 
RNA samples taken from direct (A-B) and indirect (C-D) hESC-EC differentiation. Direct 
differentiation samples included FACSorted CD326
low
CD56
+
 MP and NCF samples, whereas 
FACSorting was not performed during indirect differentiation. Histograms show RQ ± RQ Max 
calculated relative to RNU48 reference RNA. Repeated measures ANOVA with Tukey’s post hoc 
comparisons was used to calculate significance; * = p<0.05 ** = p<0.01, *** = p<0.001 vs d0 
hESCs, unless indicated, for A-B ## = p<0.01, ### = p<0.001 vs d3 MP. Samples from n=4 
differentiation experiments. MP = mesoderm progenitor, NCF = negative cell fraction, n/s = non-
significant. 
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5.4.1.9 miR-455 
Finally, the microarray screen also demonstrated significant differences in the 
expression of both -5p and -3p strands of miR-455, when direct comparisons of 
d3 CD326lowCD56+ MP and NCF samples were performed. Again, when normalised 
intensities, obtained from the microarray screen, were plotted for each sample, 
an overall increase in expression was observed during hESC-EC differentiation 
(Figure 5.21A-B). Levels in the d3 MP samples were significantly higher than 
those in cells included in the d3 NCF in data from the microarray screen, 
although this could only be validated using qRT-PCR for miR-455-3p (Figure 
5.21C-D). Both miR-455-3p and -5p were significantly upregulated in d3 MP and 
d7 hESC-EC samples, when compared to d0 pluripotent hESCs, although the 
upregulation was much smaller than that observed for both miR-483 and the 
miR-143/145 cluster. Because of this, coupled with the fact that there was no 
significant difference in miR-455-5p expression between d3 MP and NCF samples, 
it was hypothesised that this miRNA stem loop may not play an important role in 
EC differentiation. Therefore, it was decided that no further work would be 
performed involving miR-455. 
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Figure 5.21 – miR-455 during direct hESC-EC differentiation. 
Microarray analysis revealed that miR-455-5p (A) and miR-455-3p (B) were significantly changes 
between d3 MP and d3 NCF samples.  Normalised intensities, obtained from miRNA microarray, 
for each sample are plotted above (A and B), with lines signifying the mean value for specified 
group. Taqman® qRT-PCR was employed for validation of these expression profiles in total RNA 
samples from direct hESC-EC differentiation (C and D). n=4 samples, statistical significance 
calculated using a repeated measures ANOVA with Tukey post hoc comparisons, * = p<0.05, ** = 
p<0.01, *** = p< 0.001 vs. d0 hESCs, ### = p<0.001 vs. d3 MP. MP = CD326
low
CD56
+
 mesoderm 
progenitor, NCF = negative cell fraction, n/s = non-significant.  
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5.4.2 Modulation of miRNA during hESC-EC differentiation 
Combined data from the microarray screen and qRT-PCR validation in both 
differentiation systems led to the hypothesis that the miR-483 stem loop plays 
an important role in hESC-EC specification, and that the miR-143/145 cluster 
may play an important role in mesodermal, endothelial or hematopoietic lineage 
specification.  
To further investigate these hypotheses, experiments were performed to 
modulate the expression of miR-483 and the miR-143/145 cluster during hESC-EC 
differentiation. Initially, attempts were made to overexpress the miRNAs using 
lentiviral vectors. Known for their ability to integrate into the host genome, and 
therefore provide long term expression of a transgene, lentiviruses are a specific 
genus of retroviruses, and include human immunodeficiency virus 1 (HIV-1) 
(Naldini et al., 1996a, Naldini et al., 1996b, Buchschacher et al., 2000). 
Additionally, lentiviruses have the ability to infect both dividing and non-dividing 
cells, making them a powerful tool for transgene delivery both in vitro and in 
vivo. Although there have been significant improvements in methodology, hPSCs 
remain notoriously difficult to transfect (Villa-Diaz et al., 2010) and 
overexpression of miRNAs using pre-miRNAs can be challenging. Lentiviral-
mediated miRNA delivery provides an efficient and long term method of 
overexpression in this system and was, therefore, chosen for use in this study. 
Four different lentiviral vectors were generated; lenti-miR-143/145, for the 
overexpression of all four miRNAs from the 143/145 cluster, lenti-miR-143 and 
lenti-miR-145, for the overexpression of -3p and -5p strands of miR-143 and miR-
145 individually, and lenti-miR-483, for the delivery and overexpression of the 
miR-483 stem loop. 
5.4.2.1 Making lentiviral vectors 
Initially, lenti-miR-143/145, lenti-miR-143 and lenti-miR-145 were generated. 
Briefly, miRNA transgenes were obtained using PCR amplification from the 
genome of H9 hESCs. This reaction was performed using the primers described in 
section 2.8.2 (Table 2.8). DNA gel electrophoresis was performed to ensure the 
correct genomic fragments had been amplified. Once confirmed, fragments were 
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subsequently ligated into the pcDNA™3.3 plasmid, as described in section 2.8. 
After ligation into pcDNA™3.3, plasmids were transfected into 293T cells to 
assess the expression of individual mature miRNAs (Figure 5.22).  
 
Figure 5.22 – Transfection of pcDNA™3.3(+)-miR-143/145 constructs in 293s. 
HEK 293s were seeded at a density of 8x10
4
 in a 12-well tissue culture plate. Transfections were 
performed using 1 or 2 µL Lipofectamine® 2000 (indicated below graphs) and 1 µg of plasmid 
DNA. Experiments were performed using pcDNA™3.3-miR-143/145, pcDNA™3.3-miR-143, 
pcDNA™3.3-miR-145 and an empty pcDNA™3.1(+) plasmid was used as a negative control. 
Lipofectamine only and NTC (non-transfected control) groups were also used as negative controls. 
Samples were assessed for expression of miR-145-5p (A), -145-3p (B), -143-3p (C) and -143-5p 
(D). n=2, data above is shown as dCt relative to RNU48 reference RNA (Ct miRNA of interest – Ct 
reference RNA). Low dCt values represent higher levels of expression. 
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Transfection with the pcDNA™3.3-miR-143/145 plasmid caused cells to 
overexpress miR-145-5p, -145-3p and -143-3p, as demonstrated by the lower dCt 
values (Figure 5.22A-C). The expression of miR-143-5p, however, did not appear 
to change after transfection (Figure 5.22D), although this may be due to the cell 
type used, and did not conclusively show that this miRNA is not expressed using 
this plasmid. Expression of both lead and passenger strands of miR-145 (Figure 
5.22A-B) or -143 (Figure 5.22C-D) were modulated when cells were transfected 
with pcDNA™3.3-miR-145 or pcDNA™3.3-miR-143 respectively. No change in the 
expression of miR-143 (Figure 5.22C-D) was detected when cells transfected with 
pcDNA™3.3-miR-145, with the opposite true for pcDNA™3.3-miR-143 transfection 
(Figure 5.22A-B).  
Although no overexpression of miR-143-5p was detected when cells transfected 
with the plasmid containing the miR-143/145 cluster, it was concluded that 
these fragments would be excised and ligated into the pSFFV plasmid. These 
reactions were performed as described in section 2.8, with digests performed 
using MluI and XhoI restriction endonucleases. Once generated, the pSFFV-miR-
143/145, pSFFV-miR-145 and pSFFV-miR-143 constructs were used to generate 
lentiviral vectors, as described in section 2.9. 
The pcDNA™3.1(+) plasmid containing the miR-483 transgene, coding for the 
entire miR-483 stem loop (including -3p and -5p strands), was purchased from 
Geneart (Life Technologies). From this construct, miR-483 was excised and 
ligated into the pSFFV plasmid, as described for miR-143/145. 
5.4.2.2 Initial optimisation of lentiviral doses 
In order to optimise the lentiviral dose needed for transduction of pluripotent 
hESCs, Lenti-GFP was used to infect cells at a range of MOI values, with the use 
of a vector containing a fluorescent label allowing for quantitative analysis of 
transduction via flow cytometry. The lenti-GFP vector contained the GFP gene 
under the control of the SFFV promoter, the same promoter used in the miR-
143/145 and miR-483 constructs. H9 hESCs were seeded at a density of 1x105 
cells per well in a 12-well tissue culture dish. Lenti-GFP was added at an MOI of 
5, 10 or 50, with virus containing medium removed after 24 h. As stated 
previously, MOI, or multiplicity of infection, relates to the number of viral  
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Figure 5.23 – GFP transduction of hESCs. 
Pluripotent H9 hESCs were plated at a density of 1x10
5
 cells per well in a 12-well tissue culture 
dish. Cells were then transduced with Lenti-GFP at MOIs of 5, 10 and 50, with virus removed from 
media after 24 hours. Transduction efficiency was measured after 72 hours using flow cytometry. 
Average percentage of cells transduced from n=3 experiments (A), and example flow cytometry 
histograms for each MOI (B) shown above. NTC = non-transduced control (no virus). 
particles added per cell. Cells were harvested and percentage transduction was 
measured after 72 h, when the peak of lentivirus expression had been reached 
(Figure 5.23). The level of transduction was high at all MOIs, with significant 
increases in percentage of GFP+ cells for all viral concentrations when compared 
to non-transduced controls (NTC). Additionally, the percentage of GFP+ cells 
present at 72 h were significantly higher when cells were transduced with an MOI 
of 10 or 50, compared to cells treated with an MOI 5. Despite resulting in the 
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highest percentage of GFP+ cells, infection using MOI 50 resulted in wide spread 
cell death. Therefore, from these data, it was decided that an MOI 10 would be 
used in subsequent experiments as a compromise between high transduction 
efficiency and low levels of cell death. 
5.4.3 Modulation of miRNAs in hESCs and hESC-EC 
differentiation 
5.4.3.1 miR-143/145 cluster 
Before use during hESC-EC differentiation, the lentiviral vectors for 
overexpression of miR-143/145, miR-143 and miR-145 was tested in HeLa cells, 
in order to ensure overexpression of miRNAs. Monolayer transduction of HeLa 
cell was performed using each virus at an MOI of 10 and 20, and cells analysed 
for miRNA expression after 72 h (Figure 5.24). In the interest of time and to 
conserve reagents, only the lead strand of each miRNA (miR-145-5p and miR-
143-3p) was analysed. Both miR-145-5p (Figure 5.24A) and miR-143-3p (Figure 
5.24B) were overexpressed when cells were transduced with lenti-miR-143/145 
at both MOIs. Additionally, the expression of miR-143-3p was increased by 
similar levels (≈5-fold) when HeLa cells were infected using the lenti-miR-143 
virus (Figure 5.24B). The lenti-miR-145 virus, however, only induced very small 
increases in miR-145-5p expression (≈2-fold for MOI 10 and ≈2-fold for MOI 20; 
Figure 5.24A), despite the same transgene inducing marked overexpression of 
both miR-145-5p and -3p when transfected in the pcDNA 3.3 plasmid in 293T 
cells (Figure 5.22A). This may, however, be due to differences in expression 
between cell types and it was, therefore, decided to continue experiments using 
these viral vectors at an MOI of 10. 
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Figure 5.24 – miR-143/145 overexpression in HeLa cells. 
Monolayer transduction of HeLa cells was performed to check overexpression of miR-143 and miR-
145 by lenti-miR-143/145, lenti-miR-143 and lenti-miR-145. Viruses were used at 2 different doses; 
MOI 10 and MOI 20, indicated below x-axis. Analysis was performed on the two lead strands, miR-
145-5p (A) and miR-143-3p (B) using qRT-PCR. n=2, data plotted is RQ ± RQ Max. 
After optimisation, experiments were performed using the generated lentiviral 
vectors during hESC-EC differentiation. Based on previous data, it was 
hypothesised that overexpression of the miR-143/145 cluster would cause an 
increase in differentiation efficiency, as cells are driven toward a mesodermal or 
EC phenotype.  
As high levels of expression of the lentiviral construct had been observed 72 h 
post-transduction (Figure 5.22, Figure 5.23, Figure 5.24), cells were treated with 
viral vectors on d0, in order to overexpress miRNAs during hESC-EC 
differentiation. As shown previously, the initial step of direct hESC-EC 
differentiation involved the formation of size controlled EBs and, therefore, 
unlike in previous optimisation experiments, monolayer transduction of cells 
could not be performed. Instead, a protocol was developed to infect cells with 
lentiviral particles in suspension, immediately prior to EB formation. Initially, a 
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small pilot experiment was performed to ensure efficient transduction of cells 
during hESC-EC differentiation using this suspension-based protocol. Briefly, 
transduction was performed at d0, as described in section 2.10.2, using lenti-
GFP or lenti-miR-143/145 at a concentration of MOI 10, alongside a non-
transduced control (NTC) group. Differentiation was then allowed to progress to 
d3, where cells were harvested and analysed using flow cytometry and qRT-PCR. 
Using fluorescence imaging (Figure 5.25A) and flow cytometry (Figure 5.25B), 
high levels of GFP+ cells (approximately 85%) were observed by d3 of hESC-EC 
differentiation, in samples infected with the lenti-GFP virus, when compared to 
the NTC sample group, as well as the lenti-miR-143/145 transduced group, as 
this virus did not contain a fluorescent label. 
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Figure 5.25 – Preliminary testing of Lentiviral transduction – GFP expression on d3 of hESC-
EC differentiation. 
D0 pluripotent H9 hESCs were infected with lenti-GFP, at an MOI of 10, to analyse transduction 
efficiency. Cells were imaged 72 h post-transduction when cells were still in the EB phase of direct 
hESC-EC differentiation (A). Scale bars represent 200 µm, Cells were also harvested and analysed 
using flow cytometry (B). Gates show positive cells, with numbers representing numbers of cells in 
that gate. n=1.  
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Additionally, total RNA samples were taken at d0 and from all samples at d3, 
and the expression of miR-145-5p, -145-3p, -143-5p and -143-3p analysed, using 
Taqman® qRT-PCR (Figure 5.26A-D). As this was a preliminary study, only a 
single experimental replicate was performed and, therefore, RQ values could not 
be calculated. Instead, histograms were plotted using ‘dCt’ values, which 
describes the change in expression compared to the housekeeper or reference 
RNA, with lower Ct values signalling higher levels of expression. From the 
preliminary data, it was observed that all four miRNAs from the miR-143/145 
cluster were overexpressed when cells were infected with the previously 
generated lenti-miR-143/145 vector, when an MOI of 10 was used. Although all 
four miRNAs were overexpressed to some extent, miR-145-5p (classically known 
as the miR-145 ‘lead’ strand) was shown to have the highest level of expression 
(Figure 5.26A). These preliminary results demonstrated that the generated 
lentiviral vector, containing the miR-143/145 cluster, successfully overexpressed 
all four miRNAs to varying extents. Moreover, these results showed that infection 
of cells by lentivirus using the developed suspension-based protocol was 
successful, and this method could be used to modulate miRNA expression during 
a full-scale hESC-EC differentiation time course experiment. As only one 
experimental replicate was performed, however, no further conclusions could be 
made from these results.  
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Figure 5.26 – Initial analysis of miR-143/145 overexpression. 
Total RNA samples were collected from d0 pluripotent H9 hESCs, and all sample groups at d3, 
including NTC and lenti-GFP and lenti-miR-143/145 infected sample groups. Samples were 
analysed for expression of miR-145-5p (A), -145-3p (B), -143-5p (C) and -143-3p (D) to determine 
the success of lentiviral mediated overexpression. Data plotted is dCt, or the change in cycle 
threshold relative to the RNU48 reference RNA (RNU48 Ct – miRNA of interest Ct). n=1. NTC = 
non-transduced control/no virus. 
Once it had been established that overexpression could be achieved using the 
generated lentiviral vectors at an MOI of 10, a larger scale experiment was 
designed to investigate the effect of miR-143/145 overexpression during direct 
hESC-EC differentiation. Pluripotent hESCs were infected at d0 as previously 
described (section 2.10.2) and differentiation was performed. Cells were 
harvested at d3 and d7, and the percentages of CD326lowCD56+ MPs and 
CD31+CD144+ hESC-ECs assessed. Although significantly upregulated when 
compared to d0 pluripotent controls (data not shown), there was no significant 
difference in the percentages of cells positive for both CD31 and CD144 between 
control groups and those infected with the miRNA-overexpressing lentiviral 
vectors, when analysed using flow cytometry (Figure 5.27A). Cells were also 
analysed for the expression of these cell surface markers at d3 (data not shown), 
to determine if the appearance of CD31+CD144+ hESC-ECs was earlier after 
overexpression of the miR-143/145 cluster, however, there was, similarly, no 
significant difference between all sample groups. When the percentage of 
CD326lowCD56+ MP cells was examined at d3, it was also observed that there was 
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no significant difference in the levels of cells displaying this cell surface marker 
profile between all sample groups (Figure 5.27B).  
 
Figure 5.27 – d7 CD31
+
CD144
+
 and d3 CD326
low
CD56
+
 populations after miR-143/145 
overexpression. 
Infected cells were harvested at d7 (A), to assess the percentage of CD31
+
CD144
+
 hESC-ECs, 
and at d3 (B), to examine the levels of CD326
low
CD56
+
 MP cells, stained using specific antibodies 
and analysed using flow cytometry. Histograms above show average percentages of these 
populations over 3 experimental replicates. Lenti-miR-143/145 contained the entire cluster, with 
lenti-miR-143 and lenti-miR-145 containing only miR-143 and miR-145 respectively.Three different 
negative control groups were included in the analysis, NTC, lenti-GFP and lenti-control. NTC = 
non-transduced control/no virus. Statistical tests were performed using a repeated measures 
ANOVA with Tukey’s post-hoc comparisons.  
As there appeared to be no affect when miR-143 and/or miR-145 were expressed 
during direct hESC-EC differentiation, qRT-PCR was used to examine the 
expression of all four miRNAs in this cluster (miR-145-5p, -145-3p, -143-5p, -143-
3p), in all sample groups at d0, 3 and 7 (Figure 5.27). In concurrence with 
previous data, all four miRNAs were shown to be significantly upregulated during 
hESC-EC differentiation when compared to d0 pluripotent hESC, with the highest 
levels of expression in samples taken on d7 of hESC-EC differentiation. 
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Figure 5.28 – qRT-PCR analysis of miR-143/145 expression after viral transduction. 
Total RNA samples were taken from d0 pluripotent hESCs, and all sample groups at d3 and d7, including three control groups at each time point and samples 
transduced with lenti-miR-143/145, lenti-miR-145 and lenti-miR-143. Expression of miR-145-5p (A), -145-3p (B), -143-5p (C) and -143-3p (D) were assessed in all 
samples using qRT-PCR. Significance calculated using repeated measures ANOVA with Tukey’s post hoc comparisons. * = p<0.05, ** = p<0.01, *** = p<0.001 vs d0 
pluripotent control, unless indicated. NTC = non-transduced control. Lenti-control = lenti containing an ‘empty’ pSFFV. 
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In terms of miRNA overexpression using the lentiviral vectors, the data was less 
positive. Expression of all four miRNAs appeared to be higher in RNA samples 
taken from cells infected with the lenti-miR-143/145, expressing the entire miR-
143/145 cluster, however, the only significant difference was seen in miR-145-5p 
expression between d3 lenti-miR-143/145 infected samples and d3 lenti-control 
(Figure 5.28A).  
This may, therefore, explain why there were no significant changes in the 
percentages of CD31+CD144+ hESC-ECs and CD326lowCD56+ MPs during direct 
hESC-EC differentiation, in cells transduced with lenti-miR-143/145, lenti-miR-
143 or lenti-miR-145. 
5.4.3.2 miR-483 
Lentiviral vectors were also generated to allow for overexpression of miR-483 
during hESC-EC differentiation. As for the miR-143/145 overexpressing lentiviral 
vectors, the overexpression of miR-483-3p and -5p after lenti-miR-483 infection 
was initially assessed using HeLa cells (Figure 5.29). The virus was used at two 
MOIs, 10 and 20, to ensure sufficient levels of overexpression were achieved.   
 
 
Figure 5.29 – Lenti-miR-483 transduction of HeLa cells. 
Monolayer transduction of HeLa cells with lenti-miR-483 was performed, and RNA samples 
analysed to ensure sufficient overexpression of both -3p (A) and -5p (B) miR-483 strands. Virus 
was used at MOIs of 10 and 20, as indicated below graphs, and a lenti-control virus was used for 
comparison. n=2, data plotted is RQ ± RQ max. 
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Both -3p (Figure 5.29A) and -5p (Figure 5.29B) were overexpressed when cells 
were transduced using the generated lenti-miR-483 virus. Although 
overexpression was apparent when either concentration was used, cells 
transduced using an MOI of 20 demonstrated the highest level of expression for 
both mature miR-483 strands (≈10-fold and ≈75-fold for miR-438-3p and -5p 
respectively). Cells transduced with an MOI of 10 also showed a marked increase 
in expression for both miRNAs, however, and, therefore, both concentrations 
were used during hESC-EC differentiation (≈5-fold and ≈20-fold for -3p and -5p 
strands, respectively). Using both concentrations would allow for the 
observation of any dose-dependent response, as it may be hypothesised that 
increasing levels of miR-483 may drive the hESC-EC differentiation more 
efficiently, resulting in higher percentages of CD31+CD144+ hESC-ECs by d7. 
To test this hypothesis, d0 pluripotent H9 hESCs were infected with lenti-GFP, 
lenti-control or lenti-miR-483 at an MOI of 10 or 20, before they were 
differentiated using the direct hESC-EC system. Transduction was performed in 
suspension before the formation of size controlled EBs, as described in section 
2.10.2, and cells were harvested and analysed at d3 and d7 for the presence of 
CD326lowCD56+ MPs (Figure 5.30A) and CD31+CD144+ hESC-ECs (Figure 5.30B). 
Similarly to the results obtained with miR-143/145 overexpression, no significant 
difference in the percentage of d3 CD326lowCD56+ MP cells was observed 
between any of the sample groups (Figure 5.30A). Additionally, although the 
presence of CD31+CD144+ hESC-ECs was demonstrated in all d7 samples, there 
were, again, no significant differences recorded between treatment groups 
(Figure 5.30B). 
Taken together, these data show that overexpression of miR-483 does not 
increase hESC-EC differentiation efficiency, as demonstrated by the percentage 
of CD31+CD144+ cells by d7 of direct differentiation. 
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Figure 5.30 - d7 CD31
+
CD144
+
 and d3 CD326
low
CD56
+
 populations after miR-483 
overexpression. 
Infected cells were harvested at d3 (A), to assess the percentage of CD326
low
CD56
+
 hESC-ECs, 
and at d7 (B), to examine the levels of CD31
+
CD144
+
 MP cells, stained using specific antibodies 
and analysed using flow cytometry. Histograms above show average percentages of these 
populations over 3 experimental replicates, with the exception of d7 Lenti-GFP MOI 10, which was 
an experimental n=1. Three different negative control conditions included in the analysis, NTC, 
lenti-GFP and lenti-control. NTC = non-transduced control/no virus. Statistical tests were performed 
using a repeated measures ANOVA with Tukey’s post-hoc comparisons.  
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5.5 Discussion 
Governing of pluripotency and differentiation in hPSCs involves complex 
networks of genes, TFs, signalling networks and non-coding RNAs, which work 
together to tightly regulated these processes. Here, the presented studies focus 
on the identification and characterisation of novel miRNAs, with potential roles 
in commitment and lineage specification during hESC-EC differentiation, using 
microarray technology. Through comparisons performed between a purified 
CD326lowCD56+ MP and NCF samples, previously characterised in Chapter 3, it 
was demonstrated that -3p and -5p strands of three miRNA stem loops exhibited 
similar expression profiles; miR-145, miR-483 and miR-455. These stem loops 
were expressed at higher levels in MPs than in NCF samples, and were further 
upregulated by d7 of direct hESC-EC differentiation. Validation using qRT-PCR 
confirmed these expression patterns for miR-483 and miR-145, during both direct 
and indirect hESC-EC differentiation, and additionally identified miR-143, co-
transcribed alongside miR-145 as part of the miR-143/145 cluster.  Further 
modulation studies, aiming to understand the roles these miRNAs play during 
hESC-EC differentiation, however, were inconclusive, as overexpression of the 
identified miRNAs, using lentiviral vectors, did not show any significant 
differences in the percentages of either CD326lowCD56+ MPs at d3, or 
CD31+CD144+ hESC-ECs at d7 of direct hESC-EC differentiation. 
Using a global analysis, comparing all samples to d0 pluripotent controls, data 
collected from the microarray screen, and validation of results using Taqman® 
qRT-PCR, was also used to further characterise both the direct and indirect 
hESC-EC differentiation systems. The pluripotency-associated miR-302 family 
were shown to be downregulated as both differentiations progressed, 
demonstrating a loss in pluripotency. Furthermore, expression profiles of miR-
302a and -302b mimicked those of pluripotency genes, such as Nanog and Oct4, 
as their expression was lower in CD326lowCD56+  MP cells, than in NCF samples on 
d3, strengthening conclusions made in Chapter 3, that these cells are rapidly 
losing their pluripotent phenotype. Endothelial-associated miRNAs, miR-126 and 
-10a, were shown to significantly increase as cells differentiated toward an EC 
phenotype, with the highest levels in d7 (direct) and d7+3 (indirect) hESC-ECs. 
Again, these findings are in concordance with gene expression data, further 
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strengthening the conclusion that d7 cells have become committed to an 
endothelial phenotype. 
Additionally, these EC-associated miRNAs were shown to be expressed at higher 
levels in CD326lowCD56+ MPs than in NCF samples on d3, although the differences 
in expression did not reach significance. This complements data collected in 
Chapter 3, showing this same expression pattern in EC-associated genes CD31 
and CD144, and supports the hypothesis that these cells are already starting to 
develop an EC phenotype, although additional experiments would need to be 
performed to verify this. Furthermore, expression profiles of miR-302a and -302b 
mimicked those of pluripotency genes, such as Nanog and Oct4, as their 
expression was lower in CD326lowCD56+  MP cells, than in NCF samples on d3, 
strengthening conclusions made in Chapter 3, that these cells are rapidly losing 
their pluripotent phenotype. 
Although expression of the majority of previously published miRNAs was similar 
when profiled within the presented differentiation systems, miR-200c and -150, 
shown by Luo and colleagues to be involved in the generation of EC from hESCs 
(Luo et al., 2013), exhibited very different patterns of expression from those 
previously demonstrated, with miR-150 undetected and miR-200c downregulated 
during hESC-EC differentiation. One explanation for these disparities are the 
inherent differences existing between distinct hESC lines. Luo et al. used the 
Shef hESC lines, obtained from the UK Stem Cell Bank, whereas H9 hESCs were 
used in this microarray. Previously, publications have demonstrated distinct 
differences between hESC lines in terms of gene expression, surface marker 
expression and differentiation bias, possibly due to variations in factors such as 
genetics and cell culture systems (Allegrucci et al., 2007, Wu et al., 2007). It 
may be the case that miRNA expression also varies between cell lines, therefore 
offering an explanation as to why miR-200c and miR-150 are not upregulated in 
this system. Additionally, differences between hESC-EC differentiation protocols 
may also explain why these miRNAs observed different expression profiles in the 
presented direct hESC-EC system. As stated previously, there has been an 
increasing emphasis on the development of fully defined differentiation and 
culture systems, in order to reduce the number of unknown factors present in 
the cellular environment. The system developed by Luo and colleagues involved 
the use of Matrigel, an undefined cell culture matrix (Luo et al., 2013), which 
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may have had an influence in signalling, gene and miRNA expression in this 
system. Furthermore, upregulation of EC-associated genes, although significant, 
was much lower in studies performed by Luo et al. (≈3-4-fold) than in the direct 
hESC-EC differentiation studies presented in Chapter 3 (>1000-fold). Large 
variations existing between these two distinct differentiation systems may be, 
therefore, be responsible for the differences observed in the expression of miR-
200c and -150 in these two systems. These findings highlight the need for 
standardised hESC culture and differentiation protocols, in order to elucidate 
key mechanisms involved in in vitro and in vivo lineage specification, an issue 
which has been previously studied (Denning et al., 2006).  
During this study, miRNA overexpression was performed using lentiviral vectors 
coding for specific miRNA stem loop sequences. Using these vectors, miR-483 
and the miR-143/145 cluster were overexpressed, as well as miR-143 and miR-
145 individually, during hESC-EC differentiation. Although no significant 
differences were observed in the percentages of d3 CD326lowCD56+ MPs and d7 
CD31+CD144+ hESC-ECs between sample groups, this may not necessarily show 
that these miRNAs do not play a role during mesodermal and endothelial lineage 
specification. Previously, miR-145-5p has been shown to repress pluripotency 
through the targeting of Oct4, Sox2 and Klf4, TFs known to be involved in the 
regulation of the pluripotent phenotype (Xu et al., 2009). Xu and colleagues also 
demonstrated that overexpression of miR-145-5p in hESCs, through the use of a 
lentiviral vector, induced differentiation to both meso- and ectodermal lineages. 
Furthermore, a recent RNA Sequencing (RNA-Seq) experiment, performed in the 
lab of Professor Baker (data not shown), showed similar expression patterns for a 
number of lncRNAs whose genomic locations are in close proximity to the miR-
143/145 cluster. Indeed, a number of these lncRNAs were shown to include the 
sequence of pri-miR-143 or -145. Taken together, these data suggest an 
important role for the miR-143/145 axis in this system, and therefore further 
investigation and optimisation will be necessary to elucidate this.  
Firstly, the time point, at which lentiviral infection was performed may not be 
optimal and could be optimised. As cells were infected at d0 of hESC-EC 
differentiation, the peak of lentiviral-associated gene expression, which is 
thought to occur 72 h post-transduction, would coincide with the appearance of 
the d3 CD326lowCD56+ MP cell population. miRNA overexpression may, therefore, 
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not occur until cell fate has already been decided, sometime during d1-3 of 
hESC-EC differentiation. If overexpression of miR-143/145 or miR-483 does 
influence mesodermal commitment, the window for intervention may have 
already passed before expression is high enough to have a significant effect. To 
investigate this, experiments could be performed whereby hESCs are pre-treated 
with the miRNA-overexpressing lentivirus, before undergoing hESC-EC 
differentiation. This would allow for miRNA expression to reach a peak before 
any cell fate decisions were made, allowing definitive conclusions to be made as 
to whether these miRNAs are involved in mesodermal lineage commitment. 
Analysis of miR-143/145 overexpression using qRT-PCR showed that although all 
miRNAs appear to be upregulated when hESCs transduced with relevant viral 
vectors, only miR-145-5p on d3, after lenti-miR-143/145 infection, was 
significantly changed when compared to the lenti-control sample group. 
Although this may suggest that a higher concentration of virus is needed in order 
to fully overexpress these miRNAs, it could also be due to a saturation of the 
system. As these miRNAs become upregulated during hESC-EC differentiation, it 
may be that overexpression cannot drive the system any further as it has already 
reached its limit. Instead, knock down experiments could be performed in order 
to reduce the expression of miR-143/145 or miR-483 to fully investigate their 
role in hESC-EC commitment. If these miRNAs do play an important role in EC 
specification and commitment, it would be hypothesised that a decrease in the 
expression of these miRNAs would result in a reduction in hESC-EC 
differentiation efficiency. One method of miRNA knockdown is the use of 
chemically modified, synthetically designed molecules which directly target the 
miRNA of interest, known as anti-miRNAs or antago-miRNAs. These molecules 
contain sequences complementary to a specific miRNA, allowing binding of the 
anti-miRNA, therefore inhibiting the interaction between the miRNA to its target 
mRNA. These molecules, however, are delivered to the cells via transfection. As 
stated previously, transfection efficiencies in hPSCs are notoriously low, and 
therefore knockdown of miRNA expression using anti-miRs or antago-miRs may 
not be the most practical method. Instead, genetic ablation using the Cas9 
nuclease and clustered, regularly interspaced, short palindromic repeats 
(CRISPRs) system, a newly developed method for genetic modification, could be 
employed. The Cas9-CRISPR technology, first described in bacterial and archaeal 
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immunity (Bhaya et al., 2011, Wiedenheft et al., 2012), has been developed to 
produce a robust highly successful method for genomic editing (Mali et al., 2013, 
Ran et al., 2013, Shen et al., 2014). Having already been used for genetic 
modification of hPSCs (Rong et al., 2014), Cas9/CRISPR involves the use of an 
RNA-guided Cas9 nuclease to create targeted double stranded (DS) breaks in 
DNA. Depending on the mechanism of DS-break repair, either non-homologous 
end joining or homologous recombination, genes can be silenced, modified or 
inserted into the genome. This technology is currently being used within the 
laboratory to generate miR-143/145 mutant hESC lines, whereby the expression 
of one or both of the miRNAs in this cluster has been knocked out, which will be 
subsequently used to further investigate the roles of this cluster in hESC-EC 
lineage commitment and differentiation. 
As shown, the mechanism of miRNA modulation presented here employs the use 
of lentiviral vectors. Although these vectors are highly efficient and the levels of 
hESC transduction high, the transgene is randomly integrated into the host 
genome and this can have serious detrimental effects, for example through 
activation of adjacent genes (Howe et al., 2008). Activation of genes adjacent to 
the insertion site and other problems associated with random integration may 
affect hESC-EC differentiation and may, therefore, mask significant affects 
caused through miRNA overexpression. To circumvent this problem, targeted 
insertion of miRNAs into the genome could have been used. Recently, Tay and 
colleagues demonstrated targeted transgene insertion into the AAVS1 locus in 
hiPSCs (Tay et al., 2013). The AAVS1 locus has been designated as a ‘safe 
harbour’ locus, as disruption of the genome in this region does not lead to any 
phenotypic affects in human cells (Smith et al., 2008, DeKelver et al., 2010). 
Furthermore, the aforementioned Cas9-CRISPR technology could be employed to 
efficiently insert specific miRNAs into the hESC genome for overexpression. 
Although miR-143/145 and miR-483 expression was validated in samples from 
both direct and indirect hESC-EC differentiation, as well as in the control 
hematopoietic differentiation samples taken when using the indirect system, 
further studies could be performed to assess their expression during 
differentiation of cells to other lineages. For example, analysis of miR-143/145 
and miR-483 expression levels during differentiation to other mesodermal 
lineages, such as cardiac, could be used alongside data already shown from 
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hematopoietic differentiation, to definitively assess whether changes in these 
miRNAs are restricted to hESC-EC differentiation, or whether they are more 
generally associated with mesodermal lineage commitment. Furthermore, 
profiling of these miRNAs in ectodermal and endodermal differentiation systems 
would distinguish between general differentiation-associated miRNAs, which may 
play roles in the inhibition of pluripotency, and those which are specifically 
driving cells toward a mesodermal cell fate. 
First developed for high-throughput global analysis of changes in mRNA levels, 
microarray technology has been widely employed for global analysis of changes 
in miRNA expression during differentiation of hPSCs, and in the identification of 
novel miRNAs with predicted roles in these processes (Tzur et al., 2008, Wilson 
et al., 2010, Kane et al., 2012, Luo et al., 2013). As presented here, these 
screens produce large amounts of data, and analysis can be time consuming. 
Because of this, only a few of the differentially expressed miRNAs, identified 
using the miRNA screen, were chose for validation and further investigation. As 
shown in Table 5.2, 50 miRNAs were differentially expressed between d3 MP and 
NCF samples, meaning a great deal of other miRNAs whose role could be 
investigated. Furthermore, there were large numbers of previously 
uncharacterised miRNAs whose expression was changed throughout direct hESC-
EC differentiation (data not shown), whose roles in the system could also be 
examined further.  
The use of microarray technology has a number of advantages, including the 
ability to profile expression of all identified miRNAs in large numbers of samples 
in parallel. Recently, however, there has been a move toward the use of RNA 
Sequencing, or RNA-Seq, and Next Generation sequencing (NGS) technologies. 
Briefly, RNA-Seq involves converting a population of RNA to a library of cDNA 
fragments and adding adaptors onto one or both ends. Experiments can be 
performed with or without amplification, and each molecule is sequenced in a 
high throughput manner, with resulting reads aligned to a reference genome  
(Wang et al., 2009). One advantage of RNA-Seq, in comparison to microarray, is 
the ability to identify novel RNAs, as it is not limited to the detection of 
previously recognised transcripts. Indeed, this technology has already been used 
to identify number of novel lncRNAs, including during hESC-EC differentiation 
system (Kurian et al., 2015). Furthermore, it is believed that RNA-Seq 
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technology has a much greater sensitivity for lowly expressed RNAs and, 
therefore, if instead of microarray technology in the presented study, may have 
identified an even greater cohort of miRNAs whose expression is differentially 
regulated throughout hESC-EC differentiation. Indeed, using this technology, the 
similarity of the miR-143-5p expression profile to the other miRNAs in the cluster 
may have been detected. Finally, publications have demonstrated that this 
technology can be used to profile changes in a variety different RNA types in 
parallel, including mRNAs, lncRNAs, miRNAS, small nucleolar-derived RNAs 
(snoRNAs) and piwi-interacting RNAs (piRNAs) (Muller et al., 2015). Collecting 
expression data for all of these RNAs allows for a better understanding of 
possible RNA:RNA interactions, such as miRNA:mRNA, thus helping assign 
potential functions to differentially regulated RNAs. 
In conclusion, although miRNA overexpression presented here appears to be 
negative, there is a vast amount of work which could still be performed to 
investigate the role of miR-143/145 and miR-483, as well as other novel miRNAs 
identified using the microarray screen, in the differentiation and commitment of 
cells to both mesodermal and endothelial lineages.  
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6.1 Discussion 
This thesis contains work concerned with identifying roles of specific miRNAs 
during the commitment and specification of hESCs to both mesodermal and 
endothelial lineages. hESC-ECs have translational potential in the treatment for 
ischemic diseases, such as PAD, whereby administration of cells would allow 
stimulation of angiogenesis and revascularisation of the ischemic tissue. 
Although the efficiencies of hESC-EC differentiation protocols are improving 
(Orlova et al., 2014c, Patsch et al., 2015), many require a sorting step to 
achieve purity. miRNAs have been demonstrated to play roles in a variety of 
biological processes and cellular functions. Numerous publications have 
described how specific miRNAs are differentially expressed during hESC-EC 
generation (Yoo et al., 2011b, Hassel et al., 2012, Kane et al., 2012, Yoo et al., 
2012, Luo et al., 2013), and it was, therefore, hypothesised that identification 
of miRNAs playing essential roles in hESC-EC lineage commitment would allow 
for manipulation of the differentiation system, in order to increase efficiency 
and thus avoiding the need for cumbersome separation procedures.  
Initially, two distinct protocols for the derivation of hESC-ECs were developed 
and characterised. The first was described as a direct hESC-EC differentiation 
system. In this method, H1 and H9 pluripotent hESCs were taken at d0 and 
allowed to form size controlled EBs, using a 96-well plate-based spin method, in 
the presence of a number of mesoderm- and endothelial-specifying cytokines 
and growth factors. After three days in these conditions, EBs were removed from 
wells, plated out onto gelatin coated tissue culture plates and cultured in 
endothelial conditions until d7. By d7, the appearance of CD31+CD144+ hESC-ECs 
was observed, coupled with the downregulation of pluripotency-associated cell 
surface markers and TFs. Furthermore, it was demonstrated that positive 
selection of CD144+ cells using MACS allowed for isolation of pure CD31+CD144+ 
hESC-EC populations. The purified CD31+CD144+ cells could then be replated, 
cultured and expanded, and by d14 cells were ≈100% positive for both CD31 and 
CD144, similar to previously published protocols (Luo et al., 2013, Orlova et al., 
2014a, Patsch et al., 2015), and were able to form tubules when plated onto 
Matrigel. Recently, however, guidelines have been published suggesting that this 
method of measuring angiogenic potential and function is not specific, and in 
fact multiple other cell types, including VSMCs, fibroblasts and tumour cells are 
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able to form similar structures when seeded onto this matrix (Simons et al., 
2015). Other in vitro angiogenesis assays could be performed using these d14 
CD31+CD144+ hESC-ECs, including 3D collagen or fibrin EC lumen formation and 
sprouting assays and EC-pericyte co-culture assays, as used by Orlova and 
colleagues (Orlova et al., 2014a).  
During in vivo development, it has been demonstrated that the vascular and 
hematopoietic systems are closely linked (Bertrand et al., 2010, Boisset et al., 
2010, Kissa et al., 2010, Azzoni et al., 2013). More recently, studies have 
demonstrated the presence of a bipotent specialised EC, or HE, within in vitro 
differentiation systems (Choi et al., 2009, Ditadi et al., 2015). With this 
knowledge, a second, indirect protocol for the production of hESC-ECs was 
developed. The development of a second, distinct hESC-EC differentiation 
protocol allowed for and additional system in which findings could be validated; 
candidate miRNAs function could also be investigated in this second system to 
specifically define whether their function was in endothelial or mesoderm 
commitment. Using a previously characterised hematopoietic differentiation 
system, existing within the laboratory of Dr Joanne Mountford, coupled with the 
marker profile identified by Choi and colleagues (Choi et al., 2012), a 
CD31+CD144+CD235a-CD43-CD73- HE progenitor was identified on d7 of 
differentiation. Optimisation experiments, shown in Chapter 4, demonstrated 
that if these d7 HE cells were placed into endothelial-supportive conditions, 
cells could be driven toward a more mature EC phenotype, with high 
percentages of CD31+CD144+ hESC-ECs present at time point d7+3. Experiments 
to demonstrate the emergence of HP suspension cells from bipotent adherent HE 
cells could now be performed. Choi and colleagues use time-lapse imaging 
technology to visualise the production of CD43+ suspension cells, directly from 
CD144+ HE cells (Choi et al., 2012), and a similar technology could be used here. 
Furthermore, functional characterisation of generated d7+3 CD31+CD144+ hESC-
ECs must be performed.  
To further investigate mechanisms, including the role of miRNAs, involved in 
hESC commitment to mesoderm and subsequent endothelial lineages, an early 
stage progenitor population was identified. Evseenko and had previously 
characterised a CD326-CD56+ multipotent progenitor population, existing on d3.5 
in a general mesodermal differentiation system (Evseenko et al., 2010). It was 
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demonstrated that these CD326-CD56+ cells expressed high levels of mesoderm-
associated genes and could differentiate to multiple mesodermal cell types, 
including ECs, hematopoietic cells, mesenchymal cells and cardiomyocytes, but 
were not able to form cells from the endo- or ectodermal lineages (Evseenko et 
al., 2010). After performing time course analyses using both the direct and 
indirect hESC-EC differentiation protocols, it was demonstrated that this 
population existed at d3 in both systems as a CD326lowCD56+ MP, with its 
appearance coinciding with the peak of mesoderm-associated genes such as 
Brachyury and Mesp1. Gene expression analysis of purified CD326lowCD56+ MP 
cells revealed high levels of mesoderm-associated genes, as well as significantly 
higher levels of VEGFR2, a gene commonly used to characterise early endothelial 
progenitor cells, than in the d3 NCF samples. Furthermore, the endothelial-
associated genes CD144 and CD31 were significantly upregulated in 
CD326lowCD56+ MPs when compared to d0 pluripotent cells, whereas there was no 
change in their expression in the NCF samples. Taken together, the gene 
expression profile of these cells suggested that these CD326lowCD56+ cells were a 
definitive mesoderm or early stage endothelial progenitor population, or 
contained a smaller progenitor subpopulation of these progenitor cells, and this 
cell population was subsequently used to study early changes in miRNA 
expression. In addition to the work performed by Evseenko and colleagues, other 
studies have described other cell surface marker profiles for the characterisation 
of early mesodermal progenitor populations, including ROR2+ and 
APLNR+PDGFRα+ (Choi et al., 2012, Drukker et al., 2012). Therefore, further 
characterisation experiments could be performed, using large multicolour flow 
cytometry panels, as demonstrated in Chapter 4, to generate a more defined 
surface marker profile or to identify sub-populations of mesodermal or 
endothelial progenitors existing within this CD326lowCD56+ MP population. 
Furthermore, in depth gene expression profiling of CD326lowCD56+ MPs isolated 
during indirect hESC-EC differentiation could also provide insight into the exact 
phenotype of these cells, and whether they are identical to those observed 
during direct hESC-EC differentiation. Finally, experiments to differentiate the 
cells toward a variety of mesodermal lineages, such as cardiomyocytes or 
mesenchymal cells, must be performed. Testing the differentiation capacity of 
these cells would provide further evidence as to whether the CD326lowCD56+ MP 
cells, generated in this study, are biased toward endothelial differentiation, or 
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whether they still possess the capacity to differentiate to other mesodermal cell 
types. 
After characterisation of the generated protocols, and identification of an early 
stage progenitor population, as described in Chapter 3 and 4, microarray 
technology was employed to evaluate global changes in miRNA expression during 
hESC-EC differentiation, as well as for the identification of novel candidate 
miRNAs with potential roles during endothelial specification and commitment. 
Both miR-126 and miR-10a have been shown to be involved in the regulation of 
EC function and angiogenesis (Fish et al., 2008, Wang et al., 2008c, Hassel et 
al., 2012), and an upregulation of these miRNAs was observed as hESC-EC 
differentiation progressed. Additionally, the pluripotency-associated miR-302 
family was shown to be significantly downregulated during both direct and 
indirect differentiation. A study had previously identified a role for miR-145 in 
the inhibition of pluripotency during meso- and ectodermal differentiation of 
hESCs, via the targeting of pluripotent TFs Oct4, Sox2 and Klf4 (Xu et al., 2009). 
During screening and subsequent validation of miRNAs, both -3p and -5p strands 
of miR-145 were found to be regulated in a similar manner during hESC-EC 
differentiation, with higher levels in the d3 CD326lowCD56+ MPs than in NCF 
samples, and with a further increase in expression by d7. This was also coupled 
with an identical expression pattern for -3p and -5p strands of miR-143. These 
two miRNA stem loops are transcribed together as a cluster, and their role in 
VSMCs has been well documented (Robinson et al., 2012). It was also observed 
that both strands from the miR-483 stem loop, whose molecular function outside 
the field of cancer is relatively unknown, also exhibited this same expression 
profile. Classically, it was thought that only one of the mature miRNA strands 
from the pre-miRNA stem loop, referred to at the ‘lead’ strand had a biological 
function, with the other strand, known as the ‘passenger’ strand, thought to be 
targeted for degradation (Matranga et al., 2005). Recently, however, a number 
of publications have identified roles for these traditional ‘passenger’ miRNA 
molecules (Mah et al., 2010, Yang et al., 2011). Furthermore, miR-17-3p and -5p 
have been demonstrated to have complementary roles in prostate cancer and 
hepatocellular carcinoma (Shan et al., 2013, Yang et al., 2013).  
miR-143/145 and miR-483 were, therefore, chosen as potential candidates, and 
work presented at the end of Chapter 5 demonstrated how modulation of these 
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miRNAs was performed, using lentiviral vectors, during direct hESC-EC 
differentiation. Although overall results showed no significant difference in 
either CD326lowCD56+ MP or CD31+CD144+ hESC-EC populations, further 
optimisation of the time point at which lentiviral transduction is performed may 
still be beneficial. Moreover, overexpression could instead be performed using a 
Cas9/CRISPR system, whereby miRNA insertion is targeted to the AAVS1 locus 
(Smith et al., 2008, Ran et al., 2013, Tay et al., 2013, Rong et al., 2014). 
Alternatively, knockdown of these miRNAs using the Cas9/CRISPR system is 
currently being performed, and generation of miR-145, miR-143, miR-143/145 
and miR-483 knockout lines would allow definitive evidence to suggest whether 
these miRNAs play crucial roles in specification and commitment of hPSCs 
toward mesodermal and endothelial lineages. In studies presented here, 
modulation was only performed during direct hESC-EC differentiation, and not in 
cells subject to differentiation using the indirect system. As stated previously, 
the development of this second system allows for an additional level of 
interrogation in terms of whether candidate miRNAs are specifically involved in 
endothelial commitment, mesodermal commitment, general differentiation, or 
in loss of pluripotency. Therefore, further work would involve the modulation of 
miR-143/145 and miR-483 during indirect hESC-EC differentiation. 
6.2 Future perspectives 
As stated previously, large amounts of data have been generated using the 
miRNA microarray screen documented in Chapter 5. Further analysis of this data 
may reveal other novel miRNAs with potential roles in hESC-EC differentiation. 
Although identification of miRNAs involved is relatively straightforward, using 
modulation studies to determine importance in a particular system, investigating 
exactly how miRNAs function, including their specific mRNA targets, is more 
challenging. Although numerous open access, easy-to-use target prediction 
algorithms are available, e.g. TargetScan (http://www.targetscan.org/vert_70/) 
and miRWalk (Dweep et al., 2015), these programmes can often generate lists of 
thousands of predicted mRNA targets, based purely on matching of the miRNA 
seed sequence to a region in the 3’UTR of mRNAs. Alternatively, miRTarBase 
(Hsu et al., 2014) generates lists of experimentally validated miRNA targets; 
however, this also has disadvantages, as novel targets may be missed, 
particularly important as targets can be tissue and system specific. In order to 
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overcome these challenges a number of strategies can be used. Firstly, mRNA 
microarray analysis of samples where miRNAs have been modulated may provide 
an insight into mRNAs dysregulated after miRNA silencing or overexpression. Any 
potential targets identified using this technology may then be confirmed using 
luciferase reporter assays. As miRNA can function by either targeting of specific 
mRNAs for degradation, or by inhibition of mRNA translation, analysis of mRNA 
levels may miss targets not targeted for degradation. Therefore, proteomic 
screens may alternatively be used to analyse samples after miRNA modulation to 
identify targets. Ideally, these two technologies could be combined to generate 
a comprehensive list of potential targets for validation and further investigation. 
As well as large scale proteomic and mRNA screens, numerous studies have used 
RNA pull down experiments to identify specific miRNA targets. These pull downs 
are performed using antibodies specific for miRNA binding proteins, such as 
Ago2, to co-immunoprecipitate mRNA targets (Beitzinger et al., 2007), or by the 
use of synthetic biotinylated miRNA molecules, which can then be isolated using  
streptavidin beads (Orom et al., 2007). For even higher sensitivity, these two 
methods can be combined, to identify bona fide mRNA targets, where both the 
specific miRNA and RISC are bound. 
As research progresses, our understanding of how gene expression is regulated is 
becoming increasingly complex. The field of non-coding RNAs is ever expanding 
and, most recently, lncRNAs have been implicated in the differentiation of 
hESCs, specifically toward mesodermal, endothelial and other cardiovascular 
lineages (Klattenhoff et al., 2013, Kurian et al., 2015). An RNA-Seq experiment 
has recently been performed within our laboratory, on samples taken from  
direct hESC-EC differentiation, from similar time points as those run on the 
miRNA microarray screen in the present study (H9 d0 pluripotent cells, d3 MPs, 
d3 NCF, d7 CD31+CD144+ hESC-ECs). These newly collected data will be 
combined with that collected from the microarray screen to generate a 
comprehensive data set, which will allow for a better understanding of the roles 
of non-coding RNAs in this hESC-EC differentiation system. 
In terms of hESC-ECs, there is much work still to be done in order to gain a 
deeper understanding of phenotype, function, and mechanisms which drive 
pluripotent cells toward this lineage. One major area for future investigation is 
the maturity of cells generated using hESCs and hiPSCs. Phenotypic analysis has 
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demonstrated that cells derived from hESCs and hiPSCs have characteristics 
which more closely resemble those seen in foetal cells, than in adults (Qiu et 
al., 2008, Baxter et al., 2015). For example, Chang and colleagues demonstrated 
that erythroid cells derived from H1 hESCs coexpressed high levels of embryonic 
and foetal globins, with almost no cells expressing adult globin (Chang et al., 
2006). The generation of cells possessing foetal characteristics is logical, given 
the short time scales required to generate these cells in vitro and the relative 
stability of foetal cells in vivo. Research is now focusing on whether these cells 
can be driven from their current foetal phenotypes toward a more adult-like 
cell, and factors and mechanisms which may be involved in this switch (Chun et 
al., 2015). In the context of the presented study, investigation into the maturity 
of produced hESC-ECs must be performed. Studies may be performed to assess 
whether d7 hESC-ECs possess a foetal phenotype, and whether any maturation of 
cells occurs by d14, after purification and further culture of CD144+ ECs. If d14 
cells also possess a foetal phenotype, studies surrounding the switching of cells 
to an adult phenotype may be designed and performed. This could involve 
further culture of cells, or screening of small molecules and other factors which 
may be involved, including miRNAs and other non-coding RNAs. In terms of 
clinical relevance, hESC-generated cells such as cardiomyocytes and erythoid 
cells must possess an adult phenotype, due to differences in conduction velocity 
and oxygen affinity respectively. For hESC-ECs, however, it is not known 
whether cells possessing a foetal phenotype could be used therapeutically and, 
therefore, this is another aspect which must be investigated. To date, there 
have been no published studies which extensively investigate characteristic and 
phenotypic differences between foetal and adult ECs, although comparisons 
between foetal ECs isolated from different organs have been performed 
(Invernici et al., 2005). As no obvious differences exist, for example in size or 
structure, it may be that the maturity of these cells would have no implications 
for their use in the clinic. Furthermore, with this in mind, it may be suggested 
that the use of adult EC types, such as HUVECs, as a positive control in hESC-EC 
studies may be misrepresentative, and foetal ECs would be a more relevant 
comparison (Baxter et al., 2015). 
Moreover, if generated hESC-ECs do possess a foetal-like phenotype, studies 
could be performed to attempt to drive these immature cells toward a specific 
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adult EC phenotype e.g. venous, arterial or lymphatic ECs. The ability to 
produce specific EC types would potentially allow for the development of 
specialised cell therapies for different ischemic diseases, for example arterial 
ECs for the treatment of PAD and CLI. Generation of fluorescent reporter hESC 
lines, whereby a reporter gene, such as GFP or mCherry, is under the control of 
a promoter associated with arterial, venous or lymphatic specification would 
allow for large scale, high-throughput screening experiments to identify small 
molecules or growth factors which drive cells towards each specific lineage. 
These data could then be used to optimise hESC-EC differentiations to produce 
ECs with specific phenotypes and characteristics.  
Ultimately, it is hoped hPSC-ECs will provide a potentially unlimited source of 
functional, transplantable cells for the treatment of ischemic diseases. Overall, 
however, hPSC-derived cell therapies still have a number of obstacles to 
overcome if they are to make it into routine clinical practice, including safety 
concerns in terms of tumourgenicity and immune rejection. While the presented 
studies have focused on the use of hESCs in the generation of ECs, it is hiPSCs, 
generated from the reprogramming of terminally differentiated somatic cells 
(Takahashi et al., 2007), which are thought to have the greatest potential in 
terms of both cell therapies and in vitro disease modelling. Therefore, further 
experiments should be performed to determine whether the presented direct 
and indirect hESC-EC differentiation protocols are transferrable to hiPSC lines. 
Theoretically, the use of patient-specific iPSCs would overcome the problem of 
immune rejection as transplantation would be autologous, however, some 
studies have suggested that, despite this, these cells may also elicit specific 
immune responses  (Fu, 2014).  
Furthermore, standardisation of hPSC culture conditions and differentiation 
systems, as well as the standardisation of assays used to characterise both 
pluripotent and generated cells, represents one major hurdle in the 
development of cell therapies. Although some efforts have been made to 
standardise conditions (Denning et al., 2006), differences existing between hESC 
and hiPSC lines, possibly caused due to differences in derivation techniques, 
mean that often differentiation and culture systems are non-transferrable. For 
example, differences were observed in hESC-EC differentiation efficiencies 
between H1 and H9 hESC lines, both generated in the same laboratory, during 
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studies shown in Chapter 3. If, as stated previously, patient-specific iPSCs were 
to be generated for the development of personalised medicine, standardised 
protocols would be required in order to ensure that differentiation was possible 
for all hiPSCs derived from any patient. Standardisation of differentiation 
conditions is also important for the investigation of specific mechanisms 
involved. This is evident from data presented in Chapter 6 of this study, whereby 
miR-200c and miR-150, previously shown to be upregulated in an alternative 
hESC-EC differentiation system (Luo et al., 2013), were downregulated and 
undetected during the described direct hESC-EC differentiation, respectively.   
Although studying miRNA functions during hESC differentiation and commitment 
is a useful tool to understand exact mechanisms and signalling pathways involved 
during these complex processes, it would be difficult to translate this clinically. 
Manipulation of miRNA expression levels is a commonly used technique in vitro 
in order to increase hESC differentiation efficiencies, however, the majority of 
techniques used, including lentiviral vectors and Cas9/CRISPR technology, 
involves either random or targeted modification of the genome. Clinical use of 
cells containing genetic modifications may be an issue. Therefore, instead of 
using miRNA modulation to directly increase differentiation efficiency, it may be 
preferable to use small molecules, growth factors or inhibitors to target the 
same signalling pathways. These factors could be easily added to a 
differentiation system to drive hESC-EC production, or the production of other 
PSC-derived cell types. Alternatively, investigation of miRNA and their functions 
during hESC-EC differentiation could also be used to directly stimulate 
endogenous repair and regeneration mechanisms in vivo. Factors directly 
targeting pathways and mechanisms, affected by the changes in miRNA 
expression during in vitro differentiation, could possibly be directly 
administered to a patient in order to stimulate angiogenesis in an ischemic limb, 
therefore, circumventing numerous problems associated with cellular-based 
therapies. It is, therefore, imperative that improvements are made in 
technologies used to elucidate miRNA targets and mechanisms. 
Finally, research has also begun to focus of the development of 
transdifferentiation techniques, as a new approach for the generation of a 
variety of specific cell types for transplantation or use in various cell therapies. 
Briefly, transdifferentiation involves the direct conversion of one terminally 
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differentiated or multipotent adult stem cell type to another, different, cell 
type. Although the mechanisms governing transdifferentiation are relatively 
unknown, a number of studies have achieved success via the overexpression of 
specific TFs (Wang et al., 2015). More recently, it has been demonstrated that, 
much like during iPSC generation and reprogramming, miRNAs can be used 
during in vitro transdifferentiation. Originally, Yoo et al. demonstrated that 
lentivirus mediated delivery of the miR-9 stem loop (containing both -3p and -5p 
strands) and miR-124 to human fibroblasts induced expression of the neuron-
specific marker Map2 (Yoo et al., 2011a). Furthermore, when these miRNAs were 
used alongside the neurogenic TF Neurod-2, the efficiency of the conversion was 
increased. Leading on from this, Jayawardena and colleagues used only miRNAs 
to directly reprogramme fibroblasts to cardiomyocyte-like cells (Jayawardena et 
al., 2012).  In this study, they showed that transient transfection of miR-1, -133, 
-208 and -499 in combination resulted in this switch in cell fate, demonstrated 
by the expression of mature cardiomyocyte markers, sarcomeric organisation 
and exhibition of spontaneous calcium flux characteristics. From this, it may be 
hypothesised that any miRNA involved in commitment of cells to the endothelial 
lineage, as well as those involved during the later stages of differentiation, 
could be used during transdifferentiation of cells to an endothelial fate. 
Additional knowledge of the roles of specific miRNAs during the generation of 
hESC-ECs may, therefore, be valuable in the production of vascular cells for 
cellular therapy via direct reprogramming.  
6.3 Concluding remarks 
In summary, the findings presented in this thesis confirm vast changes in global 
miRNA expression profiles during hESC-EC differentiation via two distinct routes; 
one direct and one indirect. Although investigations into the functions of miR-
483 and the miR-143/145 cluster during hESC-EC differentiation were 
inconclusive, it is clear that regulation of the system by miRNAs and other non-
coding RNAs is crucial. Further work is required determine whether miR-483 and 
miR-143/145 upregulation is a critical process during hESC-EC differentiation, or 
whether it is merely a consequence of this change in phenotype. Additionally, 
studies should be performed to identify other novel miRNAs, using the 
microarray data set generate in this thesis, with potential roles in hESC-EC 
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differentiation and commitment, and to pinpoint their exact mechanisms and 
functions.    
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